-DOCSTART-	O

Title	O
:	O
Switching	O
patients	B-P
with	I-P
asthma	I-P
from	O
chlorofluorocarbon	B-I
(	I-I
CFC	I-I
)	I-I
albuterol	I-I
to	O
hydrofluoroalkane	B-I
-	I-I
134a	I-I
(	I-I
HFA	I-I
)	I-I
albuterol	I-I
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
asthma	I-P
stabilized	O
on	O
CFC	B-I
albuterol	I-I
during	O
a	O
12	O
-	O
week	O
safety	B-O
and	O
efficacy	B-O
trial	O
were	O
randomized	O
to	O
either	O
continue	O
receiving	O
CFC	B-I
albuterol	I-I
or	O
to	O
be	O
switched	O
to	O
receive	O
HFA	B-I
albuterol	I-I
in	O
a	O
yearlong	O
safety	B-O
and	O
efficacy	B-O
trial	O
.	O

Safety	B-O
and	O
efficacy	B-O
were	O
compared	O
over	O
the	O
first	O
12	O
weeks	O
of	O
the	O
yearlong	O
trial	O
between	O
patients	O
who	O
had	O
remained	O
on	O
CFC	B-I
albuterol	I-I
and	O
those	O
who	O
had	O
been	O
switched	O
to	O
HFA	B-I
albuterol	I-I
.	O

Bronchodilator	B-O
efficacy	I-O
was	O
evaluated	O
by	O
serial	B-O
spirometry	I-O
for	O
6	O
hr	O
after	O
the	O
patients	O
self	O
-	O
administered	O
the	O
study	O
drug	O
in	O
the	O
clinic	O
.	O

Safety	B-O
was	O
assessed	O
by	O
measuring	O
changes	O
in	O
pulse	B-O
rate	I-O
,	O
blood	B-O
pressure	I-O
,	O
and	O
electrocardiogram	B-O
(	I-O
ECG	I-O
)	I-O
intervals	O
after	O
dosing	O
with	O
study	O
drug	O
,	O
monitoring	O
adverse	B-O
events	I-O
,	O
and	O
performing	O
prestudy	O
and	O
poststudy	O
laboratory	B-O
testing	I-O
and	O
physical	B-O
examinations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Behavioral	O
and	O
physiological	O
effects	O
of	O
remifentanil	B-I
and	O
alfentanil	B-I
in	O
healthy	B-P
volunteers	I-P
.	O

METHODS	O
:	O
Ten	B-P
healthy	I-P
volunteers	I-P
were	O
enrolled	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
trial	O
in	O
which	O
they	O
received	O
an	B-C
infusion	I-C
of	I-C
saline	I-C
,	O
remifentanil	B-I
,	O
or	O
alfentanil	B-I
for	O
120	O
min	O
.	O

The	O
age	O
-	O
and	O
weight	O
-	O
adjusted	O
infusions	O
(	O
determined	O
with	O
STANPUMP	O
,	O
a	O
computer	O
modeling	O
software	O
package	O
)	O
were	O
given	O
to	O
achieve	O
three	O
predicted	O
constant	O
plasma	O
levels	O
for	O
40	B-I
min	I-I
each	I-I
of	I-I
remifentanil	I-I
(	O
0	O
.	O
75	O
,	O
1	O
.	O
5	O
,	O
and	O
3	O
ng	O
/	O
ml	O
)	O
and	O
alfentanil	B-I
(	O
16	O
,	O
32	O
,	O
and	O
64	O
ng	O
/	O
ml	O
)	O
.	O

Mood	B-O
forms	I-O
and	O
psychomotor	B-O
tests	I-O
were	O
completed	O
,	O
and	O
miosis	B-O
was	O
assessed	O
,	O
during	O
and	O
after	O
the	O
infusions	O
.	O

In	O
addition	O
,	O
analgesia	B-O
was	O
tested	O
at	O
each	O
dose	O
level	O
using	O
a	B-O
cold	I-O
-	I-O
pressor	I-O
test	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Genotyping	O
of	O
CYP21	O
,	O
linked	O
chromosome	O
6p	O
markers	O
,	O
and	O
a	O
sex	O
-	O
specific	O
gene	O
in	O
neonatal	O
screening	O
for	O
congenital	O
adrenal	O
hyperplasia	O
.	O

METHODS	O
:	O
Blood	B-I
-	I-I
impregnated	I-I
filter	I-I
papers	I-I
(	I-I
Guthrie	I-I
cards	I-I
)	I-I
from	O
603	O
randomly	O
chosen	O
New	O
Zealand	O
neonates	O
were	O
genotyped	O
blind	O
to	O
17	O
-	O
hydroxyprogesterone	O
(	O
17	O
-	O
OHP	O
)	O
levels	O
.	O

Another	O
50	O
samples	O
from	O
Swiss	O
and	O
North	O
American	O
infants	O
with	O
correlative	O
hormonal	O
data	O
were	O
also	O
genotyped	O
.	O

DNA	B-O
was	O
extracted	O
,	O
and	O
gene	B-O
-	I-O
specific	I-O
PCR	I-O
was	O
performed	O
.	O

CYP21	B-O
PCR	I-O
products	I-O
were	O
subjected	O
to	O
ligase	B-O
detection	I-O
reaction	I-O
,	O
simultaneously	O
analyzing	O
9	B-O
CYP21	I-O
mutations	I-O
;	O
PCR	B-O
products	I-O
of	O
other	O
genes	O
were	O
subjected	O
to	O
direct	B-O
gel	I-O
analysis	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Piperacillin	B-I
/	O
tazobactam	B-I
plus	O
tobramycin	B-I
versus	O
ceftazidime	B-C
plus	O
tobramycin	B-C
as	O
empiric	O
therapy	O
for	O
fever	O
in	O
severely	B-P
neutropenic	I-P
patients	I-P
.	O

METHODS	O
:	O
In	O
this	O
single	O
-	O
center	O
study	O
,	O
patients	B-P
who	I-P
experienced	I-P
a	I-P
total	I-P
of	I-P
247	I-P
febrile	I-P
episodes	I-P
were	O
prospectively	O
randomized	O
to	O
receive	O
either	O
our	O
standard	B-C
regimen	I-C
,	O
ceftazidime	B-C
3	O
g	O
/	O
day	O
(	O
1	O
g	O
t	O
.	O
i	O
.	O
d	O
.	O
)	O
plus	O
tobramycin	B-C
3	O
mg	O
/	O
kg	O
per	O
day	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
,	O
or	O
piperacillin	B-I
12	O
g	O
/	O
day	O
plus	O
tazobactam	B-I
1	O
.	O
5	O
g	O
/	O
day	O
(	O
4	O
g	O
+	O
0	O
.	O
5	O
g	O
t	O
.	O
i	O
.	O
d	O
.	O
)	O
plus	O
tobramycin	B-I
3	O
mg	O
/	O
kg	O
per	O
day	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
.	O

Vancomycin	O
was	O
added	O
in	O
all	O
cases	O
of	O
persistent	O
fever	O
in	O
the	O
ceftazidime	O
arm	O
,	O
but	O
only	O
when	O
there	O
was	O
microbiologically	O
documented	O
resistance	O
in	O
the	O
piperacillin	O
/	O
tazobactam	O
arm	O
.	O

-DOCSTART-	O

Title	O
:	O
Independent	O
prognostic	O
information	O
provided	O
by	O
sphygmomanometrically	B-I
determined	I-I
pulse	I-I
pressure	I-I
and	O
mean	B-I
arterial	I-I
pressure	I-I
in	O
patients	B-P
with	I-P
left	I-P
ventricular	I-P
dysfunction	I-P
.	O

METHODS	O
:	O
Pulse	B-I
and	O
mean	B-I
arterial	I-I
pressure	I-I
were	O
analyzed	O
for	O
their	O
effect	O
on	O
mortality	B-O
,	O
adjusting	O
for	O
other	O
modifiers	O
of	O
risk	O
,	O
using	O
Cox	O
proportional	O
hazards	O
regression	O
analysis	O
of	O
data	O
collected	O
from	O
6	B-P
,	I-P
781	I-P
patients	I-P
randomized	I-P
into	I-P
the	I-P
Studies	I-P
of	I-P
Left	I-P
Ventricular	I-P
Dysfunction	I-P
trials	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Rett	O
syndrome	O
:	O
randomized	O
controlled	O
trial	O
of	O
L	B-I
-	I-I
carnitine	I-I
.	O

METHODS	O
:	O
To	O
investigate	O
whether	O
L	B-I
-	I-I
carnitine	I-I
might	O
be	O
of	O
benefit	O
in	O
Rett	O
syndrome	O
,	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
crossover	O
trial	O
of	O
L	B-I
-	I-I
carnitine	I-I
has	O
been	O
completed	O
in	O
35	B-P
subjects	I-P
.	O

Eight	O
-	O
week	O
treatment	O
phases	O
were	O
completed	O
for	O
both	O
a	B-C
placebo	I-C
and	O
L	B-I
-	I-I
carnitine	I-I
.	O

Outcome	O
was	O
measured	O
by	O
parents	O
/	O
caregivers	O
and	O
at	O
medical	O
follow	O
-	O
up	O
using	O
three	O
established	O
tools	O
:	O
the	B-O
Rett	I-O
Syndrome	I-O
Motor	I-O
Behavioral	I-O
Assessment	I-O
,	O
the	B-O
Hand	I-O
Apraxia	I-O
Scale	I-O
,	O
and	O
the	B-O
Patient	I-O
Well	I-O
-	I-O
Being	I-O
Index	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Naltrexone	B-I
and	O
communication	O
skills	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
children	I-P
with	I-P
autism	I-P
,	I-P
3	I-P
.	I-P
0	I-P
to	I-P
8	I-P
.	I-P
3	I-P
years	I-P
old	I-P
(	I-P
mean	I-P
5	I-P
.	I-P
1	I-P
)	I-P
who	I-P
were	I-P
living	I-P
at	I-P
home	I-P
and	I-P
attending	I-P
appropriate	I-P
school	I-P
programs	I-P
,	O
participated	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
trial	O
.	O

Naltrexone	B-I
,	O
1	O
.	O
0	O
mg	O
/	O
kg	O
,	O
or	O
placebo	B-C
was	O
administered	O
daily	O
for	O
2	O
weeks	O
.	O

Communication	B-O
was	O
evaluated	O
from	O
videotaped	O
samples	O
of	O
seminaturalistic	O
parent	O
-	O
child	O
interaction	O
.	O

Child	B-O
and	O
parent	B-O
language	I-O
were	O
assessed	O
using	O
similar	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
term	O
response	O
to	O
therapy	O
of	O
chronic	O
anti	O
-	O
HBe	O
-	O
positive	O
hepatitis	O
B	O
is	O
poor	O
independent	O
of	O
type	O
and	O
schedule	O
of	O
interferon	O
.	O

METHODS	O
:	O
Seventy	B-P
-	I-P
two	I-P
consecutive	I-P
anti	I-P
-	I-P
HBe	I-P
-	I-P
positive	I-P
chronic	I-P
hepatitis	I-P
B	I-P
patients	I-P
(	I-P
59	I-P
male	I-P
and	I-P
13	I-P
female	I-P
,	I-P
median	I-P
age	I-P
41	I-P
yr	I-P
)	I-P
stratified	I-P
by	I-P
sex	I-P
and	I-P
histology	I-P
were	O
randomly	O
allocated	O
to	O
three	O
treatment	O
arms	O
.	O

Twenty	O
-	O
seven	O
patients	O
(	O
A	O
)	O
received	O
10	B-I
million	I-I
units	I-I
alpha	I-I
-	I-I
N1	I-I
IFN	I-I
i	O
.	O
m	O
.	O
t	O
.	O
w	O
.	O
for	O
24	O
wk	O
(	O
total	O
dose	O
:	O
720	O
million	O
units	O
)	O
;	O
21	O
(	O
B	O
)	O
received	O
9	B-I
million	I-I
units	I-I
alpha	I-I
-	I-I
2a	I-I
IFN	I-I
i	O
.	O
m	O
.	O
t	O
.	O
w	O
.	O
for	O
4	O
wk	O
,	O
followed	O
by	O
18	O
million	O
units	O
for	O
12	O
wk	O
and	O
9	O
million	O
units	O
for	O
8	O
wk	O
(	O
972	O
million	O
units	O
)	O
;	O
24	O
(	O
C	O
)	O
received	O
2	B-I
alpha	I-I
-	I-I
2a	I-I
IFN	I-I
courses	I-I
(	O
9	O
million	O
units	O
i	O
.	O
m	O
.	O
t	O
.	O
w	O
.	O
for	O
16	O
and	O
12	O
wk	O
separated	O
by	O
a	O
6	O
-	O
month	O
interval	O
[	O
756	O
million	O
units	O
]	O
)	O
.	O

Primary	O
response	O
was	O
defined	O
by	O
normal	B-O
ALT	I-O
and	O
serum	B-O
HBV	I-O
-	I-O
DNA	I-O
levels	I-O
below	I-O
10	I-O
pg	I-O
/	I-O
ml	I-O
at	O
the	O
end	O
of	O
therapy	O
and	O
sustained	B-O
response	I-O
by	I-O
normal	I-O
ALT	I-O
(	O
tested	O
monthly	O
)	O
,	O
undetectable	B-O
HBV	I-O
-	I-O
DNA	I-O
and	O
IgM	B-O
anti	I-O
-	I-O
HBc	I-O
(	O
<	O
7	O
I	O
.	O
U	O
.	O

Paul	O
Ehrlich	O
Institute	O
)	O
(	O
tested	O
every	O
3	O
months	O
)	O
during	O
the	O
posttreatment	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Adjuvant	B-I
L	I-I
-	I-I
arginine	I-I
treatment	O
for	O
in	O
-	O
vitro	O
fertilization	O
in	O
poor	O
responder	O
patients	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
34	I-P
patients	I-P
undergoing	I-P
assisted	I-P
reproduction	I-P
was	O
divided	O
in	O
two	O
groups	O
according	O
to	O
different	B-I
ovarian	I-I
stimulation	I-I
protocols	I-I
:	O
(	O
i	O
)	O
flare	B-I
-	I-I
up	I-I
gonadotrophin	I-I
-	I-I
releasing	I-I
hormone	I-I
analogue	I-I
(	I-I
GnRHa	I-I
)	I-I
plus	O
elevated	B-I
pure	I-I
follicle	I-I
stimulating	I-I
hormone	I-I
(	I-I
pFSH	I-I
)	I-I
(	O
n	O
=	O
17	O
)	O
;	O
and	O
(	O
ii	O
)	O
flare	B-I
-	I-I
up	I-I
GnRHa	I-I
plus	O
elevated	B-I
pFSH	I-I
plus	O
oral	B-I
L	I-I
-	I-I
arginine	I-I
(	O
n	O
=	O
17	O
)	O
.	O

During	O
the	B-I
ovarian	I-I
stimulation	I-I
regimen	I-I
,	O
the	O
patients	O
were	O
submitted	O
to	O
hormonal	B-O
(	O
oestradiol	B-O
and	O
growth	B-O
hormone	I-O
)	O
,	O
ultrasonographic	B-O
(	O
follicular	B-O
number	I-O
and	O
diameter	B-O
,	O
endometrial	B-O
thickness	I-O
)	O
and	O
Doppler	B-O
(	O
uterine	B-O
and	O
perifollicular	B-O
arteries	I-O
)	O
evaluations	O
.	O

Furthermore	O
,	O
the	B-O
plasma	I-O
and	O
follicular	B-O
fluid	I-O
concentrations	I-O
of	O
arginine	B-O
,	O
citrulline	B-O
,	O
nitrite	B-O
/	O
nitrate	B-O
(	B-O
NO2	I-O
-	I-O
/	O
NO3	B-O
-	I-O
)	I-O
,	O
and	O
insulin	B-O
-	I-O
like	I-O
growth	I-O
factor	I-O
-	I-O
1	I-O
(	I-O
IGF	I-O
-	I-O
1	I-O
)	I-O
were	O
assayed	O
.	O

-DOCSTART-	O

Title	O
:	O
Delineation	O
of	O
cryptogenic	O
Lennox	O
-	O
Gastaut	O
syndrome	O
and	O
myoclonic	O
astatic	O
epilepsy	O
using	O
multiple	B-I
correspondence	I-I
analysis	I-I
.	O

METHODS	O
:	O
We	O
applied	O
MCA	B-I
to	O
a	O
series	O
of	O
72	B-P
children	I-P
with	I-P
no	I-P
evidence	I-P
of	I-P
brain	I-P
damage	I-P
,	I-P
starting	I-P
epilepsy	I-P
between	I-P
1	I-P
and	I-P
10	I-P
years	I-P
,	I-P
with	I-P
two	I-P
or	I-P
more	I-P
types	I-P
of	I-P
generalised	I-P
seizures	I-P
.	O

We	O
excluded	O
patients	O
with	O
infantile	O
spasms	O
or	O
typical	O
absences	O
.	O

MCA	B-I
was	O
performed	O
on	O
all	B-O
clinical	I-O
and	O
EEG	B-O
parameters	I-O
,	O
first	O
throughout	O
follow	O
-	O
up	O
,	O
then	O
restricted	O
to	O
the	O
first	O
year	O
of	O
the	O
disease	O
.	O

-DOCSTART-	O

Title	O
:	O
Assessment	O
of	O
the	O
pain	O
of	O
blood	B-I
-	I-I
sugar	I-I
testing	I-I
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
Use	O
of	O
the	B-I
oral	I-I
neuraminidase	I-I
inhibitor	I-I
oseltamivir	I-I
in	O
experimental	O
human	O
influenza	O
:	O
randomized	O
controlled	O
trials	O
for	O
prevention	O
and	O
treatment	O
.	O

METHODS	O
:	O
Two	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trials	O
conducted	O
between	O
June	O
and	O
July	O
1997	O
.	O

Individual	O
hotel	O
rooms	O
;	O
2	O
large	O
US	O
university	O
medical	O
schools	O
.	O

A	B-P
total	I-P
of	I-P
117	I-P
healthy	I-P
adult	I-P
volunteers	I-P
(	I-P
aged	I-P
18	I-P
-	I-P
40	I-P
years	I-P
;	I-P
median	I-P
age	I-P
,	I-P
21	I-P
years	I-P
)	I-P
who	I-P
were	I-P
susceptible	I-P
(	I-P
hemagglutination	I-P
-	I-P
inhibition	I-P
antibody	I-P
titer	I-P
<	I-P
or	I-P
=1	I-P
:	I-P
8	I-P
)	I-P
.	O

All	O
subjects	O
were	O
inoculated	O
intranasally	O
with	O
influenza	O
A	O
/	O
Texas	O
/	O
36	O
/	O
91	O
(	O
H1N1	O
)	O
virus	O
.	O

For	O
the	O
prophylaxis	O
study	O
,	O
oral	B-I
oseltamivir	I-I
(	O
100	O
mg	O
once	O
daily	O
[	O
n	O
=	O
12	O
]	O
,	O
100	O
mg	O
twice	O
daily	O
[	O
n	O
=	O
12	O
]	O
,	O
or	O
matching	B-C
placebo	I-C
[	O
n	O
=	O
13	O
]	O
,	O
starting	O
26	O
hours	O
before	O
virus	O
inoculation	O
)	O
was	O
administered	O
.	O

For	O
the	O
treatment	O
study	O
,	O
the	O
same	O
drug	O
was	O
given	O
(	O
20	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
twice	O
daily	O
,	O
200	O
mg	O
once	O
daily	O
,	O
or	O
matching	B-C
placebo	I-C
[	O
n	O
=	O
16	O
]	O
,	O
in	O
each	O
group	O
starting	O
28	O
hours	O
after	O
inoculation	O
)	O
.	O

All	O
regimens	O
were	O
continued	O
for	O
5	O
days	O
.	O

Comparing	O
placebo	B-C
groups	O
with	O
pooled	O
treatment	O
groups	O
,	O
for	O
prophylaxis	O
,	O
outcomes	O
included	O
frequency	B-O
of	I-O
infection	I-O
and	O
viral	B-O
shedding	I-O
;	O
for	O
treatment	O
,	O
viral	B-O
shedding	I-O
in	I-O
titers	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Cholesterol	O
-	O
lowering	O
effect	O
of	O
stanol	B-I
ester	I-I
in	O
a	B-P
US	I-P
population	I-P
of	I-P
mildly	I-P
hypercholesterolemic	I-P
men	I-P
and	I-P
women	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
After	O
a	O
run	O
-	O
in	O
phase	O
,	O
318	B-P
subjects	I-P
were	O
randomized	O
to	O
receive	O
one	O
of	O
the	O
following	O
margarine	B-I
-	I-I
like	I-I
spreads	I-I
containing	I-I
stanol	I-I
ester	I-I
or	O
placebo	B-C
for	O
8	O
weeks	O
:	O
EU	O
3	O
G	O
:	O
1	B-I
g	I-I
of	I-I
stanol	I-I
(	O
ester	O
form	O
)	O
per	O
8	O
-	O
g	O
serving	O
of	O
a	O
European	O
formula	O
3	O
times	O
a	O
day	O
;	O
US	O
3	O
G	O
:	O
1	B-I
g	I-I
of	I-I
stanol	I-I
(	O
ester	O
form	O
)	O
per	O
8	O
-	O
g	O
serving	O
of	O
a	O
US	O
reformulation	O
3	O
times	O
a	O
day	O
;	O
US	O
2	O
G	O
:	O
0	B-I
.	I-I
67	I-I
g	I-I
of	I-I
stanol	I-I
(	O
ester	O
form	O
)	O
per	O
8	O
-	O
g	O
serving	O
of	O
a	O
US	O
reformulation	O
3	O
times	O
a	O
day	O
;	O
or	O
placebo	B-C
spread	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Randomised	O
controlled	O
trial	O
of	O
patient	O
triggered	B-I
and	O
conventional	B-C
fast	I-C
rate	I-C
ventilation	I-C
in	O
neonatal	O
respiratory	O
distress	O
syndrome	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
and	I-P
eighty	I-P
six	I-P
preterm	I-P
infants	I-P
with	I-P
birthweights	I-P
from	I-P
1000	I-P
to	I-P
2000	I-P
g	I-P
,	I-P
and	I-P
requiring	I-P
ventilation	I-P
for	I-P
respiratory	I-P
distress	I-P
syndrome	I-P
within	I-P
24	I-P
hours	I-P
of	I-P
birth	I-P
,	O
were	O
randomised	O
to	O
receive	O
either	O
conventional	B-C
or	O
trigger	B-I
ventilation	I-I
with	O
the	B-I
SLE	I-I
2000	I-I
ventilator	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Regression	O
of	O
left	O
ventricular	O
hypertrophy	O
after	O
stentless	B-I
versus	O
conventional	B-C
aortic	I-C
valve	I-C
replacement	I-C
.	O

METHODS	O
:	O
Stentless	B-I
(	O
Freestyle	O
,	O
Toronto	O
,	O
n	O
=	O
106	O
)	O
or	O
conventional	B-C
biological	I-C
aortic	I-C
valves	I-C
(	O
Carpentier	O
-	O
Edwards	O
,	O
n	O
=	O
74	O
)	O
were	O
evaluated	O
prospectively	O
.	O

-DOCSTART-	O

Title	O
:	O
Computer	B-I
-	I-I
assisted	I-I
instruction	I-I
:	O
an	O
effective	O
instructional	O
method	O
for	O
HIV	O
prevention	O
education	O
?	O
.	O

METHODS	O
:	O
Students	B-P
enrolled	I-P
in	I-P
a	I-P
Human	I-P
Sexuality	I-P
course	I-P
(	I-P
N	I-P
=	I-P
152	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
CAI	B-I
,	O
Lecture	B-I
,	O
or	O
No	B-C
Intervention	I-C
group	O
.	O

Participants	O
in	O
the	B-I
CAI	I-I
group	O
reviewed	O
a	B-I
1	I-I
-	I-I
hour	I-I
long	I-I
CAI	I-I
program	I-I
,	O
participants	O
in	O
the	B-I
Lecture	I-I
group	O
were	O
presented	O
with	O
a	O
1	B-I
-	I-I
hour	I-I
long	I-I
lecture	I-I
,	O
and	O
participants	O
in	O
the	B-C
No	I-C
Intervention	I-C
group	O
received	O
no	O
intervention	O
.	O

After	O
completing	O
the	O
respective	O
interventions	O
,	O
all	O
participants	O
completed	O
the	B-O
HIV	I-O
questionnaire	I-O
,	O
which	O
measured	O
selected	B-O
Social	I-O
Cognitive	I-O
Theory	I-O
constructs	I-O
associated	I-O
with	I-O
HIV	I-O
preventive	I-O
behaviors	I-O
.	O

MANCOVA	O
,	O
ANCOVA	O
and	O
Post	O
Hoc	O
analyses	O
were	O
utilized	O
to	O
test	O
for	O
significant	O
differences	O
among	O
the	O
three	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Photodynamic	B-I
therapy	I-I
with	I-I
5	I-I
-	I-I
aminolaevulinic	I-I
acid	I-I
or	O
placebo	B-C
for	O
recalcitrant	O
foot	O
and	O
hand	O
warts	O
:	O
randomised	O
double	O
-	O
blind	O
trial	O
.	O

METHODS	O
:	O
Recalcitrant	O
foot	O
and	O
hand	O
warts	O
were	O
randomly	O
assigned	O
to	O
six	O
repetitive	O
ALA	B-I
-	I-I
PDT	I-I
or	O
placebo	B-C
-	I-C
PDT	I-C
interventions	O
combined	O
with	O
standard	O
treatment	O
encompassing	O
paring	O
followed	O
by	O
a	O
keratolytic	O
(	O
Verucid	O
)	O
.	O

Standardised	B-O
photographs	I-O
of	I-O
each	I-O
wart	I-O
were	O
taken	O
before	O
,	O
during	O
(	O
week	O
7	O
)	O
and	O
after	O
treatment	O
(	O
weeks	O
14	O
and	O
18	O
)	O
.	O

The	B-O
area	I-O
of	I-O
each	I-O
wart	I-O
compared	I-O
with	I-O
entry	I-O
area	I-O
was	O
the	O
primary	O
outcome	O
variable	O
,	O
measured	O
from	O
photographs	B-O
by	O
an	O
evaluator	O
unaware	O
of	O
treatment	O
allocation	O
for	O
intervention	O
.	O

Pain	B-O
intensity	I-O
immediately	O
and	O
24	O
h	O
after	O
each	O
intervention	O
was	O
assessed	O
by	O
a	B-O
five	I-O
-	I-O
point	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Language	O
,	O
speech	O
sound	O
production	O
,	O
and	O
cognition	O
in	O
three	B-P
-	I-P
year	I-P
-	I-P
old	I-P
children	I-P
in	I-P
relation	I-P
to	I-P
otitis	I-P
media	I-P
in	I-P
their	I-P
first	I-P
three	I-P
years	I-P
of	I-P
life	I-P
.	O

METHODS	O
:	O
We	O
enrolled	O
6350	B-P
healthy	I-P
infants	I-P
by	I-P
2	I-P
months	I-P
of	I-P
age	I-P
who	I-P
presented	I-P
for	I-P
primary	I-P
care	I-P
at	I-P
1	I-P
of	I-P
2	I-P
urban	I-P
hospitals	I-P
or	I-P
1	I-P
of	I-P
2	I-P
small	I-P
town	I-P
/	I-P
rural	I-P
and	I-P
4	I-P
suburban	I-P
private	I-P
pediatric	I-P
practices	I-P
.	O

We	O
intensively	O
monitored	O
the	O
children	O
'	O
s	O
middle	O
ear	O
status	O
by	O
pneumatic	O
otoscopy	O
,	O
supplemented	O
by	O
tympanometry	O
,	O
throughout	O
their	O
first	O
3	O
years	O
of	O
life	O
;	O
we	O
monitored	O
the	O
validity	O
of	O
the	O
otoscopic	O
observations	O
on	O
an	O
ongoing	O
basis	O
;	O
and	O
we	O
treated	O
children	O
for	O
otitis	O
media	O
according	O
to	O
specified	O
guidelines	O
.	O

Children	O
who	O
met	O
specified	O
minimum	O
criteria	O
regarding	O
the	O
persistence	O
of	O
MEE	O
became	O
eligible	O
for	O
a	O
clinical	O
trial	O
in	O
which	O
they	O
were	O
assigned	O
randomly	O
to	O
undergo	O
tympanostomy	B-I
tube	I-I
placement	I-I
either	I-I
promptly	I-I
or	O
after	B-I
a	I-I
defined	I-I
extended	I-I
period	I-I
if	I-I
MEE	I-I
remained	I-I
present	I-I
.	O

From	O
among	O
those	O
remaining	O
,	O
we	O
selected	O
randomly	O
,	O
within	O
sociodemographic	O
strata	O
,	O
a	B-P
sample	I-P
of	I-P
241	I-P
children	I-P
who	I-P
represented	I-P
a	I-P
spectrum	I-P
of	I-P
MEE	I-P
experience	I-P
from	O
having	O
no	O
MEE	O
to	O
having	O
MEE	O
whose	O
cumulative	O
duration	O
fell	O
just	O
short	O
of	O
meeting	O
randomization	O
criteria	O
.	O

In	O
subjects	O
so	O
selected	O
,	O
the	O
estimated	O
duration	O
of	O
MEE	O
ranged	O
from	O
none	O
to	O
65	O
.	O
6	O
%	O
of	O
the	O
first	O
year	O
of	O
life	O
and	O
44	O
.	O
8	O
%	O
of	O
the	O
first	O
3	O
years	O
of	O
life	O
.	O

In	O
these	O
241	B-P
children	I-P
we	O
assessed	O
language	B-O
development	I-O
,	O
speech	B-O
sound	I-O
production	I-O
,	O
and	O
cognition	B-O
at	I-O
3	I-O
years	I-O
of	I-O
age	I-O
,	O
using	O
both	O
formal	B-O
tests	I-O
and	O
conversational	B-O
samples	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Does	O
waiting	B-I
matter	O
?	O
A	O
randomized	O
controlled	O
trial	O
of	O
new	B-I
non	I-I
-	I-I
urgent	I-I
rheumatology	I-I
out	I-I
-	I-I
patient	I-I
referrals	I-I
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
randomized	O
controlled	O
clinical	O
study	O
evaluating	O
a	B-I
'	I-I
fast	I-I
track	I-I
'	I-I
appointment	I-I
with	O
a	O
6	O
-	O
week	O
target	O
waiting	O
time	O
against	O
an	B-C
'	I-C
ordinary	I-C
'	I-C
appointment	I-C
in	O
the	O
main	O
city	O
out	O
-	O
patient	O
clinic	O
of	O
the	O
rheumatology	O
service	O
for	O
the	O
Lothian	O
and	O
Borders	O
region	O
(	O
population	O
approximately	O
1	O
million	O
)	O
.	O

Health	B-O
status	I-O
was	O
measured	O
using	O
the	B-O
SF12	I-O
physical	I-O
and	O
mental	B-O
summary	I-O
component	I-O
T	B-O
-	I-O
scores	I-O
and	O
pain	B-O
was	O
measured	O
with	O
a	B-O
100	I-O
mm	I-O
visual	I-O
analogue	I-O
pain	I-O
scale	I-O
.	O

Secondary	O
outcomes	O
were	O
health	B-O
utility	I-O
and	O
perceived	B-O
health	I-O
both	O
measured	O
with	O
the	B-O
EuroQol	I-O
instrument	I-O
,	O
mental	B-O
health	I-O
measured	O
with	O
the	B-O
Hospital	I-O
Anxiety	I-O
and	I-O
Depression	I-O
scale	I-O
,	O
disability	B-O
with	O
the	B-O
modified	I-O
Health	I-O
Assessment	I-O
Questionnaire	I-O
and	O
economic	B-O
costs	I-O
measured	O
from	O
a	B-O
societal	I-O
perspective	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Epirubicin	B-I
-	I-I
based	I-I
chemotherapy	I-I
in	O
metastatic	B-P
breast	I-P
cancer	I-P
patients	I-P
:	O
role	O
of	O
dose	O
-	O
intensity	O
and	O
duration	O
of	O
treatment	O
.	O

METHODS	O
:	O
Four	B-P
hundred	I-P
seventeen	I-P
anthracycline	I-P
-	I-P
naive	I-P
MBC	I-P
patients	I-P
were	O
randomized	O
to	O
receive	O
one	O
of	O
the	O
following	O
regimens	O
:	O
arm	O
A	O
:	O
11	B-I
cycles	I-I
of	I-I
fluorouracil	I-I
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
epirubicin	B-I
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
and	O
cyclophosphamide	B-I
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
(	O
FEC	O
75	O
)	O
every	O
21	O
days	O
;	O
arm	O
B	O
:	O
four	B-I
cycles	I-I
of	I-I
FEC	I-I
100	I-I
(	O
same	O
regimen	O
but	O
with	O
epirubicin	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
then	O
eight	B-I
cycles	I-I
of	I-I
FEC	I-I
50	I-I
(	O
epirubicin	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
;	O
and	O
arm	O
C	O
:	O
four	B-I
cycles	I-I
of	I-I
FEC	I-I
100	I-I
then	O
restart	O
the	O
same	O
regimen	O
at	O
disease	O
progression	O
in	O
case	O
of	O
prior	O
response	O
or	O
stabilization	O
.	O

-DOCSTART-	O

Title	O
:	O
Beta	B-I
radiation	I-I
as	O
an	O
adjunct	O
to	O
low	O
-	O
risk	O
trabeculectomy	O
.	O

METHODS	O
:	O
A	O
prospective	O
randomized	O
trial	O
of	O
65	B-P
eyes	I-P
was	O
designed	O
,	O
with	O
31	O
eyes	O
receiving	O
750	B-I
rads	I-I
of	I-I
intraoperative	I-I
beta	I-I
radiation	I-I
(	O
group	O
1	O
)	O
,	O
and	O
34	O
eyes	O
receiving	O
no	B-C
supplementation	I-C
(	O
group	O
2	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Short	O
-	O
and	O
long	O
-	O
term	O
results	O
after	O
thrombolytic	B-I
treatment	I-I
of	O
deep	O
venous	O
thrombosis	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
250	I-P
patients	I-P
averaging	I-P
40	I-P
years	I-P
of	I-P
age	I-P
with	I-P
acute	I-P
DVT	I-P
were	O
randomized	O
into	O
five	O
groups	O
to	O
receive	O
full	O
heparinization	O
(	O
1	O
,	O
000	O
IU	O
/	O
h	O
)	O
and	O
compression	O
treatment	O
,	O
with	O
four	O
groups	O
also	O
administered	O
locoregional	B-I
tissue	I-I
plasminogen	I-I
activator	I-I
(	O
20	O
mg	O
/	O
day	O
)	O
or	O
urokinase	B-I
(	O
100	O
,	O
000	O
IU	O
/	O
day	O
)	O
or	O
systemic	B-I
streptokinase	I-I
(	O
3	O
,	O
000	O
,	O
000	O
IU	O
daily	O
)	O
or	O
urokinase	B-I
(	O
5	O
,	O
000	O
,	O
000	O
IU	O
daily	O
)	O
.	O

All	O
groups	O
then	O
received	O
anticoagulation	O
and	O
compression	O
treatment	O
for	O
one	O
year	O
.	O

Primary	O
efficacy	O
criteria	O
included	O
the	O
change	O
after	O
one	O
year	O
in	O
the	B-O
number	I-O
of	I-O
closed	I-O
vein	I-O
segments	I-O
and	O
the	B-O
occurrence	I-O
of	I-O
postthrombotic	I-O
syndrome	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
New	B-I
therapeutic	I-I
approaches	I-I
in	O
irritable	O
bowel	O
syndrome	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Complication	O
rate	O
after	O
gastrectomy	B-I
and	I-I
pouch	I-I
reconstruction	I-I
with	I-I
Longmire	I-I
interposition	I-I
]	O
.	O

METHODS	O
:	O
49	O
patients	O
who	O
underwent	O
gastrectomy	B-I
with	I-I
Longmire	I-I
-	I-I
Interposition	I-I
with	I-I
(	O
n	O
=	O
33	O
)	O
or	O
without	B-I
(	I-I
n	I-I
=	I-I
16	I-I
)	I-I
an	I-I
additional	I-I
pouch	I-I
and	O
46	O
patients	O
with	O
a	B-I
Roux	I-I
-	I-I
en	I-I
-	I-I
Y	I-I
-	I-I
reconstruction	I-I
were	O
analysed	O
retrospectively	O
.	O

Complication	B-O
rate	I-O
and	O
mortality	B-O
were	O
studied	O
.	O

-DOCSTART-	O

Title	O
:	O
Perioperative	B-I
blood	I-I
transfusions	I-I
,	I-I
with	I-I
or	O
without	B-I
allogeneic	I-I
leucocytes	I-I
,	O
relate	O
to	O
survival	O
,	O
not	O
to	O
cancer	O
recurrence	O
.	O

METHODS	O
:	O
Packed	B-I
red	I-I
cells	I-I
without	I-I
buffy	I-I
coat	I-I
(	O
PC	B-I
group	O
)	O
were	O
compared	O
with	O
filtered	B-I
,	I-I
leucoreduced	I-I
,	I-I
red	I-I
cells	I-I
(	O
LD	B-I
group	O
)	O
in	O
a	O
randomized	O
trial	O
of	O
697	B-P
patients	I-P
with	I-P
colorectal	I-P
carcinoma	I-P
.	O

Five	B-O
-	I-O
year	I-O
survival	I-O
and	O
cancer	B-O
recurrence	I-O
rates	I-O
were	O
determined	O
,	O
with	O
special	O
emphasis	O
on	O
the	B-O
location	I-O
of	I-O
recurrence	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Phase	O
-	O
dependent	O
modulation	O
of	O
the	B-I
soleus	I-I
H	I-I
-	I-I
reflex	I-I
during	O
rhythmical	O
arm	O
swing	O
in	O
humans	O
.	O

-DOCSTART-	O

Title	O
:	O
Interferential	B-I
therapy	I-I
electrode	I-I
placement	I-I
technique	I-I
in	O
acute	O
low	O
back	O
pain	O
:	O
a	O
preliminary	O
investigation	O
.	O

METHODS	O
:	O
Single	O
-	O
blind	O
,	O
randomized	O
,	O
controlled	O
trial	O
with	O
a	O
3	O
-	O
month	O
follow	O
-	O
up	O
.	O

Outpatient	O
physiotherapy	O
departments	O
in	O
hospital	O
and	O
university	O
settings	O
.	O

A	B-P
random	I-P
sample	I-P
of	I-P
60	I-P
eligible	I-P
patients	I-P
with	I-P
back	I-P
pain	I-P
(	I-P
28	I-P
men	I-P
,	I-P
32	I-P
women	I-P
)	I-P
were	O
recruited	O
by	O
general	O
practitioners	O
and	O
self	O
-	O
referral	O
for	O
physiotherapy	O
treatment	O
and	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
groups	O
.	O

(	O
1	O
)	O
"	O
IFT	B-I
painful	I-I
area	I-I
"	O
and	O
The	B-I
Back	I-I
Book	I-I
,	O
(	O
2	O
)	O
"	O
IFT	B-I
spinal	I-I
nerve	I-I
"	O
and	O
The	B-I
Back	I-I
Book	I-I
,	O
and	O
(	O
3	O
)	O
"	O
Control	O
,	O
"	O
The	B-C
Back	I-C
Book	I-C
only	I-C
.	O

Standardized	O
IFT	O
stimulation	O
parameters	O
were	O
used	O
:	O
carrier	O
frequency	O
3	O
.	O
85	O
kHz	O
;	O
140	O
Hz	O
constant	O
;	O
pulse	O
duration	O
130	O
micros	O
;	O
30	O
minutes	O
'	O
duration	O
.	O

Pain	B-O
Rating	I-O
Index	I-O
,	O
Roland	B-O
-	I-O
Morris	I-O
Disability	I-O
Questionnaire	I-O
(	I-O
RMDQ	I-O
)	I-O
,	O
and	O
EuroQol	B-O
were	O
completed	O
by	O
subjects	O
pretreatment	O
,	O
at	O
discharge	O
,	O
and	O
3	O
-	O
month	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparative	O
evaluation	O
of	O
calcium	B-I
hydroxide	I-I
and	O
zinc	B-I
oxide	I-I
eugenol	I-I
as	O
root	O
canal	O
filling	O
materials	O
for	O
primary	O
molars	O
:	O
a	O
clinical	O
and	O
radiographic	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
controlled	O
trial	O
assessing	O
the	O
health	O
economics	O
of	O
realtime	B-I
teledermatology	I-I
compared	O
with	O
conventional	B-C
care	I-C
:	O
an	O
urban	O
versus	O
rural	O
perspective	O
.	O

METHODS	O
:	O
One	O
urban	O
and	O
one	O
rural	O
health	O
centre	O
were	O
linked	O
to	O
a	O
regional	O
hospital	O
in	O
Northern	O
Ireland	O
by	O
ISDN	O
at	O
128	O
kbit	O
/	O
s	O
.	O

Over	O
two	O
years	O
,	O
274	B-P
patients	I-P
required	I-P
a	I-P
hospital	I-P
outpatient	I-P
dermatology	I-P
referral	I-P
-	I-P
-	I-P
126	I-P
patients	I-P
(	I-P
46	I-P
%	I-P
)	I-P
were	O
randomized	O
to	O
a	B-I
telemedicine	I-I
consultation	I-I
and	O
148	O
(	O
54	O
%	O
)	O
to	O
a	B-C
conventional	I-C
hospital	I-C
outpatient	I-C
consultation	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
and	O
microbial	O
evaluation	O
of	O
a	B-I
histatin	I-I
-	I-I
containing	I-I
mouthrinse	I-I
in	O
humans	B-P
with	I-P
experimental	I-P
gingivitis	I-P
.	O

METHODS	O
:	O
159	B-P
periodontally	I-P
healthy	I-P
subjects	I-P
abstained	O
from	O
oral	O
hygiene	O
procedures	O
and	O
self	O
-	O
administered	O
either	O
0	B-I
.	I-I
005	I-I
%	I-I
,	O
0	B-I
.	I-I
01	I-I
%	I-I
,	O
0	B-I
.	I-I
05	I-I
%	I-I
P	I-I
-	I-I
113	I-I
or	O
placebo	B-C
mouthrinse	I-C
formulations	I-C
twice	O
daily	O
over	O
a	O
four	O
week	O
treatment	O
period	O
.	O

During	O
this	O
time	O
,	O
the	B-O
safety	I-O
,	O
anti	B-O
-	I-O
plaque	I-O
,	O
and	O
anti	B-O
-	I-O
gingivitis	I-O
effects	I-O
of	I-O
P	I-O
-	I-O
113	I-O
were	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
L	B-I
-	I-I
arginine	I-I
and	O
S	B-I
-	I-I
nitrosoglutathione	I-I
reduce	O
embolization	O
in	O
humans	O
.	O

-DOCSTART-	O

Title	O
:	O
"	O
Confirmatory	O
"	O
trials	O
:	O
symptom	O
reduction	O
as	O
efficacy	O
measure	O
.	O

-DOCSTART-	O

Title	O
:	O
Immune	O
reconstitution	O
after	O
allogeneic	B-I
marrow	I-I
transplantation	I-I
compared	O
with	O
blood	B-I
stem	I-I
cell	I-I
transplantation	I-I
.	O

METHODS	O
:	O
Immune	B-O
reconstitution	I-O
was	O
studied	O
in	O
115	B-P
patients	I-P
randomly	O
assigned	O
to	O
receive	O
either	O
allogeneic	B-I
marrow	I-I
or	O
filgrastim	B-I
-	I-I
mobilized	I-I
blood	I-I
stem	I-I
cell	I-I
transplantation	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
tolerability	O
of	O
antibiotics	B-I
in	O
patients	B-P
undergoing	I-P
H	I-P
.	I-P
pylori	I-P
eradication	I-P
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
ninety	I-P
-	I-P
three	I-P
(	I-P
193	I-P
)	I-P
H	I-P
.	I-P
pylori	I-P
-	I-P
positive	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
following	O
7	O
-	O
day	O
treatments	O
:	O
Group	O
A	O
(	O
N	O
=	O
64	O
)	O
:	O
amoxicillin	B-I
,	O
clarithromycin	B-I
and	O
rabeprazole	B-I
;	O
Group	O
B	O
(	O
N	O
=	O
64	O
)	O
:	O
tinidazole	B-I
,	O
clarithromycin	B-I
and	O
ranitidine	B-I
bismuth	I-I
citrate	I-I
;	O
Group	O
C	O
(	O
N	O
=	O
65	O
)	O
:	O
tinidazole	B-I
,	O
clarithromycin	B-I
and	O
rabeprazole	B-I
Eradication	B-O
was	O
assessed	O
by	O
13C	B-O
-	I-O
Urea	I-O
Breath	I-O
Test	I-O
6	O
-	O
8	O
weeks	O
after	O
the	O
end	O
of	O
the	O
therapy	O
.	O

Not	O
-	O
eradicated	O
patients	O
underwent	O
a	O
second	O
cycle	O
with	O
tinidazole	B-I
,	O
tetracycline	B-I
,	O
bismuth	B-I
and	O
rabeprazole	B-I
.	O

All	O
patients	O
were	O
asked	O
to	O
complete	O
a	B-O
validated	I-O
questionnaire	I-O
regarding	O
presence	B-O
and	O
intensity	B-O
of	I-O
drug	I-O
side	I-O
effects	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Rehabilitation	O
outcomes	O
following	O
percutaneous	B-I
coronary	I-I
interventions	I-I
(	I-I
PCI	I-I
)	I-I
.	O

METHODS	O
:	O
Data	B-O
were	O
collected	O
at	O
time	O
1	O
(	O
T	O
(	O
1	O
)	O
)	O
during	O
hospital	B-O
admission	I-O
,	O
time	O
2	O
(	O
T	O
(	O
2	O
)	O
)	O
approximately	O
2	O
months	O
post	O
-	O
PCI	B-I
,	O
and	O
time	O
3	O
(	O
T	O
(	O
3	O
)	O
)	O
approximately	O
12	O
months	O
post	O
-	O
PCI	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Is	O
psychotherapy	O
more	O
effective	O
when	O
therapists	O
disclose	O
information	B-I
about	I-I
themselves	I-I
?	O
.	O

METHODS	O
:	O
To	O
test	O
these	O
competing	O
positions	O
,	O
therapists	B-P
at	I-P
a	I-P
university	I-P
counseling	I-P
center	I-P
were	O
instructed	O
to	O
increase	O
the	B-I
number	I-I
of	I-I
self	I-I
-	I-I
disclosures	I-I
they	O
made	O
during	O
treatment	O
of	O
one	O
client	O
and	O
refrain	O
from	O
making	O
self	B-I
-	I-I
disclosures	I-I
during	O
treatment	O
of	O
another	O
client	O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
a	B-I
new	I-I
computer	I-I
intervention	I-I
to	O
teach	O
people	B-P
with	I-P
autism	I-P
or	I-P
Asperger	I-P
syndrome	I-P
to	O
recognize	O
and	O
predict	O
emotions	O
in	O
others	O
.	O

METHODS	O
:	O
Two	B-P
groups	I-P
of	I-P
11	I-P
children	I-P
(	I-P
age	I-P
12	I-P
-	I-P
18	I-P
)	I-P
with	I-P
autism	I-P
or	I-P
Asperger	I-P
syndrome	I-P
at	I-P
two	I-P
special	I-P
schools	I-P
participated	O
:	O
one	O
group	O
used	O
the	B-I
computer	I-I
program	I-I
for	O
10	O
half	O
-	O
hour	O
sessions	O
over	O
2	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Pharmacokinetic	O
study	O
of	O
human	B-I
immunodeficiency	I-I
virus	I-I
protease	I-I
inhibitors	I-I
used	O
in	O
combination	O
with	O
amprenavir	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Prognostic	O
significance	O
of	O
the	B-I
dobutamine	I-I
echocardiography	I-I
test	I-I
in	O
idiopathic	O
dilated	O
cardiomyopathy	O
.	O

METHODS	O
:	O
From	O
February	O
1	O
,	O
1997	O
,	O
to	O
October	O
1	O
,	O
1999	O
,	O
186	B-P
patients	I-P
(	I-P
131	I-P
men	I-P
and	I-P
55	I-P
women	I-P
,	I-P
mean	I-P
age	I-P
56	I-P
+	I-P
/	I-P
-	I-P
12	I-P
years	I-P
)	I-P
with	I-P
IDC	I-P
,	I-P
ejection	I-P
fraction	I-P
<	I-P
35	I-P
%	I-P
,	I-P
and	I-P
angiographically	I-P
normal	I-P
coronary	I-P
arteries	I-P
were	O
studied	O
by	O
high	B-I
-	I-I
dose	I-I
(	I-I
up	I-I
to	I-I
40	I-I
micro	I-I
/	I-I
kg	I-I
/	I-I
min	I-I
)	I-I
dobutamine	I-I
echo	I-I
in	O
6	O
centers	O
,	O
all	O
quality	O
controlled	O
for	O
stress	O
echo	O
reading	O
.	O

-DOCSTART-	O

Title	O
:	O
Pacifier	B-I
as	O
a	O
risk	O
factor	O
for	O
acute	O
otitis	O
media	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
oxolamine	B-I
on	O
cough	O
sensitivity	O
in	O
COPD	B-P
patients	I-P
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
application	O
of	O
irradiated	B-I
drug	I-I
-	I-I
containing	I-I
porcine	I-I
-	I-I
cornea	I-I
to	O
patients	B-P
with	I-P
ocular	I-P
burns	I-P
]	O
.	O

METHODS	O
:	O
Fifty	B-P
-	I-P
five	I-P
cases	I-P
of	I-P
patients	I-P
with	I-P
ocular	I-P
burns	I-P
(	I-P
in	I-P
88	I-P
eyes	I-P
)	I-P
were	O
randomly	O
divided	O
into	O
treatment	O
and	O
control	O
groups	O
.	O

Thirty	O
cases	O
in	O
treatment	O
group	O
with	O
49	O
eyes	O
were	O
transplanted	O
with	O
irradiated	B-I
drug	I-I
-	I-I
containing	I-I
(	I-I
ofloxacin	I-I
,	I-I
acetyl	I-I
cysteine	I-I
and	I-I
reduced	I-I
glutathione	I-I
)	I-I
porcine	I-I
-	I-I
cornea	I-I
.	O

25	O
cases	O
in	O
control	O
group	O
with	O
39	O
eyes	O
were	O
treated	O
with	O
routine	B-C
program	I-C
.	O

-DOCSTART-	O

Title	O
:	O
The	O
interaction	O
between	O
propofol	B-I
and	O
clonidine	B-I
for	O
loss	O
of	O
consciousness	O
.	O

Clonidine	O
premedication	O
reduces	O
the	O
intraoperative	O
requirement	O
for	O
opioids	O
and	O
volatile	O
anesthetics	O
.	O

Clonidine	O
also	O
reduces	O
the	O
induction	O
dose	O
of	O
IV	O
anesthetics	O
.	O

There	O
is	O
no	O
information	O
,	O
however	O
,	O
regarding	O
the	O
effect	O
of	O
oral	O
clonidine	O
premedication	O
on	O
the	O
propofol	O
blood	O
concentrations	O
required	O
for	O
loss	O
of	O
consciousness	O
,	O
and	O
the	O
interaction	O
between	O
propofol	O
and	O
clonidine	O
.	O

We	O
randomly	O
administered	O
target	O
effect	O
-	O
site	O
concentrations	O
of	O
propofol	O
ranging	O
from	O
0	O
.	O
5	O
to	O
5	O
.	O

0	O
microg	O
/	O
mL	O
by	O
using	O
computer	O
-	O
assisted	O
target	O
-	O
controlled	O
infusion	O
to	O
3	O
groups	O
of	O
healthy	O
male	O
patients	O
:	O
Control	O
(	O
n	O
=	O
35	O
)	O
,	O
2	O
.	O
5	O
microg	O
/	O
kg	O
Clonidine	O
(	O
n	O
=	O
36	O
)	O
,	O
and	O
5	O
.	O
0	O
microg	O
/	O
kg	O
Clonidine	O
(	O
n	O
=	O
36	O
)	O
groups	O
.	O

Nothing	O
was	O
administered	O
to	O
the	O
Control	O
group	O
.	O

Clonidine	O
(	O
2	O
.	O
5	O
or	O
5	O
.	O
0	O
microg	O
/	O
kg	O
)	O
was	O
administered	O
orally	O
90	O
min	O
before	O
the	O
induction	O
of	O
anesthesia	O
in	O
the	O
Clonidine	O
groups	O
.	O

After	O
equilibration	O
between	O
the	O
blood	O
and	O
effect	O
-	O
site	O
for	O
15	O
min	O
,	O
a	O
verbal	O
command	O
to	O
open	O
their	O
eyes	O
was	O
given	O
two	O
times	O
to	O
the	O
patients	O
.	O

Arterial	O
blood	O
samples	O
for	O
analysis	O
of	O
the	O
serum	O
propofol	O
and	O
clonidine	O
concentrations	O
were	O
taken	O
immediately	O
before	O
verbal	O
commands	O
were	O
given	O
.	O

Measured	O
serum	O
propofol	O
concentrations	O
in	O
equilibrium	O
with	O
the	O
effect	O
-	O
site	O
at	O
which	O
50	O
%	O
of	O
the	O
patients	O
did	O
not	O
respond	O
to	O
verbal	O
commands	O
(	O
EC50	O
for	O
loss	O
of	O
consciousness	O
)	O
were	O
determined	O
by	O
logistic	O
regression	O
.	O

The	O
EC50	O
+	O
/	O
-	O
SE	O
values	O
in	O
the	O
Control	O
,	O
2	O
.	O
5	O
microg	O
/	O
kg	O
Clonidine	O
,	O
and	O
5	O
.	O
0	O
microg	O
/	O
kg	O
Clonidine	O
groups	O
were	O
2	O
.	O
67	O
+	O
/	O
-	O
0	O
.	O
18	O
,	O
1	O
.	O
31	O
+	O
/	O
-	O
0	O
.	O
12	O
,	O
and	O
0	O
.	O
91	O
+	O
/	O
-	O
0	O
.	O
13	O
microg	O
/	O
mL	O
,	O
respectively	O
.	O

The	O
EC50	O
in	O
the	O
2	O
.	O
5	O
and	O
5	O
.	O
0	O
microg	O
/	O
kg	O
clonidine	O
groups	O
was	O
significantly	O
smaller	O
than	O
that	O
in	O
the	O
Control	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
use	O
of	O
a	O
response	O
surface	O
modeling	O
analysis	O
indicated	O
that	O
there	O
was	O
an	O
additive	O
interaction	O
between	O
measured	O
arterial	O
propofol	O
and	O
clonidine	O
concentrations	O
in	O
relation	O
to	O
loss	O
of	O
consciousness	O
.	O

These	O
results	O
indicate	O
that	O
propofol	O
and	O
clonidine	O
act	O
additively	O
for	O
loss	O
of	O
consciousness	O
.	O

-DOCSTART-	O

Title	O
:	O
Short	B-I
-	I-I
term	I-I
intravenous	I-I
antibiotic	I-I
treatment	I-I
of	O
acute	O
hematogenous	O
bone	O
and	O
joint	O
infection	O
in	O
children	O
:	O
a	O
prospective	O
randomized	O
trial	O
.	O

METHODS	O
:	O
The	O
treatment	O
outcome	O
was	O
measured	O
through	O
a	B-O
detailed	I-O
scoring	I-O
system	I-O
that	O
included	O
the	O
ability	O
to	O
eradicate	O
infection	O
,	O
the	O
functional	O
status	O
of	O
the	O
limb	O
,	O
and	O
the	O
radiographic	O
appearance	O
of	O
the	O
bone	O
and	O
joint	O
.	O

-DOCSTART-	O

Title	O
:	O
Oat	B-I
ingestion	I-I
reduces	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
in	O
patients	B-P
with	I-P
mild	I-P
or	I-P
borderline	I-P
hypertension	I-P
:	O
a	O
pilot	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
controlled	O
,	O
parallel	O
-	O
group	O
pilot	O
study	O
designed	O
to	O
compare	O
an	B-I
oat	I-I
cereal	I-I
group	O
(	O
standardized	O
to	O
5	O
.	O
52	O
g	O
/	O
day	O
beta	O
-	O
glucan	O
)	O
to	O
a	B-C
low	I-C
-	I-C
fiber	I-C
cereal	I-C
control	O
group	O
(	O
less	O
than	O
1	O
.	O
0	O
g	O
/	O
day	O
total	O
fiber	O
)	O
over	O
6	O
weeks	O
.	O

A	B-P
total	I-P
of	I-P
18	I-P
hypertensive	I-P
and	I-P
hyperinsulinemic	I-P
(	I-P
=	I-P
10	I-P
U	I-P
/	I-P
mL	I-P
or	I-P
more	I-P
)	I-P
men	I-P
and	I-P
women	I-P
completed	O
the	O
trial	O
.	O

Primary	O
study	O
outcomes	O
were	O
changes	O
in	O
systolic	B-O
blood	I-O
pressure	I-O
(	I-O
SBP	I-O
)	I-O
and	O
diastolic	B-O
blood	I-O
pressure	I-O
(	I-O
DBP	I-O
)	I-O
.	O

Secondary	O
outcomes	O
included	O
blood	B-O
lipid	I-O
,	O
fasting	B-O
glucose	I-O
,	O
and	O
insulin	B-O
levels	I-O
and	O
side	B-O
effects	I-O
related	O
to	O
elevated	B-O
blood	I-O
pressure	I-O
and	O
increased	B-O
dietary	I-O
fiber	I-O
intake	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Prolonged	B-I
GnRH	I-I
agonist	I-I
and	O
add	B-I
-	I-I
back	I-I
therapy	I-I
for	O
symptomatic	O
endometriosis	O
:	O
long	O
-	O
term	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
post	O
-	O
treatment	O
follow	O
-	O
up	O
analysis	O
of	O
a	O
randomized	O
,	O
double	O
-	O
masked	O
,	O
placebo	O
-	O
controlled	O
52	O
-	O
week	O
trial	O
.	O

All	O
patients	O
had	O
received	O
monthly	O
leuprolide	O
acetate	O
and	O
were	O
randomized	O
to	O
one	O
of	O
four	O
groups	O
:	O
A	O
-	O
daily	B-C
placebo	I-C
;	O
B	O
-	O
daily	B-I
norethindrone	I-I
acetate	I-I
5	O
mg	O
;	O
C	O
-	O
daily	B-I
norethindrone	I-I
acetate	I-I
5	O
mg	O
and	O
conjugated	B-I
equine	I-I
estrogens	I-I
0	O
.	O
625	O
mg	O
;	O
and	O
D	O
-	O
daily	B-I
norethindrone	I-I
acetate	I-I
5	O
mg	O
and	O
conjugated	B-I
equine	I-I
estrogens	I-I
1	O
.	O
25	O
mg	O
.	O

Of	O
201	B-P
patients	I-P
enrolled	I-P
in	I-P
the	I-P
initial	I-P
trial	I-P
,	I-P
123	I-P
completed	I-P
at	I-P
least	I-P
280	I-P
days	I-P
of	I-P
therapy	I-P
and	I-P
entered	I-P
the	I-P
follow	I-P
-	I-P
up	I-P
period	I-P
.	O

Physical	B-O
findings	I-O
and	O
symptoms	B-O
were	O
quantified	O
,	O
and	O
lumbar	B-O
spine	I-O
bone	I-O
mineral	I-O
density	I-O
was	O
determined	O
at	O
intervals	O
for	O
up	O
to	O
12	O
and	O
24	O
months	O
post	O
-	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
Lack	O
of	O
benefit	O
of	O
an	B-I
active	I-I
pectoral	I-I
pulse	I-I
generator	I-I
on	O
atrial	O
defibrillation	O
thresholds	O
.	O

-DOCSTART-	O

Title	O
:	O
Do	O
colonic	O
short	O
-	O
chain	O
fatty	O
acids	O
contribute	O
to	O
the	O
long	O
-	O
term	O
adaptation	O
of	O
blood	O
lipids	O
in	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
consuming	O
a	B-I
high	I-I
-	I-I
fiber	I-I
diet	I-I
?	O
.	O

METHODS	O
:	O
Subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
(	I-P
n	I-P
=	I-P
62	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
approximately	O
10	O
%	O
of	O
energy	O
from	O
low	B-I
-	I-I
fiber	I-I
breakfast	I-I
cereal	I-I
(	I-I
LF	I-I
diet	I-I
)	I-I
,	O
high	B-I
-	I-I
fiber	I-I
breakfast	I-I
cereal	I-I
(	I-I
HF	I-I
diet	I-I
)	I-I
,	O
or	O
monounsaturated	B-I
fatty	I-I
acids	I-I
(	I-I
MUFA	I-I
diet	I-I
)	I-I
for	O
6	O
mo	O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
different	O
platelet	B-I
glycoprotein	I-I
IIb	I-I
/	I-I
IIIa	I-I
receptor	I-I
inhibitors	I-I
among	O
diabetic	B-P
patients	I-P
undergoing	I-P
percutaneous	I-P
coronary	I-P
intervention	I-P
:	O
:	O
Do	O
Tirofiban	B-I
and	O
ReoPro	B-I
Give	O
Similar	O
Efficacy	O
Outcomes	O
Trial	O
(	O
TARGET	O
)	O
1	O
-	O
year	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Superior	O
survival	O
with	O
capecitabine	B-I
plus	I-I
docetaxel	I-I
combination	I-I
therapy	I-I
in	O
anthracycline	B-P
-	I-P
pretreated	I-P
patients	I-P
with	I-P
advanced	I-P
breast	I-P
cancer	I-P
:	O
phase	O
III	O
trial	O
results	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
to	O
21	B-I
-	I-I
day	I-I
cycles	I-I
of	I-I
oral	I-I
capecitabine	I-I
1	O
,	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
twice	O
daily	O
on	O
days	O
1	O
to	O
14	O
plus	O
docetaxel	B-I
75	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
255	O
)	O
or	O
to	O
docetaxel	B-I
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
256	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Heparan	B-I
sulfate	I-I
in	O
the	O
treatment	O
of	O
intermittent	O
claudication	O
:	O
results	O
of	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
doubleblind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
,	O
performed	O
in	O
24	O
Italian	O
centers	O
.	O

Two	B-P
hundred	I-P
seventeen	I-P
patients	I-P
with	I-P
intermittent	I-P
claudication	I-P
(	I-P
stages	I-P
IIa	I-P
and	I-P
IIb	I-P
of	I-P
Fontaine	I-P
'	I-P
s	I-P
PAD	I-P
classification	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
heparan	B-I
sulfate	I-I
(	O
40	O
mg	O
orally	O
twice	O
a	O
day	O
)	O
or	O
placebo	B-C
for	O
6	O
months	O
.	O

The	O
primary	O
end	O
-	O
point	O
was	O
an	B-O
increase	I-O
in	I-O
pain	I-O
-	I-O
free	I-O
walking	I-O
distance	I-O
[	O
initial	B-O
claudication	I-O
distance	I-O
(	I-O
ICD	I-O
)	I-O
]	O
during	O
the	O
24	O
weeks	O
of	O
treatment	O
.	O

The	B-O
pain	I-O
-	I-O
free	I-O
and	O
the	B-O
absolute	I-O
walking	I-O
distance	I-O
(	I-O
ACD	I-O
)	I-O
were	O
monitored	O
by	O
standardized	B-O
treadmill	I-O
test	I-O
at	O
baseline	O
and	O
at	O
4	O
,	O
12	O
and	O
24	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
valociclovir	B-I
hydrochloride	I-I
on	O
patients	B-P
with	I-P
herpes	I-P
zoster	I-P
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Marimastat	B-I
as	O
maintenance	O
therapy	O
for	O
patients	B-P
with	I-P
advanced	I-P
gastric	I-P
cancer	I-P
:	O
a	O
randomised	O
trial	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
and	I-P
sixty	I-P
-	I-P
nine	I-P
patients	I-P
with	I-P
histological	I-P
proof	I-P
of	I-P
adenocarcinoma	I-P
,	O
who	O
had	O
received	O
no	O
more	O
than	O
a	O
single	O
regimen	O
of	O
5	O
-	O
fluorouracil	O
-	O
based	O
chemotherapy	O
,	O
were	O
randomised	O
to	O
receive	O
either	O
marimastat	B-I
(	O
10	O
mg	O
b	O
.	O
d	O
.	O
)	O
or	O
placebo	B-C
.	O

Patients	O
were	O
treated	O
for	O
as	O
long	O
as	O
was	O
tolerable	O
.	O

The	O
primary	O
endpoint	O
was	O
overall	B-O
survival	I-O
with	O
secondary	O
endpoints	O
of	O
time	B-O
to	I-O
disease	I-O
progression	I-O
and	O
quality	B-O
of	I-O
life	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Overexpression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
cellular	O
receptor	O
KDR	O
(	O
VEGFR	O
-	O
2	O
)	O
in	O
the	O
bone	O
marrow	O
of	O
patients	B-P
with	I-P
acute	I-P
myeloid	I-P
leukemia	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Pain	B-I
and	I-I
fatigue	I-I
management	I-I
:	O
results	O
of	O
a	O
nursing	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Chemotherapy	O
clinics	O
of	O
two	O
comprehensive	O
and	O
two	O
community	O
cancer	O
centers	O
.	O

Interviews	O
were	O
conducted	O
at	O
baseline	O
and	O
10	O
and	O
20	O
weeks	O
.	O

An	B-I
18	I-I
-	I-I
week	I-I
,	I-I
10	I-I
-	I-I
contact	I-I
nursing	I-I
intervention	I-I
utilizing	O
problem	B-I
-	I-I
solving	I-I
approaches	I-I
to	I-I
symptom	I-I
management	I-I
and	O
improving	B-I
physical	I-I
functioning	I-I
and	O
emotional	B-I
health	I-I
was	O
implemented	O
.	O

The	O
sample	O
consisted	O
of	O
53	O
patients	O
in	O
the	O
experimental	O
arm	O
and	O
60	O
in	O
the	O
control	O
arm	O
who	O
reported	O
pain	B-O
and	O
fatigue	B-O
at	O
baseline	O
.	O

Pain	B-O
and	O
fatigue	B-O
,	O
numbers	B-O
of	I-O
other	I-O
symptoms	I-O
,	O
and	O
physical	B-O
role	I-O
impact	I-O
and	O
social	B-O
-	I-O
functioning	I-O
subscales	I-O
from	O
the	B-O
Medical	I-O
Outcomes	I-O
Study	I-O
36	I-O
Short	I-O
Form	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
of	O
secretin	B-I
:	O
effects	O
on	O
aberrant	O
behavior	O
in	O
children	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
examined	O
the	O
effect	O
of	O
a	B-I
single	I-I
dose	I-I
of	I-I
synthetic	I-I
human	I-I
secretin	I-I
on	O
aberrant	B-O
behavior	I-O
.	O

Parent	O
and	O
teacher	O
data	O
from	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
for	O
eight	B-P
male	I-P
children	I-P
were	O
analyzed	O
for	O
reliable	O
change	O
in	O
a	O
clinical	O
replication	O
series	O
.	O

-DOCSTART-	O

Title	O
:	O
Monitoring	O
tumour	O
cells	O
in	O
the	O
peripheral	O
blood	O
of	O
small	B-P
cell	I-P
lung	I-P
cancer	I-P
patients	I-P
.	O

METHODS	O
:	O
Fresh	B-I
venous	I-I
blood	I-I
was	O
taken	O
throughout	O
treatment	O
and	O
follow	O
-	O
up	O
.	O

Aliquots	O
were	O
stained	O
with	O
a	B-I
"	I-I
tumour	I-I
-	I-I
specific	I-I
"	I-I
antibody	I-I
against	I-I
epithelial	I-I
tissue	I-I
(	I-I
Ber	I-I
EP4	I-I
)	I-I
,	O
verified	O
as	O
a	O
good	O
marker	O
of	O
SCLC	O
cells	O
by	O
immunohistochemistry	O
.	O

Matched	O
samples	O
labelled	O
with	O
Ber	O
EP4	O
were	O
separated	O
magnetically	O
by	O
adding	O
a	O
secondary	O
bead	O
-	O
antibody	O
conjugate	O
for	O
confirmation	O
of	O
tumour	B-O
cell	I-O
identity	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Oral	B-I
desensitization	I-I
in	O
papular	O
urticaria	O
in	O
children	O
.	O

METHODS	O
:	O
In	O
this	O
double	O
blind	O
placebo	O
controlled	O
study	O
,	O
an	B-I
oral	I-I
vaccine	I-I
prepared	O
from	O
insect	O
saliva	O
was	O
compared	O
with	O
placebo	B-C
(	I-C
stable	I-C
vaccine	I-C
solvent	I-C
)	I-C
.	O

Vaccine	B-I
and	O
placebo	B-C
effectiveness	B-O
were	O
tested	O
by	O
counting	O
active	B-O
PU	I-O
lesions	I-O
,	O
serum	B-O
eosinophils	I-O
,	O
and	O
IgE	B-O
,	O
before	O
and	O
after	O
4	O
months	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Combined	O
therapy	O
in	O
the	O
treatment	O
of	O
primary	O
mediastinal	O
B	O
-	O
cell	O
lymphoma	O
:	O
conventional	B-C
versus	O
escalated	B-I
chemotherapy	I-I
.	O

METHODS	O
:	O
From	O
1989	O
to	O
1997	O
,	O
68	B-P
patients	I-P
diagnosed	I-P
with	I-P
previously	I-P
untreated	I-P
PMBCL	I-P
,	I-P
aged	I-P
18	I-P
-	I-P
65	I-P
years	I-P
and	I-P
negative	I-P
for	I-P
immunodeficiency	I-P
virus	I-P
test	I-P
,	O
were	O
considered	O
candidates	O
to	O
receive	O
either	O
conventional	B-C
chemotherapy	I-C
with	I-C
CEOP	I-C
-	I-C
Bleo	I-C
(	O
cyclophosphamide	B-C
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
vincristine	B-C
1	O
.	O
4	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
prednisone	B-C
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
epirubicin	B-C
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
and	O
bleomycin	B-C
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
or	O
mega	B-I
CEOP	I-I
-	I-I
Bleo	I-I
(	O
cyclophosphamide	B-I
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
epirubicin	B-I
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
vincristine	B-I
,	O
prednisone	B-I
,	O
and	O
bleomycin	B-I
at	O
the	O
same	O
doses	O
)	O
every	O
21	O
days	O

for	O
six	O
cycles	O
,	O
followed	O
by	O
radiotherapy	B-I
to	I-I
the	I-I
mediastinum	I-I
with	O
the	B-I
mantle	I-I
technique	I-I
(	O
35	O
-	O
45	O
Gy	O
,	O
mean	O
38	O
Gy	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Home	B-I
sleep	I-I
studies	I-I
in	O
the	O
assessment	O
of	O
sleep	O
apnea	O
/	O
hypopnea	O
syndrome	O
.	O

METHODS	O
:	O
Prospective	O
case	O
study	O
.	O

The	O
sleep	O
-	O
disorders	O
unit	O
of	O
a	O
tertiary	O
referral	O
university	O
hospital	O
.	O

Fifty	B-P
-	I-P
five	I-P
patients	I-P
suspected	I-P
of	I-P
having	I-P
SAHS	I-P
and	I-P
living	I-P
within	I-P
30	I-P
km	I-P
of	I-P
our	I-P
laboratory	I-P
.	O

Patients	O
were	O
studied	O
first	O
in	O
their	O
homes	O
with	O
the	B-I
limited	I-I
sleep	I-I
-	I-I
recording	I-I
device	I-I
.	O

Polysomnography	B-I
was	O
performed	O
within	O
30	O
days	O
of	O
the	O
first	O
study	O
.	O

Both	O
studies	O
were	O
read	O
by	O
independent	O
investigators	O
blinded	O
to	O
the	O
results	O
of	O
the	O
other	O
study	O
.	O

Diagnoses	B-O
and	O
therapeutic	B-O
decisions	I-O
regarding	O
the	B-O
use	I-O
of	I-O
continuous	I-O
positive	I-O
airway	I-O
pressure	I-O
obtained	O
from	O
the	O
home	O
and	O
laboratory	O
studies	O
were	O
compared	O
.	O

Agreement	O
between	O
the	O
home	O
and	O
laboratory	O
study	O
recordings	O
was	O
also	O
assessed	O
using	O
receiver	B-O
operating	I-O
characteristic	I-O
(	I-O
ROC	I-O
)	I-O
curves	I-O
and	O
Bland	B-O
-	I-O
Altman	I-O
analysis	I-O
.	O

One	O
half	O
of	O
the	O
home	O
studies	O
were	O
randomly	O
assigned	O
to	O
be	O
performed	O
with	O
a	B-I
sleep	I-I
technician	I-I
'	I-I
s	I-I
set	I-I
up	I-I
of	I-I
the	I-I
equipment	I-I
in	I-I
the	I-I
patient	I-I
'	I-I
s	I-I
home	I-I
(	O
group	O
1	O
)	O
,	O
and	O
the	O
other	O
half	O
with	O
the	B-I
patient	I-I
'	I-I
s	I-I
own	I-I
setup	I-I
of	I-I
the	I-I
sleep	I-I
-	I-I
recording	I-I
device	I-I
(	O
group	O
2	O
)	O
,	O
after	O
an	O
instruction	O
period	O
in	O
the	O
hospital	O
.	O

An	O
economic	O
analysis	O
was	O
performed	O
,	O
considering	O
the	O
cost	O
of	O
repeating	O
studies	O
in	O
cases	O
with	O
faulty	O
or	O
inconclusive	O
home	O
studies	O
(	O
these	O
patients	O
should	O
undergo	O
polysomnography	O
as	O
a	O
second	O
step	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Transurethral	O
prostate	O
resection	O
and	O
bleeding	O
:	O
a	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
of	O
role	O
of	O
finasteride	B-I
for	O
decreasing	O
operative	O
blood	O
loss	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
70	I-P
patients	I-P
scheduled	I-P
to	I-P
undergo	I-P
elective	I-P
transurethral	I-P
prostate	I-P
resection	I-P
were	O
randomized	O
to	O
receive	O
5	B-I
mg	I-I
.	I-I

finasteride	I-I
daily	O
or	O
placebo	B-C
for	O
2	O
weeks	O
before	O
surgery	O
.	O

Serum	B-O
hemoglobin	I-O
was	O
measured	O
before	O
and	O
after	O
surgery	O
,	O
and	O
the	O
following	O
day	O
.	O

The	B-O
volume	I-O
of	I-O
irrigation	I-O
fluid	I-O
used	O
and	O
its	B-O
hemoglobin	I-O
concentration	I-O
as	O
well	O
as	B-O
resected	I-O
prostate	I-O
weight	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
vehicle	O
-	O
controlled	O
study	O
to	O
assess	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
for	O
the	O
treatment	O
of	O
multiple	O
actinic	O
keratoses	O
.	O

METHODS	O
:	O
Patients	O
in	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
vehicle	O
-	O
controlled	O
study	O
applied	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
or	O
vehicle	B-C
to	O
AK	O
lesions	O
3	O
times	O
per	O
week	O
for	O
a	O
maximum	O
of	O
12	O
weeks	O
or	O
until	O
lesions	O
had	O
resolved	O
.	O

In	O
the	O
event	O
of	O
an	O
adverse	O
reaction	O
,	O
application	O
of	O
imiquimod	B-I
was	O
reduced	O
to	O
1	O
or	O
2	O
times	O
per	O
week	O
.	O

Rest	O
periods	O
were	O
also	O
allowed	O
if	O
necessary	O
.	O

A	O
specialized	O
outpatient	O
dermatology	O
clinic	O
within	O
a	O
state	O
-	O
funded	O
hospital	O
in	O
Germany	O
.	O

The	O
study	O
population	O
was	O
aged	O
45	O
to	O
85	O
years	O
.	O

Of	O
52	O
patients	O
screened	O
,	O
36	B-P
men	I-P
and	I-P
women	I-P
with	I-P
AK	I-P
confirmed	I-P
by	I-P
histological	I-P
diagnosis	I-P
were	I-P
enrolled	I-P
.	O

Patients	O
were	O
excluded	O
from	O
the	O
study	O
if	O
they	O
did	O
not	O
have	O
a	O
histological	O
diagnosis	O
for	O
AK	O
,	O
if	O
they	O
were	O
older	O
than	O
85	O
years	O
,	O
or	O
if	O
they	O
did	O
not	O
comply	O
with	O
the	O
protocol	O
.	O

All	O
patients	O
had	O
responded	O
to	O
a	O
notice	O
asking	O
for	O
volunteers	O
.	O

The	B-O
number	I-O
and	O
appearance	B-O
of	I-O
lesions	I-O
were	O
evaluated	O
before	O
,	O
during	O
,	O
and	O
after	O
treatment	O
.	O

All	O
adverse	O
effects	O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Pharmacokinetics	O
of	O
azithromycin	B-I
in	O
lung	O
tissue	O
,	O
bronchial	O
washing	O
,	O
and	O
plasma	O
in	O
patients	B-P
given	I-P
multiple	I-P
oral	I-P
doses	I-P
of	I-P
500	I-P
and	I-P
1000	I-P
mg	I-P
daily	I-P
.	O

METHODS	O
:	O
Samples	O
were	O
taken	O
during	O
surgery	O
for	O
lung	O
resection	O
at	O
various	O
time	O
points	O
up	O
to	O
204	O
h	O
after	O
the	O
last	O
drug	O
dose	O
,	O
and	O
azithromycin	B-O
levels	I-O
were	O
analyzed	O
by	O
HPLC	B-O
method	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Treatment	O
effects	O
of	O
eptifibatide	B-I
in	O
planned	O
coronary	O
stent	O
implantation	O
in	O
patients	B-P
with	I-P
chronic	I-P
kidney	I-P
disease	I-P
(	O
ESPRIT	O
Trial	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
S	B-I
-	I-I
phase	I-I
kinase	I-I
-	I-I
associated	I-I
protein	I-I
2	I-I
expression	I-I
in	O
laryngeal	O
squamous	O
cell	O
carcinomas	O
and	O
its	O
prognostic	O
implications	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
a	B-O
potential	I-O
distribution	I-O
of	I-O
Skp2	I-O
in	I-O
LSCC	I-O
and	O
its	O
clinical	B-O
implications	I-O
was	O
investigated	O
by	O
an	O
immunohistochemical	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Sustained	O
ventricular	O
arrhythmias	O
and	O
mortality	O
among	O
patients	B-P
with	I-P
acute	I-P
myocardial	I-P
infarction	I-P
:	O
results	O
from	O
the	O
GUSTO	O
-	O
III	O
trial	O
.	O

METHODS	O
:	O
We	O
identified	O
independent	B-O
predictors	I-O
of	I-O
inhospital	I-O
ventricular	I-O
fibrillation	I-O
(	I-O
VF	I-O
)	I-O
and	O
ventricular	B-O
tachycardia	I-O
(	I-O
VT	I-O
)	I-O
and	O
compared	O
30	O
-	O
day	O
and	O
1	O
-	O
year	O
mortality	B-O
rates	I-O
of	O
patients	O
who	O
did	O
(	O
n	O
=	O
1121	O
)	O
and	O
did	O
not	O
(	O
n	O
=	O
13	O
,	O
921	O
)	O
have	O
these	O
arrhythmias	O
during	O
the	O
index	O
hospitalization	O
.	O

-DOCSTART-	O

Title	O
:	O
Dose	O
-	O
response	O
characteristics	O
during	O
long	B-I
-	I-I
term	I-I
inhalation	I-I
of	I-I
nitric	I-I
oxide	I-I
in	O
patients	B-P
with	I-P
severe	I-P
acute	I-P
respiratory	I-P
distress	I-P
syndrome	I-P
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
for	O
conventional	B-C
therapy	I-C
(	O
control	O
)	O
or	O
continuous	B-I
treatment	I-I
with	I-I
10	I-I
parts	I-I
per	I-I
million	I-I
(	I-I
ppm	I-I
)	I-I
inhaled	I-I
NO	I-I
until	O
weaning	O
was	O
initiated	O
.	O

We	O
measured	O
DR	B-O
curves	I-O
of	I-O
PaO2	I-O
/	O
FIO2	B-O
versus	O
the	B-O
inhaled	I-O
NO	I-O
dose	I-O
at	O
regular	O
intervals	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
exposure	O
prevention	O
rating	O
method	O
for	O
intervention	O
needs	O
assessment	O
and	O
effectiveness	O
evaluation	O
.	O

METHODS	O
:	O
We	O
developed	O
a	B-I
checklist	I-I
containing	O
six	O
unique	O
sets	O
of	O
yes	O
/	O
no	O
variables	O
organized	O
in	O
a	O
2	O
x	O
3	O
matrix	O
of	O
exposure	O
potential	O
versus	O
protection	O
(	O
two	O
columns	O
)	O
at	O
the	O
levels	O
of	O
materials	O
,	O
processes	O
,	O
and	O
human	O
interface	O
(	O
three	O
rows	O
)	O
.	O

The	O
three	O
levels	O
correspond	O
to	O
a	O
simplified	O
hierarchy	O
of	O
controls	O
.	O

Each	O
of	O
the	O
six	O
sets	O
of	O
indicator	O
variables	O
was	O
reduced	O
to	O
a	O
high	O
/	O
moderate	O
/	O
low	O
rating	O
.	O

Ratings	O
from	O
the	O
matrix	O
were	O
then	O
combined	O
to	O
generate	O
a	O
single	O
overall	O
exposure	O
prevention	O
rating	O
for	O
each	O
area	O
.	O

Reflecting	O
the	O
hierarchy	O
of	O
controls	O
,	O
material	O
factors	O
were	O
weighted	O
highest	O
,	O
followed	O
by	O
process	O
,	O
and	O
then	O
human	O
interface	O
.	O

The	B-I
checklist	I-I
was	O
filled	O
out	O
by	O
an	O
industrial	O
hygienist	O
while	O
conducting	O
a	O
walk	O
-	O
through	O
inspection	O
(	O
N	O
=	O
131	O
manufacturing	O
processes	O
/	O
areas	O
in	O
17	O
large	O
work	O
sites	O
)	O
.	O

One	B-O
area	I-O
or	O
process	B-O
per	I-O
manufacturing	I-O
department	I-O
was	O
assessed	O
and	O
rated	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
trial	O
of	O
the	O
canalith	B-I
repositioning	I-I
procedure	I-I
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
controlled	O
trial	O
in	O
the	O
setting	O
of	O
a	O
neurotological	O
clinic	O
in	O
Thailand	O
.	O

Fifty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
posterior	I-P
benign	I-P
paroxysmal	I-P
positional	I-P
vertigo	I-P
were	O
randomly	O
assigned	O
to	O
treatment	O
and	O
control	O
groups	O
using	O
a	O
block	O
of	O
four	O
.	O

The	O
treatment	O
group	O
was	O
treated	O
with	O
the	B-I
modified	I-I
CRP	I-I
technique	I-I
until	O
the	O
nystagmus	O
disappeared	O
.	O

A	O
mastoid	O
oscillator	O
was	O
not	O
used	O
,	O
nor	O
were	O
any	O
instructions	O
given	O
for	O
patients	O
after	O
the	O
maneuver	O
.	O

Both	O
groups	O
recorded	O
the	B-O
daily	I-O
grading	I-O
of	I-O
symptoms	I-O
and	O
the	B-O
amount	I-O
of	I-O
anti	I-O
-	I-O
vertiginous	I-O
drugs	I-O
(	I-O
cinnarizine	I-O
)	I-O
taken	O
.	O

Objective	O
and	O
subjective	O
assessments	O
were	O
made	O
weekly	O
until	O
the	O
nystagmus	O
disappeared	O
or	O
until	O
4	O
weeks	O
had	O
passed	O
since	O
treatment	O
began	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
prospective	O
randomized	O
trial	O
of	O
two	B-I
different	I-I
endoscopic	I-I
resection	I-I
techniques	I-I
for	O
early	O
stage	O
cancer	O
of	O
the	O
esophagus	O
.	O

METHODS	O
:	O
In	O
a	O
prospective	O
randomized	O
study	O
,	O
100	O
consecutive	O
endoscopic	O
resections	O
were	O
performed	O
in	O
72	B-P
patients	I-P
with	I-P
early	I-P
stage	I-P
esophageal	I-P
cancer	I-P
.	O

Fifty	O
endoscopic	O
resections	O
were	O
performed	O
with	O
a	B-I
"	I-I
suck	I-I
-	I-I
and	I-I
-	I-I
ligate	I-I
"	I-I
device	I-I
without	I-I
prior	I-I
submucosa	I-I
injection	I-I
and	O
50	O
with	O
the	B-I
cap	I-I
technique	I-I
with	I-I
prior	I-I
submucosa	I-I
injection	I-I
of	I-I
a	I-I
dilute	I-I
saline	I-I
solution	I-I
of	I-I
epinephrine	I-I
.	O

The	O
main	O
assessment	O
criteria	O
were	O
maximum	B-O
diameter	I-O
of	I-O
the	I-O
resection	I-O
specimen	I-O
and	O
of	O
the	B-O
resection	I-O
area	I-O
,	O
and	O
the	B-O
complication	I-O
rate	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Children	B-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
.	O

I	O
:	O
comparison	O
of	O
placebo	B-C
and	O
single	B-I
dose	I-I
of	I-I
human	I-I
synthetic	I-I
secretin	I-I
.	O

METHODS	O
:	O
Randomised	O
,	O
crossover	O
,	O
double	O
blind	O
,	O
and	O
placebo	O
controlled	O
trial	O
of	O
a	B-I
single	I-I
intravenous	I-I
dose	I-I
of	I-I
human	I-I
synthetic	I-I
secretin	I-I
(	I-I
HSS	I-I
)	I-I
2	O
CU	O
/	O
kg	O
.	O

The	B-P
62	I-P
subjects	I-P
(	I-P
3	I-P
-	I-P
8	I-P
years	I-P
)	I-P
were	O
assigned	O
to	O
group	O
1	O
(	O
saline	B-C
placebo	I-C
/	O
HSS	B-I
)	O
or	O
group	O
2	O
(	O
HSS	B-I
/	O
saline	B-C
placebo	I-C
)	O
.	O

Diagnosis	O
was	O
confirmed	O
by	O
ADI	B-O
-	I-O
R	I-O
(	I-O
Autism	I-O
Diagnostic	I-O
Interview	I-O
-	I-O
Revised	I-O
)	I-O
algorithm	I-O
.	O

Severity	B-O
of	I-O
symptoms	I-O
was	O
rated	O
using	O
the	B-O
CARS	I-O
(	I-O
Childhood	I-O
Autism	I-O
Rating	I-O
Scale	I-O
)	I-O
.	O

Outcome	O
measures	O
included	O
Communication	B-O
and	I-O
Symbolic	I-O
Behavior	I-O
Scale	I-O
(	I-O
CSBS	I-O
)	I-O
,	O
Ritvo	B-O
Real	I-O
-	I-O
life	I-O
Rating	I-O
Scale	I-O
,	O
weekly	B-O
Global	I-O
Rating	I-O
Scale	I-O
(	I-O
GBRS	I-O
)	O
by	O
parents	O
and	O
teachers	O
,	O
and	O
daily	B-O
log	I-O
of	I-O
gastrointestinal	I-O
symptoms	I-O
.	O

The	B-O
communication	I-O
subscale	I-O
of	I-O
the	I-O
CSBS	I-O
,	O
specifying	O
communication	B-O
function	I-O
,	O
reciprocity	B-O
,	O
and	O
social	B-O
-	I-O
affective	I-O
signalling	O
was	O
videotaped	O
and	O
scored	O
by	O
a	O
blinded	O
,	O
trained	O
observer	O
.	O

-DOCSTART-	O

Title	O
:	O
Cone	O
biopsy	O
:	O
has	O
endocervical	B-I
sampling	I-I
a	O
role	O
?	O
.	O

METHODS	O
:	O
A	O
randomized	O
study	O
of	O
two	O
methods	O
of	O
endocervical	O
sampling	O
.	O

Colposcopy	O
clinic	O
at	O
Aberdeen	O
Royal	O
Infirmary	O
.	O

100	B-P
women	I-P
with	I-P
abnormal	I-P
cervical	I-P
smears	I-P
selected	I-P
for	I-P
cone	I-P
biopsy	I-P
according	I-P
to	I-P
current	I-P
colposcopy	I-P
criteria	I-P
.	O

53	O
women	O
were	O
randomized	O
to	O
have	O
endocervical	B-I
sampling	I-I
with	I-I
the	I-I
Kevorkian	I-I
curette	I-I
and	O
47	O
to	O
have	O
sampling	O
with	O
the	B-I
Medscand	I-I
endocervical	I-I
brush	I-I
.	O

Cytology	B-O
and	O
histology	B-O
results	I-O
from	O
endocervical	O
sampling	O
compared	O
with	O
cone	B-O
biopsy	I-O
histology	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Perioperative	B-I
immunotherapy	I-I
with	O
recombinant	B-I
interleukin	I-I
2	I-I
in	O
patients	B-P
undergoing	I-P
surgery	I-P
for	I-P
colorectal	I-P
cancer	I-P
.	O

METHODS	O
:	O
Patients	O
were	O
randomly	O
allocated	O
to	O
control	O
(	O
n	O
=	O
13	O
)	O
or	O
treatment	O
groups	O
(	O
n	O
=	O
12	O
)	O
.	O

Immunological	B-O
studies	I-O
of	O
both	O
lymphocyte	B-O
function	I-O
and	O
subset	B-O
number	I-O
were	O
performed	O
preoperatively	O
and	O
on	O
Days	O
1	O
,	O
4	O
,	O
7	O
,	O
and	O
10	O
.	O

-DOCSTART-	O

Title	O
:	O
Micronized	B-I
flavonoids	I-I
in	O
pain	O
control	O
after	O
hemorrhoidectomy	O
:	O
a	O
prospective	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
The	B-P
subjects	I-P
were	I-P
112	I-P
consecutive	I-P
patients	I-P
randomly	O
assigned	O
either	O
to	O
receive	O
MFF	B-I
(	O
group	O
1	O
)	O
for	O
1	O
week	O
or	O
not	B-C
to	I-C
receive	I-C
MFF	I-C
,	O
as	O
a	O
control	O
(	O
group	O
2	O
)	O
,	O
after	O
hemorrhoidectomy	O
,	O
The	B-O
severity	I-O
of	I-O
pain	I-O
and	O
the	B-O
number	I-O
of	I-O
intramuscular	I-O
analgesic	I-O
injections	I-O
required	O
were	O
recorded	O
for	O
the	O
first	O
3	O
days	O
,	O
then	O
1	O
week	O
after	O
hemorrhoidectomy	O
.	O

The	B-O
number	I-O
of	I-O
days	I-O
that	I-O
intramuscular	I-O
analgesic	I-O
injections	I-O
were	O
required	O
,	O
hospital	B-O
stay	I-O
,	O
and	O
patient	B-O
satisfaction	I-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Parent	O
-	O
defined	O
target	O
symptoms	O
respond	O
to	O
risperidone	B-I
in	O
RUPP	O
autism	O
study	O
:	O
customer	O
approach	O
to	O
clinical	O
trials	O
.	O

METHODS	O
:	O
In	O
the	O
Research	O
Units	O
on	O
Pediatric	O
Psychopharmacology	O
(	O
RUPP	O
)	O
Autism	O
Network	O
8	O
-	O
week	O
double	O
-	O
blind	O
trial	O
of	O
risperidone	B-I
versus	O
placebo	B-C
,	O
the	B-O
chief	I-O
concerns	I-O
of	I-O
parents	I-O
were	O
collected	O
at	O
0	O
,	O
4	O
,	O
and	O
8	O
weeks	O
(	O
endpoint	O
)	O
,	O
in	O
addition	O
to	O
standardized	O
primary	O
measures	O
.	O

Blinded	B-O
clinical	I-O
judges	I-O
rated	O
change	O
from	O
baseline	O
to	O
4	O
and	O
8	O
weeks	O
on	O
a	O
9	O
-	O
point	O
scale	O
(	O
1	O
=	O
normalized	O
,	O
5	O
=	O
unchanged	O
,	O
9	O
=	O
disastrous	O
)	O
;	O
94	O
participants	O
had	O
usable	O
data	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
carbohydrate	I-I
-	I-I
protein	I-I
supplement	I-I
on	O
endurance	O
performance	O
during	O
exercise	O
of	O
varying	O
intensity	O
.	O

METHODS	O
:	O
Nine	B-P
trained	I-P
cyclists	I-P
exercised	I-P
on	I-P
3	I-P
separate	I-P
occasions	I-P
at	I-P
intensities	I-P
that	I-P
varied	I-P
between	I-P
45	I-P
%	I-P
and	I-P
75	I-P
%	I-P
VO2max	I-P
for	I-P
3	I-P
h	I-P
and	I-P
then	I-P
at	I-P
85	I-P
%	I-P
VO2max	I-P
until	I-P
fatigued	I-P
.	O

Supplements	B-I
(	O
200	O
ml	O
)	O
were	O
provided	O
every	O
20	O
min	O
and	O
consisted	O
of	O
placebo	B-C
,	O
a	B-I
7	I-I
.	I-I
75	I-I
%	I-I
carbohydrate	I-I
solution	I-I
,	O
and	O
a	B-I
7	I-I
.	I-I
75	I-I
%	I-I
carbohydrate	I-I
/	O
1	B-I
.	I-I
94	I-I
%	I-I
protein	I-I
solution	I-I
.	O

Treatments	O
were	O
administered	O
using	O
a	O
double	O
-	O
blind	O
randomized	O
design	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
efficacy	O
of	O
sublingual	O
immunotherapy	O
for	O
respiratory	O
allergy	O
is	O
not	O
affected	O
by	O
different	B-I
dosage	I-I
regimens	I-I
in	O
the	O
induction	O
phase	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Combined	B-I
preoperative	I-I
xeloda	I-I
and	O
radiotherapy	B-I
for	O
lower	O
rectal	O
cancer	O
]	O
.	O

METHODS	O
:	O
Sixty	B-P
lower	I-P
rectal	I-P
cancer	I-P
patients	I-P
were	O
divided	O
randomly	O
into	O
two	O
groups	O
.	O

30	O
patients	O
(	O
Group	O
A	O
)	O
were	O
treated	O
with	O
operation	B-C
alone	I-C
and	O
30	O
patients	O
(	O
Group	O
B	O
)	O
were	O
treated	O
with	O
xeloda	B-I
and	O
radiotherapy	B-I
before	O
operation	O
.	O

-DOCSTART-	O

Title	O
:	O
Outcomes	O
in	O
patients	B-P
with	I-P
diabetes	I-P
mellitus	I-P
undergoing	I-P
percutaneous	I-P
coronary	I-P
intervention	I-P
in	O
the	O
current	O
era	O
:	O
a	O
report	O
from	O
the	O
Prevention	O
of	O
REStenosis	O
with	O
Tranilast	B-I
and	O
its	O
Outcomes	O
(	O
PRESTO	O
)	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
long	O
-	O
term	O
effect	O
of	O
oxandrolone	B-I
on	O
hepatic	O
acute	O
phase	O
proteins	O
in	O
severely	B-P
burned	I-P
children	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
five	I-P
children	I-P
with	I-P
>	I-P
or	I-P
=40	I-P
%	I-P
total	I-P
body	I-P
surface	I-P
area	I-P
burns	I-P
were	O
randomized	O
to	O
receive	O
either	O
placebo	B-C
or	O
oxandrolone	B-I
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
by	O
mouth	O
twice	O
daily	O
)	O
from	O
postoperative	O
day	O
5	O
to	O
1	O
year	O
postburn	O
.	O

Levels	B-O
of	I-O
constitutive	I-O
proteins	I-O
and	O
acute	B-O
phase	I-O
proteins	I-O
were	O
measured	O
at	O
admission	O
;	O
at	O
discharge	O
;	O
and	O
at	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
after	O
burn	O
.	O

Total	B-O
albumin	I-O
supplementation	I-O
and	O
hepatic	B-O
transaminases	I-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Clonidine	B-I
treatment	I-I
of	O
hyperactive	B-P
and	I-P
impulsive	I-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
.	O

METHODS	O
:	O
Eight	B-P
male	I-P
children	I-P
(	I-P
8	I-P
.	I-P
1	I-P
+	I-P
/	I-P
-	I-P
2	I-P
.	I-P
8	I-P
years	I-P
)	I-P
with	I-P
autistic	I-P
disorder	I-P
,	I-P
diagnosed	I-P
by	I-P
DSM	I-P
-	I-P
III	I-P
-	I-P
R	I-P
criteria	I-P
,	O
completed	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
crossover	O
trial	O
of	O
clonidine	B-I
.	O

Subjects	O
were	O
included	O
in	O
the	O
study	O
if	O
they	O
had	O
inattention	O
,	O
impulsivity	O
,	O
and	O
hyperactivity	O
that	O
was	O
excessive	O
for	O
their	O
developmental	O
level	O
.	O

Subjects	O
had	O
not	O
tolerated	O
or	O
responded	O
to	O
other	O
psychopharmacologic	O
treatments	O
(	O
neuroleptics	O
,	O
methylphenidate	O
,	O
or	O
desipramine	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Oscillatory	B-I
potentials	I-I
,	O
retinopathy	B-I
,	O
and	O
long	B-I
-	I-I
term	I-I
glucose	I-I
control	I-I
in	O
insulin	O
-	O
dependent	O
diabetes	O
.	O

METHODS	O
:	O
Individual	B-O
(	O
OP	B-O
-	I-O
1	I-O
,	O
OP	B-O
-	I-O
2	I-O
,	O
OP	B-O
-	I-O
3	I-O
)	O
and	O
summed	B-O
(	I-O
OP	I-O
-	I-O
sum	I-O
)	I-O
amplitudes	I-O
of	I-O
oscillatory	I-O
potentials	I-O
(	I-O
OPs	I-O
)	I-O
of	I-O
electroretinography	I-O
were	O
recorded	O
at	O
study	O
start	O
and	O
7	O
-	O
years	O
later	O
in	O
45	B-P
patients	I-P
(	O
the	O
Oslo	O
study	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	O
combination	O
of	O
evening	B-I
primrose	I-I
oil	I-I
(	I-I
gamma	I-I
linolenic	I-I
acid	I-I
)	I-I
and	O
fish	B-I
oil	I-I
(	O
eicosapentaenoic	B-I
+	O
docahexaenoic	B-I
acid	I-I
)	O
versus	O
magnesium	B-I
,	O
and	O
versus	O
placebo	B-C
in	O
preventing	O
pre	O
-	O
eclampsia	O
.	O

METHODS	O
:	O
All	O
were	O
given	O
as	O
nutritional	B-I
supplements	I-I
for	O
six	O
months	O
to	O
a	B-P
group	I-P
of	I-P
primiparous	I-P
and	I-P
multiparous	I-P
pregnant	I-P
women	I-P
.	O

Some	O
of	O
these	O
women	O
had	O
personal	O
or	O
family	O
histories	O
of	O
hypertension	O
(	O
21	O
%	O
)	O
.	O

Only	O
those	O
patients	O
who	O
received	O
prenatal	O
care	O
at	O
the	O
Central	O
Maternity	O
Hospital	O
for	O
Luanda	O
were	O
included	O
in	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Injection	O
pain	O
and	O
postinjection	O
pain	O
of	O
the	B-I
palatal	I-I
-	I-I
anterior	I-I
superior	I-I
alveolar	I-I
injection	I-I
,	O
administered	O
with	O
the	O
Wand	O
Plus	O
system	O
,	O
comparing	O
2	B-I
%	I-I
lidocaine	I-I
with	O
1	B-I
:	I-I
100	I-I
,	I-I
000	I-I
epinephrine	I-I
to	O
3	B-I
%	I-I
mepivacaine	I-I
.	O

METHODS	O
:	O
Using	O
a	O
crossover	O
design	O
,	O
40	B-P
subjects	I-P
randomly	O
received	O
,	O
in	O
a	O
double	O
-	O
blind	O
manner	O
,	O
P	B-I
-	I-I
ASA	I-I
injections	I-I
of	I-I
1	I-I
.	I-I
4	I-I
mL	I-I
of	I-I
2	I-I
%	I-I
lidocaine	I-I
with	O
1	B-I
:	I-I
100	I-I
,	I-I
000	I-I
epinephrine	I-I
and	O
1	B-I
.	I-I
4	I-I
mL	I-I
of	I-I
3	I-I
%	I-I
mepivacaine	I-I
,	O
at	O
2	O
separate	O
appointments	O
.	O

The	B-I
P	I-I
-	I-I
ASA	I-I
injection	I-I
was	O
administered	O
,	O
utilizing	O
the	O
Wand	O
Plus	O
system	O
,	O
6	O
to	O
10	O
mm	O
into	O
the	O
incisive	O
canal	O
located	O
lingual	O
to	O
the	O
central	O
incisors	O
.	O

The	B-O
pain	I-O
of	I-O
needle	I-O
insertion	I-O
,	O
needle	B-O
placement	I-O
,	O
solution	B-O
deposition	I-O
and	O
postinjection	B-O
pain	I-O
were	O
recorded	O
on	O
a	B-O
Heft	I-O
-	I-O
Parker	I-O
visual	I-O
analog	I-O
scale	I-O
for	O
the	B-I
2	I-I
P	I-I
-	I-I
ASA	I-I
injections	I-I
.	O

Eighty	O
injections	O
were	O
randomly	O
administered	O
in	O
the	O
study	O
,	O
40	O
using	O
topical	B-C
anesthetic	I-C
gel	I-C
and	O
40	O
using	O
a	B-C
placebo	I-C
gel	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Rapid	O
-	O
sequence	O
intubation	O
of	O
head	B-P
trauma	I-P
patients	I-P
:	O
prevention	O
of	O
fasciculations	O
with	O
pancuronium	B-I
versus	O
minidose	B-I
succinylcholine	I-I
.	O

METHODS	O
:	O
A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

An	O
inner	O
-	O
city	O
county	O
trauma	O
center	O
with	O
70	O
,	O
000	O
patient	O
visits	O
per	O
year	O
.	O

Sequential	B-P
adult	I-P
head	I-P
trauma	I-P
patients	I-P
requiring	I-P
rapid	I-P
-	I-P
sequence	I-P
intubation	I-P
who	I-P
had	I-P
no	I-P
contraindications	I-P
to	I-P
succinylcholine	I-P
or	I-P
pancuronium	I-P
.	O

Each	O
head	O
trauma	O
patient	O
requiring	O
rapid	O
-	O
sequence	O
intubation	O
who	O
met	O
the	O
inclusion	O
criteria	O
received	O
standard	O
rapid	O
-	O
sequence	O
intubation	O
maneuvers	O
and	O
lidocaine	O
(	O
1	O
mg	O
/	O
kg	O
)	O
IV	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
either	O
minidose	B-I
succinylcholine	I-I
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
or	O
pancuronium	B-I
(	O
0	O
.	O
03	O
mg	O
/	O
kg	O
)	O
IV	O
one	O
minute	O
prior	O
to	O
the	O
full	O
paralytic	O
dose	O
of	O
succinylcholine	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
IV	O
.	O

Fasciculations	B-O
were	O
recorded	O
using	O
a	B-O
graded	I-O
visual	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Metoprolol	B-I
CR	I-I
/	O
XL	B-I
improves	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
.	O

METHODS	O
:	O
In	O
an	O
echocardiographic	O
substudy	O
to	O
the	B-I
Metoprolol	I-I
CR	I-I
/	O
XL	B-I
Randomized	O
Intervention	O
Trial	O
in	O
Heart	O
Failure	O
(	O
MERIT	O
-	O
HF	O
)	O
,	O
66	B-P
patients	I-P
were	O
examined	O
three	O
times	O
during	O
a	O
12	O
-	O
month	O
period	O
blinded	O
to	O
treatment	O
group	O
,	O
assessing	O
left	B-O
ventricular	I-O
dimensions	I-O
and	O
ejection	B-O
fraction	I-O
,	O
and	O
Doppler	B-O
mitral	I-O
inflow	I-O
parameters	I-O
,	O
all	O
measured	O
in	O
a	O
core	O
laboratory	O
.	O

-DOCSTART-	O

Title	O
:	O
Bitewing	O
film	O
quality	O
:	O
a	O
clinical	O
comparison	O
of	O
the	B-I
loop	I-I
vs	O
.	O
holder	B-I
techniques	I-I
.	O

METHODS	O
:	O
Four	O
bitewing	O
films	O
were	O
taken	O
from	O
the	B-P
right	I-P
and	I-P
left	I-P
premolar	I-P
and	I-P
molar	I-P
regions	I-P
of	I-P
45	I-P
dental	I-P
students	I-P
using	O
both	O
the	B-I
bitewing	I-I
holder	I-I
and	O
paper	B-I
loop	I-I
techniques	I-I
.	O

A	B-P
total	I-P
of	I-P
360	I-P
films	I-P
were	O
taken	O
and	O
assessed	O
by	O
an	O
experienced	O
practitioner	O
not	O
apprised	O
of	O
the	B-I
bitewing	I-I
technique	I-I
used	O
.	O

Of	O
interest	O
were	O
:	O
(	O
1	O
)	O
the	B-O
number	I-O
of	I-O
overlaps	I-O
and	O
the	B-O
percentage	I-O
of	I-O
teeth	I-O
showing	I-O
the	I-O
alveolar	I-O
crest	I-O
;	O
(	O
2	O
)	O
proper	B-O
film	I-O
positioning	I-O
;	O
and	O
(	O
3	O
)	O
the	B-O
percentage	I-O
of	I-O
cone	I-O
cutting	I-O
.	O

A	O
Poisson	O
regression	O
using	O
generalized	O
estimating	O
equations	O
(	O
GEEs	O
)	O
was	O
used	O
to	O
estimate	O
the	O
difference	O
in	O
overlap	O
between	O
the	O
two	O
techniques	O
.	O

For	O
proper	O
positioning	O
and	O
cone	O
cutting	O
,	O
logistic	O
regressions	O
using	O
GEEs	O
were	O
used	O
.	O

-DOCSTART-	O

Title	O
:	O
Mouth	B-I
closing	I-I
device	I-I
(	I-I
chinstrap	I-I
)	I-I
reduces	O
mouth	O
leak	O
during	O
nasal	O
CPAP	O
.	O

METHODS	O
:	O
Fifteen	B-P
patients	I-P
with	I-P
mouth	I-P
leak	I-P
complaining	I-P
of	I-P
mouth	I-P
dryness	I-P
and	I-P
nasal	I-P
obstruction	I-P
underwent	O
two	O
consecutive	O
overnight	O
polysomnographies	O
,	O
one	O
with	O
a	B-I
chinstrap	I-I
,	O
in	O
random	O
order	O
.	O

Cephalometry	B-O
with	B-I
and	O
without	B-C
a	I-C
chinstrap	I-C
was	O
randomly	O
performed	O
on	O
six	O
patients	O
.	O

-DOCSTART-	O

Title	O
:	O
Clarithromycin	B-I
reduces	O
the	O
severity	O
of	O
bronchial	O
hyperresponsiveness	O
in	O
patients	B-P
with	I-P
asthma	I-P
.	O

METHODS	O
:	O
Adult	B-P
asthma	I-P
patients	I-P
undergoing	I-P
treatment	I-P
with	I-P
budesonide	I-P
400	I-P
microg	I-P
b	I-P
.	I-P
i	I-P
.	I-P
d	I-P
.	I-P
and	I-P
salbutamol	I-P
200	I-P
microg	I-P
p	I-P
.	I-P
r	I-P
.	I-P
n	I-P
.	I-P
less	I-P
than	I-P
twice	I-P
weekly	I-P
were	O
studied	O
.	O

Arm	O
A	O
(	O
16	O
males	O
/	O
six	O
females	O
,	O
aged	O
48	O
+	O
/	O
-	O
16	O
yrs	O
)	O
received	O
clarithromycin	B-I
250	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
for	O
8	O
weeks	O
,	O
arm	O
B	O
(	O
eight	O
males	O
/	O
12	O
females	O
,	O
aged	O
42	O
+	O
/	O
-	O
12	O
yrs	O
)	O
clarithromycin	B-I
250	O
mg	O
t	O
.	O
id	O
.	O
and	O
arm	O
C	O
(	O
six	O
males	O
/	O
15	O
females	O
,	O
aged	O
41	O
+	O
/	O
-	O
16	O
yrs	O
)	O
placebo	B-C
dextrose	I-C
tablets	O
.	O

Bronchial	B-O
hyperresponsiveness	I-O
was	O
quantified	O
by	O
measurement	O
of	O
the	O
provocative	O
dose	O
of	O
methacholine	O
causing	O
a	O
20	O
%	O
fall	O
in	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
PD20	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Chronic	B-I
fatigue	I-I
syndrome	I-I
versus	O
neuroendocrineimmune	B-I
dysfunction	I-I
syndrome	I-I
:	O
differential	O
attributions	O
.	O

METHODS	O
:	O
Nurses	O
and	O
physician	O
assistants	O
(	O
PAs	O
)	O
were	O
presented	O
a	O
case	O
study	O
of	O
a	O
patient	O
with	O
symptoms	O
of	O
CFS	B-I
.	O

They	O
were	O
told	O
that	O
the	O
patient	O
had	O
either	O
"	O
chronic	B-I
fatigue	I-I
syndrome	I-I
,	O
"	O
"	O
chronic	B-I
neuroendocrineimmune	I-I
dysfunction	I-I
syndrome	I-I
,	O
"	O
or	O
"	O
chronic	B-I
neuroendocrineimmune	I-I
dysfunction	I-I
syndrome	I-I
,	O
which	O
had	O
formerly	O
been	O
called	O
chronic	O
fatigue	O
syndrome	O
.	O

-DOCSTART-	O

Title	O
:	O
Needle	B-I
versus	O
loop	B-I
diathermy	I-I
excision	I-I
of	I-I
the	I-I
transformation	I-I
zone	I-I
for	O
the	O
treatment	O
of	O
cervical	O
intraepithelial	O
neoplasia	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
prospective	O
randomised	O
controlled	O
trial	O
.	O

A	O
gynaecological	O
oncology	O
centre	O
and	O
a	O
teaching	O
hospital	O
in	O
West	O
London	O
.	O

Four	B-P
hundred	I-P
and	I-P
four	I-P
women	I-P
due	I-P
to	I-P
receive	I-P
treatment	I-P
for	I-P
suspected	I-P
CIN	I-P
.	O

Women	O
were	O
randomised	O
to	O
receive	O
either	O
LLETZ	B-I
or	O
NETZ	B-I
.	O

The	O
study	O
was	O
designed	O
to	O
demostrate	O
a	O
difference	O
in	O
the	B-O
proportion	I-O
of	I-O
women	I-O
with	I-O
clear	I-O
histological	I-O
margins	I-O
of	O
82	O
%	O
for	O
LLETZ	B-I
compared	O
to	O
94	O
%	O
for	O
NETZ	B-I
with	O
90	O
%	O
power	O
at	O
a	O
5	O
%	O
significance	O
level	O
,	O
allowing	O
for	O
absence	O
of	O
CIN	O
in	O
the	O
treatment	O
specimen	O
in	O
15	O
%	O
.	O

-DOCSTART-	O

Title	O
:	O
Public	O
and	O
private	O
heart	O
rate	O
feedback	O
in	O
social	O
phobia	O
:	O
a	O
manipulation	O
of	O
anxiety	O
visibility	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
32	I-P
social	I-P
phobics	I-P
and	I-P
32	I-P
controls	I-P
were	O
asked	O
twice	O
to	O
sit	B-I
in	I-I
a	I-I
chair	I-I
and	O
appear	B-I
relaxed	I-I
while	O
being	O
evaluated	O
.	O

Half	O
of	O
the	O
participants	O
heard	O
their	B-O
heart	I-O
sounds	I-O
first	O
via	O
headphones	O
and	O
then	O
via	O
loudspeakers	O
which	O
were	O
also	O
audible	O
to	O
observers	O
.	O

The	O
presentation	O
order	O
of	O
the	O
heart	O
sound	O
was	O
reversed	O
for	O
the	O
other	O
half	O
of	O
the	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Peripheral	O
arterial	O
disease	O
:	O
therapeutic	O
confidence	O
of	O
CT	B-I
versus	O
digital	B-I
subtraction	I-I
angiography	I-I
and	O
effects	O
on	O
additional	O
imaging	O
recommendations	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
controlled	O
trial	O
,	O
73	O
patients	O
were	O
assigned	O
to	O
CT	B-I
angiography	I-I
,	O
and	O
72	O
were	O
assigned	O
to	O
DSA	B-I
.	O

Physician	B-O
confidence	I-O
in	O
the	O
treatment	O
decision	O
was	O
measured	O
as	O
a	O
continuous	O
outcome	O
on	O
a	B-O
scale	I-O
of	I-O
0	I-O
-	I-O
10	I-O
(	I-O
uncertain	I-O
to	I-O
certain	I-O
)	I-O
and	O
as	O
a	B-O
dichotomous	I-O
outcome	I-O
(	I-O
further	I-O
imaging	I-O
recommended	I-O
,	I-O
yes	I-O
or	I-O
no	I-O
)	I-O
.	O

Mean	B-O
confidence	I-O
scores	I-O
and	O
additional	B-O
imaging	I-O
recommendations	I-O
were	O
compared	O
between	O
CT	B-I
and	O
DSA	B-I
groups	O
in	O
an	O
intention	O
-	O
to	O
-	O
diagnose	O
-	O
and	O
-	O
treat	O
analysis	O
.	O

To	O
detect	O
trends	O
in	O
confidence	O
,	O
confidence	O
scores	O
were	O
plotted	O
over	O
time	O
,	O
and	O
multiple	O
linear	O
regression	O
analysis	O
was	O
performed	O
.	O

To	O
detect	O
trends	O
in	O
additional	O
imaging	O
recommendations	O
,	O
logistic	O
regression	O
analysis	O
was	O
used	O
.	O

Data	O
from	O
eligible	O
nonrandomized	O
patients	O
were	O
analyzed	O
separately	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
ibuprofen	B-I
on	O
cyclooxygenase	O
and	O
nitric	O
oxide	O
synthase	O
of	O
gastric	O
mucosa	O
:	O
correlation	O
with	O
endoscopic	O
lesions	O
and	O
adverse	O
reactions	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
Helicobacter	I-P
pylori	I-P
-	I-P
negative	I-P
subjects	I-P
were	O
randomized	O
to	O
treatment	O
with	O
ibuprofen	B-I
or	O
ibuprofen	B-I
-	I-I
arginate	I-I
(	O
each	O
600	O
mg	O
/	O
6	O
hr	O
during	O
3	O
days	O
)	O
.	O

Endoscopies	B-O
were	O
performed	O
1	O
week	O
before	O
and	O
after	O
treatment	O
.	O

Biopsies	B-O
were	O
taken	O
from	O
the	B-O
gastric	I-O
antrum	I-O
and	O
corpus	B-O
for	O
determination	B-O
of	I-O
prostaglandin	I-O
E2	I-O
(	I-O
PGE2	I-O
)	I-O
by	O
ELISA	B-O
and	O
cyclooxygenase	B-O
(	B-O
COX	I-O
-	I-O
1	I-O
and	O
COX	B-O
-	I-O
2	I-O
)	I-O
and	O
nitric	B-O
oxide	I-O
synthase	I-O
(	B-O
eNOS	I-O
and	O
iNOS	B-O
)	I-O
by	O
western	B-O
blot	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Risperidone	B-I
in	O
the	O
treatment	O
of	O
disruptive	O
behavioral	O
symptoms	O
in	O
children	B-P
with	I-P
autistic	I-P
and	I-P
other	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
.	O

METHODS	O
:	O
In	O
this	O
8	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
risperidone	B-I
/	O
placebo	B-C
solution	I-C
(	O
0	O
.	O
01	O
-	O
0	O
.	O

06	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
administered	O
to	O
79	B-P
children	I-P
who	I-P
were	I-P
aged	I-P
5	I-P
to	I-P
12	I-P
years	I-P
and	I-P
had	I-P
PDD	I-P
.	O

Behavioral	B-O
symptoms	I-O
were	O
assessed	O
using	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
(	I-O
ABC	I-O
)	I-O
,	O
Nisonger	B-O
Child	I-O
Behavior	I-O
Rating	I-O
Form	I-O
,	O
and	O
Clinical	B-O
Global	I-O
Impression	I-O
-	I-O
Change	I-O
.	O

Safety	B-O
assessments	O
included	O
vital	B-O
signs	I-O
,	O
electrocardiogram	B-O
,	O
extrapyramidal	B-O
symptoms	I-O
,	O
adverse	B-O
events	I-O
,	O
and	O
laboratory	B-O
tests	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
antioxidants	B-I
,	O
zinc	B-I
,	O
and	O
copper	B-I
on	O
cognition	O
in	O
the	B-P
elderly	I-P
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Participants	B-P
in	I-P
the	I-P
Age	I-P
-	I-P
Related	I-P
Eye	I-P
Disease	I-P
Study	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
daily	B-I
antioxidants	I-I
(	O
vitamin	B-I
C	I-I
,	O
500	O
mg	O
;	O
vitamin	B-I
E	I-I
,	O
400	O
IU	O
;	O
beta	B-I
carotene	I-I
,	O
15	O
mg	O
)	O
,	O
zinc	B-I
and	O
copper	B-I
(	O
zinc	B-I
,	O
80	O
mg	O
;	O
cupric	B-I
oxide	I-I
,	O
2	O
mg	O
)	O
,	O
antioxidants	B-I
plus	O
zinc	B-I
and	O
copper	B-I
,	O
or	O
placebo	B-C
.	O

A	B-O
cognitive	I-O
battery	I-O
was	O
administered	O
to	O
2	B-P
,	I-P
166	I-P
elderly	I-P
persons	I-P
after	I-P
a	I-P
median	I-P
of	I-P
6	I-P
.	I-P
9	I-P
years	I-P
of	I-P
treatment	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Syncope	O
Evaluation	O
in	O
the	O
Emergency	O
Department	O
Study	O
(	O
SEEDS	O
)	O
:	O
a	O
multidisciplinary	O
approach	O
to	O
syncope	B-I
management	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Dual	O
-	O
task	O
-	O
related	O
gait	O
changes	O
in	O
transitionally	B-P
frail	I-P
older	I-P
adults	I-P
:	O
the	O
type	O
of	O
the	O
walking	O
-	O
associated	O
cognitive	O
task	O
matters	O
.	O

METHODS	O
:	O
Gait	O
was	O
tested	O
in	O
30	B-P
transitionally	I-P
frail	I-P
older	I-P
adults	I-P
(	I-P
mean	I-P
age	I-P
82	I-P
.	I-P
6	I-P
+	I-P
/	I-P
-	I-P
7	I-P
.	I-P
1	I-P
years	I-P
,	I-P
90	I-P
%	I-P
female	I-P
)	I-P
while	O
either	O
walking	B-I
alone	I-I
,	O
performing	B-I
a	I-I
simple	I-I
arithmetic	I-I
task	I-I
,	O
or	O
performing	B-I
a	I-I
task	I-I
of	I-I
verbal	I-I
fluency	I-I
.	O

Walking	B-O
time	I-O
in	I-O
seconds	I-O
,	O
number	B-O
of	I-O
steps	I-O
,	O
frequency	B-O
of	I-O
lateral	I-O
line	I-O
stepping	I-O
-	I-O
over	I-O
,	O
and	O
stops	B-O
were	O
recorded	O
.	O

Health	B-O
status	I-O
was	O
assessed	O
using	O
standard	B-O
instruments	I-O
of	I-O
geriatric	I-O
assessment	I-O
.	O

The	O
classification	O
of	O
Speechley	B-O
and	I-O
Tinetti	I-O
was	O
used	O
to	O
define	O
the	B-O
participants	I-O
'	I-O
degree	I-O
of	I-O
frailty	I-O
.	O

-DOCSTART-	O

Title	O
:	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
and	O
reflectance	B-I
-	I-I
mode	I-I
confocal	I-I
microscopy	I-I
as	O
adjunct	O
modalities	O
to	O
Mohs	O
micrographic	O
surgery	O
for	O
treatment	O
of	O
basal	O
cell	O
carcinoma	O
.	O

METHODS	O
:	O
Subjects	O
applied	O
study	B-I
cream	I-I
to	I-I
one	I-I
biopsy	I-I
-	I-I
confirmed	I-I
basal	I-I
cell	I-I
carcinoma	I-I
tumor	I-I
5	O
x	O
/	O
week	O
for	O
2	O
,	O
4	O
,	O
or	O
6	O
weeks	O
in	O
this	O
vehicle	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

Confocal	B-I
microscopy	I-I
was	O
used	O
for	O
the	O
6	O
-	O
week	O
treatment	O
group	O
to	O
examine	O
the	B-O
target	I-O
tumor	I-O
area	I-O
at	O
each	O
interval	O
visit	O
and	O
immediately	O
before	O
Mohs	O
micrographic	O
surgery	O
.	O

After	O
the	O
Mohs	O
micrographic	O
surgery	O
excision	O
,	O
the	B-O
tissue	I-O
was	O
evaluated	O
histologically	B-O
,	O
and	O
the	B-O
excision	I-O
area	I-O
was	O
measured	O
.	O

Confocal	B-O
microscopy	I-O
readings	I-O
were	O
correlated	O
to	O
the	B-O
histologic	I-O
diagnosis	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Group	B-I
-	I-I
based	I-I
HIV	I-I
risk	I-I
reduction	I-I
intervention	I-I
for	O
adolescent	B-P
girls	I-P
:	O
evidence	O
of	O
feasibility	O
and	O
efficacy	O
.	O

METHODS	O
:	O
The	B-O
feasibility	I-O
of	O
the	O
intervention	O
was	O
demonstrated	O
by	O
successfully	O
implementing	O
it	O
with	O
33	O
sexually	O
-	O
active	O
,	O
single	O
girls	O
.	O

Preliminary	O
evidence	O
of	O
the	B-O
efficacy	I-O
of	O
the	O
intervention	O
was	O
obtained	O
using	O
a	O
randomized	O
trial	O
with	O
62	B-P
sexually	I-P
-	I-P
active	I-P
,	I-P
single	I-P
girls	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Immunogenicity	O
and	O
reactogenicity	O
of	O
two	O
regimens	O
of	O
diphtheria	B-I
-	I-I
tetanus	I-I
-	I-I
acellular	I-I
pertussis	I-I
-	I-I
hepatitis	I-I
B	I-I
-	I-I
inactivated	I-I
polio	I-I
and	O
Haemophilus	B-I
influenzae	I-I
type	I-I
b	I-I
vaccines	I-I
administered	O
to	O
infants	B-P
primed	I-P
at	I-P
birth	I-P
with	I-P
hepatitis	I-P
B	I-P
vaccine	I-P
.	O

METHODS	O
:	O
One	O
-	O
half	O
of	O
the	O
150	O
healthy	O
,	O
full	O
-	O
term	O
infants	O
received	O
a	B-I
DTPa	I-I
HBV	I-I
-	I-I
IPV	I-I
-	I-I
Hib	I-I
vaccine	I-I
at	O
1	O
1	O
/	O
2	O
,	O
3	O
and	O
5	O
months	O
of	O
age	O
;	O
the	O
other	O
received	O
a	B-I
DTPa	I-I
-	I-I
IPV	I-I
-	I-I
Hib	I-I
vaccine	I-I
at	O
1	O
1	O
/	O
2	O
,	O
3	O
and	O
5	O
months	O
of	O
age	O
with	O
separate	B-I
HBV	I-I
vaccine	I-I
at	O
1	O
and	O
5	O
months	O
of	O
age	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
a	O
randomized	O
trial	O
of	O
fludarabine	B-I
-	O
mitoxantrone	B-I
,	O
compared	O
with	O
cyclophosphamide	B-I
,	I-I
doxorubicin	I-I
,	I-I
vindesine	I-I
,	I-I
prednisone	I-I
(	I-I
CHVP	I-I
)	I-I
,	O
as	O
first	O
-	O
line	O
treatment	O
of	O
elderly	B-P
patients	I-P
with	I-P
advanced	I-P
,	I-P
low	I-P
-	I-P
grade	I-P
non	I-P
-	I-P
Hodgkin	I-P
'	I-P
s	I-P
lymphoma	I-P
before	O
the	O
era	O
of	O
monoclonal	O
antibodies	O
.	O

METHODS	O
:	O
End	O
points	O
were	O
remission	B-O
rates	I-O
[	O
overall	B-O
response	I-O
(	I-O
OR	I-O
)	I-O
and	O
complete	B-O
response	I-O
(	I-O
CR	I-O
)	I-O
]	O
,	O
failure	B-O
-	I-O
free	I-O
survival	I-O
(	I-O
FFS	I-O
)	I-O
,	O
survival	B-O
and	O
toxicity	B-O
.	O

One	B-P
hundred	I-P
and	I-P
fifty	I-P
-	I-P
five	I-P
patients	I-P
were	O
randomized	O
,	O
144	O
were	O
evaluable	O
for	O
safety	B-O
and	O
142	O
for	O
response	B-O
.	O

Each	O
treatment	O
arm	O
was	O
given	O
as	O
six	O
monthly	O
cycles	O
,	O
followed	O
by	O
three	O
bimonthly	O
cycles	O
.	O

FM	B-I
comprised	O
fludarabine	B-I
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
)	O
,	O
days	O
1	O
-	O
5	O
,	O
plus	O
mitoxantrone	B-I
(	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
)	O
,	O
day	O
1	O
.	O

CHVP	B-I
cycles	O
comprised	O
cyclophosphamide	B-I
(	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
infusion	O
)	O
,	O
doxorubicin	B-I
(	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
)	O
and	O
vindesine	B-I
(	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
)	O
on	O
day	O
1	O
,	O
and	O
prednisone	B-I
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
-	O
5	O
.	O

-DOCSTART-	O

Title	O
:	O
Reducing	O
blood	O
loss	O
at	O
open	O
myomectomy	O
using	O
triple	B-I
tourniquets	I-I
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomised	O
controlled	O
trial	O
.	O

Two	O
University	O
teaching	O
hospitals	O
.	O

Twenty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
symptomatic	I-P
fibroids	I-P
and	I-P
uterine	I-P
sizes	I-P
ranging	I-P
from	I-P
14	I-P
to	I-P
24	I-P
weeks	I-P
of	I-P
gestation	I-P
undergoing	I-P
open	I-P
myomectomy	I-P
.	O

A	B-I
number	I-I
1	I-I
polyglactin	I-I
suture	I-I
was	O
tied	O
around	O
the	O
cervix	O
to	O
occlude	O
the	O
uterine	O
arteries	O
,	O
and	O
polythene	B-I
tourniquets	I-I
were	O
tied	O
around	O
the	O
infundibulopelvic	O
ligament	O
to	O
obstruct	O
the	O
ovarian	O
vessels	O
.	O

At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
the	O
ovarian	O
ties	O
were	O
released	O
but	O
the	O
uterine	O
artery	O
suture	O
remained	O
in	O
situ	O
.	O

Intra	B-O
-	I-O
operative	I-O
blood	I-O
loss	I-O
,	O
post	B-O
-	I-O
operative	I-O
blood	I-O
loss	I-O
,	O
blood	B-O
transfusion	I-O
rates	I-O
,	O
operative	B-O
morbidity	I-O
,	O
uterine	B-O
blood	I-O
flow	I-O
and	O
ovarian	B-O
function	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Controlled	O
clinical	O
trial	O
of	O
IV	B-I
cyclophosphamide	I-I
versus	O
IV	B-I
methylprednisolone	I-I
in	O
severe	O
neurological	O
manifestations	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
controlled	O
clinical	O
trial	O
at	O
two	O
tertiary	O
care	O
centres	O
of	O
patients	B-P
with	I-P
SLE	I-P
according	I-P
to	I-P
the	I-P
ACR	I-P
criteria	I-P
,	I-P
with	I-P
incident	I-P
(	I-P
no	I-P
more	I-P
than	I-P
15	I-P
days	I-P
)	I-P
onset	I-P
of	I-P
severe	I-P
NP	I-P
manifestations	I-P
such	I-P
as	I-P
seizures	I-P
,	I-P
optic	I-P
neuritis	I-P
,	I-P
peripheral	I-P
or	I-P
cranial	I-P
neuropathy	I-P
,	I-P
coma	I-P
,	I-P
brainstem	I-P
disease	I-P
,	I-P
or	I-P
transverse	I-P
myelitis	I-P
.	O

Induction	O
treatment	O
with	O
3	B-I
g	I-I
of	I-I
IV	I-I
methylprednisolone	I-I
(	I-I
MP	I-I
)	I-I
followed	O
by	O
either	O
IV	B-I
monthly	I-I
cyclophosphamide	I-I
(	I-I
Cy	I-I
)	I-I
versus	O
IV	B-I
MP	I-I
bimonthly	O
every	O
4	O
months	O
for	O
1	O
year	O
and	O
then	O
IV	B-I
Cy	I-I
or	O
IV	B-I
MP	I-I
every	O
3	O
months	O
for	O
another	O
year	O
.	O

The	O
primary	O
end	O
point	O
was	O
response	B-O
to	I-O
treatment	I-O
:	O
at	O
least	O
20	O
%	O
improvement	O
from	O
basal	O
conditions	O
on	O
clinical	B-O
,	O
laboratory	B-O
,	O
or	O
specific	B-O
neurological	I-O
testing	I-O
variables	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
nutritional	I-I
supplement	I-I
containing	O
vitamin	B-I
E	I-I
,	O
selenium	B-I
,	O
vitamin	B-I
c	I-I
and	O
coenzyme	B-I
Q10	I-I
on	O
serum	O
PSA	O
in	O
patients	B-P
with	I-P
hormonally	I-P
untreated	I-P
carcinoma	I-P
of	I-P
the	I-P
prostate	I-P
:	O
a	O
randomised	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
Eighty	B-P
patients	I-P
were	O
randomised	O
to	O
receive	O
a	B-I
daily	I-I
supplement	I-I
with	I-I
either	O
vitamin	B-I
E	O
,	O
selenium	B-I
,	O
vitamin	B-I
C	I-I
,	O
coenzyme	B-I
Q10	I-I
(	O
intervention	O
group	O
)	O
or	O
placebo	B-C
over	O
21	O
weeks	O
.	O

Serum	B-O
levels	I-O
of	I-O
PSA	I-O
were	O
assessed	O
at	O
baseline	O
(	O
-	O
2	O
,	O
-	O
1	O
,	O
0	O
weeks	O
)	O
and	O
after	O
6	O
,	O
13	O
,	O
19	O
,	O
20	O
and	O
21	O
weeks	O
.	O

Mean	O
changes	O
in	O
log	B-O
serum	I-O
level	I-O
of	I-O
PSA	I-O
,	O
testosterone	B-O
,	O
dihydrotestosterone	B-O
,	O
luteinizing	B-O
hormone	I-O
and	O
sex	B-O
hormone	I-O
binding	I-O
globulin	I-O
over	O
21	O
weeks	O
between	O
the	B-I
verum	I-I
and	O
the	B-C
placebo	I-C
group	O
were	O
compared	O
by	O
analysis	O
of	O
covariance	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
of	O
the	O
efficacy	O
of	O
heparinized	B-I
and	O
nonheparinized	B-I
solutions	I-I
for	O
maintenance	O
of	O
perioperative	O
radial	O
arterial	O
catheter	O
patency	O
and	O
subsequent	O
occlusion	O
.	O

METHODS	O
:	O
Two	B-P
-	I-P
hundred	I-P
patients	I-P
were	O
randomized	O
into	O
2	O
groups	O
to	O
receive	O
heparinized	B-I
(	O
group	O
H	O
,	O
n	O
=	O
100	O
)	O
or	O
nonheparinized	B-I
(	I-I
group	I-I
S	I-I
,	I-I
n	I-I
=	I-I
100	I-I
)	I-I
flush	I-I
solutions	I-I
.	O

Radial	B-O
and	O
ulnar	B-O
blood	I-O
flows	I-O
were	O
assessed	O
using	O
Doppler	B-O
probe	I-O
and	O
pulse	B-O
oximetry	I-O
before	O
,	O
just	O
after	O
,	O
and	O
24	O
h	O
after	O
decannulation	O
by	O
the	O
same	O
investigator	O
.	O

The	B-O
cannulation	I-O
site	I-O
was	O
examined	O
for	O
complications	B-O
such	O
as	O
hematoma	B-O
,	O
nerve	B-O
injury	I-O
,	O
and	O
infection	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Calcium	B-I
acetate	I-I
versus	O
calcium	B-I
carbonate	I-I
as	O
phosphate	O
binders	O
in	O
hemodialysis	B-P
patients	I-P
.	O

METHODS	O
:	O
All	O
patients	O
were	O
dialyzed	O
against	O
the	O
same	O
calcium	B-I
dialyzate	I-I
(	O
1	O
.	O
62	O
mmol	O
/	O
l	O
)	O
.	O

The	B-O
serum	I-O
analytical	I-O
tests	I-O
included	O
:	O
calcium	B-O
corrected	I-O
to	I-O
total	I-O
protein	I-O
,	O
P	B-O
,	O
PTH	B-O
(	B-O
intact	I-O
molecule	I-O
)	I-O
and	O
bicarbonate	B-O
.	O

The	O
study	O
was	O
divided	O
into	O
the	O
following	O
periods	O
:	O
P0	O
:	O
baseline	O
measurements	O
;	O
P1	O
:	O
washout	O
(	O
withdrawal	O
of	O
AH	O
for	O
15	O
days	O
)	O
;	O
P2	O
:	O
random	O
allocation	O
to	O
CA	B-I
and	O
CC	B-I
treatment	O
at	O
doses	O
equivalent	O
to	O
75	O
mEq	O
of	O
elemental	O
calcium	O
,	O
stratified	O
according	O
to	O
previous	O
doses	O
of	O
AH	O
(	O
2	O
months	O
)	O
;	O
P3	O
:	O
adjustment	O
of	O
doses	O
until	O
control	O
P	O
(	O
2	O
months	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Outcome	O
at	O
7	O
years	O
of	O
children	B-P
diagnosed	I-P
with	I-P
autism	I-P
at	I-P
age	I-P
2	I-P
:	O
predictive	O
validity	O
of	O
assessments	O
conducted	O
at	O
2	O
and	O
3	O
years	O
of	O
age	O
and	O
pattern	O
of	O
symptom	O
change	O
over	O
time	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
six	I-P
children	I-P
diagnosed	I-P
with	I-P
autism	I-P
at	I-P
age	I-P
2	I-P
were	O
re	O
-	O
assessed	O
at	O
ages	O
3	O
and	O
7	O
years	O
.	O

At	O
each	O
age	O
symptom	B-O
severity	I-O
,	O
cognitive	B-O
and	O
language	B-O
assessments	I-O
were	O
completed	O
.	O

-DOCSTART-	O

Title	O
:	O
Problem	O
-	O
based	O
learning	O
:	O
is	O
anatomy	O
a	O
casualty	O
?	O
.	O

METHODS	O
:	O
Testing	O
was	O
done	O
using	O
a	B-O
Questionnaire	I-O
in	I-O
a	I-O
"	I-O
True	I-O
/	I-O
False	I-O
"	I-O
format	I-O
.	O

There	O
were	O
80	O
students	O
in	O
each	O
group	O
.	O

There	O
was	O
no	O
penalty	O
for	O
an	O
incorrect	O
answer	O
.	O

The	O
test	O
was	O
performed	O
under	O
examination	O
conditions	O
.	O

Papers	O
were	O
marked	O
under	O
blind	O
conditions	O
.	O

Results	O
were	O
analysed	O
using	O
a	O
Student	O
'	O
s	O
t	O
test	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
home	B-I
strength	I-I
training	I-I
and	I-I
stretching	I-I
versus	O
stretching	B-C
alone	I-C
after	O
lumbar	O
disk	O
surgery	O
:	O
a	O
randomized	O
study	O
with	O
a	O
1	O
-	O
year	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
trial	O
.	O

Departments	O
of	O
physical	O
medicine	O
and	O
rehabilitation	O
and	O
orthopedics	O
at	O
a	O
Finnish	O
hospital	O
.	O

Patients	B-P
(	I-P
N=126	I-P
)	I-P
were	O
randomized	O
into	O
either	O
a	B-I
combined	I-I
strength	I-I
training	I-I
and	I-I
stretching	I-I
group	O
(	O
STG	O
,	O
n=65	O
)	O
or	O
a	O
control	O
group	O
(	O
CG	O
,	O
n=61	O
)	O
.	O

The	O
STG	O
was	O
instructed	O
to	O
perform	O
strength	O
training	O
and	O
both	O
the	O
STG	O
and	O
CG	O
were	O
instructed	O
in	O
the	O
same	O
stretching	O
and	O
stabilization	O
exercises	O
for	O
12	O
months	O
.	O

Pain	B-O
on	O
the	B-O
visual	I-O
analog	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
,	O
the	B-O
Oswestry	I-O
and	I-O
the	I-O
Million	I-O
disability	I-O
indexes	I-O
,	O
isometric	B-O
and	O
dynamic	B-O
trunk	I-O
muscle	I-O
strength	I-O
,	O
mobility	B-O
in	I-O
the	I-O
lumbar	I-O
spine	I-O
,	O
and	O
straight	B-O
-	I-O
leg	I-O
raising	I-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Enhancement	O
of	O
blood	O
glucose	O
lowering	O
effect	O
of	O
a	B-I
sulfonylurea	I-I
when	O
coadministered	O
with	O
an	B-I
ACE	I-I
inhibitor	I-I
:	O
results	O
of	O
a	O
glucose	O
-	O
clamp	O
study	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
crossover	O
study	O
with	O
nine	B-P
healthy	I-P
normotensive	I-P
volunteers	I-P
(	I-P
age	I-P
27	I-P
+	I-P
/	I-P
-	I-P
3	I-P
y	I-P
,	I-P
BMI	I-P
23	I-P
.	I-P
3	I-P
+	I-P
/	I-P
-	I-P
2	I-P
.	I-P
0	I-P
kg	I-P
m	I-P
(	I-P
-	I-P
2	I-P
)	I-P
;	I-P
mean	I-P
+	I-P
/	I-P
-	I-P
SD	I-P
)	I-P
-	O
randomly	O
assigned	O
to	O
a	O
3	O
-	O
day	O
treatment	O
of	O
either	O
5	B-I
mg	I-I
enalapril	I-I
or	O
placebo	B-C
.	O

In	O
the	O
morning	O
of	O
the	O
fourth	O
day	O
,	O
volunteers	O
orally	O
received	O
3	B-I
.	I-I
5	I-I
mg	I-I
glibenclamide	I-I
together	O
with	O
either	O
10	B-I
mg	I-I
enalapril	I-I
or	O
placebo	B-C
.	O

Blood	B-O
glucose	I-O
levels	I-O
of	O
volunteers	O
were	O
allowed	O
to	O
fall	O
by	O
10	O
%	O
from	O
fasting	O
levels	O
and	O
were	O
kept	O
constant	O
thereafter	O
by	O
employing	O
a	B-O
Biostator	I-O
-	I-O
based	I-O
euglycemic	I-O
glucose	I-O
clamp	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
of	O
urinary	O
and	O
sexual	O
outcomes	O
in	O
women	O
experiencing	O
vaginal	B-I
and	O
Caesarean	B-I
births	I-I
.	O

METHODS	O
:	O
We	O
performed	O
a	O
cohort	O
analysis	O
of	O
data	O
from	O
a	O
randomized	O
controlled	O
trial	O
of	O
episiotomy	O
conducted	O
in	O
3	O
Montreal	O
hospitals	O
in	O
1990	O
-	O
1991	O
.	O

Of	O
the	O
999	B-P
trial	I-P
participants	I-P
for	I-P
whom	I-P
follow	I-P
-	I-P
up	I-P
data	I-P
were	I-P
available	I-P
,	O
135	O
delivered	O
by	O
Caesarean	B-I
section	I-I
(	I-I
CS	I-I
)	I-I
,	O
and	O
864	O
had	O
a	B-I
vaginal	I-I
birth	I-I
(	I-I
VB	I-I
)	I-I
.	O

After	O
stratifying	O
for	O
parity	O
,	O
we	O
compared	O
rates	B-O
of	I-O
urinary	I-O
incontinence	I-O
(	I-O
UI	I-O
)	I-O
and	O
sexual	B-O
functioning	I-O
at	O
3	O
months	O
postpartum	O
in	O
women	O
who	O
had	O
a	B-I
VB	I-I
with	O
the	O
rates	O
in	O
women	O
who	O
had	O
a	B-I
CS	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
,	O
tolerability	O
,	O
and	O
changes	O
in	O
amyloid	O
beta	O
concentrations	O
after	O
administration	O
of	O
a	B-I
gamma	I-I
-	I-I
secretase	I-I
inhibitor	I-I
in	O
volunteers	O
.	O

METHODS	O
:	O
Volunteer	B-P
subjects	I-P
(	I-P
N	I-P
=	I-P
37	I-P
)	I-P
were	O
studied	O
using	O
doses	B-I
from	I-I
5	I-I
to	I-I
50	I-I
mg	I-I
/	I-I
day	I-I
given	O
for	O
14	O
days	O
.	O

Plasma	B-O
and	O
CSF	B-O
concentrations	I-O
of	I-O
LY450139	I-O
,	O
Abeta	B-O
(	I-O
1	I-O
-	I-O
40	I-O
)	I-O
and	O
Abeta	B-O
(	I-O
1	I-O
-	I-O
X	I-O
)	I-O
(	B-O
"	I-O
Abeta	I-O
(	I-O
total	I-O
)	I-O
"	I-O
)	I-O
were	O
determined	O
,	O
and	O
safety	B-O
and	O
tolerability	B-O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
assessment	O
of	O
erythema	O
and	O
thickness	O
on	O
burn	O
related	O
scars	O
during	O
pressure	B-I
garment	I-I
therapy	I-I
as	O
a	O
preventive	O
measure	O
for	O
hypertrophic	O
scarring	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
prospective	O
trial	O
in	O
which	O
76	B-P
burn	I-P
scars	I-P
in	I-P
60	I-P
patients	I-P
were	O
objectively	O
assessed	O
with	O
the	B-O
Minolta	I-O
Chromameter	I-O
CR	I-O
-	I-O
300	I-O
for	O
erythema	B-O
and	O
with	O
the	B-O
Dermascan	I-O
C	I-O
for	O
thickness	B-O
of	I-O
the	I-O
scar	I-O
over	O
a	O
period	O
of	O
3	O
months	O
.	O

Each	O
patient	O
was	O
randomly	O
assigned	O
to	O
a	B-I
"	I-I
normal	I-I
"	I-I
or	O
"	O
lower	B-I
"	I-I
compression	I-I
class	I-I
treatment	I-I
,	O
with	O
respectively	O
mean	O
values	O
of	O
15	O
and	O
10	O
mmHg	O
pressure	O
after	O
wearing	O
the	O
garment	O
for	O
1	O
month	O
.	O

Measurements	O
for	O
both	O
parameters	O
were	O
taken	O
at	O
0	O
,	O
1	O
,	O
2	O
and	O
3	O
months	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Determinants	O
of	O
the	O
effect	O
of	O
estrogen	B-I
on	O
the	O
progression	O
of	O
subclinical	O
atherosclerosis	O
:	O
Estrogen	B-I
in	O
the	O
Prevention	O
of	O
Atherosclerosis	O
Trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
center	O
trial	O
enrolling	O
222	B-P
postmenopausal	I-P
women	I-P
45	I-P
years	I-P
and	I-P
older	I-P
without	I-P
cardiovascular	I-P
disease	I-P
and	I-P
with	I-P
low	I-P
-	I-P
density	I-P
lipoprotein	I-P
(	I-P
LDL	I-P
)	I-P
cholesterol	I-P
levels	I-P
of	I-P
3	I-P
.	I-P
37	I-P
mmol	I-P
/	I-P
L	I-P
or	I-P
greater	I-P
(	I-P
>	I-P
or	I-P
=	I-P
130	I-P
mg	I-P
/	I-P
dL	I-P
)	I-P
.	O

Intervention	O
was	O
unopposed	B-I
micronized	I-I
17beta	I-I
-	I-I
estradiol	I-I
versus	O
placebo	B-C
.	O

Measurements	O
were	O
made	O
using	O
high	B-O
-	I-O
resolution	I-O
B	I-O
-	I-O
mode	I-O
ultrasonography	I-O
to	O
measure	O
carotid	B-O
artery	I-O
IMT	I-O
at	O
baseline	O
and	O
every	O
6	O
months	O
on	O
-	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
Reactivation	O
of	O
unstable	O
angina	O
after	O
the	B-I
discontinuation	I-I
of	I-I
heparin	I-I
.	O

METHODS	O
:	O
The	O
study	O
population	O
included	O
403	B-P
of	I-P
the	I-P
original	I-P
479	I-P
patients	I-P
in	I-P
the	I-P
trial	I-P
who	I-P
had	I-P
completed	I-P
six	I-P
days	I-P
of	I-P
blinded	I-P
therapy	I-P
without	I-P
refractory	I-P
angina	I-P
or	I-P
myocardial	I-P
infarction	I-P
.	O

After	O
the	B-I
discontinuation	I-I
of	I-I
therapy	I-I
,	O
clinical	B-O
events	I-O
,	O
including	O
reactivation	B-O
of	I-O
unstable	I-O
angina	I-O
and	O
myocardial	B-O
infarction	I-O
occurring	O
within	O
96	O
hours	O
after	O
hospitalization	O
,	O
were	O
closely	O
monitored	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
immunogenicity	O
of	O
an	B-I
oral	I-I
,	O
inactivated	B-I
,	O
whole	B-I
-	I-I
cell	I-I
vaccine	I-I
for	I-I
Shigella	I-I
sonnei	I-I
:	O
preclinical	O
studies	O
and	O
a	O
Phase	O
I	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
Phase	O
I	O
study	O
,	O
10	B-I
evaluable	I-I
subjects	I-I
received	O
either	O
three	B-I
doses	I-I
of	I-I
SsWC	I-I
on	O
Days	O
0	O
,	O
14	O
,	O
and	O
28	O
(	O
N	O
=	O
3	O
)	O
;	O
five	B-I
doses	I-I
of	I-I
SsWC	I-I
on	O
Days	O
0	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
28	O
(	O
N	O
=	O
4	O
)	O
;	O
or	O
placebo	B-C
(	O
N	O
=	O
3	O
)	O
.	O

Each	O
dose	O
contained	O
2	B-I
.	I-I
0	I-I
x	I-I
10	I-I
(	I-I
10	I-I
)	I-I
inactivated	I-I
cells	I-I
.	O

Serum	B-O
and	O
fecal	B-O
antibodies	I-O
against	I-O
SsWC	I-O
,	O
LPS	B-O
,	O
and	O
IpaC	B-O
were	O
measured	O
by	O
ELISA	B-O
.	O

A	O
>	O
or	O
=	O
4	O
-	O
fold	O
increase	O
in	O
titer	O
was	O
considered	O
significant	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
exercise	B-I
,	O
training	B-I
,	O
and	O
glycogen	B-I
availability	I-I
on	O
IL	O
-	O
6	O
receptor	O
expression	O
in	O
human	O
skeletal	O
muscle	O
.	O

METHODS	O
:	O
Human	B-P
subjects	I-P
performed	O
either	O
10	B-I
wk	I-I
of	I-I
training	I-I
with	I-I
an	I-I
acute	I-I
exercise	I-I
bout	O
before	O
and	O
after	O
the	O
training	O
period	O
,	O
or	O
a	B-I
low	I-I
-	I-I
glycogen	I-I
vs	O
.	O
normal	B-I
-	I-I
glycogen	I-I
acute	I-I
exercise	I-I
trial	I-I
.	O

The	B-O
IL	I-O
-	I-O
6R	I-O
mRNA	I-O
response	I-O
was	O
evaluated	O
in	O
both	O
trials	O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
blind	O
,	O
placebo	O
controlled	O
study	O
of	O
metronidazole	B-I
as	O
a	O
disease	O
modifying	O
agent	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

METHODS	O
:	O
Fifty	B-P
patients	I-P
with	I-P
active	I-P
rheumatoid	I-P
arthritis	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
active	O
drug	O
(	O
n	O
=	O
24	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
26	O
)	O
and	O
reviewed	O
at	O
weeks	O
0	O
,	O
1	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
and	O
24	O
.	O

Detailed	O
assessment	O
of	O
drug	B-O
safety	I-O
,	O
biochemical	B-O
and	O
haematological	B-O
parameters	I-O
,	O
and	O
efficacy	B-O
was	O
made	O
at	O
these	O
dates	O
.	O

Dose	O
regimen	O
was	O
400	O
mg	O
twice	O
daily	O
from	O
weeks	O
0	O
to	O
eight	O
,	O
increasing	O
to	O
400	O
mg	O
three	O
times	O
a	O
day	O
from	O
weeks	O
nine	O
to	O
24	O
provided	O
that	O
no	O
adverse	B-O
effects	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Usage	O
of	O
titanoreine	B-I
after	O
procedure	O
for	O
prolapse	O
and	O
hemorrhoids	O
]	O
.	O

METHODS	O
:	O
From	O
November	O
2002	O
to	O
July	O
2003	O
,	O
80	B-P
patients	I-P
who	I-P
received	I-P
PPH	I-P
were	O
randomly	O
divided	O
in	O
to	O
titanoreine	B-I
group	O
(	O
n=42	O
)	O
and	O
control	O
group	O
without	B-C
titanoreine	I-C
(	O
n=38	O
)	O
.	O

Symptom	B-O
relief	I-O
was	O
recorded	O
24	O
hours	O
,	O
6	O
days	O
and	O
12	O
days	O
after	O
PPH	O
,	O
urine	B-O
retention	I-O
24h	O
after	O
PPH	O
,	O
first	B-O
stool	I-O
time	I-O
,	O
wound	B-O
healing	I-O
time	I-O
,	O
mean	B-O
hospital	I-O
stay	I-O
were	O
also	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Family	B-I
education	I-I
for	O
people	B-P
with	I-P
schizophrenia	I-P
in	I-P
Beijing	I-P
,	I-P
China	I-P
:	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomised	O
controlled	O
trial	O
was	O
conducted	O
in	O
a	O
large	O
hospital	O
with	O
a	O
was	O
conducted	O
in	O
a	O
large	O
hospital	O
with	O
a	B-P
sample	I-P
of	I-P
101	I-P
patients	I-P
with	I-P
schizophrenia	I-P
and	I-P
their	I-P
families	I-P
.	O

Data	O
were	O
collected	O
at	O
admission	O
and	O
at	O
discharge	O
,	O
and	O
then	O
at	O
3	O
and	O
9	O
months	O
after	O
discharge	O
.	O

The	O
intervention	O
group	O
received	O
family	B-I
education	I-I
,	O
and	O
data	O
on	O
their	O
knowledge	B-O
about	I-O
schizophrenia	I-O
,	O
symptoms	B-O
,	O
functioning	B-O
,	O
psychosocial	B-O
behaviour	I-O
,	O
relapse	B-O
and	O
medication	B-O
adherence	I-O
were	O
collected	O
and	O
compared	O
with	O
the	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Single	O
-	O
use	O
plaque	O
removal	O
efficacy	O
of	O
three	B-I
power	I-I
toothbrushes	I-I
.	O

METHODS	O
:	O
After	O
refraining	O
from	O
all	O
oral	O
hygiene	O
procedures	O
for	O
23	O
-	O
25	O
hours	O
,	O
subjects	B-P
received	I-P
an	I-P
oral	I-P
tissue	I-P
examination	I-P
and	I-P
those	I-P
with	I-P
pre	I-P
-	I-P
brushing	I-P
whole	I-P
mouth	I-P
mean	I-P
plaque	I-P
scores	I-P
>	I-P
or	I-P
=	I-P
0	I-P
.	I-P
6	I-P
based	I-P
on	I-P
the	I-P
Rustogi	I-P
et	I-P
al	I-P
.	I-P

Modified	I-P
Navy	I-P
Plaque	I-P
Index	I-P
were	O
randomly	O
assigned	O
to	O
treatment	O
sequence	O
.	O

After	O
brushing	O
with	O
the	B-I
assigned	I-I
toothbrush	I-I
and	O
a	O
commercially	O
available	O
dentifrice	O
for	O
2	O
minutes	O
,	O
oral	B-O
tissues	I-O
were	O
then	O
re	O
-	O
examined	O
and	O
post	B-O
-	I-O
brushing	I-O
plaque	I-O
scores	I-O
recorded	O
.	O

Following	O
a	O
brief	O
washout	O
period	O
between	O
two	O
additional	O
visits	O
,	O
the	O
above	O
procedures	O
were	O
repeated	O
with	O
the	O
two	O
alternate	O
toothbrushes	O
.	O

One	O
examiner	O
,	O
blinded	O
to	O
the	O
treatment	O
sequence	O
,	O
performed	O
all	O
clinical	O
measurements	O
.	O

-DOCSTART-	O

Title	O
:	O
Intensive	B-I
behavioral	I-I
treatment	I-I
for	O
children	B-P
with	I-P
autism	I-P
:	O
four	O
-	O
year	O
outcome	O
and	O
predictors	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
children	I-P
with	I-P
autism	I-P
were	O
randomly	O
assigned	O
to	O
a	B-I
clinic	I-I
-	I-I
directed	I-I
group	O
,	O
replicating	O
the	O
parameters	O
of	O
the	B-I
early	I-I
intensive	I-I
behavioral	I-I
treatment	I-I
developed	O
at	O
UCLA	O
,	O
or	O
to	O
a	O
parent	O
-	O
directed	O
group	O
that	O
received	O
intensive	B-I
hours	I-I
but	I-I
less	I-I
supervision	I-I
by	I-I
equally	I-I
well	I-I
-	I-I
trained	I-I
supervisors	I-I
.	O

Outcome	O
after	O
4	O
years	O
of	O
treatment	O
,	O
including	O
cognitive	B-O
,	O
language	B-O
,	O
adaptive	B-O
,	O
social	B-O
,	O
and	O
academic	B-O
measures	I-O
,	O
was	O
similar	O
for	O
both	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
trials	O
of	O
intrasplenic	B-I
arterial	I-I
infusion	I-I
of	I-I
interleukin	I-I
-	I-I
2	I-I
(	I-I
IS	I-I
-	I-I
IL	I-I
-	I-I
2	I-I
)	I-I
to	O
patients	B-P
with	I-P
advanced	I-P
cancer	I-P
.	O

METHODS	O
:	O
Eighteen	B-P
patients	I-P
of	I-P
colorectal	I-P
cancer	I-P
with	I-P
metastases	I-P
to	I-P
the	I-P
liver	I-P
or	I-P
lung	I-P
or	I-P
of	I-P
unresectable	I-P
hepatoma	I-P
received	O
a	B-I
24	I-I
hour	I-I
continuous	I-I
infusion	I-I
with	I-I
low	I-I
dose	I-I
recombinant	I-I
of	I-I
IL	I-I
-	I-I
2	I-I
(	O
mainly	O
8	O
x	O
10	O
(	O
5	O
)	O
JRU	O
/	O
day	O
)	O
for	O
25	O
-	O
40	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
effects	O
of	O
risperidone	B-I
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
placebo	O
discontinuation	O
study	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
six	I-P
children	I-P
with	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
5	I-P
-	I-P
17	I-P
years	I-P
old	I-P
)	I-P
accompanied	I-P
by	I-P
severe	I-P
tantrums	I-P
,	I-P
aggression	I-P
,	I-P
or	I-P
self	I-P
-	I-P
injurious	I-P
behavior	I-P
,	O
started	O
8	B-I
-	I-I
week	I-I
open	I-I
-	I-I
label	I-I
treatment	I-I
with	I-I
risperidone	I-I
.	O

Responders	O
(	O
n	O
=	O
26	O
)	O
continued	O
treatment	O
for	O
another	O
16	O
weeks	O
,	O
followed	O
by	O
a	O
double	O
-	O
blind	O
discontinuation	O
(	O
n	O
=	O
24	O
;	O
two	O
patients	O
discontinued	O
treatment	O
because	O
of	O
weight	O
gain	O
)	O
consisting	O
of	O
either	B-I
3	I-I
weeks	I-I
of	I-I
taper	I-I
and	O
5	B-C
weeks	I-C
of	I-C
placebo	I-C
only	I-C
or	O
continuing	B-I
use	I-I
of	I-I
risperidone	I-I
.	O

Relapse	B-O
was	O
defined	O
as	O
a	B-O
significant	I-O
deterioration	I-O
of	I-O
symptoms	I-O
based	I-O
on	I-O
clinical	I-O
judgment	I-O
and	O
a	B-O
parent	I-O
questionnaire	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
antihypertensives	B-I
after	O
coronary	O
artery	O
surgery	O
.	O

METHODS	O
:	O
Diltiazem	B-I
was	O
administered	O
as	O
an	O
intravenous	O
bolus	O
of	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
within	O
5	O
min	O
,	O
followed	O
by	O
infusion	O
of	O
0	O
.	O
1	O
-	O
0	O
.	O

8	O
mg	O
.	O
kg	O
-	O
1	O
.	O
h	O
-	O
1	O
in	O
group	O
1	O
.	O

Nitroglycerin	B-I
was	O
infused	O
at	O
a	O
rate	O
of	O
1	O
-	O
3	O
microg	O
.	O
kg	O
.	O
h	O
-	O
1	O
in	O
group	O
2	O
,	O
and	O
sodium	B-I
nitroprusside	I-I
was	O
given	O
at	O
a	O
rate	O
of	O
1	O
-	O
3	O
microg	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
in	O
group	O
3	O
.	O

Hemodynamic	B-O
measurements	I-O
were	O
carried	O
out	O
before	O
infusion	O
(	O
T1	O
)	O
and	O
at	O
30	O
min	O
(	O
T2	O
)	O
,	O
2	O
h	O
(	O
T3	O
)	O
,	O
and	O
12	O
h	O
(	O
T4	O
)	O
after	O
initiation	O
of	O
treatment	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

-DOCSTART-	O

Title	O
:	O
Phytase	B-I
and	O
1alpha	B-I
-	I-I
hydroxycholecalciferol	I-I
supplementation	I-I
of	O
broiler	B-P
chickens	I-P
during	O
the	O
starting	O
and	O
growing	O
/	O
finishing	O
phases	O
.	O

METHODS	O
:	O
In	O
both	O
experiments	O
,	O
at	O
least	O
4	O
replicates	O
per	O
treatment	O
(	O
50	O
chicks	O
per	O
replicate	O
)	O
were	O
used	O
.	O

Corn	B-I
-	I-I
soybean	I-I
-	I-I
meal	I-I
-	O
and	O
soybean	B-I
-	I-I
oil	I-I
-	I-I
based	I-I
diets	I-I
were	O
fed	O
and	O
birds	O
were	O
raised	O
in	O
a	O
house	O
impervious	O
to	O
ultraviolet	O
light	O
.	O

During	O
the	O
starter	O
phase	O
(	O
ST	O
)	O
,	O
from	O
0	O
to	O
18	O
d	O
,	O
chicks	O
were	O
fed	O
a	O
23	O
%	O
CP	O
diet	O
containing	O
0	O
.	O
60	O
%	O
Ca	O
and	O
0	O
.	O
47	O
%	O
total	O
P	O
(	O
tP	O
)	O
.	O

During	O
the	O
grower	O
/	O
finisher	O
phase	O
(	O
GF	O
)	O
,	O
from	O
19	O
to	O
35	O
d	O
,	O
birds	O
were	O
fed	O
a	O
19	O
%	O
CP	O
diet	O
containing	O
0	O
.	O
30	O
%	O
Ca	O
and	O
0	O
.	O
37	O
%	O
tP	O
.	O

A	B-I
combination	I-I
of	I-I
1	I-I
,	I-I
000	I-I
phytase	I-I
units	I-I
/	I-I
kg	I-I
of	I-I
Natuphos	I-I
phytase	I-I
and	O
5	B-I
microg	I-I
/	I-I
kg	I-I
of	I-I
1alpha	I-I
-	I-I
OHD3	I-I
(	I-I
P	I-I
+	I-I
1A	I-I
)	I-I
was	O
supplemented	O
to	O
some	O
of	O
the	O
feed	O
during	O
the	O
ST	O
and	O
GF	O
.	O

Diets	O
containing	O
adequate	O
Ca	O
and	O
P	O
were	O
also	O
fed	O
during	O
the	O
ST	O
(	O
0	O
.	O
90	O
%	O
Ca	O
,	O
0	O
.	O
68	O
%	O
tP	O
)	O
and	O
GF	O
(	O
0	O
.	O
80	O
%	O
Ca	O
,	O
0	O
.	O
67	O
%	O
tP	O
)	O
.	O

Performance	B-O
characteristics	I-O
and	O
the	B-O
incidence	I-O
of	I-O
rickets	I-O
and	I-O
tibial	I-O
dyschondroplasia	I-O
were	O
measured	O
at	O
18	O
and	O
35	O
d	O
.	O

In	O
experiment	O
1	O
,	O
unsupplemented	O
chicks	O
performed	O
well	O
but	O
had	O
considerable	O
leg	O
problems	O
.	O

-DOCSTART-	O

Title	O
:	O
Project	O
Towards	O
No	O
Drug	O
Abuse	O
:	O
long	O
-	O
term	O
substance	O
use	O
outcomes	O
evaluation	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
a	B-I
9	I-I
-	I-I
session	I-I
health	I-I
motivation	I-I
-	I-I
-	I-I
social	I-I
skills	I-I
-	I-I
-	I-I
decision	I-I
-	I-I
making	I-I
curriculum	I-I
were	O
evaluated	O
.	O

Twenty	O
-	O
one	O
schools	O
recruited	O
were	O
randomly	O
assigned	O
to	O
standard	B-C
care	I-C
(	O
control	O
)	O
,	O
classroom	B-I
only	I-I
,	O
or	O
a	B-I
classroom	I-I
plus	O
semester	B-I
-	I-I
long	I-I
school	I-I
-	I-I
as	I-I
-	I-I
community	I-I
component	I-I
.	O

Last	B-O
30	I-O
-	I-O
day	I-O
use	I-O
of	I-O
cigarettes	I-O
,	O
alcohol	B-O
,	O
marijuana	B-O
,	O
and	O
hard	B-O
drugs	I-O
were	O
assessed	O
at	O
three	O
time	O
intervals	O
:	O
short	O
-	O
term	O
(	O
year	O
1	O
)	O
,	O
middle	O
-	O
term	O
(	O
years	O
2	O
or	O
3	O
)	O
,	O
and	O
long	O
-	O
term	O
(	O
years	O
4	O
or	O
5	O
)	O
.	O

Multilevel	O
random	O
coefficients	O
modeling	O
were	O
employed	O
to	O
estimate	O
the	O
adjusted	O
levels	O
of	O
substance	O
use	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
remifentanil	B-I
with	O
fentanyl	B-I
for	O
deep	O
sedation	O
in	O
oral	O
surgery	O
.	O

METHODS	O
:	O
This	O
investigation	O
was	O
designed	O
as	O
a	O
randomized	O
,	O
prospective	O
,	O
single	O
-	O
blinded	O
controlled	O
study	O
.	O

Group	O
1	O
,	O
the	O
control	O
,	O
received	O
midazolam	B-C
0	O
.	O
03	O
mg	O
/	O
kg	O
,	O
fentanyl	B-C
1	O
microg	O
/	O
kg	O
,	O
and	O
propofol	B-C
initially	O
at	O
140	O
microg	O
/	O
kg	O
/	O
min	O
.	O

Group	O
2	O
received	O
midazolam	B-I
0	O
.	O
03	O
mg	O
/	O
kg	O
,	O
remifentanil	B-I
:	O
propofol	B-I
(	O
1	O
:	O
500	O
)	O
given	O
at	O
an	O
initial	O
propofol	O
infusion	O
rate	O
of	O
40	O
microg	O
/	O
kg	O
/	O
min	O
.	O

Outcome	O
measures	O
included	O
time	B-O
to	I-O
response	I-O
to	I-O
verbal	I-O
command	I-O
,	O
Aldrete	B-O
score	I-O
=	I-O
9	I-O
,	O
Postanesthesia	B-O
Discharge	I-O
Scoring	I-O
System	I-O
=	I-O
7	I-O
,	O
and	O
assessment	O
by	O
the	B-O
Digit	I-O
Symbol	I-O
Substitution	I-O
Test	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
rTMS	B-I
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
on	O
Stroop	O
task	O
performance	O
.	O

METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
the	B-I
influence	I-I
of	I-I
high	I-I
-	I-I
frequency	I-I
rTMS	I-I
over	O
the	O
left	O
DLPFC	O
on	O
Stroop	B-O
task	I-O
performance	I-O
in	O
healthy	B-P
female	I-P
volunteers	I-P
was	O
investigated	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Comparison	O
of	O
the	O
efficacy	O
/	O
tolerability	O
ratio	O
of	O
cibenzoline	B-I
and	O
propafenone	B-I
in	O
the	O
treatment	O
of	O
ventricular	O
arrhythmia	O
]	O
.	O

METHODS	O
:	O
After	O
a	O
therapeutic	O
wash	O
-	O
out	O
period	O
corresponding	O
to	O
5	O
times	O
the	O
half	O
-	O
life	O
of	O
previous	O
anti	O
-	O
arrhythmic	O
drugs	O
,	O
patients	B-P
with	I-P
more	I-P
than	I-P
100	I-P
premature	I-P
ventricular	I-P
contractions	I-P
(	I-P
PVC	I-P
)	I-P
per	I-P
hour	I-P
in	I-P
two	I-P
24	I-P
hour	I-P
Holter	I-P
records	I-P
obtained	I-P
at	I-P
an	I-P
interval	I-P
of	I-P
7	I-P
days	I-P
were	O
treated	O
in	O
succession	O
and	O
after	O
randomised	O
by	O
C	B-I
(	O
390	O
mg	O
/	O
day	O
in	O
3	O
divided	O
doses	O
)	O
and	O
P	B-I
(	O
900	O
mg	O
/	O
day	O
in	O
3	O
divided	O
doses	O
)	O
for	O
a	O
period	O
of	O
two	O
weeks	O
,	O
each	O
active	O
sequence	O
being	O
followed	O
by	O
a	O
two	O
week	O
wash	O
-	O
out	O
period	O
.	O

Efficacy	B-O
(	O
based	O
upon	O
the	O
decrease	O
in	O
PVC	B-O
/	I-O
hour	I-O
in	O
a	O
24	O
hour	O
Holter	O
)	O
and	O
tolerability	B-O
were	O
evaluated	O
at	O
the	O
end	O
of	O
each	O
sequence	O
,	O
with	O
samples	O
drawn	O
at	O
the	O
same	O
times	O
for	O
assay	O
of	O
the	O
study	O
drugs	O
.	O

-DOCSTART-	O

Title	O
:	O
Sham	B-I
device	I-I
v	O
inert	B-I
pill	I-I
:	O
randomised	O
controlled	O
trial	O
of	O
two	O
placebo	O
treatments	O
.	O

METHODS	O
:	O
A	O
single	O
blind	O
randomised	O
controlled	O
trial	O
created	O
from	O
the	O
two	O
week	O
placebo	O
run	O
-	O
in	O
periods	O
for	O
two	O
nested	O
trials	O
that	O
compared	O
acupuncture	O
and	O
amitriptyline	O
with	O
their	O
respective	O
placebo	O
controls	O
.	O

Comparison	O
of	O
participants	O
who	O
remained	O
on	O
placebo	B-C
continued	O
beyond	O
the	O
run	O
-	O
in	O
period	O
to	O
the	O
end	O
of	O
the	O
study	O
.	O

Academic	O
medical	O
centre	O
.	O

270	B-P
adults	I-P
with	I-P
arm	I-P
pain	I-P
due	I-P
to	I-P
repetitive	I-P
use	I-P
that	I-P
had	I-P
lasted	I-P
at	I-P
least	I-P
three	I-P
months	I-P
despite	I-P
treatment	I-P
and	I-P
who	I-P
scored	I-P
>	I-P
or	I-P
=3	I-P
on	I-P
a	I-P
10	I-P
point	I-P
pain	I-P
scale	I-P
.	O

Acupuncture	B-I
with	I-I
sham	I-I
device	I-I
twice	O
a	O
week	O
for	O
six	O
weeks	O
or	O
placebo	B-C
pill	I-C
once	O
a	O
day	O
for	O
eight	O
weeks	O
.	O

Arm	B-O
pain	I-O
measured	O
on	O
a	B-O
10	I-O
point	I-O
pain	I-O
scale	I-O
.	O

Secondary	O
outcomes	O
were	O
symptoms	B-O
measured	O
by	O
the	B-O
Levine	I-O
symptom	I-O
severity	I-O
scale	I-O
,	O
function	B-O
measured	O
by	O
Pransky	B-O
'	I-O
s	I-O
upper	I-O
extremity	I-O
function	I-O
scale	I-O
,	O
and	O
grip	B-O
strength	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Perceptual	O
wind	O
-	O
up	O
in	O
the	O
human	O
oesophagus	O
is	O
enhanced	O
by	O
central	B-I
sensitisation	I-I
.	O

METHODS	O
:	O
In	B-P
eight	I-P
healthy	I-P
volunteers	I-P
(	I-P
seven	I-P
males	I-P
;	I-P
mean	I-P
age	I-P
32	I-P
years	I-P
)	I-P
,	O
perception	B-O
at	I-O
pain	I-O
threshold	I-O
to	O
a	B-I
train	I-I
of	I-I
20	I-I
electrical	I-I
stimuli	I-I
applied	O
to	O
the	O
hand	O
and	O
upper	O
oesophagus	O
(	O
UO	O
)	O
at	O
either	O
0	O
.	O
1	O
Hz	O
(	O
control	O
)	O
or	O
2	O
Hz	O
was	O
determined	O
before	O
and	O
one	O
hour	O
after	O
a	O
30	O
minute	O
lower	O
oesophageal	O
acid	O
infusion	O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
prostaglandin	B-I
E1	I-I
for	O
prevention	O
of	O
respiratory	O
failure	O
in	O
high	B-P
risk	I-P
trauma	I-P
patients	I-P
:	O
a	O
prospective	O
clinical	O
trial	O
and	O
correlation	O
with	O
plasma	O
suppressive	O
factors	O
for	O
neutrophil	O
activation	O
.	O

METHODS	O
:	O
Secondary	O
assessments	O
examined	O
the	O
effects	O
of	O
the	B-I
PGE1	I-I
infusion	I-I
on	O
plasma	B-O
mediated	I-O
suppression	I-O
of	I-O
PMN	I-O
superoxide	I-O
production	I-O
and	O
loss	B-O
of	I-O
PMN	I-O
granule	I-O
enzyme	I-O
content	I-O
.	O

METHODS	O
:	O
The	B-O
suppressive	I-O
activity	I-O
of	I-O
the	I-O
patient	I-O
plasma	I-O
was	O
assayed	O
by	O
measurement	O
of	O
normal	B-O
PMN	I-O
superoxide	I-O
production	I-O
relative	I-O
to	I-O
normal	I-O
control	I-O
plasma	I-O
(	O
ratio	B-O
P	I-O
:	I-O
C	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Endurance	B-I
training	I-I
has	O
little	O
effect	O
on	O
active	O
muscle	O
free	O
fatty	O
acid	O
,	O
lipoprotein	O
cholesterol	O
,	O
or	O
triglyceride	O
net	O
balances	O
.	O

METHODS	O
:	O
Eight	B-P
sedentary	I-P
men	I-P
(	I-P
26	I-P
+	I-P
/	I-P
-	I-P
1	I-P
yr	I-P
,	I-P
77	I-P
.	I-P
4	I-P
+	I-P
/	I-P
-	I-P
3	I-P
.	I-P
7	I-P
kg	I-P
)	I-P
were	O
studied	O
in	O
the	O
postprandial	O
state	O
during	O
90	B-I
min	I-I
of	I-I
rest	I-I
and	O
60	B-I
min	I-I
of	I-I
exercise	I-I
twice	O
before	O
(	O
45	O
%	O
and	O
65	O
%	O
V	O
(	O
O2	O
peak	O
)	O
)	O
and	O
twice	O
after	O
9	B-I
wk	I-I
of	I-I
endurance	I-I
training	I-I
(	O
55	O
%	O
and	O
65	O
%	O
posttraining	O
V	O
(	O
O2	O
peak	O
)	O
)	O
.	O

Measurements	O
across	O
an	O
exercising	O
leg	O
were	O
taken	O
to	O
be	O
a	O
surrogate	O
for	O
active	B-O
skeletal	I-O
muscle	I-O
.	O

To	O
determine	O
limb	B-O
lipid	I-O
exchange	I-O
,	O
femoral	B-O
arterial	I-O
and	O
venous	B-O
blood	I-O
samples	I-O
drawn	O
simultaneously	O
at	O
rest	O
and	O
during	O
exercise	O
were	O
analyzed	O
for	O
total	B-O
and	O
individual	B-O
FFA	I-O
(	O
e	O
.	O
g	O
.	O
,	O
palmitate	B-O
,	O
oleate	B-O
)	O
,	O
LDL	B-O
-	I-O
C	I-O
,	O
HDL	B-O
-	I-O
C	I-O
,	O
and	O
TG	B-O
concentrations	I-O
,	O
and	O
limb	B-O
blood	I-O
flow	O
was	O
determined	O
by	O
thermodilution	O
.	O

-DOCSTART-	O

Title	O
:	O
Late	O
miscarriage	O
and	O
preterm	O
birth	O
after	O
treatment	O
with	O
clindamycin	B-I
:	O
a	O
randomised	O
consent	O
design	O
study	O
according	O
to	O
Zelen	O
.	O

METHODS	O
:	O
Randomised	O
consent	O
design	O
for	O
clinical	O
trials	O
according	O
to	O
Zelen	O
.	O

Southeast	O
region	O
of	O
Sweden	O
.	O

A	O
total	O
of	O
9025	O
women	O
were	O
screened	O
in	O
early	O
pregnancy	O
.	O

A	B-P
total	I-P
of	I-P
819	I-P
women	I-P
with	I-P
a	I-P
Nugent	I-P
score	I-P
of	I-P
6	I-P
and	I-P
above	I-P
were	I-P
considered	I-P
to	I-P
have	I-P
BV	I-P
and	I-P
treated	I-P
according	I-P
to	I-P
Zelen	I-P
allocation	I-P
.	O

The	B-O
incidence	I-O
of	I-O
late	I-O
miscarriage	I-O
and	O
spontaneous	B-O
(	I-O
noniatrogenic	I-O
)	I-O
preterm	I-O
birth	I-O
was	O
assessed	O
.	O

Late	B-O
miscarriage	I-O
and	O
spontaneous	B-O
preterm	I-O
delivery	I-O
before	O
37	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Confidential	B-I
registration	I-I
in	O
health	O
services	O
:	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomised	O
controlled	O
trial	O
.	O

Emergency	O
Department	O
,	O
University	O
Hospital	O
of	O
Wales	O
.	O

A	B-P
total	I-P
of	I-P
302	I-P
patients	I-P
aged	I-P
over	I-P
15	I-P
years	I-P
.	O

Binary	B-O
choices	I-O
and	O
ordinal	B-O
visual	I-O
analogue	I-O
scores	I-O
from	O
a	B-O
validated	I-O
questionnaire	I-O
on	O
self	O
reported	O
measures	O
:	O
patient	B-O
ability	I-O
and	O
preference	B-O
to	I-O
speak	I-O
to	I-O
receptionists	I-O
and	O
disclose	B-O
confidential	I-O
information	I-O
without	I-O
being	I-O
overhead	I-O
and	O
concern	B-O
about	I-O
disclosure	I-O
of	I-O
items	I-O
of	I-O
confidential	I-O
personal	I-O
information	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Neurocognitive	O
outcomes	O
in	O
off	B-I
-	I-I
pump	I-I
versus	O
on	B-I
-	I-I
pump	I-I
bypass	I-I
surgery	I-I
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Consecutively	B-P
listed	I-P
candidates	I-P
for	I-P
elective	I-P
bypass	I-P
were	O
randomly	O
assigned	O
to	O
either	O
off	B-I
-	I-I
pump	I-I
or	O
on	B-I
-	I-I
pump	I-I
techniques	I-I
(	O
n	O
=	O
107	O
)	O
.	O

A	B-O
battery	I-O
of	I-O
11	I-O
standardized	I-O
neuropsychological	I-O
tests	I-O
was	O
administered	O
before	O
surgery	O
,	O
and	O
again	O
at	O
2	O
and	O
6	O
months	O
after	O
surgery	O
.	O

The	O
two	O
groups	O
were	O
compared	O
using	O
a	O
range	O
of	O
statistical	O
procedures	O
,	O
including	O
growth	O
modeling	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Profiles	O
of	O
irregular	O
bleeding	O
induced	O
by	O
low	B-I
-	I-I
dose	I-I
hormone	I-I
therapy	I-I
and	O
Chinese	B-I
formulated	I-I
herbs	I-I
products	I-I
]	O
.	O

METHODS	O
:	O
Applied	O
with	O
open	O
-	O
labeled	O
,	O
randomized	O
,	O
and	O
clinical	O
trial	O
design	O
,	O
136	B-P
postmenopausal	I-P
women	I-P
were	O
assigned	O
into	O
four	O
groups	O
:	O
group	O
A	O
:	O
estradiol	B-I
valerate	I-I
(	I-I
E2	I-I
V	I-I
)	I-I
1	O
mg	O
/	O
d	O
+	O
medroxyprogesterone	B-I
acetate	I-I
(	I-I
MPA	I-I
)	I-I
2	O
mg	O
/	O
d	O
;	O
group	O
B	O
:	O
conjugated	B-I
equine	I-I
estrogen	I-I
0	O
.	O
45	O
mg	O
/	O
d	O
+	O
MPA	B-I
2	O
mg	O
/	O
d	O
;	O
group	O
C	O
:	O
tibolone	B-I
1	O
.	O
25	O
mg	O
/	O
d	O
;	O
group	O
D	O
:	O
a	B-I
Chinese	I-I
formulated	I-I
herbs	I-I
product	I-I
(	I-I
Kuntai	I-I
)	I-I
4	O
#	O
tid	O
.	O

Each	O
subject	O
took	O
element	O
calcium	O
400	O
mg	O
/	O
d	O
and	O
vitamin	O
D	O
200	O
IU	O
/	O
d	O
concomitantly	O
.	O

Modified	B-O
Kupperman	I-O
scores	I-O
were	O
assessed	O
on	O
baseline	O
and	O
every	O
3	O
months	O
thereafter	O
and	O
irregular	B-O
bleeding	I-O
was	O
recorded	O
on	O
menopausal	O
diary	O
every	O
day	O
.	O

The	O
duration	O
of	O
this	O
study	O
was	O
1	O
year	O
.	O

Results	O
The	O
efficacies	O
were	O
similar	O
in	O
three	O
HT	O
-	O
managed	O
groups	O
,	O
but	O
was	O
better	O
than	O
in	O
group	O
D	O
,	O
although	O
the	O
latter	O
was	O
also	O
effective	O
in	O
alleviating	O
menopausal	O
symptoms	O
.	O

Hazard	O
ratio	O
(	O
HR	O
)	O
of	O
irregular	O
bleeding	O
was	O
1	O
.	O
00	O
in	O
group	O
C	O
,	O
2	O
.	O
43	O
in	O
group	O
A	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
08	O
-	O
5	O
.	O

46	O
)	O
,	O
3	O
.	O
12	O
in	O
group	O
B	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
42	O
-	O
6	O
.	O

88	O
)	O
,	O
and	O
0	O
.	O
73	O
in	O
group	O
D	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
26	O
-	O
2	O
.	O
04	O
)	O
.	O

Most	O
cases	O
initially	O
experienced	O
bleeding	O
in	O
the	O
first	O
3	O
months	O
but	O
such	O
initiation	O
was	O
a	O
bit	O
later	O
in	O
group	O
C	O
.	O

Endometrium	O
,	O
as	O
detected	O
by	O
B	O
-	O
mode	O
ultrasound	O
,	O
increased	O
approximately	O
1	O
mm	O
in	O
HT	O
groups	O
,	O
while	O
it	O
was	O
a	O
bit	O
thicker	O
in	O
group	O
C	O
.	O

Long	O
periods	O
in	O
reproductive	O
age	O
and	O
short	O
time	O
since	O
menopause	O
were	O
high	O
risk	O
factors	O
for	O
irregular	O
bleeding	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
clinical	O
trial	O
of	O
clinician	B-I
feedback	I-I
to	O
improve	O
quality	O
of	O
care	O
for	O
inner	B-P
-	I-P
city	I-P
children	I-P
with	I-P
asthma	I-P
.	O

METHODS	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
the	B-O
effectiveness	I-O
of	O
timely	B-I
patient	I-I
feedback	I-I
in	O
the	O
form	O
of	O
a	O
letter	O
providing	O
recent	O
patient	B-O
-	I-O
specific	I-O
symptoms	I-O
,	O
medication	B-O
,	O
and	O
health	B-O
service	I-O
use	I-O
combined	I-O
with	I-O
guideline	I-O
-	I-O
based	I-O
recommendations	I-O
for	I-O
changes	I-O
in	I-O
therapy	I-O
on	O
improving	O
the	B-O
quality	I-O
of	I-O
asthma	I-O
care	I-O
by	I-O
inner	I-O
-	I-O
city	I-O
primary	I-O
care	I-O
providers	I-O
and	O
on	O
resultant	B-O
asthma	I-O
morbidity	I-O
.	O

This	O
was	O
a	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
in	O
5	B-P
-	I-P
to	I-P
11	I-P
-	I-P
year	I-P
-	I-P
old	I-P
children	I-P
(	I-P
n	I-P
=	I-P
937	I-P
)	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
asthma	I-P
receiving	O
health	O
care	O
in	O
hospital	O
-	O
and	O
community	O
-	O
based	O
clinics	O
and	O
private	O
practices	O
in	O
7	O
inner	O
-	O
city	O
urban	O
areas	O
.	O

The	O
caretaker	O
of	O
each	O
child	O
received	O
a	O
bimonthly	O
telephone	O
call	O
to	O
collect	O
clinical	B-O
information	I-O
about	I-O
the	I-O
child	I-O
'	I-O
s	I-O
asthma	I-O
.	O

For	O
a	O
full	O
year	O
,	O
the	O
providers	O
of	O
intervention	O
group	O
children	O
received	O
bimonthly	B-O
computer	I-O
-	I-O
generated	I-O
letters	I-O
based	O
on	O
these	O
calls	O
summarizing	O
the	B-O
child	I-O
'	I-O
s	I-O
asthma	I-O
symptoms	I-O
,	O
health	B-O
service	I-O
use	I-O
,	O
and	O
medication	B-O
use	I-O
with	O
a	O
corresponding	O
recommendation	O
to	O
step	O
up	O
or	O
step	O
down	O
medications	O
.	O

We	O
measured	O
the	B-O
number	I-O
and	O
proportion	B-O
of	I-O
scheduled	I-O
visits	I-O
resulting	O
in	O
stepping	O
up	O
of	O
medications	O
,	O
asthma	B-O
symptoms	I-O
(	O
2	O
-	O
week	O
recall	O
)	O
,	O
and	O
health	B-O
care	I-O
use	I-O
(	O
2	O
-	O
month	O
recall	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Paraesthesia	O
during	O
the	B-I
needle	I-I
-	I-I
through	I-I
-	I-I
needle	I-I
and	O
the	B-I
double	I-I
segment	I-I
technique	I-I
for	O
combined	O
spinal	O
epidural	O
anaesthesia	O
.	O

METHODS	O
:	O
We	O
randomly	O
allocated	O
116	B-P
parturients	I-P
undergoing	I-P
elective	I-P
Caesarean	I-P
section	I-P
to	O
receive	O
anaesthesia	O
using	O
one	O
of	O
these	O
techniques	O
.	O

Both	O
techniques	O
were	O
performed	O
using	O
a	B-I
27G	I-I
pencil	I-I
point	I-I
needle	I-I
,	O
an	B-I
18G	I-I
Tuohy	I-I
needle	I-I
,	O
and	O
a	B-I
20G	I-I
multiport	I-I
epidural	I-I
catheter	I-I
from	O
the	O
same	O
manufacturer	O
.	O

-DOCSTART-	O

Title	O
:	O
Psychological	O
well	O
-	O
being	O
correlates	O
with	O
free	O
thyroxine	O
but	O
not	O
free	O
3	O
,	O
5	O
,	O
3	O
'	O
-	O
triiodothyronine	O
levels	O
in	O
patients	O
on	O
thyroid	B-I
hormone	I-I
replacement	I-I
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
relationship	O
between	O
psychological	B-O
well	I-O
-	I-O
being	I-O
and	O
free	O
T	O
(	O
4	O
)	O
(	O
fT4	O
)	O
,	O
free	O
T	O
(	O
3	O
)	O
(	O
fT3	O
)	O
,	O
TSH	O
,	O
and	O
total	O
rT	O
(	O
3	O
)	O
in	O
697	B-P
patients	I-P
on	O
thyroid	B-I
hormone	I-I
replacement	I-I
therapy	I-I
at	O
entry	O
to	O
a	O
randomized	O
,	O
controlled	O
trial	O
of	O
combined	B-I
T	I-I
(	I-I
4	I-I
)	I-I
and	O
T	B-I
(	I-I
3	I-I
)	I-I
replacement	I-I
therapy	I-I
.	O

All	O
patients	O
were	O
on	O
100	B-I
mug	I-I
or	O
more	B-I
T	I-I
(	I-I
4	I-I
)	I-I
.	O

Psychological	B-O
well	I-O
-	I-O
being	I-O
was	O
assessed	O
with	O
General	B-O
Health	I-O
Questionnaire	I-O
-	I-O
12	I-O
(	I-O
GHQ	I-O
-	I-O
12	I-O
)	I-O
,	O
Thyroid	B-O
Symptom	I-O
Questionnaire	I-O
,	O
and	O
Hospital	B-O
Anxiety	I-O
and	I-O
Depression	I-O
Scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Specific	B-I
immunoglobulin	I-I
for	O
treatment	O
of	O
whooping	O
cough	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
conducted	O
at	O
three	O
Swedish	O
hospitals	O
.	O

We	O
enrolled	O
73	B-P
children	I-P
aged	I-P
less	I-P
than	I-P
36	I-P
months	I-P
who	I-P
were	I-P
admitted	I-P
with	I-P
a	I-P
clinical	I-P
diagnosis	I-P
of	I-P
whooping	I-P
cough	I-P
.	O

On	O
admission	O
they	O
were	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
(	O
a	O
)	O
monocomponent	B-I
pertussis	I-I
toxoid	I-I
vaccine	I-I
;	O
(	O
b	O
)	O
two	B-I
-	I-I
component	I-I
acellular	I-I
vaccine	I-I
also	I-I
containing	I-I
filamentous	I-I
haemagglutinin	I-I
;	O
or	O
(	O
c	O
)	O
20	B-C
%	I-C
albumin	I-C
solution	I-C
(	O
placebo	B-C
)	O
.	O

The	B-I
immunoglobulins	I-I
had	O
a	O
high	O
antitoxin	O
content	O
and	O
had	O
been	O
raised	O
with	O
acellular	O
pertussis	O
vaccines	O
.	O

-DOCSTART-	O

Title	O
:	O
Teaching	O
young	B-P
nonverbal	I-P
children	I-P
with	I-P
autism	I-P
useful	O
speech	O
:	O
a	O
pilot	O
study	O
of	O
the	O
Denver	O
Model	O
and	O
PROMPT	O
interventions	O
.	O

METHODS	O
:	O
Ten	B-P
young	I-P
,	I-P
nonverbal	I-P
children	I-P
with	I-P
autism	I-P
were	O
matched	O
in	O
pairs	O
and	O
randomized	O
to	O
treatment	O
.	O

They	O
received	O
12	B-I
1	I-I
-	I-I
h	I-I
weekly	I-I
sessions	I-I
of	I-I
therapy	I-I
and	O
daily	B-I
1	I-I
-	I-I
h	I-I
home	I-I
intervention	I-I
delivered	O
by	O
parents	O
.	O

Fidelity	B-O
criteria	I-O
were	O
maintained	O
throughout	O
.	O

-DOCSTART-	O

Title	O
:	O
Gemcitabine	B-I
and	O
split	B-I
-	I-I
dose	I-I
paclitaxel	I-I
or	O
docetaxel	B-I
in	O
metastatic	O
breast	O
cancer	O
:	O
a	O
randomised	O
phase	O
II	O
study	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
210	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
treatment	O
arms	O
:	O
gemcitabine	B-I
1	O
,	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
Days	O
1	O
and	O
8	O
and	O
paclitaxel	B-I
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
3	O
-	O
h	O
infusion	O
on	O
Day	O
1	O
(	O
GP1	O
)	O
;	O
gemcitabine	B-I
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
Days	O
1	O
and	O
8	O
and	O
paclitaxel	B-I
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
1	O
-	O
h	O
infusion	O
on	O
Days	O
1	O
and	O
8	O
(	O
GP2	O
)	O
;	O
gemcitabine	B-I
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
Days	O
1	O
and	O
8	O
and	O
docetaxel	B-I
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
1	O
-	O
h	O
infusion	O
on	O
Days	O
1	O
and	O
8	O
(	O
GD	O
)	O
.	O

Cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Divalproex	B-I
versus	O
placebo	B-C
for	O
the	O
prevention	O
of	O
irritability	O
associated	O
with	O
fluoxetine	O
treatment	O
in	O
autism	O
spectrum	O
disorder	O
.	O

-DOCSTART-	O

Title	O
:	O
Enhanced	O
bioavailability	O
of	O
zeaxanthin	B-I
in	O
a	B-I
milk	I-I
-	I-I
based	I-I
formulation	I-I
of	I-I
wolfberry	I-I
(	I-I
Gou	I-I
Qi	I-I
Zi	I-I
;	I-I
Fructus	I-I
barbarum	I-I
L	I-I
.	I-I
)	I-I
.	O

METHODS	O
:	O
The	O
present	O
study	O
investigated	O
zeaxanthin	B-I
bioavailability	B-O
from	O
three	O
wolfberry	O
formulations	O
.	O

Berries	O
were	O
homogenised	O
in	O
hot	O
(	O
80	O
degrees	O
C	O
)	O
water	O
,	O
warm	O
(	O
40	O
degrees	O
C	O
)	O
skimmed	O
milk	O
and	O
hot	O
(	O
80	O
degrees	O
C	O
)	O
skimmed	O
milk	O
,	O
with	O
freeze	O
drying	O
of	O
each	O
preparation	O
into	O
a	O
powdered	O
form	O
.	O

A	B-I
zeaxanthin	I-I
-	I-I
standardised	I-I
dose	I-I
(	O
15	O
mg	O
)	O
of	O
each	O
was	O
consumed	O
,	O
in	O
randomised	O
order	O
,	O
together	O
with	O
a	B-C
standardised	I-C
breakfast	I-C
by	O
twelve	B-P
healthy	I-P
,	I-P
consenting	I-P
subjects	I-P
in	I-P
a	I-P
cross	I-P
-	I-P
over	I-P
trial	I-P
,	I-P
with	I-P
a	I-P
3	I-P
-	I-P
5	I-P
-	I-P
week	I-P
washout	I-P
period	I-P
between	I-P
treatments	I-P
.	O

Blood	B-O
samples	I-O
were	O
taken	O
via	O
a	O
venous	O
cannula	O
immediately	O
before	O
(	O
fasting	O
)	O
and	O
2	O
,	O
4	O
,	O
6	O
,	O
7	O
,	O
8	O
and	O
10	O
h	O
post	O
-	O
ingestion	O
.	O

Zeaxanthin	B-O
concentration	I-O
in	I-O
the	I-O
triacylglycerol	I-O
-	I-O
rich	I-O
lipoprotein	I-O
fraction	I-O
of	I-O
plasma	I-O
was	O
measured	O
by	O
HPLC	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
zoledronic	B-I
acid	I-I
in	O
patients	B-P
with	I-P
breast	I-P
cancer	I-P
metastatic	I-P
to	I-P
bone	I-P
:	O
a	O
multicenter	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Patients	B-P
diagnosed	I-P
with	I-P
bone	I-P
metastases	I-P
<	I-P
or	I-P
=	I-P
6	I-P
weeks	I-P
prior	I-P
to	I-P
first	I-P
visit	I-P
were	O
enrolled	O
.	O

Zoledronic	B-I
acid	I-I
(	O
4	O
mg	O
)	O
was	O
administered	O
via	O
a	O
15	O
-	O
minute	O
infusion	O
every	O
3	O
or	O
4	O
weeks	O
for	O
12	O
infusions	O
.	O

Skeletal	B-O
-	I-O
related	I-O
events	I-O
(	I-O
SREs	I-O
)	I-O
were	O
defined	O
as	O
pathologic	B-O
bone	I-O
fractures	I-O
,	O
spinal	B-O
cord	I-O
compression	I-O
,	O
surgery	B-O
to	I-O
bone	I-O
,	O
radiation	B-O
therapy	I-O
to	I-O
bone	I-O
,	O
and	O
hypercalcemia	B-O
of	I-O
malignancy	I-O
.	O

Primary	O
efficacy	O
end	O
points	O
were	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
with	I-O
at	I-O
least	I-O
one	I-O
SRE	I-O
and	O
the	B-O
time	I-O
to	I-O
first	I-O
SRE	I-O
.	O

Secondary	O
end	O
points	O
included	O
pain	B-O
,	O
analgesic	B-O
use	I-O
,	O
and	O
quality	B-O
of	I-O
life	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Control	O
of	O
the	O
lumbar	O
neutral	O
zone	O
decreases	O
low	O
back	O
pain	O
and	O
improves	O
self	O
-	O
evaluated	O
work	O
ability	O
:	O
a	O
12	O
-	O
month	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
A	O
randomized	O
controlled	O
study	O
with	O
12	O
months	O
intervention	O
.	O

METHODS	O
:	O
Middle	B-P
-	I-P
aged	I-P
working	I-P
men	I-P
with	I-P
recent	I-P
LBP	I-P
but	I-P
without	I-P
severe	I-P
disability	I-P
were	O
randomly	O
allocated	O
to	O
either	O
a	B-I
training	I-I
(	O
TG	O
,	O
n	O
=	O
52	O
)	O
or	O
control	O
group	O
(	O
CG	O
,	O
n	O
=	O
54	O
)	O
.	O

The	O
aim	O
was	O
to	O
exercise	B-I
twice	O
a	O
week	O
for	O
12	O
months	O
,	O
once	O
guided	O
and	O
once	O
independently	O
.	O

The	O
outcome	O
measures	O
were	O
the	O
changes	O
in	O
intensity	B-O
of	I-O
LBP	I-O
,	O
disability	B-O
,	O
self	B-O
-	I-O
evaluated	I-O
future	I-O
work	I-O
ability	I-O
,	O
and	O
neuromuscular	B-O
fitness	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Rationale	O
and	O
design	O
of	O
the	B-I
Folic	I-I
Acid	I-I
for	O
Vascular	O
Outcome	O
Reduction	O
In	O
Transplantation	O
(	O
FAVORIT	O
)	O
trial	O
.	O

METHODS	O
:	O
FAVORIT	O
is	O
a	O
multicenter	O
double	O
-	O
blind	O
randomized	O
controlled	O
clinical	O
trial	O
.	O

Participants	B-P
are	I-P
clinically	I-P
stable	I-P
renal	I-P
transplant	I-P
recipients	I-P
who	I-P
are	I-P
6	I-P
months	I-P
or	I-P
longer	I-P
posttransplant	I-P
with	I-P
elevated	I-P
tHcy	I-P
.	O

Patients	O
are	O
randomized	O
to	O
a	B-I
multivitamin	I-I
that	O
includes	O
either	O
a	B-I
high	I-I
-	I-I
dose	I-I
or	O
low	B-I
-	I-I
dose	I-I
of	I-I
folic	I-I
acid	I-I
(	O
5	O
or	O
0	O
mg	O
)	O
,	O
vitamin	B-I
B6	I-I
(	O
50	O
or	O
1	O
.	O
4	O
mg	O
)	O
,	O
and	O
vitamin	B-I
B12	I-I
(	O
1000	O
or	O
2	O
microg	O
)	O
.	O

The	O
primary	O
end	O
point	O
is	O
a	O
composite	O
of	O
incident	B-O
or	O
recurrent	B-O
CVD	I-O
outcomes	I-O
,	O
that	O
is	O
,	O
coronary	B-O
heart	I-O
,	O
cerebrovascular	B-O
,	O
or	O
abdominal	B-O
aortic	I-O
/	I-O
lower	I-O
extremity	I-O
arterial	I-O
events	I-O
.	O

A	O
sample	O
size	O
of	O
4000	O
is	O
estimated	O
to	O
provide	O
87	O
%	O
power	O
to	O
detect	O
a	O
20	O
%	O
treatment	O
effect	O
.	O

Recruitment	O
is	O
expected	O
to	O
continue	O
until	O
July	O
2006	O
,	O
with	O
follow	O
-	O
up	O
through	O
June	O
2010	O
.	O

-DOCSTART-	O

Title	O
:	O
Heart	O
rate	O
variability	O
and	O
QT	O
dispersion	O
in	O
patients	B-P
with	I-P
subclinical	I-P
hypothyroidism	I-P
.	O

The	O
effect	O
of	O
subclinical	O
hypothyroidism	O
(	O
SH	O
)	O
on	O
cardiovascular	O
autonomic	O
function	O
and	O
ventricular	O
repolarization	O
has	O
not	O
been	O
yet	O
elucidated	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
dispersion	O
of	O
QT	O
interval	O
,	O
i	O
.	O
e	O
.	O
an	O
index	O
of	O
inhomogeneity	O
of	O
repolarization	O
,	O
and	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
,	O
i	O
.	O
e	O
.	O
a	O
measure	O
of	O
cardiac	O
autonomic	O
modulation	O
,	O
in	O
SH	O
patients	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
42	B-P
patients	I-P
(	I-P
29	I-P
women	I-P
and	I-P
13	I-P
men	I-P
;	I-P
mean	I-P
age	I-P
53	I-P
.	I-P
2	I-P
+	I-P
/	I-P
-	I-P
14	I-P
.	I-P

2	I-P
years	I-P
;	I-P
body	I-P
surface	I-P
area	I-P
1	I-P
.	I-P
76	I-P
+	I-P
/	I-P
-	I-P
0	I-P
.	I-P

14	I-P
m2	I-P
)	I-P
with	I-P
SH	I-P
,	I-P
as	I-P
judged	I-P
by	I-P
elevated	I-P
serum	I-P
TSH	I-P
levels	I-P
(	I-P
>	I-P
3	I-P
.	I-P
6	I-P
mIU	I-P
/	I-P
l	I-P
;	I-P
range	I-P
,	I-P
3	I-P
.	I-P
8	I-P
-	I-P
12	I-P
.	I-P

0	I-P
)	I-P
and	I-P
normal	I-P
free	I-P
thyroid	I-P
hormones	I-P
(	I-P
FT4	I-P
and	I-P
FT3	I-P
)	I-P
and	I-P
30	I-P
euthyroid	I-P
volunteer	I-P
.	O

Subjects	O
with	O
cardiac	O
,	O
metabolic	O
,	O
neurological	O
disease	O
or	O
any	O
other	O
systemic	O
disease	O
that	O
could	O
affect	O
autonomic	O
activity	O
were	O
excluded	O
from	O
the	O
study	O
.	O

Patients	O
with	O
SH	O
and	O
control	O
subjects	O
underwent	O
a	O
full	O
history	O
,	O
physical	O
examination	O
,	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
and	O
24	O
-	O
h	O
ambulatory	O
ECG	O
monitoring	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
treatment	O
with	O
L	O
-	B-I
thyroxine	I-I
on	O
QT	B-O
dispersion	I-O
and	O
HRV	B-O
,	O
15	O
patients	O
with	O
SH	O
were	O
randomly	O
assigned	O
to	O
receive	O
therapy	O
with	O
L	B-I
-	I-I
thyroxine	I-I
.	O

All	O
the	O
subjects	O
were	O
evaluated	O
at	O
enrolment	O
and	O
after	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Virtual	B-I
reality	I-I
exposure	I-I
therapy	I-I
and	O
standard	B-C
(	I-C
in	I-C
vivo	I-C
)	I-C
exposure	I-C
therapy	I-C
in	O
the	O
treatment	O
of	O
fear	O
of	O
flying	O
.	O

METHODS	O
:	O
Eighty	B-P
-	I-P
three	I-P
participants	I-P
with	I-P
FOF	I-P
were	O
randomly	O
assigned	O
to	O
VRE	B-I
,	O
SE	B-C
,	O
or	O
WL	O
.	O

Seventy	O
-	O
five	O
participants	O
,	O
25	O
per	O
group	O
,	O
completed	O
the	O
study	O
.	O

Twenty	O
-	O
three	O
WL	O
participants	O
completed	O
randomly	O
assigned	O
treatment	O
following	O
the	O
waiting	O
period	O
.	O

Treatment	O
consisted	O
of	O
4	B-I
sessions	I-I
of	I-I
anxiety	I-I
management	I-I
training	I-I
followed	O
either	O
by	O
exposure	B-I
to	I-I
a	I-I
virtual	I-I
airplane	I-I
(	I-I
VRE	I-I
)	I-I
or	O
an	B-C
actual	I-C
airplane	I-C
at	I-C
the	I-C
airport	I-C
(	I-C
SE	I-C
)	I-C
conducted	O
over	O
6	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Nordic	B-I
walking	I-I
and	O
chronic	O
low	O
back	O
pain	O
:	O
design	O
of	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
fifty	I-P
patients	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
for	I-P
at	I-P
least	I-P
eight	I-P
weeks	I-P
and	I-P
referred	I-P
to	I-P
a	I-P
specialized	I-P
secondary	I-P
sector	I-P
outpatient	I-P
back	I-P
pain	I-P
clinic	I-P
are	O
included	O
in	O
the	O
study	O
.	O

After	O
completion	O
of	O
the	O
standard	O
back	O
centre	O
treatment	O
patients	O
are	O
randomized	O
into	O
one	O
of	O
three	O
groups	O
:	O
A	O
)	O
Nordic	B-I
Walking	I-I
twice	O
a	O
week	O
for	O
eight	O
weeks	O
under	O
supervision	O
of	O
a	O
specially	O
trained	O
instructor	O
;	O
B	O
)	O
Unsupervised	B-I
Nordic	I-I
Walking	I-I
for	O
eight	O
weeks	O
after	O
one	O
training	O
session	O
with	O
an	O
instructor	O
;	O
C	O
)	O
A	B-I
one	I-I
hour	I-I
motivational	I-I
talk	I-I
including	O
advice	O
to	O
stay	O
active	O
.	O

Outcome	O
measures	O
are	O
pain	B-O
,	O
function	B-O
,	O
overall	B-O
health	I-O
,	O
cardiovascular	B-O
ability	I-O
and	O
activity	B-O
level	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Endocrine	O
response	O
to	O
cataract	B-I
surgery	I-I
under	I-I
total	I-I
intravenous	I-I
anaesthesia	I-I
,	O
local	B-I
anaesthesia	I-I
under	I-I
sedation	I-I
or	O
local	B-I
anaesthesia	I-I
alone	I-I
:	O
a	O
comparative	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Evolution	O
of	O
neuropathy	O
and	O
myopathy	O
during	O
intensive	B-I
vincristine	I-I
/	O
corticosteroid	B-I
chemotherapy	I-I
for	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
vincristine	B-I
was	O
administered	O
by	O
bolus	O
injection	O
followed	O
by	O
a	O
3	O
-	O
day	O
continuous	O
intravenous	O
(	O
IV	O
)	O
infusion	O
(	O
total	O
dose	O
of	O
2	O
.	O
0	O
mg	O
/	O
m2	O
every	O
other	O
week	O
)	O
;	O
the	O
maximum	O
dose	O
of	O
vincristine	B-I
was	O
not	O
arbitrarily	O
limited	O
.	O

Cronassial	B-I
,	O
a	O
mixture	O
of	O
four	O
naturally	O
occurring	O
gangliosides	O
,	O
was	O
administered	O
in	O
a	O
randomized	O
double	O
-	O
blind	O
test	O
to	O
evaluate	O
whether	O
this	O
agent	O
could	O
prevent	O
vincristine	B-O
-	I-O
induced	I-O
neuropathy	I-O
.	O

High	B-I
doses	I-I
of	I-I
dexamethasone	I-I
(	O
50	O
mg	O
/	O
d	O
for	O
3	O
days	O
weekly	O
or	O
every	O
other	O
week	O
)	O
were	O
also	O
prescribed	O
.	O

Patients	O
were	O
monitored	O
every	O
4	O
weeks	O
with	O
comprehensive	B-O
physical	I-O
and	O
neurologic	B-O
examinations	I-O
and	O
electrophysiologic	B-O
studies	I-O
of	I-O
peripheral	I-O
nerve	I-O
function	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Polydioxanone	B-I
sternal	I-I
sutures	I-I
for	O
prevention	O
of	O
sternal	O
dehiscence	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
sixty	I-P
-	I-P
six	I-P
patients	I-P
undergoing	I-P
elective	I-P
cardiac	I-P
surgery	I-P
with	I-P
full	I-P
median	I-P
sternotomy	I-P
and	I-P
having	I-P
body	I-P
surface	I-P
area	I-P
(	I-P
BSA	I-P
)	I-P
less	I-P
than	I-P
1	I-P
.	I-P
5	I-P
m	I-P
(	I-P
2	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
PDS	B-I
(	O
n	O
=	O
181	O
)	O
or	O
stainless	B-C
steel	I-C
(	I-C
SS	I-C
,	I-C
n	I-C
=	I-C
185	I-C
)	I-C
sternal	I-C
approximation	I-C
.	O

The	O
study	O
was	O
focused	O
on	O
aseptic	O
sternal	O
complications	O
,	O
namely	O
bone	B-O
dehiscence	I-O
and	O
superficial	B-O
wound	I-O
instability	I-O
.	O

-DOCSTART-	O

Title	O
:	O
B	B-I
-	I-I
vitamins	I-I
reduce	O
plasma	O
levels	O
of	O
beta	O
amyloid	O
.	O

METHODS	O
:	O
We	O
randomized	O
299	B-P
older	I-P
men	I-P
to	O
treatment	O
with	O
2mg	B-I
of	I-I
folate	I-I
,	O
plus	O
25mg	B-I
of	I-I
B6	I-I
and	O
400	B-I
microg	I-I
of	I-I
B12	I-I
,	O
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ultrasound	B-I
-	I-I
guided	I-I
laser	I-I
photocoagulation	I-I
for	O
treatment	O
of	O
benign	O
thyroid	O
nodules	O
.	O

METHODS	O
:	O
Twenty	B-P
six	I-P
subjects	I-P
were	O
randomized	O
to	O
the	O
intervention	O
(	O
no	O
.	O

13	O
,	O
age	O
68	O
+	O
/	O
-	O
3	O
yr	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
or	O
observation	B-C
(	O
no	O
.	O

13	O
,	O
age	O
71	O
+	O
/	O
-	O
2	O
yr	O
)	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
of	O
chewing	B-I
versus	O
caffeine	B-I
on	O
alertness	O
,	O
cognitive	O
performance	O
and	O
cardiac	O
autonomic	O
activity	O
during	O
sleep	O
deprivation	O
.	O

METHODS	O
:	O
Fourteen	B-P
adults	I-P
participated	O
in	O
a	O
randomized	O
,	O
counterbalanced	O
protocol	O
employing	O
a	B-I
chewing	I-I
,	O
placebo	B-C
and	O
caffeine	B-I
condition	I-I
.	O

Participants	O
completed	O
tasks	O
assessing	O
psychomotor	B-O
vigilance	I-O
,	O
tracking	B-O
,	O
grammatical	B-O
reasoning	I-O
,	O
alertness	B-O
and	O
sleepiness	B-O
each	I-O
hour	I-O
across	I-O
the	I-O
night	I-O
.	O

All	O
participants	O
received	O
either	O
placebo	B-C
or	O
caffeine	B-I
(	O
200	O
mg	O
)	O
,	O
while	O
the	B-I
chewing	I-I
condition	I-I
also	O
chewed	O
on	O
a	O
tasteless	O
and	O
odorless	O
substance	O
for	O
15	O
min	O
each	O
hour	O
.	O

Heart	B-O
rate	I-O
(	I-O
HR	I-O
)	I-O
,	O
root	B-O
mean	I-O
square	I-O
of	I-O
the	I-O
successive	I-O
differences	I-O
in	I-O
R	I-O
-	I-O
R	I-O
intervals	I-O
on	I-O
the	I-O
ECG	I-O
(	I-O
RMSSD	I-O
)	I-O
,	O
and	O
preejection	B-O
period	I-O
(	I-O
PEP	I-O
)	I-O
were	O
simultaneously	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
disease	B-I
severity	I-I
on	O
outcome	O
of	O
antiviral	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
:	O
Lessons	O
from	O
the	O
HALT	O
-	O
C	O
trial	O
.	O

METHODS	O
:	O
All	O
patients	O
had	O
failed	O
prior	O
treatment	O
with	O
IFN	O
or	O
peginterferon	O
+	O
/	O
-	O
RBV	O
and	O
had	O
Ishak	O
fibrosis	O
scores	O
>	O
or	O
=	O
3	O
.	O

Four	B-P
groups	I-P
of	I-P
patients	I-P
with	I-P
increasingly	I-P
severe	I-P
liver	I-P
disease	I-P
were	O
compared	O
:	O
(	O
A	O
)	O
bridging	B-I
fibrosis	I-I
(	I-I
Ishak	I-I
3	I-I
and	I-I
4	I-I
)	I-I
with	I-I
platelet	I-I
counts	I-I
>	I-I
125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
559	O
)	O
;	O
(	O
B	O
)	O
bridging	B-I
fibrosis	I-I
with	I-I
platelet	I-I
counts	I-I
<	I-I
or	I-I
=125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
96	O
)	O
;	O
(	O
C	O
)	O
cirrhosis	B-I
(	I-I
Ishak	I-I
5	I-I
and	I-I
6	I-I
)	I-I
with	I-I
platelet	I-I
counts	I-I
>	I-I
125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
198	O
)	O
;	O
and	O
(	O
D	O
)	O
cirrhosis	B-I
with	I-I
platelet	I-I
counts	I-I
<	I-I
or	I-I
=125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
193	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	B-I
-	I-I
behavioural	I-I
stress	I-I
management	I-I
with	O
HIV	B-P
-	I-P
positive	I-P
homosexual	I-P
men	I-P
:	O
mechanisms	O
of	O
sustained	O
reductions	O
in	O
depressive	O
symptoms	O
.	O

METHODS	O
:	O
Men	O
were	O
randomized	O
to	O
either	O
a	B-I
10	I-I
-	I-I
week	I-I
,	I-I
group	I-I
-	I-I
based	I-I
CBSM	I-I
intervention	O
(	O
n	O
=	O
83	O
)	O
or	O
a	B-I
psychoeducational	I-I
seminar	I-I
group	O
(	O
n	O
=	O
46	O
)	O
.	O

All	O
participants	O
completed	O
a	B-O
battery	I-O
of	I-O
psychosocial	I-O
questionnaires	I-O
administered	O
by	O
a	O
research	O
assistant	O
at	O
baseline	O
,	O
immediately	O
following	O
the	B-I
10	I-I
-	I-I
week	I-I
CBSM	I-I
intervention	O
period	O
,	O
and	O
at	O
a	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Dietary	O
status	O
and	O
impact	O
of	O
risperidone	B-I
on	O
nutritional	O
balance	O
in	O
children	B-P
with	I-P
autism	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
Using	O
a	B-O
quantitative	I-O
Food	I-O
Frequency	I-O
Questionnaire	I-O
(	I-O
FFQ	I-O
)	I-O
,	O
we	O
prospectively	O
examined	O
the	B-O
nutritional	I-O
intake	I-O
of	O
20	B-P
children	I-P
with	I-P
autism	I-P
participating	O
in	O
a	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
of	O
risperidone	B-I
for	O
disruptive	O
behaviours	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
additional	O
value	O
of	O
a	B-I
night	I-I
splint	I-I
to	I-I
eccentric	I-I
exercises	I-I
in	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
single	O
-	O
blind	O
,	O
prospective	O
,	O
single	O
centre	O
,	O
randomised	O
controlled	O
trial	O
set	O
in	O
the	O
Sports	O
Medical	O
Department	O
,	O
The	O
Hague	O
Medical	O
Centre	O
,	O
The	O
Netherlands	O
.	O

Inclusion	O
criteria	O
were	O
:	O
age	O
18	O
-	O
70	O
years	O
,	O
active	O
participation	O
in	O
sports	O
,	O
and	O
tendon	O
pain	O
localised	O
at	O
2	O
-	O
7	O
cm	O
from	O
distal	O
insertion	O
.	O

Exclusion	O
criteria	O
were	O
:	O
insertional	O
disorders	O
,	O
partial	O
or	O
complete	O
ruptures	O
,	O
or	O
systemic	O
illness	O
.	O

70	B-P
tendons	I-P
were	O
included	O
and	O
randomised	O
into	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
eccentric	B-I
exercises	I-I
with	I-I
a	I-I
night	I-I
splint	I-I
(	O
night	B-I
splint	I-I
group	O
,	O
n	O
=	O
36	O
)	O
or	O
eccentric	B-I
exercises	I-I
only	I-I
(	O
eccentric	B-I
group	O
,	O
n	O
=	O
34	O
)	O
.	O

Both	O
groups	O
completed	O
a	B-I
12	I-I
-	I-I
week	I-I
heavy	I-I
-	I-I
load	I-I
eccentric	I-I
training	I-I
programme	I-I
.	O

One	O
group	O
received	O
a	O
night	O
splint	O
in	O
addition	O
to	O
eccentric	O
exercises	O
.	O

At	O
baseline	O
and	O
follow	O
-	O
up	O
at	O
12	O
weeks	O
,	O
patient	B-O
satisfaction	I-O
,	O
Victorian	B-O
Institute	I-O
of	I-O
Sport	I-O
Assessment	I-O
-	I-O
Achilles	I-O
questionnaire	I-O
(	I-O
VISA	I-O
-	I-O
A	I-O
)	I-O
score	I-O
and	O
reported	B-O
compliance	I-O
were	O
recorded	O
by	O
a	O
single	O
-	O
blind	O
trained	O
researcher	O
who	O
was	O
blinded	O
to	O
the	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Developmental	B-I
disabilities	I-I
modification	I-I
of	I-I
the	I-I
Children	I-I
'	I-I
s	I-I
Global	I-I
Assessment	I-I
Scale	I-I
.	O

METHODS	O
:	O
Developmental	B-I
disabilities	I-I
-	I-I
relevant	I-I
descriptors	I-I
were	O
developed	O
for	O
the	B-O
DD	I-O
-	I-O
CGAS	I-O
,	O
and	O
administration	O
procedures	O
were	O
established	O
to	O
enhance	O
rater	O
consistency	O
.	O

Ratings	B-O
of	I-O
clinical	I-O
case	I-O
vignettes	I-O
were	O
used	O
to	O
assess	O
inter	B-O
-	I-O
rater	I-O
reliability	I-O
and	O
temporal	B-O
stability	I-O
.	O

Validity	B-O
was	O
assessed	O
by	O
correlating	O
the	B-O
DD	I-O
-	I-O
CGAS	I-O
with	O
measures	B-O
of	I-O
functioning	I-O
and	O
symptoms	B-O
in	O
83	B-P
youngsters	I-P
with	I-P
PDD	I-P
.	O

Sensitivity	O
to	O
change	O
was	O
assessed	O
by	O
comparing	O
change	O
from	O
baseline	O
to	O
post	O
-	O
treatment	O
with	O
change	O
on	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
-	I-O
Irritability	I-O
and	O
Clinical	B-O
Global	I-O
Impressions	I-O
-	I-O
Improvement	I-O
subscale	I-O
scores	I-O
in	O
a	O
subset	O
of	O
14	O
children	O
.	O

-DOCSTART-	O

Title	O
:	O
Desmopressin	B-I
in	O
the	O
treatment	O
of	O
nocturia	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
Adults	B-P
aged	I-P
>	I-P
or	I-P
=18	I-P
yr	I-P
with	I-P
nocturia	I-P
(	I-P
>	I-P
or	I-P
=2	I-P
voids	I-P
/	I-P
night	I-P
)	I-P
received	O
desmopressin	B-I
tablets	I-I
(	O
0	O
.	O
1	O
,	O
0	O
.	O
2	O
,	O
or	O
0	O
.	O
4	O
mg	O
)	O
during	O
a	O
3	O
-	O
wk	O
dose	O
-	O
titration	O
period	O
.	O

Patients	O
should	O
show	O
sufficient	O
response	O
during	O
the	O
dose	O
-	O
titration	O
period	O
(	O
>	O
or	O
=20	O
%	O
reduction	O
in	O
nocturnal	O
diuresis	O
)	O
and	O
a	O
return	O
of	O
nocturnal	O
diuresis	O
to	O
>	O
or	O
=80	O
%	O
of	O
baseline	O
levels	O
during	O
washout	O
.	O

Eligible	O
patients	O
then	O
entered	O
a	O
3	O
-	O
wk	O
double	O
-	O
blind	O
treatment	O
period	O
and	O
received	O
either	O
desmopressin	B-I
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
alpha	B-I
dihydroergocryptine	I-I
in	O
patients	B-P
with	I-P
fibrocystic	I-P
breast	I-P
disease	I-P
]	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
diagnosis	I-P
of	I-P
fibrocystic	I-P
breast	I-P
disease	I-P
were	O
included	O
in	O
a	O
prospective	O
longitudinal	O
blind	O
double	O
,	O
controlled	O
with	O
placebo	O
study	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
of	O
treatment	O
group	O
A	O
:	O
Alpha	B-I
dihidroergocriptine	I-I
tablets	I-I
of	O
10	O
mg	O
,	O
group	O
B	O
:	O
Placebo	B-C
,	O
during	O
6	O
months	O
.	O

After	O
to	O
basal	O
evaluation	O
,	O
the	O
patients	O
were	O
revised	O
in	O
a	O
monthly	O
way	O
evaluating	O
the	O
following	O
symptoms	B-O
and	I-O
signs	I-O
:	O
mastalgia	B-O
,	O
mammary	B-O
tension	I-O
,	O
presence	B-O
of	I-O
nodules	I-O
,	O
nipple	B-O
secretion	I-O
,	O
and	O
the	B-O
presence	I-O
of	I-O
adverse	I-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Immediately	O
restored	O
,	O
single	B-I
-	I-I
tapered	I-I
implants	I-I
in	O
the	O
anterior	O
maxilla	O
:	O
prosthodontic	O
and	O
aesthetic	O
outcomes	O
after	O
1	O
year	O
.	O

METHODS	O
:	O
Participants	B-P
(	I-P
mean	I-P
age	I-P
:	I-P
43	I-P
.	I-P
25	I-P
years	I-P
;	I-P
range	I-P
:	I-P
23	I-P
-	I-P
71	I-P
years	I-P
)	I-P
satisfying	I-P
specified	I-P
inclusion	I-P
criteria	I-P
were	O
randomly	O
allocated	O
to	O
conventional	B-C
two	I-C
-	I-C
stage	I-C
restoration	I-C
(	O
control	O
group	O
;	O
n=14	O
)	O
and	O
immediate	B-I
restoration	I-I
groups	O
(	O
test	O
group	O
;	O
n	O
=14	O
)	O
in	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
.	O

Tapered	B-I
,	I-I
roughened	I-I
-	I-I
surface	I-I
Southern	I-I
implants	I-I
were	O
placed	O
using	O
a	O
standardized	O
technique	O
,	O
and	O
implant	B-O
level	I-O
bone	I-O
impressions	I-O
were	O
made	O
.	O

Provisional	O
screw	O
-	O
retained	O
crowns	O
,	O
out	O
of	O
occlusion	O
,	O
were	O
placed	O
at	O
second	O
-	O
stage	O
surgery	O
after	O
26	O
weeks	O
for	O
the	B-C
conventional	I-C
restoration	I-C
group	O
,	O
and	O
within	O
4	O
hours	O
of	O
implant	O
placement	O
for	O
the	B-I
immediate	I-I
restoration	I-I
group	O
.	O

Both	O
groups	O
had	O
definitive	O
screw	O
-	O
retained	O
metal	O
-	O
ceramic	O
crowns	O
placed	O
in	O
occlusion	O
8	O
weeks	O
later	O
.	O

Peri	B-O
-	I-O
implant	I-O
mucosal	I-O
response	I-O
and	O
papilla	B-O
index	I-O
were	O
recorded	O
4	O
weeks	O
after	O
definitive	O
crown	O
placement	O
to	O
allow	O
for	O
mucosal	O
maturation	O
and	O
at	O
1	O
year	O
.	O

Prosthodontic	B-O
and	O
aesthetic	B-O
outcomes	I-O
were	O
assessed	O
using	O
established	O
criteria	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	O
efficacy	O
of	O
mebendazole	B-I
against	O
hookworm	O
in	O
Vietnam	B-P
:	O
two	O
randomized	O
controlled	O
trials	O
.	O

METHODS	O
:	O
We	O
tested	O
the	O
efficacy	O
of	O
single	B-I
dose	I-I
mebendazole	I-I
500	O
mg	O
in	O
the	O
therapy	O
of	O
hookworm	O
infection	O
in	O
a	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
among	O
271	B-P
Vietnamese	I-P
schoolchildren	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
evaluation	O
of	O
imidapril	B-I
in	O
congestive	O
heart	O
failure	O
in	O
dogs	B-P
:	O
results	O
of	O
the	O
EFFIC	O
study	O
.	O

METHODS	O
:	O
This	O
good	O
,	O
clinical	O
practice	O
compliant	O
,	O
multicentre	O
study	O
(	O
EFFIC	O
study	O
)	O
enrolled	O
142	B-P
client	I-P
-	I-P
owned	I-P
dogs	I-P
and	O
was	O
conducted	O
in	O
20	O
locations	O
in	O
France	O
,	O
Belgium	O
and	O
Germany	O
.	O

Dogs	O
of	O
various	O
breed	O
,	O
age	O
and	O
weight	O
were	O
included	O
in	O
the	O
study	O
.	O

These	O
dogs	O
were	O
randomised	O
into	O
two	O
groups	O
that	O
were	O
treated	O
for	O
84	O
days	O
with	O
either	O
the	O
test	O
product	O
,	O
imidapril	B-I
,	O
or	O
the	O
positive	O
control	O
,	O
benazepril	B-C
,	O
and	O
followed	O
up	O
in	O
parallel	O
over	O
this	O
period	O
.	O

Both	O
treatments	O
were	O
administered	O
at	O
a	O
dose	O
of	O
0	O
.	O
25	O
mg	O
/	O
kg	O
once	O
a	O
day	O
with	O
the	O
possibility	O
of	O
doubling	O
this	O
dose	O
to	O
0	O
.	O
5	O
mg	O
/	O
kg	O
if	O
considered	O
necessary	O
from	O
a	O
clinical	O
point	O
of	O
view	O
.	O

In	O
addition	O
,	O
concomitant	O
treatment	O
was	O
given	O
to	O
dogs	O
presenting	O
with	O
pulmonary	O
oedema	O
and	O
/	O
or	O
ascites	O
,	O
supraventricular	O
tachyarrhythmia	O
and	O
/	O
or	O
dilated	O
cardiomyopathy	O
.	O

The	O
evolution	O
of	O
the	B-O
New	I-O
York	I-O
Heart	I-O
Association	I-O
stage	I-O
and	O
the	B-O
"	I-O
functional	I-O
signs	I-O
"	I-O
score	I-O
were	O
evaluated	O
as	O
primary	O
efficacy	O
criteria	O
.	O

-DOCSTART-	O

Title	O
:	O
Fine	B-I
needle	I-I
aspiration	I-I
coupled	O
with	O
real	B-I
-	I-I
time	I-I
PCR	I-I
:	O
a	O
painless	O
methodology	O
to	O
study	O
adaptive	O
functional	O
changes	O
in	O
skeletal	O
muscle	O
.	O

-DOCSTART-	O

Title	O
:	O
Injury	O
and	O
illness	O
costs	O
in	O
the	B-I
Certified	I-I
Safe	I-I
Farm	I-I
study	O
.	O

METHODS	O
:	O
Farms	B-P
(	I-P
316	I-P
)	I-P
located	I-P
in	I-P
a	I-P
9	I-P
-	I-P
county	I-P
area	I-P
of	I-P
northwestern	I-P
Iowa	I-P
were	O
recruited	O
and	O
randomized	O
into	O
intervention	O
and	O
control	O
cohorts	O
.	O

Intervention	O
farms	O
received	O
occupational	B-I
health	I-I
screenings	I-I
,	O
health	B-I
and	I-I
wellness	I-I
screening	I-I
,	O
education	B-I
,	O
on	B-I
-	I-I
farm	I-I
safety	I-I
reviews	I-I
,	O
and	O
performance	B-I
incentives	I-I
.	O

For	O
both	O
cohorts	O
,	O
quarterly	O
calls	O
over	O
3	O
years	O
were	O
used	O
to	O
collect	B-O
self	I-O
-	I-O
reported	I-O
occupational	I-O
injury	I-O
and	O
illness	B-O
information	I-O
,	O
including	O
costs	B-O
to	I-O
the	I-O
farmers	I-O
and	O
their	B-O
insurers	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effects	O
of	O
hetero	B-I
-	I-I
thermal	I-I
water	I-I
administration	O
on	O
leg	O
vein	O
hemodynamics	O
,	O
skin	O
microcirculation	O
and	O
O2	O
tension	O
in	O
chronic	O
venous	O
insufficiency	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
exploratory	O
,	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
of	O
practice	B-I
nurse	I-I
training	I-I
in	O
the	O
use	O
of	O
asthma	O
action	O
plans	O
.	O

METHODS	O
:	O
A	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
with	O
an	O
intervention	O
(	O
an	B-I
interactive	I-I
seminar	I-I
)	O
delivered	O
at	O
practice	O
level	O
(	O
n=13	O
practices	O
;	O
6=intervention	O
,	O
7=control	O
)	O
.	O

The	O
impact	O
of	O
the	O
intervention	O
was	O
assessed	O
against	O
patient	O
outcomes	O
:	O
routinely	B-O
available	I-O
asthma	I-O
outcome	I-O
measures	I-O
(	O
beta2	B-O
-	I-O
agonist	I-O
prescription	I-O
rate	I-O
and	O
number	B-O
of	I-O
oral	I-O
steroid	I-O
courses	I-O
)	O
for	O
asthma	O
patients	O
identified	O
as	O
being	O
poorly	O
-	O
controlled	O
from	O
practice	O
records	O
;	O
and	O
questionnaire	B-O
data	I-O
-	O
Mini	B-O
Asthma	I-O
Quality	I-O
of	I-O
Life	I-O
Questionnaire	I-O
(	I-O
AQLQ	I-O
)	I-O
and	O
the	B-O
Asthma	I-O
Control	I-O
Questionnaire	I-O
(	I-O
ACQ	I-O
)	I-O
-	O
from	O
a	O
subset	O
of	O
consenting	O
patients	O
.	O

Data	O
was	O
collected	O
at	O
baseline	O
and	O
at	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

ANALYSISs	O
:	O
Routine	O
data	O
was	O
analysed	O
for	O
629	O
patients	O
.	O

236	O
(	O
37	O
%	O
)	O
of	O
these	O
patients	O
consented	O
to	O
provide	O
questionnaire	O
data	O
at	O
baseline	O
,	O
with	O
75	O
%	O
returning	O
questionnaires	O
at	O
follow	O
-	O
up	O
.	O

After	O
adjustment	O
for	O
baseline	O
and	O
practice	O
,	O
there	O
was	O
a	O
significant	O
difference	O
at	O
followup	O
between	O
intervention	O
and	O
control	O
practices	O
on	O
the	O
Mini	O
AQLQ	O
only	O
(	O
p=0	O
.	O
03	O
)	O
.	O

Estimates	O
for	O
subsequent	O
sample	O
sizes	O
to	O
inform	O
future	O
trials	O
of	O
asthma	O
training	O
were	O
identified	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
vacuum	B-I
-	I-I
compression	I-I
therapy	I-I
on	O
healing	O
of	O
diabetic	B-P
foot	I-P
ulcers	I-P
:	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Eighteen	B-P
diabetic	I-P
patients	I-P
with	I-P
foot	I-P
ulcers	I-P
were	O
recruited	O
through	O
simple	O
nonprobability	O
sampling	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
an	O
experimental	O
or	O
a	O
control	O
group	O
.	O

Before	O
and	O
after	O
intervention	O
,	O
the	B-O
foot	I-O
ulcer	I-O
surface	I-O
area	I-O
was	O
estimated	O
stereologically	O
,	O
based	O
on	B-O
Cavalieri	I-O
'	I-O
s	I-O
principle	I-O
.	O

The	O
experimental	O
group	O
was	O
treated	O
with	O
VCT	B-I
in	O
addition	O
to	O
conventional	B-C
therapy	I-C
for	O
10	O
sessions	O
.	O

The	O
control	O
group	O
received	O
only	B-C
conventional	I-C
therapy	I-C
,	O
including	O
debridement	B-C
,	O
blood	B-C
glucose	I-C
control	I-C
agents	I-C
,	O
systemic	B-C
antibiotics	I-C
,	O
wound	B-C
cleaning	I-C
with	I-C
normal	I-C
saline	I-C
,	O
offloading	B-C
(	I-C
pressure	I-C
relief	I-C
)	I-C
,	O
and	O
daily	B-C
wound	I-C
dressings	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
intravenous	B-I
acetaminophen	I-I
and	O
lidocaine	B-I
on	O
propofol	O
injection	O
pain	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
fifty	I-P
ASA	I-P
I	I-P
-	I-P
II	I-P
patients	I-P
undergoing	I-P
general	I-P
anaesthesia	I-P
were	O
randomly	O
allocated	O
into	O
three	O
groups	O
.	O

A	O
20	O
-	O
gauge	O
catheter	O
was	O
inserted	O
into	O
a	O
superficial	O
radial	O
vein	O
of	O
the	O
left	O
hand	O
,	O
and	O
after	O
the	O
occlusion	O
of	O
venous	O
drainage	O
,	O
Groups	O
I	O
,	O
II	O
,	O
and	O
III	O
were	O
pretreated	O
with	O
40	B-I
mg	I-I
of	I-I
lidocaine	I-I
in	I-I
saline	I-I
,	O
50	B-I
mg	I-I
of	I-I
i	I-I
.	I-I
v	I-I
.	I-I
acetaminophen	I-I
,	O
and	O
5	B-C
ml	I-C
of	I-C
saline	I-C
,	O
respectively	O
.	O

The	O
occlusion	O
was	O
released	O
after	O
2	O
min	O
and	O
one	O
-	O
fourth	O
of	O
the	O
total	O
propofol	O
dose	O
was	O
injected	O
into	O
the	O
vein	O
over	O
a	O
period	O
of	O
5	O
s	O
.	O

During	O
the	O
injection	O
of	O
both	O
pretreatment	O
solution	O
and	O
propofol	O
,	O
patients	B-O
'	I-O
pain	I-O
was	O
assessed	O
and	O
recorded	O
as	O
0	O
-	O
3	O
,	O
corresponding	O
to	O
no	B-O
,	O
mild	B-O
,	O
moderate	B-O
or	O
severe	B-O
pain	I-O
,	O
respectively	O
.	O

Chi2	O
and	O
Kruskal	O
-	O
Wallis	O
tests	O
were	O
used	O
for	O
the	O
statistical	O
analysis	O
.	O

For	O
all	O
analyses	O
,	O
differences	O
were	O
considered	O
to	O
be	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
prospective	O
randomized	O
treatment	O
study	O
comparing	O
three	O
treatment	O
options	O
for	O
chalazia	O
:	O
triamcinolone	B-I
acetonide	I-I
injections	I-I
,	O
incision	B-I
and	O
curettage	B-I
and	O
treatment	O
with	O
hot	B-I
compresses	I-I
.	O

METHODS	O
:	O
This	O
was	O
a	O
single	O
centre	O
randomized	O
treatment	O
study	O
.	O

Patients	B-P
with	I-P
a	I-P
chalazion	I-P
underwent	O
either	O
of	O
the	O
three	O
treatment	O
options	O
.	O

Chalazion	B-O
resolution	I-O
,	O
pain	B-O
,	O
satisfaction	B-O
and	O
inconvenience	B-O
experienced	I-O
because	I-O
of	I-O
treatments	I-O
were	O
the	O
outcomes	O
assessed	O
via	O
a	O
telephone	O
interview	O
at	O
3	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Minimally	B-I
invasive	I-I
treatment	I-I
combined	O
with	O
cytokine	B-I
-	I-I
induced	I-I
killer	I-I
cells	I-I
therapy	I-I
lower	O
the	O
short	O
-	O
term	O
recurrence	O
rates	O
of	O
hepatocellular	O
carcinomas	O
.	O

METHODS	O
:	O
Therefore	O
,	O
85	B-P
HCC	I-P
patients	I-P
after	I-P
transcatheter	I-P
arterial	I-P
chemoembolization	I-P
and	I-P
radiofrequency	I-P
ablation	I-P
therapy	I-P
were	O
randomized	O
to	O
immunotherapy	B-I
group	O
and	O
no	B-I
adjuvant	I-I
therapy	I-I
group	O
.	O

Autologous	O
cytokine	O
-	O
induced	O
killer	O
(	O
CIK	O
)	O
cells	O
were	O
transfused	O
via	O
hepatic	O
artery	O
to	O
the	O
patients	O
.	O

The	B-O
alteration	I-O
of	I-O
levels	I-O
of	I-O
lymphocyte	I-O
subsets	I-O
in	O
peripheral	B-O
blood	I-O
of	O
patients	O
was	O
examined	O
by	O
flow	B-O
cytometry	I-O
.	O

All	O
patients	O
were	O
screened	O
by	O
computed	B-O
tomography	I-O
every	O
2	O
months	O
to	O
observe	O
the	B-O
tumor	I-O
recurrent	I-O
conditions	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
coenzyme	B-I
Q10	I-I
on	O
microcirculatory	O
endothelial	O
function	O
of	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Reduced	O
albuminuria	O
with	O
sarpogrelate	B-I
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
levels	O
in	O
type	O
2	O
diabetes	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
who	I-P
had	I-P
diabetes	I-P
with	I-P
nephropathy	I-P
and	I-P
arteriosclerosis	I-P
obliterans	I-P
and	I-P
had	I-P
already	I-P
been	I-P
treated	I-P
with	I-P
angiotensin	I-P
II	I-P
receptor	I-P
blocker	I-P
(	I-P
n	I-P
=	I-P
40	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
sarpogrelate	B-I
(	O
300	O
mg	O
/	O
d	O
;	O
n	O
=	O
20	O
)	O
or	O
aspirin	B-I
group	O
(	O
100	O
mg	O
/	O
d	O
;	O
n	O
=	O
20	O
)	O
.	O

Plasma	B-O
monocyte	I-O
chemoattractant	I-O
protein	I-O
-	I-O
1	I-O
and	O
urinary	B-O
albumin	I-O
-	I-O
to	I-O
-	I-O
creatinine	I-O
ratio	I-O
and	O
monocyte	B-O
chemoattractant	I-O
protein	I-O
-	I-O
1	I-O
were	O
measured	O
at	O
baseline	O
and	O
16	O
wk	O
after	O
administration	O
.	O

-DOCSTART-	O

Title	O
:	O
The	B-I
dipeptidyl	I-I
peptidase	I-I
-	I-I
4	I-I
inhibitor	I-I
PHX1149	I-I
improves	O
blood	O
glucose	O
control	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

METHODS	O
:	O
This	O
is	O
a	O
multicentre	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
4	O
-	O
week	O
study	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
with	I-P
suboptimal	I-P
metabolic	I-P
control	I-P
.	O

Patients	B-P
with	I-P
a	I-P
baseline	I-P
haemoglobin	I-P
A	I-P
(	I-P
1c	I-P
)	I-P
(	I-P
HbA	I-P
(	I-P
1c	I-P
)	I-P
)	I-P
of	I-P
7	I-P
.	I-P
3	I-P
to	I-P
11	I-P
.	I-P
0	I-P
%	I-P
were	O
randomized	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
once	O
-	O
daily	O
oral	O
therapy	O
with	O
either	O
PHX1149	B-I
(	O
100	O
,	O
200	O
or	O
400	O
mg	O
)	O
or	O
placebo	B-C
;	O
patients	O
were	O
on	O
a	O
constant	O
background	O
therapy	O
of	O
either	O
metformin	O
alone	O
or	O
metformin	O
plus	O
a	O
glitazone	O
.	O

-DOCSTART-	O

Title	O
:	O
Testosterone	B-I
and	O
gonadotropins	B-I
but	O
not	O
estrogen	B-I
associated	O
with	O
spatial	O
ability	O
in	O
women	B-P
suffering	I-P
from	I-P
schizophrenia	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
For	O
this	O
purpose	O
,	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
three	O
-	O
time	O
cross	O
-	O
over	O
study	O
using	O
17beta	B-I
-	I-I
estradiol	I-I
combined	O
with	O
norethisterone	B-I
acetate	I-I
for	O
replacement	O
therapy	O
and	O
as	O
an	O
adjunct	O
to	O
a	O
naturalistic	O
maintenance	O
antipsychotic	O
treatment	O
was	O
carried	O
out	O
over	O
a	O
period	O
of	O
8	O
months	O
.	O

Nineteen	B-P
women	I-P
(	I-P
mean	I-P
age=38	I-P
.	I-P
0	I-P
years	I-P
,	I-P
SD=9	I-P
.	I-P
9	I-P
years	I-P
)	I-P
with	I-P
schizophrenia	I-P
hospitalized	I-P
for	I-P
the	I-P
first	I-P
time	I-P
or	I-P
repeatedly	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	O

Sex	B-O
hormones	I-O
-	O
17beta	B-O
-	I-O
estradiol	I-O
,	I-O
luteinizing	B-O
hormone	I-O
(	I-O
LH	I-O
)	I-O
,	O
follicle	B-O
-	I-O
stimulating	I-O
hormone	I-O
(	I-O
FSH	I-O
)	I-O
,	O
prolactin	B-O
,	O
testosterone	B-O
,	O
and	O
dehydroepiandrosterone	B-O
sulfate	I-O
-	O
were	O
measured	O
and	O
the	O
patients	O
completed	O
a	B-O
neuropsychological	I-O
test	I-O
in	O
the	O
last	O
two	O
active	O
drug	O
and	O
/	O
or	O
placebo	B-C
phases	O
.	O

Three	O
different	O
spatial	O
ability	O
tasks	O
-	O
spatial	B-O
orientation	I-O
,	O
spatial	B-O
visualization	I-O
,	O
and	O
flexibility	B-O
of	I-O
closure	I-O
-	O
were	O
measured	O
by	O
a	B-O
paper	I-O
-	I-O
and	I-O
-	I-O
pencil	I-O
test	I-O
.	O

-DOCSTART-	O

Title	O
:	O
New	B-I
introducer	I-I
PEG	I-I
gastropexy	I-I
does	O
not	O
require	O
prophylactic	B-I
antibiotics	I-I
:	O
multicenter	O
prospective	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
Prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Multicenter	O
;	O
a	O
university	O
tertiary	O
-	O
care	O
hospital	O
and	O
a	O
private	O
practice	O
endoscopy	O
clinic	O
.	O

A	O
total	O
of	O
633	O
patients	O
undergoing	O
PEG	O
were	O
assessed	O
for	O
inclusion	O
.	O

Ninety	B-P
-	I-P
seven	I-P
patients	I-P
who	I-P
had	I-P
malignant	I-P
stenotic	I-P
oropharyngeal	I-P
stricture	I-P
were	O
randomized	O
:	O
group	O
I	O
(	O
49	O
patients	O
)	O
received	O
prophylactic	B-I
ceftriaxone	I-I
,	O
and	O
group	O
II	O
(	O
48	O
patients	O
)	O
received	O
a	B-C
placebo	I-C
.	O

Both	O
groups	O
were	O
similar	O
in	O
patient	O
characteristics	O
.	O

Introducer	B-I
PEG	I-I
was	O
performed	O
by	O
using	O
the	B-I
Freka	I-I
Pexact	I-I
-	I-I
15	I-I
CH	I-I
/	I-I
FR	I-I
,	O
with	O
the	O
gastric	O
wall	O
nonsurgically	O
sutured	O
to	O
the	O
anterior	O
abdominal	O
wall	O
by	O
use	O
of	O
an	O
endoscope	O
.	O

The	B-O
peristomal	I-O
area	I-O
was	O
assessed	O
daily	O
for	O
7	O
days	O
by	O
using	O
2	B-O
different	I-O
types	I-O
of	I-O
infection	I-O
scores	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
simplified	I-I
4	I-I
-	I-I
site	I-I
economical	I-I
intradermal	I-I
post	I-I
-	I-I
exposure	I-I
rabies	I-I
vaccine	I-I
regimen	I-I
:	O
a	O
randomised	O
controlled	O
comparison	O
with	O
standard	O
methods	O
.	O

METHODS	O
:	O
Two	B-P
hundred	I-P
and	I-P
fifty	I-P
-	I-P
four	I-P
volunteers	I-P
were	O
randomly	O
allocated	O
to	O
a	O
single	O
blind	O
controlled	O
trial	O
.	O

Each	O
received	O
purified	O
vero	O
cell	O
rabies	O
vaccine	O
by	O
one	O
of	O
four	B-I
PEP	I-I
regimens	I-I
:	O
the	B-I
currently	I-I
accepted	I-I
2	I-I
-	I-I
site	I-I
ID	I-I
;	O
the	B-I
8	I-I
-	I-I
site	I-I
regimen	I-I
using	O
0	O
.	O
05	O
ml	O
per	O
ID	O
site	O
;	O
a	B-I
new	I-I
4	I-I
-	I-I
site	I-I
ID	I-I
regimen	I-I
(	O
on	O
day	O
0	O
,	O
approximately	O
0	O
.	O
1	O
ml	O
at	O
4	O
ID	O
sites	O
,	O
using	O
the	O
whole	O
0	O
.	O
5	O
ml	O
ampoule	O
of	O
vaccine	O
;	O
on	O
day	O
7	O
,	O
0	O
.	O
1	O
ml	O
ID	O
at	O
2	O
sites	O
and	O
at	O
one	O
site	O
on	O
days	O
28	O
and	O
90	O
)	O
;	O
or	O
the	B-C
standard	I-C
5	I-C
-	I-C
dose	I-C
intramuscular	I-C
regimen	I-C
.	O

All	O
ID	O
regimens	O
required	O
the	O
same	O
total	O
amount	O
of	O
vaccine	O
,	O
60	O
%	O
less	O
than	O
the	O
intramuscular	O
method	O
.	O

Neutralising	B-O
antibody	I-O
responses	I-O
were	O
measured	O
five	O
times	O
over	O
a	O
year	O
in	O
229	O
people	O
,	O
for	O
whom	O
complete	O
data	O
were	O
available	O
.	O

-DOCSTART-	O

Title	O
:	O
Predictive	O
validity	O
of	O
a	B-I
medication	I-I
adherence	I-I
measure	I-I
in	O
an	O
outpatient	O
setting	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
esomeprazole	B-I
triple	I-I
therapy	I-I
on	O
eradication	O
rates	O
of	O
Helicobacter	O
pylori	O
,	O
gastric	O
ulcer	O
healing	O
and	O
prevention	O
of	O
relapse	O
in	O
gastric	B-P
ulcer	I-P
patients	I-P
.	O

METHODS	O
:	O
In	O
this	O
double	O
-	O
blind	O
study	O
,	O
401	B-P
H	I-P
.	I-P
pylori	I-P
-	I-P
positive	I-P
patients	I-P
with	I-P
more	I-P
than	I-P
or	I-P
equal	I-P
to	I-P
two	I-P
GUs	I-P
were	O
randomized	O
to	O
:	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
twice	O
daily	O
(	O
bid	O
)	O
and	O
amoxicillin	B-I
(	O
1000	O
mg	O
)	O
bid	O
and	O
clarithromycin	B-I
(	O
500	O
mg	O
)	O
bid	O
(	O
EAC	B-I
)	O
for	O
1	O
week	O
,	O
followed	O
by	O
placebo	B-C
for	O
3	O
weeks	O
(	O
EAC	B-I
and	O
placebo	B-C
)	O
;	O
EAC	B-I
for	O
1	O
week	O
,	O
followed	O
by	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
once	O
daily	O
(	O
E20	B-I
)	O
for	O
3	O
weeks	O
(	O
EAC	B-I
and	O
E20	B-I
)	O
;	O
or	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
bid	O
and	O
placebo	B-C
antimicrobials	I-C
for	O
1	O
week	O
,	O
followed	O
by	O
E20	B-I
for	O
3	O
weeks	O
(	O
E20	B-I
bid	O
and	O
E20	B-I
)	O
.	O

Patients	O
with	O
unhealed	O
GUs	O
at	O
4	O
weeks	O
received	O
E20	B-I
for	O
an	O
additional	O
4	O
weeks	O
.	O

Healed	O
patients	O
were	O
followed	O
up	O
for	O
12	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Penetration	O
and	O
accumulation	O
of	O
moxifloxacin	B-I
in	O
uterine	O
tissue	O
.	O

METHODS	O
:	O
In	O
a	O
prospective	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
we	O
determined	O
the	O
concentration	B-O
of	I-O
moxifloxacin	I-O
in	I-O
plasma	I-O
and	O
uterine	B-O
tissue	I-O
after	O
a	B-I
single	I-I
,	I-I
400	I-I
-	I-I
mg	I-I
intravenous	I-I
dose	I-I
of	I-I
moxifloxacin	I-I
.	O

Study	O
participants	O
were	O
randomized	O
for	O
time	O
of	O
tissue	O
sampling	O
,	O
which	O
was	O
performed	O
1	O
,	O
2	O
,	O
4	O
,	O
7	O
,	O
or	O
24	O
hours	O
following	O
the	B-I
moxifloxacin	I-I
infusion	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Heart	O
rate	O
variability	O
characteristics	O
in	O
sedentary	B-P
postmenopausal	I-P
women	I-P
following	O
six	B-I
months	I-I
of	I-I
exercise	I-I
training	I-I
:	O
the	O
DREW	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Use	O
of	O
topical	B-I
selamectin	I-I
for	O
the	O
treatment	O
of	O
Syphacia	O
muris	O
infection	O
in	O
laboratory	B-P
rats	I-P
.	O

METHODS	O
:	O
Fourty	B-P
-	I-P
eight	I-P
S	I-P
.	I-P
muris	I-P
-	I-P
positive	I-P
rats	I-P
were	O
divided	O
into	O
six	O
treated	O
and	O
two	O
control	O
groups	O
.	O

Selamectin	B-I
(	O
6	O
mg	O
/	O
kg	O
)	O
was	O
applied	O
topically	O
to	O
the	O
skin	O
in	O
a	O
single	O
spot	O
at	O
the	O
base	O
of	O
the	O
neck	O
in	O
the	O
treatment	O
group	O
.	O

The	O
rats	O
of	O
treated	O
and	O
control	O
groups	O
were	O
necropsied	B-O
on	O
the	O
24th	O
day	O
after	O
the	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
between	O
the	O
effect	O
of	O
oxytocin	B-I
only	I-I
and	O
oxytocin	B-I
plus	O
propranolol	B-I
on	O
the	O
labor	O
(	O
a	O
double	O
blind	O
randomized	O
trial	O
)	O
.	O

METHODS	O
:	O
A	O
double	O
blind	O
randomized	O
controlled	O
trial	O
was	O
performed	O
on	O
150	B-P
nulliparas	I-P
with	I-P
a	I-P
gestational	I-P
age	I-P
of	I-P
39	I-P
-	I-P
41	I-P
weeks	I-P
of	I-P
pregnancy	I-P
and	I-P
a	I-P
Bishop	I-P
score	I-P
of	I-P
<	I-P
or	I-P
=5	I-P
.	O

In	O
the	O
first	O
group	O
(	O
oxytocin	O
group	O
=	O
75	O
)	O
,	O
oxytocin	B-I
alone	I-I
was	O
used	O
for	O
induction	O
of	O
labor	O
.	O

In	O
the	O
second	O
group	O
(	O
propranolol	B-I
group	O
=	O
75	O
cases	O
)	O
,	O
before	O
the	O
beginning	O
of	O
oxytocin	B-I
,	O
2	B-I
mg	I-I
propranolol	I-I
was	O
slowly	O
injected	O
intravenously	O
then	O
the	B-I
oxytocin	I-I
was	O
initiated	O
.	O

-DOCSTART-	O

Title	O
:	O
Central	O
neuronal	O
mechanisms	O
of	O
gastric	B-I
electrical	I-I
stimulation	I-I
in	O
diabetic	O
gastroparesis	O
.	O

METHODS	O
:	O
A	B-I
gastric	I-I
electrical	I-I
stimulator	I-I
was	O
implanted	O
in	O
seven	B-P
diabetic	I-P
patients	I-P
with	I-P
medically	I-P
refractory	I-P
gastroparesis	I-P
.	O

A	O
double	O
-	O
blinded	O
protocol	O
was	O
used	O
to	O
investigate	O
the	O
patients	O
at	O
baseline	O
and	O
one	O
month	O
after	O
recovery	O
with	O
the	B-I
stimulator	I-I
turned	O
on	O
and	O
off	O
(	O
1	O
-	O
month	O
periods	O
)	O
.	O

The	O
following	O
assessments	O
were	O
carried	O
out	O
:	O
mechanical	B-O
,	O
thermal	B-O
and	O
electrical	B-O
stimulations	I-O
with	I-O
sensory	I-O
recordings	I-O
in	I-O
the	I-O
esophagus	I-O
and	I-O
duodenum	I-O
,	O
and	O
standardized	B-O
,	O
self	B-O
-	I-O
administered	I-O
,	O
daily	B-O
symptom	I-O
questionnaires	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Combination	B-I
chemotherapy	I-I
and	O
ALVAC	B-I
-	I-I
CEA	I-I
/	I-I
B7	I-I
.	I-I
1	I-I
vaccine	I-I
in	O
patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
were	O
treated	O
with	O
fluorouracil	B-I
,	O
leucovorin	B-I
,	O
and	O
irinotecan	B-I
and	O
were	O
also	O
given	O
ALVAC	B-I
-	I-I
CEA	I-I
/	I-I
B7	I-I
.	I-I
1	I-I
vaccine	I-I
with	I-I
or	O
without	B-I
tetanus	I-I
toxoid	I-I
adjuvant	I-I
.	O

Eligible	O
patients	O
were	O
randomized	O
to	O
ALVAC	B-I
followed	O
by	O
chemotherapy	B-I
and	O
booster	B-I
vaccination	I-I
(	O
group	O
1	O
)	O
,	O
ALVAC	B-I
and	O
tetanus	B-I
toxoid	I-I
followed	O
by	O
chemotherapy	B-I
(	O
group	O
2	O
)	O
,	O
or	O
chemotherapy	B-I
alone	I-I
followed	O
by	O
ALVAC	B-I
in	O
patients	O
without	O
disease	O
progression	O
(	O
group	O
3	O
)	O
.	O

Humoral	B-O
immune	I-O
responses	I-O
were	O
measured	O
by	O
standard	B-O
ELISA	I-O
assay	I-O
,	O
and	O
carcinoembryonic	B-O
antigen	I-O
(	I-O
CEA	I-O
)	I-O
-	I-O
specific	I-O
T	I-O
-	I-O
cell	I-O
responses	I-O
were	O
measured	O
by	O
IFN	B-O
-	I-O
gamma	I-O
enzyme	I-O
-	I-O
linked	I-O
immunospot	I-O
assay	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Beneficial	O
effects	O
of	O
a	B-I
diabetes	I-I
specific	I-I
formula	I-I
on	O
insulin	O
sensitivity	O
and	O
free	O
fatty	O
acid	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

METHODS	O
:	O
In	B-P
total	I-P
of	I-P
71	I-P
type	I-P
2	I-P
diabetics	I-P
completed	O
the	O
study	O
.	O

Enteral	B-I
formulas	I-I
were	O
given	O
orally	O
as	O
the	O
sole	O
source	O
of	O
nutrition	O
to	O
the	O
subjects	O
for	O
6	O
days	O
.	O

Venous	O
blood	O
samples	O
(	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
hours	O
)	O
were	O
collected	O
at	O
day	O
-	O
7	O
after	O
a	O
75	O
g	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
,	O
day	O
1	O
after	O
a	O
standard	O
test	O
meal	O
(	O
1673	O
.	O
6	O
kJ	O
)	O
and	O
after	O
6	O
days	O
of	O
either	O
the	B-I
test	I-I
diabetes	I-I
specific	I-I
formula	I-I
or	O
a	B-C
standard	I-C
formula	I-C
.	O

Plasma	B-O
glucose	I-O
,	O
serum	B-O
insulin	I-O
,	O
C	B-O
peptide	I-O
and	O
lipids	B-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Social	B-I
stories	I-I
:	O
mechanisms	O
of	O
effectiveness	O
in	O
increasing	O
game	O
play	O
skills	O
in	O
children	B-P
diagnosed	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
using	I-P
a	I-P
pretest	I-P
posttest	I-P
repeated	I-P
measures	I-P
randomized	I-P
control	I-P
group	I-P
design	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
45	I-P
children	I-P
diagnosed	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
(	I-P
ASD	I-P
)	I-P
ages	I-P
7	I-P
-	I-P
14	I-P
were	O
randomly	O
assigned	O
to	O
standard	B-I
,	O
directive	B-I
,	O
or	O
control	B-C
story	I-C
conditions	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Behavior	O
in	O
children	B-P
with	I-P
Down	I-P
syndrome	I-P
.	O

METHODS	O
:	O
Eight	B-P
children	I-P
with	I-P
Down	I-P
syndrome	I-P
who	I-P
displayed	I-P
autistic	I-P
features	I-P
were	O
compared	O
with	O
eight	O
Down	O
syndrome	O
children	O
without	O
autistic	O
features	O
.	O

These	O
children	O
were	O
randomly	O
selected	O
and	O
were	O
matched	O
for	O
age	O
and	O
level	O
of	O
retardation	O
.	O

Standardized	B-O
Psychological	I-O
tests	I-O
were	O
administered	O
to	O
tap	O
the	B-O
behavioral	I-O
differences	I-O
.	O

Mann	O
-	O
Whitney	O
U	O
test	O
was	O
used	O
for	O
significance	O
of	O
difference	O
between	O
both	O
the	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
latanoprost	B-I
when	I-I
stored	I-I
at	I-I
room	I-I
temperature	I-I
.	O

METHODS	O
:	O
Latanoprost	B-I
0	I-I
.	I-I
005	I-I
%	I-I
(	I-I
Xalatan	I-I
)	I-I
was	O
stored	O
at	O
4	O
degrees	O
C	O
or	O
30	O
degrees	O
C	O
for	O
4	O
weeks	O
in	O
the	O
dark	O
.	O

The	O
subjects	O
enrolled	O
to	O
the	O
study	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
latanoprost	B-I
stored	I-I
at	I-I
4	I-I
degrees	I-I
C	I-I
or	O
that	B-I
stored	I-I
at	I-I
30	I-I
degrees	I-I
C	I-I
.	O

The	O
eye	O
drop	O
was	O
applied	O
to	O
the	O
right	O
eye	O
of	O
each	O
subject	O
for	O
3	O
days	O
.	O

The	O
left	O
eye	O
served	O
as	O
a	O
control	O
without	B-C
administration	I-C
.	O

Slit	B-O
-	I-O
lamp	I-O
biomicroscopy	I-O
and	O
circadian	B-O
intra	I-O
ocular	I-O
pressure	I-O
(	I-O
IOP	I-O
)	I-O
curve	I-O
was	O
performed	O
at	O
Day	O
3	O
,	O
every	O
3	O
hours	O
from	O
6	O
pm	O
.	O

This	O
procedure	O
was	O
repeated	O
7	O
days	O
after	O
changing	O
the	O
drug	O
from	O
4	O
degrees	O
C	O
to	O
30	O
degrees	O
C	O
or	O
vice	O
versa	O
,	O
and	O
application	O
to	O
the	O
left	O
eye	O
for	O
3	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
The	O
CARESS	O
-	O
in	O
-	O
AMI	O
trial	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Monitoring	B-I
of	I-I
the	I-I
central	I-I
pulse	I-I
pressure	I-I
is	O
useful	O
for	O
detecting	O
cardiac	O
overload	O
during	O
antiadrenergic	O
treatment	O
:	O
the	O
Japan	O
Morning	O
Surge	O
1	O
study	O
.	O

METHODS	O
:	O
We	O
studied	O
434	B-P
treated	I-P
hypertensive	I-P
patients	I-P
whose	I-P
home	I-P
systolic	I-P
blood	I-P
pressure	I-P
was	I-P
135	I-P
mmHg	I-P
or	I-P
higher	I-P
.	I-P

They	O
were	O
followed	O
for	O
6	O
months	O
after	O
allocation	O
to	O
either	O
a	O
control	O
group	O
or	O
an	O
added	O
treatment	O
group	O
(	O
doxazosin	O
1	O
-	O
4	O
mg	O
and	O
atenolol	O
when	O
needed	O
)	O
.	O

We	O
measured	O
the	B-O
brachial	I-O
and	O
central	B-O
(	I-O
carotid	I-O
)	I-O
blood	I-O
pressure	I-O
simultaneously	O
using	O
a	B-O
validated	I-O
device	I-O
,	O
and	O
the	B-O
B	I-O
-	I-O
type	I-O
natriuretic	I-O
peptide	I-O
at	O
baseline	O
and	O
at	O
the	O
sixth	O
month	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
immunogenicity	O
of	O
a	B-I
cluster	I-I
specific	I-I
immunotherapy	I-I
in	O
children	B-P
with	I-P
bronchial	I-P
asthma	I-P
and	I-P
mite	I-P
allergy	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
34	I-P
children	I-P
(	I-P
6	I-P
-	I-P
18	I-P
years	I-P
)	I-P
with	I-P
allergic	I-P
asthma	I-P
were	O
assigned	O
to	O
cluster	B-I
(	O
n	O
=	O
22	O
)	O
or	O
classic	B-C
SIT	I-C
(	O
n	O
=	O
12	O
)	O
.	O

To	O
achieve	O
a	O
maintenance	O
dose	O
of	O
allergen	O
extract	O
,	O
cluster	B-I
patients	O
received	O
14	O
injections	O
of	O
house	O
dust	O
mite	O
allergen	O
within	O
6	O
weeks	O
,	O
whereas	O
the	O
classic	B-C
SIT	I-C
group	O
received	O
14	O
injections	O
within	O
14	O
weeks	O
.	O

Safety	B-O
was	O
monitored	O
by	O
recording	O
adverse	B-O
events	I-O
.	O

Immunogenicity	B-O
was	O
measured	O
by	O
specific	B-O
IgG	I-O
(	I-O
Mite	I-O
)	I-O
and	O
IgG4	B-O
(	I-O
Mite	I-O
)	O
,	O
by	O
antibody	B-O
-	I-O
blocking	I-O
properties	I-O
on	I-O
basophil	I-O
activation	I-O
,	O
and	O
by	O
the	B-O
T	I-O
cell	I-O
subset	I-O
transcription	I-O
factors	I-O
Foxp3	I-O
,	O
T	B-O
-	I-O
bet	I-O
,	O
and	O
GATA	B-O
-	I-O
3	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Two	O
-	O
year	O
prospective	O
clinical	O
comparison	O
of	O
immediate	B-I
replacement	I-I
vs	O
.	O
immediate	B-C
restoration	I-C
of	I-C
single	I-C
tooth	I-C
in	O
the	O
esthetic	O
zone	O
.	O

METHODS	O
:	O
Sixteen	B-P
patients	I-P
(	I-P
10	I-P
women	I-P
and	I-P
6	I-P
men	I-P
)	I-P
with	I-P
a	I-P
mean	I-P
age	I-P
of	I-P
35	I-P
years	I-P
(	I-P
ranging	I-P
from	I-P
21	I-P
to	I-P
49	I-P
years	I-P
old	I-P
)	I-P
were	O
treated	O
from	O
2004	O
to	O
2005	O
for	O
single	B-I
-	I-I
tooth	I-I
replacement	I-I
in	O
the	O
upper	O
arch	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
in	O
the	O
test	O
group	O
patients	O
received	O
implants	B-I
placed	I-I
and	I-I
restored	I-I
(	I-I
non	I-I
-	I-I
occlusal	I-I
loading	I-I
)	I-I
at	I-I
the	I-I
time	I-I
of	I-I
tooth	I-I
extraction	I-I
;	O
in	O
the	O
control	O
group	O
implants	B-C
were	I-C
placed	I-C
8	I-C
weeks	I-C
after	I-C
tooth	I-C
extraction	I-C
and	I-C
immediately	I-C
restored	I-C
.	O

All	O
the	O
patients	O
received	O
tapered	B-I
effect	I-I
(	I-I
TE	I-I
)	I-I
implants	I-I
from	I-I
the	I-I
Straumann	I-I
Dental	I-I
Implant	I-I
System	I-I
.	O

The	O
following	O
parameters	O
were	O
evaluated	O
at	O
the	O
moment	O
of	O
provisional	O
restoration	O
(	O
within	O
48	O
h	O
after	O
implant	O
placement	O
)	O
and	O
at	O
the	O
2	O
years	O
follow	O
-	O
up	O
visit	O
:	O
marginal	B-O
bone	I-O
resorption	I-O
,	O
papilla	B-O
index	I-O
,	O
position	B-O
of	I-O
the	I-O
mucosal	I-O
margin	I-O
.	O

The	B-O
implant	I-O
stability	I-O
quotient	I-O
was	O
measured	O
at	O
the	B-O
moment	I-O
of	I-O
implant	I-O
placement	I-O
and	O
at	O
the	B-O
moment	I-O
of	I-O
the	I-O
delivery	I-O
of	I-O
the	I-O
definitive	I-O
restoration	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Maintenance	O
of	O
response	O
following	O
stabilization	O
of	O
mixed	O
index	O
episodes	O
with	O
olanzapine	B-I
monotherapy	I-I
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
bipolar	O
1	O
disorder	O
.	O

METHODS	O
:	O
Post	O
-	O
hoc	O
analyses	O
were	O
conducted	O
on	O
data	O
from	O
patients	B-P
presenting	I-P
with	I-P
a	I-P
mixed	I-P
index	I-P
episode	I-P
who	O
were	O
enrolled	O
in	O
a	O
larger	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Patients	O
who	O
met	O
remission	O
criteria	O
at	O
2	O
consecutive	O
weekly	O
visits	O
during	O
6	O
to	O
12	O
weeks	O
of	O
open	O
-	O
label	O
olanzapine	O
treatment	O
were	O
randomly	O
assigned	O
to	O
olanzapine	B-I
or	O
placebo	B-C
treatment	O
for	O
48	O
weeks	O
.	O

The	B-O
incidence	I-O
of	I-O
and	O
time	B-O
to	I-O
symptomatic	I-O
relapse	I-O
were	O
calculated	O
for	O
any	B-O
mood	I-O
episode	I-O
,	O
and	O
for	O
depressive	B-O
,	O
manic	B-O
,	O
hypo	B-O
-	I-O
manic	I-O
,	O
and	O
mixed	B-O
mood	I-O
episodes	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Acceleration	O
of	O
insulin	O
pharmacodynamic	O
profile	O
by	O
a	B-I
novel	I-I
insulin	I-I
infusion	I-I
site	I-I
warming	I-I
device	I-I
.	O

METHODS	O
:	O
Each	O
subject	O
underwent	O
two	O
euglycemic	O
clamp	O
procedures	O
on	O
separate	O
occasions	O
:	O
one	O
with	B-I
IP	I-I
and	O
one	O
without	B-C
IP	I-C
activation	I-C
in	O
random	O
order	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
strontium	B-I
on	O
the	O
quality	O
of	O
bone	O
apatite	O
crystals	O
:	O
a	O
paired	O
biopsy	O
study	O
in	O
postmenopausal	O
osteoporotic	O
women	O
.	O

In	O
paired	O
biopsies	O
of	O
osteoporotic	O
women	O
treated	O
with	O
either	O
strontium	O
ranelate	O
or	O
a	O
placebo	O
for	O
36	O
months	O
,	O
characteristics	O
of	O
bone	O
apatite	O
crystals	O
were	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
strontium	O
.	O

The	O
mean	O
rate	O
of	O
substitutions	O
of	O
calcium	O
by	O
strontium	O
ions	O
was	O
4	O
.	O
5	O
%	O
.	O

METHODS	O
:	O
In	O
ten	B-P
paired	I-P
biopsies	I-P
,	O
crystallinity	B-O
,	O
apparent	B-O
length	I-O
and	O
width	B-O
/	I-O
thickness	I-O
of	I-O
crystals	I-O
,	O
interplanar	B-O
distances	I-O
,	O
and	O
lattice	B-O
parameters	I-O
of	I-O
unit	I-O
cells	I-O
were	O
assessed	O
by	O
X	B-O
-	I-O
ray	I-O
diffraction	I-O
and	O
selected	B-O
area	I-O
electron	I-O
diffraction	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Social	B-I
robots	I-I
as	O
embedded	O
reinforcers	O
of	O
social	O
behavior	O
in	O
children	B-P
with	I-P
autism	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Parents	O
'	O
state	O
and	O
trait	O
anxiety	O
:	O
relationships	O
with	O
anxiety	O
severity	O
and	O
treatment	O
response	O
in	O
adolescents	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	O

-DOCSTART-	O

Title	O
:	O
A	O
phase	O
III	O
study	O
of	O
laparoscopy	B-I
-	I-I
assisted	I-I
versus	O
open	B-I
distal	I-I
gastrectomy	I-I
with	I-I
nodal	I-I
dissection	I-I
for	O
clinical	O
stage	O
IA	O
/	O
IB	O
gastric	O
Cancer	O
(	O
JCOG0912	O
)	O
.	O

METHODS	O
:	O
This	O
study	O
followed	O
the	O
previous	O
Phase	O
II	O
study	O
to	O
confirm	O
the	O
safety	O
of	O
laparoscopy	B-I
-	I-I
assisted	I-I
distal	I-I
gastrectomy	I-I
(	O
JCOG0703	O
)	O
and	O
began	O
in	O
March	O
2010	O
.	O

A	B-P
total	I-P
of	I-P
920	I-P
patients	I-P
will	O
be	O
accrued	O
from	O
33	O
institutions	O
within	O
5	O
years	O
.	O

The	O
primary	O
endpoint	O
is	O
overall	B-O
survival	I-O
.	O

The	O
secondary	O
endpoints	O
are	O
relapse	B-O
-	I-O
free	I-O
survival	I-O
,	O
proportion	B-O
of	I-O
laparoscopy	I-O
-	I-O
assisted	I-O
distal	I-O
gastrectomy	I-O
completion	I-O
,	O
proportion	B-O
of	I-O
conversion	I-O
to	I-O
open	I-O
surgery	I-O
,	O
adverse	B-O
events	I-O
,	O
short	B-O
-	I-O
term	I-O
clinical	I-O
outcomes	I-O
,	O
postoperative	B-O
quality	I-O
of	I-O
life	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Antihistamines	B-I
do	O
not	O
inhibit	O
the	O
wheal	O
induced	O
by	O
the	O
intradermal	O
injection	O
of	O
autologous	O
serum	O
in	O
resistant	O
chronic	O
idiopathic	O
urticaria	O
.	O

METHODS	O
:	O
CIU	B-P
patients	I-P
with	I-P
treatment	I-P
failure	I-P
under	I-P
fexofenadine	I-P
at	I-P
180	I-P
mg	I-P
q	I-P
.	I-P
d	I-P
.	I-P
increased	O
their	O
daily	B-I
dose	I-I
of	I-I
AH	I-I
to	O
4	O
tablets	O
daily	O
.	O

Those	O
with	O
significant	O
improvement	O
of	O
urticaria	O
activity	O
score	O
under	O
fexofenadine	O
at	O
180	O
mg	O
were	O
included	O
in	O
the	O
CIU	O
group	O
.	O

Subjects	O
with	O
treatment	O
failure	O
despite	O
a	O
full	O
8	O
-	O
week	O
fourfold	O
fexofenadine	O
treatment	O
were	O
included	O
in	O
the	O
resistant	O
CIU	O
(	O
R	O
-	O
CIU	O
group	O
)	O
.	O

The	O
control	O
group	O
consisted	O
of	O
sex	O
-	O
and	O
age	O
-	O
matched	O
patents	O
with	O
allergic	O
rhinitis	O
.	O

The	B-O
AS	I-O
skin	I-O
test	I-O
and	O
intradermal	B-O
histamine	I-O
-	I-O
induced	I-O
wheal	I-O
and	O
flare	B-O
reaction	I-O
were	O
performed	O
at	O
baseline	O
(	O
without	O
AH	O
)	O
,	O
after	O
8	O
and	O
16	O
weeks	O
(	O
under	O
AH	O
treatment	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	O
body	O
mass	O
index	O
and	O
dyslipidemia	O
in	O
dialysis	B-P
patients	I-P
linked	I-P
to	I-P
elevated	I-P
plasma	I-P
fibroblast	I-P
growth	I-P
factor	I-P
23	I-P
.	O

METHODS	O
:	O
This	O
study	O
was	O
conducted	O
among	O
654	B-P
patients	I-P
receiving	I-P
chronic	I-P
hemodialysis	I-P
.	O

C	B-O
-	I-O
terminal	I-O
FGF23	I-O
concentrations	I-O
were	O
measured	O
in	O
stored	O
plasma	O
samples	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
examine	O
the	O
cross	O
-	O
sectional	O
associations	O
of	O
plasma	B-O
FGF23	I-O
concentrations	I-O
with	O
BMI	B-O
,	O
total	B-O
cholesterol	I-O
(	I-O
TC	I-O
)	I-O
,	O
low	B-O
-	I-O
density	I-O
lipoprotein	I-O
-	I-O
cholesterol	I-O
(	I-O
LDL	I-O
-	I-O
C	I-O
)	I-O
,	O
high	B-O
-	I-O
density	I-O
lipoprotein	I-O
-	I-O
cholesterol	I-O
(	I-O
HDL	I-O
-	I-O
C	I-O
)	I-O
and	O
triglycerides	B-O
.	O

Cox	O
proportional	O
hazard	O
models	O
were	O
used	O
to	O
examine	O
the	O
association	O
between	O
FGF23	B-O
concentrations	I-O
and	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Topical	O
treatment	O
of	O
tinea	O
pedis	O
using	O
6	B-I
%	I-I
coriander	I-I
oil	I-I
in	O
unguentum	O
leniens	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
comparative	O
pilot	O
study	O
.	O

METHODS	O
:	O
Half	O
-	O
side	O
comparative	O
pilot	O
study	O
on	O
subjects	O
with	O
symmetric	O
,	O
bilateral	O
interdigital	O
tinea	O
pedis	O
.	O

Active	O
drug	O
and	O
placebo	B-C
control	O
were	O
applied	O
twice	O
daily	O
on	O
the	O
affected	O
areas	O
,	O
and	O
follow	O
-	O
up	O
visits	O
were	O
performed	O
on	O
days	O
14	O
and	O
28	O
.	O

-DOCSTART-	O

Title	O
:	O
The	B-I
Tiotropium	I-I
Safety	O
and	O
Performance	O
in	O
Respimat	B-I
Trial	O
(	O
TIOSPIR	O
)	O
,	O
a	O
large	O
scale	O
,	O
randomized	O
,	O
controlled	O
,	O
parallel	O
-	O
group	O
trial	O
-	O
design	O
and	O
rationale	O
.	O

METHODS	O
:	O
The	O
TIOSPIR	O
trial	O
(	O
NCT01126437	O
)	O
compares	O
the	O
safety	O
and	O
efficacy	O
of	O
tiotropium	B-I
Respimat	I-I
5	O
?g	O
once	O
daily	O
(	O
marketed	O
)	O
and	O
2	O
.	O
5	O
?g	O
once	O
daily	O
(	O
investigational	O
)	O
with	O
tiotropium	B-I
HandiHaler	I-I
18	O
?	O
once	O
daily	O
(	O
marketed	O
)	O
.	O

The	O
hypotheses	O
to	O
be	O
tested	O
are	O
1	O
)	O
.	O

that	O
tiotropium	B-I
Respimat	I-I
5	O
?g	O
once	O
daily	O
and	O
Respimat	B-I
2	O
.	O
5	O
?g	O
once	O
daily	O
are	O
non	O
-	O
inferior	O
to	O
HandiHaler	B-I
in	O
terms	O
of	O
all	O
-	O
cause	O
mortality	O
,	O
and	O
2	O
)	O
.	O

that	O
tiotropium	B-I
Respimat	I-I
5	O
?g	O
once	O
daily	O
is	O
superior	O
to	O
HandiHaler	B-I
in	O
terms	O
of	O
time	O
to	O
first	O
exacerbation	O
.	O

A	B-O
spirometry	I-O
substudy	I-O
evaluates	O
the	B-O
bronchodilator	I-O
efficacy	I-O
.	O

The	O
trial	O
is	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
double	O
dummy	O
,	O
event	O
-	O
driven	O
,	O
parallel	O
group	O
study	O
.	O

Participants	O
can	O
use	O
any	O
background	O
treatment	O
for	O
COPD	O
except	O
inhaled	O
anticholinergic	O
agents	O
.	O

The	O
study	O
encompasses	O
a	O
wide	O
range	O
of	O
COPD	B-P
patients	I-P
,	I-P
e	I-P
.	I-P
g	I-P
.	I-P
patients	I-P
with	I-P
stable	I-P
cardiac	I-P
diseases	I-P
including	I-P
arrhythmia	I-P
can	O
be	O
included	O
.	O

Clinical	O
sites	O
are	O
international	O
and	O
include	O
both	O
primary	O
care	O
as	O
well	O
as	O
specialists	O
.	O

-DOCSTART-	O

Title	O
:	O
Nasal	O
eosinophilia	O
and	O
serum	O
soluble	O
intercellular	O
adhesion	O
molecule	O
1	O
in	O
patients	B-P
with	I-P
allergic	I-P
rhinitis	I-P
treated	O
with	O
montelukast	B-I
alone	I-I
or	O
in	B-I
combination	I-I
with	I-I
desloratadine	I-I
or	O
levocetirizine	B-I
.	O

METHODS	O
:	O
In	O
this	O
single	O
-	O
center	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
,	O
two	O
-	O
arm	O
study	O
,	O
40	B-P
patients	I-P
with	I-P
persistent	I-P
AR	I-P
were	O
randomized	O
to	O
receive	O
either	O
montelukast	B-I
and	O
/	O
or	O
levocetirizine	B-I
or	O
placebo	B-C
(	O
n	O
=	O
20	O
)	O
or	O
to	O
receive	O
treatment	O
with	O
montelukast	B-I
and	O
/	O
or	O
desloratadine	B-I
or	O
placebo	B-C
(	O
n	O
=	O
20	O
)	O
.	O

Nasal	B-O
eosinophilia	I-O
and	O
concentration	B-O
of	I-O
sICAM	I-O
-	I-O
1	I-O
in	I-O
peripheral	I-O
blood	I-O
were	O
assessed	O
before	O
and	O
on	O
the	O
last	O
day	O
of	O
each	O
treatment	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	B-I
-	I-I
term	I-I
treatment	I-I
with	I-I
atomoxetine	I-I
for	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
symptoms	O
in	O
children	B-P
and	I-P
adolescents	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	O
an	O
open	O
-	O
label	O
extension	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
88	B-P
patients	I-P
6	I-P
-	I-P
17	I-P
years	I-P
of	I-P
age	I-P
,	I-P
with	I-P
ADHD	I-P
and	I-P
ASD	I-P
,	O
were	O
treated	O
with	O
1	B-I
.	I-I
2	I-I
mg	I-I
/	I-I
kg	I-I
/	I-I
day	I-I
atomoxetine	I-I
for	O
20	O
weeks	O
as	O
follow	O
-	O
up	O
of	O
an	O
8	O
week	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
period	O
.	O

Primary	O
endpoint	O
was	O
the	B-O
ADHD	I-O
Rating	I-O
Scale	I-O
(	I-O
ADHD	I-O
-	I-O
RS	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Prevalence	O
and	O
treatment	O
outcome	O
of	O
cervicitis	O
of	O
unknown	O
etiology	O
.	O

METHODS	O
:	O
Five	B-P
hundred	I-P
seventy	I-P
-	I-P
seven	I-P
women	I-P
were	I-P
screened	I-P
for	I-P
MPC	I-P
.	O

Women	B-P
with	I-P
MPC	I-P
were	O
randomized	O
to	O
the	O
treatment	O
or	O
placebo	B-C
arm	O
of	O
the	O
study	O
,	O
and	O
the	O
2	O
arms	O
were	O
evaluated	O
based	O
on	O
the	B-O
etiology	I-O
,	O
clinical	B-O
cure	I-O
rates	I-O
,	O
adverse	B-O
events	I-O
(	I-O
AEs	I-O
)	I-O
,	O
and	O
rates	B-O
of	I-O
pelvic	I-O
inflammatory	I-O
disease	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
pharmacokinetics	O
of	O
buffered	B-I
propranolol	I-I
sublingual	I-I
tablet	I-I
(	I-I
Promptol?	I-I
)	I-I
-	O
application	O
of	O
a	O
new	O
"	O
physiologically	O
based	O
"	O
model	O
to	O
assess	O
absorption	O
and	O
disposition	O
.	O

METHODS	O
:	O
Eighteen	B-P
healthy	I-P
volunteers	I-P
received	O
10	B-I
mg	I-I
sublingual	I-I
Promptol	I-I
or	O
oral	B-I
Inderal	I-I
(	I-I
	I-I
)	I-I
.	O

Multiple	O
Cp	O
-	O
prop	O
were	O
determined	O
and	O
their	O
pharmacokinetics	O
compared	O
.	O

Additional	O
data	O
following	O
sublingual	B-I
40	I-I
mg	I-I
Promptol	I-I
or	O
Inderal	B-I
(	I-I
	I-I
)	I-I
were	O
utilized	O
for	O
evaluation	O
of	O
a	O
special	O
advanced	O
compartmental	O
absorption	O
and	O
transit	O
(	O
ACAT	O
)	O
model	O
.	O

For	O
model	O
simulation	O
,	O
the	B-O
physicochemical	I-O
parameters	I-O
were	O
imported	O
from	O
AMET	B-O
predictor	I-O
,	O
whereas	O
the	B-O
pharmacokinetic	I-O
parameters	I-O
were	O
calculated	O
and	O
optimized	O
by	O
Gastroplus	B-O
(	I-O
	I-O
)	I-O
.	O

Based	O
on	O
this	O
model	O
,	O
the	B-O
quantity	I-O
of	I-O
drug	I-O
absorbed	I-O
via	I-O
buccal	I-O
/	I-O
sublingual	I-O
mucosa	I-O
was	O
estimated	O
.	O

-DOCSTART-	O

Title	O
:	O
Health	B-I
-	I-I
education	I-I
package	I-I
to	O
prevent	O
worm	O
infections	O
in	O
Chinese	B-P
schoolchildren	I-P
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
single	O
-	O
blind	O
,	O
unmatched	O
,	O
cluster	O
-	O
randomized	O
intervention	O
trial	O
involving	O
1718	B-P
children	I-P
,	I-P
9	I-P
to	I-P
10	I-P
years	I-P
of	I-P
age	I-P
,	I-P
in	I-P
38	I-P
schools	I-P
over	I-P
the	I-P
course	I-P
of	I-P
1	I-P
school	I-P
year	I-P
.	O

Schools	O
were	O
randomly	O
assigned	O
to	O
the	B-I
health	I-I
-	I-I
education	I-I
package	I-I
,	O
which	O
included	O
a	B-I
cartoon	I-I
video	I-I
,	O
or	O
to	O
a	B-C
control	I-C
package	I-C
,	O
which	O
involved	O
only	O
the	B-C
display	I-C
of	I-C
a	I-C
health	I-C
-	I-C
education	I-C
poster	I-C
.	O

Infection	B-O
rates	I-O
,	O
knowledge	B-O
about	I-O
soil	I-O
-	I-O
transmitted	I-O
helminths	I-O
(	O
as	O
assessed	O
with	O
the	B-O
use	I-O
of	I-O
a	I-O
questionnaire	I-O
)	O
,	O
and	O
hand	B-O
-	I-O
washing	I-O
behavior	I-O
were	O
assessed	O
before	O
and	O
after	O
the	O
intervention	O
.	O

Albendazole	O
was	O
administered	O
in	O
all	O
the	O
participants	O
at	O
baseline	O
and	O
in	O
all	O
the	O
children	O
who	O
were	O
found	O
to	O
be	O
positive	O
for	O
infection	O
with	O
soil	O
-	O
transmitted	O
helminths	O
at	O
the	O
follow	O
-	O
up	O
assessment	O
at	O
the	O
end	O
of	O
the	O
school	O
year	O
.	O

-DOCSTART-	O

Title	O
:	O
Ultrasonography	B-I
-	I-I
guided	I-I
bilateral	I-I
rectus	I-I
sheath	I-I
block	I-I
vs	O
local	B-I
anesthetic	I-I
infiltration	I-I
after	O
pediatric	O
umbilical	O
hernia	O
repair	O
:	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Prospective	O
,	O
observer	O
-	O
blinded	O
,	O
randomized	O
clinical	O
trial	O
.	O

Tertiary	O
-	O
referral	O
urban	O
children	O
'	O
s	O
hospital	O
.	O

Eligible	O
children	O
3	O
to	O
12	O
years	O
of	O
age	O
undergoing	O
elective	O
umbilical	O
hernia	O
repair	O
from	O
November	O
16	O
,	O
2009	O
,	O
through	O
May	O
31	O
,	O
2011	O
.	O

Ropivacaine	B-I
hydrochloride	I-I
administered	O
at	O
the	O
conclusion	O
of	O
surgery	O
as	O
LAI	B-I
by	O
the	O
surgeon	O
(	O
n	O
=	O
25	O
)	O
or	O
as	O
ultrasonography	B-I
-	I-I
guided	I-I
BRSB	I-I
by	O
the	O
anesthesiologist	O
(	O
n	O
=	O
27	O
)	O
.	O

Scores	B-O
on	I-O
the	I-O
FACES	I-O
Pain	I-O
Rating	I-O
Scale	I-O
measured	O
at	O
10	O
-	O
minute	O
intervals	O
and	O
all	O
use	O
of	O
analgesic	O
medications	O
in	O
the	O
PACU	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
head	O
-	O
to	O
-	O
head	O
comparison	O
of	O
aripiprazole	B-I
and	O
risperidone	B-I
for	O
safety	O
and	O
treating	O
autistic	O
disorders	O
,	O
a	O
randomized	O
double	O
blind	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Fifty	B-P
nine	I-P
children	I-P
and	I-P
adolescents	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
were	O
randomized	O
to	O
receive	O
either	O
aripiprazole	B-I
or	O
risperidone	B-I
for	O
2	O
months	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
change	O
in	O
Aberrant	B-O
Behavior	I-O
Checklist	I-O
(	I-O
ABC	I-O
)	I-O
scores	I-O
.	O

Adverse	B-O
events	I-O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Riluzole	B-I
as	O
an	O
adjunctive	O
therapy	O
to	O
risperidone	B-I
for	O
the	O
treatment	O
of	O
irritability	O
in	O
children	B-P
with	I-P
autistic	I-P
disorder	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
10	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

The	O
study	O
enrolled	O
male	B-P
and	I-P
female	I-P
outpatients	I-P
aged	I-P
5	I-P
-	I-P
12	I-P
years	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
autistic	I-P
disorder	I-P
based	I-P
on	I-P
the	I-P
DSM	I-P
-	I-P
IV	I-P
-	I-P
TR	I-P
criteria	I-P
and	I-P
a	I-P
score	I-P
of	I-P
?12	I-P
on	I-P
the	I-P
Aberrant	I-P
Behavior	I-P
Checklist	I-P
-	I-P
Community	I-P
(	I-P
ABC	I-P
-	I-P
C	I-P
)	I-P
irritability	I-P
subscale	I-P
who	I-P
had	I-P
discontinued	I-P
other	I-P
medications	I-P
because	I-P
of	I-P
a	I-P
lack	I-P
of	I-P
efficacy	I-P
.	O

Subjects	O
received	O
riluzole	B-I
(	O
titrated	O
to	O
50	O
or	O
100	O
mg	O
/	O
day	O
based	O
on	O
bodyweight	O
)	O
or	O
placebo	B-C
in	O
addition	O
to	O
risperidone	B-I
(	O
titrated	O
up	O
to	O
2	O
or	O
3	O
mg	O
/	O
day	O
based	O
on	O
bodyweight	O
)	O
for	O
10	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Can	O
a	B-I
questionnaire	I-I
predict	O
vitamin	O
D	O
status	O
in	O
postmenopausal	B-P
women	I-P
?	O
.	O

METHODS	O
:	O
Women	O
completed	O
the	B-I
Vitamin	I-I
D	I-I
&	I-I
Sun	I-I
(	I-I
VIDSUN	I-I
)	I-I
questionnaire	I-I
and	O
we	O
measured	O
their	B-O
serum	I-O
25	I-O
-	I-O
hydrocyvitamin	I-O
D	I-O
(	I-O
25	I-O
(	I-O
OH	I-O
)	I-O
D	I-O
)	I-O
levels	I-O
.	O

We	O
assessed	O
the	B-O
sensitivity	I-O
and	O
specificity	B-O
of	O
the	B-I
questionnaire	I-I
to	O
identify	O
VDI	B-O
(	I-O
25	I-O
(	I-O
OH	I-O
)	I-O
D	I-O
level	I-O
<	I-O
50	I-O
nmol	I-O
/	I-O
l	I-O
)	O
.	O

Clinical	O
Research	O
Unit	O
,	O
University	O
of	O
Wisconsin	O
-	O
Madison	O
.	O

Postmenopausal	B-P
women	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Low	B-I
protein	I-I
provision	I-I
during	O
the	O
first	O
year	O
of	O
life	O
,	O
but	O
not	O
during	O
foetal	O
life	O
,	O
affects	O
metabolic	O
traits	O
,	O
organ	O
mass	O
development	O
and	O
growth	O
in	O
male	O
mink	O
(	O
Neovison	O
vison	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Tissue	B-I
microarray	I-I
in	O
a	O
subset	O
of	O
South	B-P
African	I-P
patients	I-P
with	I-P
DLBCL	I-P
.	O

METHODS	O
:	O
Tissue	O
samples	O
from	O
93	B-P
de	I-P
novo	I-P
diffuse	I-P
large	I-P
B	I-P
-	I-P
cell	I-P
lymphoma	I-P
patients	I-P
seen	I-P
between	I-P
1995	I-P
and	I-P
2009	I-P
randomly	O
receiving	O
either	O
standard	B-C
combination	I-C
chemotherapy	I-C
(	O
CHOP	B-C
,	O
n=48	O
)	O
or	O
the	B-I
identical	I-I
program	I-I
with	I-I
rituximab	I-I
(	O
n=45	O
)	O
were	O
subtyped	O
using	O
an	O
investigational	O
immunohistochemical	O
(	O
IHC	O
)	O
based	O
tissue	O
microarray	O
(	O
TMA	O
)	O
and	O
contrasted	O
to	O
the	O
approximately	O
corresponding	O
categories	O
as	O
defined	O
either	O
by	O
Hans	O
and	O
associates	O
using	O
a	O
three	O
marker	O
panel	O
into	O
germinal	O
or	O
non	O
-	O
germinal	O
centre	O
subtypes	O
or	O
by	O

Choi	O
and	O
colleagues	O
with	O
two	O
additional	O
antibodies	O
into	O
germinal	O
centre	O
(	O
GCB	O
)	O
or	O
activated	O
B	O
-	O
cells	O
(	O
ABC	O
)	O
.	O

Each	O
of	O
these	O
primary	O
subdivisions	O
was	O
further	O
evaluated	O
for	O
expression	B-O
of	I-O
BCL2	O
and	O
LMO2	B-O
both	O
of	O
which	O
are	O
recognised	O
to	O
predicate	O
response	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
study	O
to	O
evaluate	O
safety	O
and	O
tolerability	O
of	O
repeated	B-I
doses	I-I
of	I-I
tirasemtiv	I-I
in	O
patients	B-P
with	I-P
amyotrophic	I-P
lateral	I-P
sclerosis	I-P
.	O

METHODS	O
:	O
Tirasemtiv	B-I
was	O
given	O
as	O
a	O
single	O
daily	O
dose	O
up	O
to	O
375	O
mg	O
for	O
two	O
weeks	O
,	O
with	O
and	O
without	O
concomitant	O
riluzole	O
.	O

In	O
a	O
separate	O
cohort	O
,	O
an	O
ascending	O
dose	O
protocol	O
evaluated	O
a	O
total	O
dose	O
of	O
500	O
mg	O
daily	O
given	O
in	O
two	O
divided	O
doses	O
.	O

Safety	B-O
and	O
tolerability	B-O
were	O
assessed	O
,	O
as	O
well	O
as	O
measures	O
of	O
function	B-O
,	O
muscle	B-O
strength	I-O
and	O
endurance	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Assessment	O
of	O
global	B-I
functioning	I-I
in	O
adolescents	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
utility	O
of	O
the	O
Developmental	O
Disability	O
-	O
Child	O
Global	O
Assessment	O
Scale	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
person	B-I
-	I-I
centred	I-I
dementia	I-I
care	I-I
to	O
prevent	O
agitation	O
and	O
other	O
neuropsychiatric	O
symptoms	O
and	O
enhance	O
quality	O
of	O
life	O
in	O
nursing	B-P
home	I-P
patients	I-P
:	O
a	O
10	O
-	O
month	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
10	O
-	O
month	O
three	O
-	O
armed	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
compared	O
DCM	B-I
and	O
VPM	B-I
with	O
control	O
.	O

Of	O
624	O
nursing	O
home	O
patients	O
with	O
dementia	O
,	O
446	O
completed	O
follow	O
-	O
up	O
assessments	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
change	O
on	O
the	B-O
Brief	I-O
Agitation	I-O
Rating	I-O
Scale	I-O
(	I-O
BARS	I-O
)	I-O
.	O

Secondary	O
outcomes	O
were	O
changes	O
on	O
the	B-O
10	I-O
-	I-O
item	I-O
version	I-O
of	I-O
the	I-O
Neuropsychiatric	I-O
Inventory	I-O
Questionnaire	I-O
(	I-O
NPI	I-O
-	I-O
Q	I-O
)	I-O
,	O
the	B-O
Cornell	I-O
Scale	I-O
for	I-O
Depression	I-O
in	I-O
Dementia	I-O
(	I-O
CSDD	I-O
)	I-O
and	O
the	B-O
Quality	I-O
of	I-O
Life	I-O
in	I-O
Late	I-O
-	I-O
Stage	I-O
Dementia	I-O
(	I-O
QUALID	I-O
)	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Baseline	O
factors	O
predicting	O
placebo	B-I
response	O
to	O
treatment	O
in	O
children	B-P
and	I-P
adolescents	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
multisite	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
clinical	O
trial	O
of	O
citalopram	O
hydrobromide	O
for	O
children	O
and	O
adolescents	O
with	O
autism	O
spectrum	O
disorders	O
and	O
prominent	O
repetitive	O
behavior	O
.	O

Baseline	O
data	O
at	O
study	O
entry	O
were	O
examined	O
with	O
respect	O
to	O
final	O
outcome	O
to	O
determine	O
if	O
response	O
predictors	O
could	O
be	O
identified	O
.	O

A	B-P
total	I-P
of	I-P
149	I-P
children	I-P
and	I-P
adolescents	I-P
5	I-P
to	I-P
17	I-P
years	I-P
of	I-P
age	I-P
(	I-P
mean	I-P
[	I-P
SD	I-P
]	I-P
age	I-P
,	I-P
9	I-P
.	I-P
4	I-P
[	I-P
3	I-P
.	I-P
1	I-P
]	I-P
years	I-P
)	I-P
from	O
6	O
academic	O
centers	O
were	O
randomly	O
assigned	O
to	O
citalopram	B-I
(	O
n	O
=	O
73	O
)	O
or	O
placebo	B-I
(	O
n	O
=	O
76	O
)	O
.	O

Participants	O
had	O
autistic	O
disorder	O
,	O
Asperger	O
syndrome	O
,	O
or	O
pervasive	O
developmental	O
disorder	O
,	O
not	O
otherwise	O
specified	O
;	O
had	O
illness	O
severity	O
ratings	O
that	O
were	O
moderate	O
or	O
more	O
than	O
moderate	O
on	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Severity	O
scale	O
;	O
and	O
scored	O
moderate	O
or	O
more	O
than	O
moderate	O
on	O
compulsive	O
behaviors	O
measured	O
with	O
the	O
modified	O
Children	O
'	O
s	O
Yale	O
-	O
Brown	O
Obsessive	O
-	O
Compulsive	O
Scale	O
.	O

Twelve	O
weeks	O
of	O
treatment	O
with	O
citalopram	B-I
(	O
10	O
mg	O
/	O
5	O
mL	O
)	O
or	O
placebo	B-C
.	O

The	O
mean	O
(	O
SD	O
)	O
maximum	O
dose	O
of	O
citalopram	B-I
was	O
16	O
.	O
5	O
(	O
6	O
.	O
5	O
)	O
mg	O
by	O
mouth	O
daily	O
(	O
maximum	O
dose	O
,	O
20	O
mg	O
/	O
d	O
)	O
.	O

A	O
positive	O
response	O
was	O
defined	O
as	O
having	O
a	O
score	O
of	O
at	O
least	O
much	O
improved	O
on	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Improvement	O
scale	O
at	O
week	O
12	O
.	O

Baseline	B-O
measures	I-O
included	O
demographic	B-O
(	O
sex	B-O
,	O
age	B-O
,	O
weight	B-O
,	O
and	O
pubertal	B-O
status	I-O
)	O
,	O
clinical	B-O
,	O
and	O
family	B-O
measures	I-O
.	O

Clinical	B-O
variables	I-O
included	O
baseline	O
illness	B-O
severity	I-O
ratings	I-O
(	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
,	O
the	B-O
Child	I-O
and	I-O
Adolescent	I-O
Symptom	I-O
Inventory	I-O
,	O
the	B-O
Vineland	I-O
Adaptive	I-O
Behavior	I-O
Scales	I-O
,	O
the	B-O
Repetitive	I-O
Behavior	I-O
Scale	I-O
-	I-O
Revised	I-O
,	O
and	O
the	B-O
Children	I-O
'	I-O
s	I-O
Yale	I-O
-	I-O
Brown	I-O
Obsessive	I-O
-	I-O
Compulsive	I-O
Scale	I-O
)	O
.	O

Family	B-O
measures	I-O
included	O
the	B-O
Caregiver	I-O
Strain	I-O
Questionnaire	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
shortened	I-I
versus	O
standard	B-C
matched	I-C
postpartum	I-C
magnesium	I-C
sulphate	I-C
regimen	I-C
in	O
the	O
treatment	O
of	O
eclampsia	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
The	B-O
maternal	I-O
and	O
fetal	B-O
outcomes	I-O
were	O
compared	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
recurrence	B-O
of	I-O
fits	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Local	B-I
contextual	I-I
processing	I-I
in	O
major	O
depressive	O
disorder	O
.	O

METHODS	O
:	O
We	O
recorded	O
EEG	O
in	O
15	O
MDD	O
patients	O
and	O
14	O
age	O
-	O
matched	O
controls	O
.	O

Recording	O
blocks	O
consisted	O
of	O
targets	O
preceded	O
by	O
randomized	O
sequences	O
of	O
standards	O
and	O
by	O
sequences	O
of	O
standards	O
that	O
included	O
a	O
predictive	O
sequence	O
signaling	O
the	O
occurrence	O
of	O
a	O
subsequent	O
target	O
event	O
.	O

-DOCSTART-	O

Title	O
:	O
Group	B-I
cognitive	I-I
behavioural	I-I
therapy	I-I
and	O
group	B-I
recreational	I-I
activity	I-I
for	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
preliminary	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
preliminary	O
randomized	O
controlled	O
open	O
trial	O
with	O
a	O
parallel	O
design	O
developed	O
two	O
group	O
interventions	O
for	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
and	I-P
intelligence	I-P
within	I-P
the	I-P
normal	I-P
range	I-P
:	O
cognitive	B-I
behavioural	I-I
therapy	I-I
and	O
recreational	B-I
activity	I-I
.	O

Both	O
interventions	O
comprised	O
36	O
weekly	O
3	O
-	O
h	O
sessions	O
led	O
by	O
two	O
therapists	O
in	O
groups	O
of	O
6	O
-	O
8	O
patients	O
.	O

A	B-P
total	I-P
of	I-P
68	I-P
psychiatric	I-P
patients	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
participated	O
in	O
the	O
study	O
.	O

Outcome	O
measures	O
were	O
Quality	B-O
of	I-O
Life	I-O
Inventory	I-O
,	O
Sense	B-O
of	I-O
Coherence	I-O
Scale	I-O
,	O
Rosenberg	B-O
Self	I-O
-	I-O
Esteem	I-O
Scale	I-O
and	O
an	O
exploratory	O
analysis	O
on	O
measures	B-O
of	I-O
psychiatric	I-O
health	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Group	B-I
therapy	I-I
for	O
anxiety	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
32	I-P
children	I-P
aged	I-P
9	I-P
-	I-P
13	I-P
years	I-P
were	O
randomised	O
to	O
immediate	B-I
or	O
delayed	B-I
therapy	I-I
using	O
the	B-I
'	I-I
Exploring	I-I
Feelings	I-I
'	I-I
manual	I-I
(	O
Attwood	O
,	O
2004	O
)	O
.	O

Child	O
and	O
parent	O
groups	O
were	O
run	O
in	O
parallel	O
,	O
for	O
seven	O
weekly	O
sessions	O
,	O
under	O
the	O
supervision	O
of	O
experienced	O
psychologists	O
.	O

The	O
primary	O
blinded	O
outcome	O
measures	O
addressed	O
change	O
in	O
overall	B-O
functioning	I-O
and	O
in	O
severity	B-O
of	I-O
the	I-O
primary	I-O
anxiety	I-O
diagnosis	I-O
after	O
3	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Sequential	B-I
therapy	I-I
versus	O
standard	B-C
triple	I-C
-	I-C
drug	I-C
therapy	I-C
for	O
Helicobacter	O
pylori	O
eradication	O
:	O
a	O
randomized	O
study	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
open	O
-	O
labeled	O
,	O
prospective	O
controlled	O
trial	O
comparing	O
sequential	B-I
vs	O
.	O
standard	B-C
triple	I-C
-	I-C
drug	I-C
therapy	I-C
was	O
carried	O
out	O
at	O
Lokmanya	O
Tilak	O
Municipal	O
General	O
Hospital	O
,	O
Mumbai	O
.	O

Two	B-P
hundred	I-P
and	I-P
thirty	I-P
-	I-P
one	I-P
patients	I-P
with	I-P
dyspepsia	I-P
were	O
randomized	O
to	O
a	B-I
10	I-I
-	I-I
day	I-I
sequential	I-I
regimen	I-I
(	O
40	B-I
mg	I-I
of	I-I
pantoprazole	I-I
,	O
1	B-I
g	I-I
of	I-I
amoxicillin	I-I
,	O
each	O
administered	O
twice	O
daily	O
for	O
the	O
first	O
5	O
days	O
,	O
followed	O
by	O
40	B-I
mg	I-I
of	I-I
pantoprazole	I-I
,	O
500	B-I
mg	I-I
of	I-I
clarithromycin	I-I
,	O
and	O
500	B-I
mg	I-I
of	I-I
tinidazole	I-I
,	O
each	O
administered	O
twice	O
daily	O
for	O
the	O
remaining	O
5	O
days	O
)	O
or	O
to	O
standard	B-C
14	I-C
-	I-C
day	I-C
therapy	I-C
(	O
40	B-C
mg	I-C
of	I-C
pantoprazole	I-C
,	O
500	B-C
mg	I-C
of	I-C
clarithromycin	I-C
,	O
and	O
1	B-C
g	I-C
of	I-C
amoxicillin	I-C
,	O
each	O
administered	O
twice	O
daily	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Hypotension	O
in	O
response	O
to	O
iloprost	B-I
,	O
a	B-I
prostacyclin	I-I
analogue	I-I
.	O

-DOCSTART-	O

Title	O
:	O
An	O
intervention	O
for	O
sensory	O
difficulties	O
in	O
children	B-P
with	I-P
autism	I-P
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Diagnosis	O
of	O
autism	O
was	O
confirmed	O
using	O
gold	O
standard	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Humoral	O
immunity	O
after	O
kidney	O
transplantation	O
:	O
impact	O
of	O
two	B-I
randomized	I-I
immunosuppressive	I-I
protocols	I-I
.	O

METHODS	O
:	O
We	O
performed	O
a	O
post	O
-	O
hoc	O
analysis	O
on	O
307	B-P
kidney	I-P
transplant	I-P
recipients	I-P
included	O
in	O
a	O
prospective	O
randomized	O
trial	O
comparing	O
tacrolimus	B-I
/	O
mycophenolate	B-I
mofetil	I-I
(	O
Tac	B-I
/	O
MMF	B-I
)	O
vs	O
.	O
cyclosporine	B-I
/	O
azathioprine	B-I
(	O
CsA	B-I
/	O
AZA	B-I
)	O
,	O
both	O
used	O
with	O
antithymocyte	O
globulin	O
induction	O
and	O
steroids	O
.	O

Humoral	B-O
parameters	I-O
were	O
analyzed	O
at	O
D0	O
,	O
D15	O
,	O
and	O
M12	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
augmented	O
sensorimotor	O
input	O
on	O
learning	B-I
verbal	I-I
and	O
nonverbal	O
tasks	O
among	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
four	I-P
children	I-P
,	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
,	I-P
ages	I-P
4	I-P
-	I-P
14	I-P
years	I-P
,	O
were	O
matched	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
conditions	O
for	O
learning	B-I
a	I-I
novel	I-I
juice	I-I
-	I-I
making	I-I
task	I-I
and	O
producing	B-I
two	I-I
novel	I-I
words	I-I
about	I-I
the	I-I
event	I-I
.	O

Seventeen	O
sighted	O
children	O
were	O
manually	O
guided	O
to	O
perform	O
the	O
task	O
and	O
tactually	O
prompted	O
during	O
imitated	O
productions	O
of	O
novel	O
words	O
for	O
the	O
event	O
.	O

Their	O
matched	O
controls	O
heard	O
the	B-C
novel	I-C
words	I-C
and	O
watched	O
the	B-C
juice	I-C
-	I-C
making	I-C
task	I-C
being	I-C
performed	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
controlled	O
effectiveness	O
trial	O
of	O
executive	B-I
function	I-I
intervention	I-I
for	O
children	B-P
on	I-P
the	I-P
autism	I-P
spectrum	I-P
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
UOT	B-I
compared	O
with	O
a	B-I
social	I-I
skills	I-I
intervention	I-I
(	I-I
SS	I-I
)	I-I
,	O
3rd	B-P
-	I-P
5th	I-P
graders	I-P
with	I-P
ASD	I-P
(	I-P
mean	I-P
IQ	I-P
=	I-P
108	I-P
;	I-P
UOT	I-P
n	I-P
=	I-P
47	I-P
;	I-P
SS	I-P
n	I-P
=	I-P
20	I-P
)	I-P
received	O
interventions	O
delivered	O
by	O
school	O
staff	O
in	O
small	O
group	O
sessions	O
.	O

Students	O
were	O
matched	O
for	O
gender	O
,	O
age	O
,	O
race	O
,	O
IQ	O
,	O
ASD	O
symptomotolgy	O
,	O
medication	O
status	O
,	O
and	O
parents	O
'	O
education	O
.	O

Interventions	O
were	O
matched	O
for	O
'	O
dose	O
'	O
of	O
intervention	O
and	O
training	O
.	O

Measures	O
of	O
pre	O
-	O
post	O
change	O
included	O
classroom	B-O
observations	I-O
,	O
parent	B-O
/	I-O
teacher	I-O
report	I-O
,	O
and	O
direct	B-O
child	I-O
measures	I-O
of	I-O
problem	I-O
-	I-O
solving	I-O
,	O
EF	B-O
,	O
and	O
social	B-O
skills	I-O
.	O

Schools	O
were	O
randomized	O
and	O
evaluators	O
,	O
but	O
not	O
parents	O
or	O
teachers	O
,	O
were	O
blinded	O
to	O
intervention	O
type	O
.	O

-DOCSTART-	O

Title	O
:	O
Influence	O
of	O
two	B-I
different	I-I
doses	I-I
of	I-I
antithymocyte	I-I
globulin	I-I
in	O
patients	B-P
with	I-P
standard	I-P
-	I-P
risk	I-P
disease	I-P
following	I-P
haploidentical	I-P
transplantation	I-P
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
the	B-I
different	I-I
doses	I-I
of	I-I
antithymocyte	I-I
globulin	I-I
(	I-I
ATG	I-I
)	I-I
on	O
the	B-O
incidence	I-O
of	I-O
acute	I-O
GVHD	I-O
among	O
patients	B-P
receiving	I-P
hematopoietic	I-P
SCT	I-P
without	I-P
ex	I-P
vivo	I-P
T	I-P
-	I-P
cell	I-P
-	I-P
depletion	I-P
from	I-P
haploidentical	I-P
donors	I-P
,	O
224	B-P
patients	I-P
with	I-P
standard	I-P
-	I-P
risk	I-P
hematological	I-P
malignancy	I-P
were	O
randomized	O
in	O
this	O
study	O
.	O

One	O
hundred	O
and	O
twelve	O
patients	O
received	O
6	B-I
mg	I-I
/	I-I
kg	I-I
ATG	I-I
,	O
whereas	O
the	O
remaining	O
patients	O
received	O
10	B-I
mg	I-I
/	I-I
kg	I-I
ATG	I-I
.	O

This	O
study	O
was	O
registered	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
chictr	O
.	O
org	O
as	O
No	O
.	O

ChiCTR	O
-	O
TRC	O
-	O
11001761	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
intervention	O
to	O
decrease	O
stigma	O
in	O
young	B-P
adults	I-P
with	I-P
sickle	I-P
cell	I-P
disease	I-P
.	O

METHODS	O
:	O
Young	B-P
adults	I-P
with	I-P
SCD	I-P
ages	I-P
18	I-P
to	I-P
35	I-P
years	I-P
(	O
n	O
=	O
90	O
)	O
were	O
randomized	O
to	O
either	O
the	B-I
care	I-I
-	I-I
seeking	I-I
intervention	I-I
(	I-I
CSI	I-I
)	I-I
or	O
an	B-C
attention	I-C
control	O
group	O
that	O
participated	O
in	O
life	O
review	O
interviews	O
.	O

The	O
two	O
groups	O
were	O
compared	O
by	O
t	O
tests	O
and	O
longitudinal	O
data	O
analyses	O
on	O
the	O
change	O
from	O
baseline	O
to	O
the	O
last	O
time	O
point	O
in	O
total	B-O
health	I-O
-	I-O
related	I-O
stigma	I-O
and	O
health	B-O
-	I-O
related	I-O
stigma	I-O
by	O
doctors	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	B-I
-	I-I
dose	I-I
versus	O
standard	B-C
-	I-C
dose	I-C
gemcitabine	I-C
infusion	I-C
and	O
cisplatin	B-C
for	O
patients	B-P
with	I-P
advanced	I-P
bladder	I-P
cancer	I-P
:	O
a	O
randomized	O
phase	O
II	O
trial	O
-	O
an	O
update	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
twenty	I-P
untreated	I-P
patients	I-P
with	I-P
stage	I-P
III	I-P
/	I-P
IV	I-P
bladder	I-P
cancer	I-P
were	O
randomized	O
to	O
receive	O
either	O
gemcitabine	B-I
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
6	O
-	O
h	O
infusion	O
on	O
days	O
1	O
and	O
8	O
,	O
and	O
cisplatin	B-I
(	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
2	O
every	O
21	O
-	O
day	O
cycle	O
(	O
arm	O
1	O
)	O
or	O
gemcitabine	B-I
(	O
1	O
,	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
30	O
-	O
min	O
infusion	O
on	O
days	O
1	O
and	O
8	O
,	O
with	O
the	B-I
same	I-I
dose	I-I
of	I-I
cisplatin	I-I
(	O
arm	O
2	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Population	O
pharmacokinetic	O
/	O
pharmacodynamic	O
analysis	O
of	O
the	B-I
DPP	I-I
-	I-I
4	I-I
inhibitor	I-I
linagliptin	I-I
in	O
Japanese	B-P
patients	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

METHODS	O
:	O
Linagliptin	B-O
plasma	I-O
concentration	I-O
and	O
DPP	B-O
-	I-O
4	I-O
inhibition	I-O
measurements	I-O
from	O
a	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
multiple	O
(	O
28	O
days	O
)	O
dose	O
trial	O
that	O
included	O
36	B-P
T2DM	I-P
patients	I-P
(	I-P
18	I-P
patients	I-P
each	I-P
in	I-P
2	I-P
.	I-P
5	I-P
mg	I-P
and	I-P
10	I-P
mg	I-P
dose	I-P
group	I-P
)	I-P
were	O
used	O
for	O
analysis	O
.	O

Modeling	O
was	O
performed	O
using	O
FOCE	O
INTERACTION	O
estimation	O
method	O
implemented	O
in	O
NONMEM	O
V	O
.	O

The	B-O
linagliptin	I-O
plasma	I-O
concentration	I-O
-	I-O
and	O
DPP	B-O
-	I-O
4	I-O
inhibition	I-O
-	I-O
time	I-O
profiles	I-O
were	O
simulated	O
for	O
Japanese	B-P
patients	I-P
receiving	O
5	B-I
mg	I-I
linagliptin	I-I
once	O
daily	O
by	O
the	O
model	O
established	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
controlled	O
trial	O
of	O
the	B-I
Korean	I-I
version	I-I
of	I-I
the	I-I
PEERS	I-I
(	I-I
?	I-I
)	I-I
parent	I-I
-	I-I
assisted	I-I
social	I-I
skills	I-I
training	I-I
program	I-I
for	O
teens	B-P
with	I-P
ASD	I-P
.	O

METHODS	O
:	O
Items	O
identified	O
as	O
culturally	O
sensitive	O
were	O
surveyed	O
by	O
447	O
middle	O
school	O
students	O
,	O
and	O
material	O
was	O
modified	O
accordingly	O
.	O

Participants	O
included	O
47	B-P
teens	I-P
between	I-P
12	I-P
and	I-P
18	I-P
years	I-P
of	I-P
age	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
ASD	I-P
and	I-P
a	I-P
verbal	I-P
intelligence	I-P
quotient	I-P
(	I-P
IQ	I-P
)	I-P
??	I-P
65	I-P
.	O

Eligible	O
teens	O
were	O
randomly	O
assigned	O
to	O
a	O
treatment	O
group	O
(	O
TG	O
)	O
or	O
delayed	O
treatment	O
control	O
group	O
(	O
CG	O
)	O
.	O

Primary	O
outcome	O
measures	O
included	O
questionnaires	B-O
and	O
direct	B-O
observations	I-O
quantifying	O
social	B-O
ability	I-O
and	O
problems	B-O
directly	I-O
related	I-O
to	I-O
ASD	I-O
.	O

Secondary	O
outcome	O
measures	O
included	O
scales	O
for	O
depressive	B-O
symptoms	I-O
,	O
anxiety	B-O
,	O
and	O
other	B-O
behavioral	I-O
problems	I-O
.	O

Rating	O
scales	O
for	O
parental	B-O
depressive	I-O
symptoms	I-O
and	O
anxiety	B-O
were	O
examined	O
to	O
detect	O
changes	O
in	O
parental	O
psychosocial	O
functioning	O
throughout	O
the	B-I
PEERS	I-I
(	I-I
?	I-I
)	I-I
treatment	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Management	O
of	O
large	O
bowel	O
obstruction	O
with	O
self	B-I
-	I-I
expanding	I-I
metal	I-I
stents	I-I
.	O

A	O
multicentre	O
retrospective	O
study	O
of	O
factors	O
determining	O
outcome	O
.	O

METHODS	O
:	O
A	O
regional	O
programme	O
of	O
colonic	B-I
stenting	I-I
for	O
large	O
bowel	O
obstruction	O
,	O
in	O
five	O
UK	O
centres	O
from	O
2005	O
to	O
2010	O
was	O
evaluated	O
for	O
outcome	O
including	O
technical	B-O
and	O
clinical	B-O
success	I-O
,	O
survival	B-O
,	O
complications	B-O
and	O
reoperation	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Alleviating	O
social	O
avoidance	O
:	O
effects	O
of	O
single	B-I
dose	I-I
testosterone	I-I
administration	O
on	O
approach	O
-	O
avoidance	O
action	O
.	O

METHODS	O
:	O
The	O
present	O
study	O
sets	O
out	O
to	O
test	O
the	O
effects	O
of	O
testosterone	B-I
administration	O
in	O
healthy	B-P
female	I-P
volunteers	I-P
using	I-P
an	I-P
objective	I-P
implicit	I-P
measure	I-P
of	I-P
social	I-P
motivational	I-P
behavior	I-P
:	O
the	B-O
social	I-O
Approach	I-O
-	I-O
Avoidance	I-O
Task	I-O
,	O
a	O
reaction	O
time	O
task	O
requiring	O
participants	O
to	O
approach	O
or	O
avoid	O
visually	O
presented	O
emotional	O
(	O
happy	O
,	O
angry	O
,	O
and	O
neutral	O
)	O
faces	O
.	O

-DOCSTART-	O

Title	O
:	O
Dentists	O
United	O
to	O
Extinguish	O
Tobacco	O
(	O
DUET	O
)	O
:	O
a	O
study	O
protocol	O
for	O
a	O
cluster	O
randomized	O
,	O
controlled	O
trial	O
for	O
enhancing	O
implementation	O
of	O
clinical	O
practice	O
guidelines	O
for	O
treating	O
tobacco	O
dependence	O
in	O
dental	O
care	O
settings	O
.	O

METHODS	O
:	O
Guided	O
by	O
a	O
multi	O
-	O
level	O
,	O
conceptual	O
framework	O
that	O
emphasizes	O
changes	O
in	O
provider	O
beliefs	O
and	O
organizational	O
characteristics	O
as	O
drivers	O
of	O
improvement	O
in	O
tobacco	O
treatment	O
delivery	O
,	O
the	O
current	O
protocol	O
will	O
use	O
a	O
cluster	O
,	O
randomized	O
design	O
and	O
multiple	O
data	O
sources	O
(	O
patient	O
exit	O
interviews	O
,	O
provider	O
surveys	O
,	O
site	O
observations	O
,	O
chart	O
audits	O
,	O
and	O
semi	O
-	O
structured	O
provider	O
interviews	O
)	O
to	O
study	O
the	O
process	O
of	O
implementing	O
clinical	O
practice	O
guidelines	O
for	O
treating	O
tobacco	O
dependence	O
in	O
18	O
public	O

dental	O
care	O
clinics	O
in	O
New	O
York	O
City	O
.	O

The	O
specific	O
aims	O
of	O
this	O
comparative	O
-	O
effectiveness	O
research	O
trial	O
are	O
to	O
:	O
compare	O
the	O
effectiveness	O
of	O
three	B-I
promising	I-I
strategies	I-I
for	I-I
implementation	I-I
of	I-I
tobacco	I-I
use	I-I
treatment	I-I
guidelines	I-I
-	O
staff	B-I
training	I-I
and	O
current	B-I
best	I-I
practices	I-I
(	I-I
CBP	I-I
)	I-I
,	O
CBP	B-I
+	O
provider	B-I
performance	I-I
feedback	I-I
(	I-I
PF	I-I
)	I-I
,	O
and	O
CBP	B-I
+	O
PF	B-I
+	O
provider	B-I
reimbursement	I-I
for	I-I
delivery	I-I
of	I-I
tobacco	I-I
cessation	I-I
treatment	I-I
(	I-I
pay	I-I
-	I-I
for	I-I
-	I-I
performance	I-I
,	I-I
or	I-I
P4P	I-I
)	I-I
;	O
examine	O
potential	O
theory	O
-	O
driven	O
mechanisms	O
hypothesized	O
to	O
explain	O
the	O
comparative	O
effectiveness	O
of	O
three	O
strategies	O

for	O
implementation	O
;	O
and	O
identify	O
baseline	O
organizational	O
factors	O
that	O
influence	O
the	O
implementation	O
of	O
evidence	O
-	O
based	O
tobacco	O
use	O
treatment	O
practices	O
in	O
dental	O
clinics	O
.	O

The	O
primary	O
outcome	O
is	O
change	O
in	O
providers	B-O
'	I-O
tobacco	I-O
treatment	I-O
practices	I-O
and	O
the	O
secondary	O
outcomes	O
are	O
cost	B-O
per	I-O
quit	I-O
,	O
use	B-O
of	I-O
tobacco	I-O
cessation	I-O
treatments	I-O
,	O
quit	B-O
attempts	I-O
,	O
and	O
smoking	B-O
abstinence	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
lowering	B-I
LDL	I-I
cholesterol	I-I
on	O
vascular	O
access	O
patency	O
:	O
post	O
hoc	O
analysis	O
of	O
the	O
Study	O
of	O
Heart	O
and	O
Renal	O
Protection	O
.	O

METHODS	O
:	O
The	O
Study	O
of	O
Heart	O
and	O
Renal	O
Protection	O
(	O
SHARP	O
)	O
randomized	O
patients	B-P
with	I-P
CKD	I-P
to	O
20	B-I
mg	I-I
simvastatin	I-I
plus	O
10	B-I
mg	I-I
ezetimibe	I-I
daily	O
versus	O
matching	B-C
placebo	I-C
.	O

This	O
study	O
aimed	O
to	O
explore	O
the	O
effects	O
of	O
treatment	O
on	O
vascular	B-O
access	I-O
occlusive	I-O
events	I-O
,	O
defined	O
as	O
any	B-O
access	I-O
revision	I-O
procedure	I-O
,	O
access	B-O
thrombosis	I-O
,	O
removal	B-O
of	I-O
an	I-O
old	I-O
dialysis	I-O
access	I-O
,	O
or	O
formation	B-O
of	I-O
new	I-O
permanent	I-O
dialysis	I-O
access	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Factors	O
associated	O
with	O
low	B-I
consumption	I-I
of	I-I
fruits	I-I
and	O
vegetables	B-I
by	O
preschoolers	B-P
of	I-P
low	I-P
socio	I-P
-	I-P
economic	I-P
level	I-P
.	O

METHODS	O
:	O
This	O
was	O
a	O
cohort	O
study	O
nested	O
in	O
a	O
randomized	O
field	O
trial	O
.	O

Data	O
collection	O
was	O
performed	O
through	O
structured	O
questionnaires	O
to	O
obtain	O
demographic	O
and	O
dietary	O
data	O
,	O
combined	O
with	O
two	O
24	O
-	O
hour	O
recalls	O
in	O
the	O
age	O
groups	O
12	O
-	O
16	O
months	O
and	O
again	O
at	O
2	O
-	O
3	O
years	O
of	O
age	O
.	O

Data	O
on	O
the	B-I
consumption	I-I
of	I-I
one	I-I
daily	I-I
serving	I-I
of	I-I
fruits	I-I
(	O
80	O
g	O
)	O
and	O
vegetables	B-I
(	O
60	O
g	O
)	O
were	O
evaluated	O
,	O
as	O
well	O
as	O
consumption	B-I
of	I-I
non	I-I
-	I-I
recommended	I-I
foods	I-I
such	O
as	O
candy	B-I
,	O
chocolate	B-I
,	O
and	O
soft	B-I
drinks	I-I
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
Poisson	O
regression	O
with	O
robust	O
estimation	O
.	O

-DOCSTART-	O

Title	O
:	O
Weight	O
loss	O
maintenance	O
in	O
overweight	B-P
subjects	I-P
on	O
ad	B-I
libitum	I-I
diets	I-I
with	I-I
high	I-I
or	O
low	B-I
protein	I-I
content	I-I
and	O
glycemic	B-I
index	I-I
:	O
the	O
DIOGENES	O
trial	O
12	O
-	O
month	O
results	O
.	O

METHODS	O
:	O
After	O
an	O
8	O
-	O
week	O
low	O
-	O
calorie	O
diet	O
(	O
LCD	O
)	O
,	O
256	B-P
adults	I-P
(	I-P
body	I-P
mass	I-P
index	I-P
>	I-P
27	I-P
kg	I-P
m	I-P
(	I-P
-	I-P
)	I-P
(	I-P
2	I-P
)	I-P
)	I-P
were	O
randomized	O
to	O
five	B-I
ad	I-I
libitum	I-I
diets	I-I
for	O
12	O
months	O
:	O
high	B-I
P	I-I
/	O
LGI	B-I
(	O
HP	B-I
/	O
LGI	B-I
)	O
,	O
HP	B-I
/	O
high	B-I
GI	I-I
(	O
HP	B-I
/	O
HGI	B-I
)	O
,	O
low	B-I
P	I-I
/	O
LGI	B-I
(	O
LP	B-I
/	O
LGI	B-I
)	O
,	O
LP	B-I
/	O
HGI	B-I
and	O
a	B-C
control	I-C
diet	I-C
.	O

During	O
the	O
first	O
6	O
months	O
,	O
foods	O
were	O
provided	O
for	O
free	O
through	O
a	O
shop	O
system	O
and	O
during	O
the	O
whole	O
12	O
-	O
month	O
period	O
,	O
subjects	O
received	O
guidance	O
by	O
a	O
dietician	O
.	O

Primary	O
outcome	O
variable	O
was	O
the	O
change	O
in	O
body	B-O
weight	I-O
over	O
the	O
12	O
-	O
month	O
intervention	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
clinical	O
trial	O
comparing	O
mitoxantrone	B-I
with	O
doxorubicin	B-I
in	O
previously	B-P
treated	I-P
patients	I-P
with	I-P
metastatic	I-P
breast	I-P
cancer	I-P
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
twenty	I-P
-	I-P
five	I-P
women	I-P
with	I-P
metastatic	I-P
adenocarcinoma	I-P
of	I-P
the	I-P
breast	I-P
who	I-P
had	I-P
failed	I-P
one	I-P
prior	I-P
chemotherapeutic	I-P
regimen	I-P
for	I-P
advanced	I-P
disease	I-P
were	O
randomized	O
to	O
receive	O
14	B-I
mg	I-I
/	I-I
m2	I-I
of	I-I
mitoxantrone	I-I
or	O
75	B-I
mg	I-I
/	I-I
m2	I-I
of	I-I
doxorubicin	I-I
intravenously	O
(	O
IV	O
)	O
every	O
3	O
weeks	O
.	O

Enrollment	O
was	O
closed	O
on	O
October	O
31	O
,	O
1984	O
,	O
after	O
165	O
patients	O
were	O
randomized	O
to	O
mitoxantrone	B-I
and	O
160	O
patients	O
to	O
doxorubicin	B-I
.	O

Patients	O
randomized	O
to	O
the	O
two	O
treatment	O
groups	O
were	O
compared	O
for	O
response	B-O
rate	I-O
,	O
duration	B-O
of	I-O
response	I-O
,	O
time	B-O
to	I-O
progression	I-O
or	O
death	B-O
,	O
time	B-O
to	I-O
treatment	I-O
failure	I-O
(	I-O
TTF	I-O
)	I-O
,	O
and	O
survival	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Hemodialysis	O
catheter	O
design	O
and	O
catheter	O
performance	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Single	O
-	O
center	O
randomized	O
clinical	O
trial	O
.	O

302	B-P
hemodialysis	I-P
patients	I-P
who	I-P
required	I-P
a	I-P
tunneled	I-P
cuffed	I-P
catheter	I-P
as	I-P
temporary	I-P
or	I-P
definite	I-P
vascular	I-P
access	I-P
.	O

Palindrome	B-I
Symmetric	I-I
Tip	I-I
Dialysis	I-I
Catheter	I-I
or	O
HemoStar	B-I
Long	I-I
-	I-I
Term	I-I
Hemodialysis	I-I
Catheter	I-I
.	O

The	O
primary	O
end	O
point	O
was	O
primary	B-O
assisted	I-O
patency	I-O
.	O

Secondary	O
end	O
points	O
were	O
incidence	B-O
of	I-O
catheter	I-O
-	I-O
related	I-O
bloodstream	I-O
infections	I-O
(	I-O
CRBSIs	I-O
)	I-O
,	O
thrombosis	B-O
,	O
and	O
2	B-O
indicators	I-O
of	I-O
rheologic	I-O
function	I-O
:	O
mean	B-O
effective	I-O
blood	I-O
flow	I-O
rate	I-O
and	O
urokinase	B-O
use	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
mixed	I-I
kinesio	I-I
taping	I-I
-	I-I
compression	I-I
technique	I-I
on	O
quality	O
of	O
life	O
and	O
clinical	O
and	O
gait	O
parameters	O
in	O
postmenopausal	B-P
women	I-P
with	I-P
chronic	I-P
venous	I-P
insufficiency	I-P
:	O
double	O
-	O
blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Double	O
-	O
blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O

Clinical	O
setting	O
.	O

Consecutive	B-P
postmenopausal	I-P
women	I-P
(	I-P
N=130	I-P
;	I-P
mean	I-P
age	I-P
	I-P
SD	I-P
,	I-P
65	I-P
.	I-P
4414	I-P
.	I-P
7y	I-P
)	I-P
with	I-P
mild	I-P
CVI	I-P
.	O

No	O
participant	O
withdrew	O
because	O
of	O
adverse	O
effects	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
either	O
(	O
1	O
)	O
an	O
experimental	O
group	O
to	O
receive	O
a	B-I
mixed	I-I
KT	I-I
-	I-I
compression	I-I
treatment	I-I
following	O
KT	B-I
recommendations	I-I
for	I-I
gastrocnemius	I-I
muscle	I-I
enhancement	I-I
and	I-I
functional	I-I
correction	I-I
of	I-I
the	I-I
ankle	I-I
,	O
and	O
adding	O
2	B-I
tapes	I-I
to	I-I
simulate	I-I
traditional	I-I
compression	I-I
bandages	I-I
(	O
no	O
KT	O
guidelines	O
)	O
;	O
or	O
(	O
2	O
)	O
a	B-C
placebo	I-C
control	O
group	O
for	O
sham	B-C
KT	I-C
.	O

Both	O
interventions	O
were	O
performed	O
3	O
times	O
a	O
week	O
during	O
a	O
4	O
-	O
week	O
period	O
.	O

ROAM	B-O
,	O
gait	B-O
,	O
pain	B-O
,	O
perimeter	B-O
of	I-O
right	I-O
and	I-O
left	I-O
lower	I-O
limb	I-O
,	O
and	O
quality	B-O
of	I-O
life	I-O
were	O
assessed	O
at	O
baseline	O
and	O
48	O
hours	O
posttreatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
olanzapine	B-I
long	I-I
-	I-I
acting	I-I
injection	I-I
and	O
oral	B-I
olanzapine	I-I
:	O
a	O
2	O
-	O
year	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
in	O
outpatients	B-P
with	I-P
schizophrenia	I-P
.	O

METHODS	O
:	O
Outpatients	B-P
with	I-P
2	I-P
or	I-P
more	I-P
episodes	I-P
of	I-P
psychotic	I-P
worsening	I-P
in	I-P
the	I-P
past	I-P
24	I-P
months	I-P
with	I-P
Positive	I-P
and	I-P
Negative	I-P
Syndrome	I-P
Scale	I-P
total	I-P
score	I-P
of	I-P
lower	I-P
than	I-P
70	I-P
were	O
randomized	O
to	O
405	B-I
mg	I-I
/	I-I
4	I-I
weeks	I-I
of	I-I
olanzapine	I-I
LAI	I-I
(	O
n	O
=	O
264	O
)	O
or	O
10	B-I
mg	I-I
/	I-I
d	I-I
of	I-I
oral	I-I
olanzapine	I-I
(	O
n	O
=	O
260	O
)	O
for	O
2	O
years	O
of	O
open	O
-	O
label	O
treatment	O
.	O

Dosing	O
thereafter	O
was	O
flexible	O
(	O
150	O
-	O
405	O
mg	O
/	O
4	O
weeks	O
of	O
LAI	O
vs	O
5	O
-	O
20	O
mg	O
/	O
d	O
of	O
oral	O
)	O
.	O

Primary	O
outcome	O
was	O
time	B-O
to	I-O
all	I-O
-	I-O
cause	I-O
discontinuation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
additional	O
counselling	O
sessions	B-I
through	I-I
phone	I-I
calls	I-I
on	O
smoking	O
cessation	O
outcomes	O
among	O
smokers	B-P
in	I-P
Penang	I-P
State	I-P
,	I-P
Malaysia	I-P
.	O

METHODS	O
:	O
The	O
study	O
was	O
conducted	O
at	O
Quit	O
Smoking	O
Clinic	O
of	O
two	O
major	O
hospitals	O
in	O
Penang	O
,	O
Malaysia	O
.	O

All	B-P
the	I-P
eligible	I-P
smokers	I-P
who	I-P
attended	I-P
the	I-P
clinics	I-P
between	I-P
February	I-P
1st	I-P
and	I-P
October	I-P
31st	I-P
2012	I-P
were	O
invited	O
.	O

Participants	O
were	O
randomly	O
assigned	O
by	O
using	O
urn	B-I
design	I-I
method	I-I
either	O
to	O
receive	O
the	B-C
usual	I-C
care	I-C
that	O
followed	O
in	O
the	O
clinics	O
(	O
control	O
)	O
or	O
the	B-I
usual	I-I
care	I-I
procedure	I-I
plus	O
extra	B-I
counselling	I-I
sessions	I-I
through	I-I
phone	I-I
calls	I-I
during	O
the	O
first	O
month	O
of	O
quit	O
attempt	O
(	O
intervention	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
the	O
use	O
of	O
oxytocin	B-I
on	O
blood	O
loss	O
during	O
different	O
postpartum	O
periods	O
.	O

METHODS	O
:	O
In	O
the	O
study	O
,	O
89	O
pregnant	O
women	O
to	O
whom	O
oxytocin	B-I
was	O
administered	O
after	O
placenta	O
separation	O
were	O
studied	O
in	O
Group	O
1	O
,	O
89	O
pregnant	O
women	O
were	O
included	O
in	O
Group	O
2	O
,	O
and	O
oxytocin	B-I
was	O
administered	O
after	O
delivery	O
of	O
the	O
shoulder	O
.	O

The	B-O
levels	I-O
of	I-O
hemoglobin	I-O
and	O
hematocrit	B-O
before	O
and	O
after	O
delivery	O
were	O
quantified	O
.	O

-DOCSTART-	O

Title	O
:	O
Chocolate	B-I
frogs	I-I
do	O
not	O
increase	O
completion	O
of	O
parent	O
survey	O
:	O
randomised	O
study	O
.	O

METHODS	O
:	O
Families	B-P
enrolled	I-P
between	I-P
15	I-P
March	I-P
and	I-P
25	I-P
May	I-P
2012	I-P
were	O
randomised	O
to	O
receive	O
a	B-I
chocolate	I-I
frog	I-I
versus	O
no	B-C
chocolate	I-C
frog	I-C
.	O

Both	O
groups	O
received	O
a	O
written	O
reminder	O
and	O
replacement	O
survey	O
2	O
weeks	O
after	O
the	O
survey	O
was	O
posted	O
and	O
up	O
to	O
two	O
telephone	O
reminders	O
thereafter	O
.	O

We	O
analysed	O
the	O
effect	O
of	O
the	O
incentive	O
using	O
?	O
(	O
2	O
)	O
tests	O
for	O
the	B-O
categorical	I-O
response	I-O
variable	O
and	O
t	O
-	O
tests	O
for	O
the	B-O
continuous	I-O
reminder	I-O
and	O
length	B-O
of	I-O
response	I-O
variables	I-O
at	O
the	O
end	O
of	O
(	O
i	O
)	O
randomisation	O
and	O
(	O
ii	O
)	O
the	O
study	O
(	O
1	O
November	O
2012	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
phase	O
II	O
study	O
of	O
afatinib	B-I
versus	O
cetuximab	B-I
in	O
metastatic	O
or	O
recurrent	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
.	O

METHODS	O
:	O
An	O
open	O
-	O
label	O
,	O
randomized	O
,	O
phase	O
II	O
trial	O
was	O
conducted	O
in	O
43	O
centers	O
;	O
124	B-P
patients	I-P
were	O
randomized	O
(	O
1	O
:	O
1	O
)	O
to	O
either	O
afatinib	B-I
(	O
50	O
mg	O
/	O
day	O
)	O
or	O
cetuximab	B-I
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
)	O
until	O
disease	O
progression	O
or	O
intolerable	O
adverse	O
events	O
(	O
AEs	O
)	O
(	O
stage	O
I	O
)	O
,	O
with	O
optional	O
crossover	O
(	O
stage	O
II	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
tumor	B-O
shrinkage	I-O
before	O
crossover	O
assessed	O
by	O
investigator	O
(	O
IR	O
)	O
and	O
independent	O
central	O
review	O
(	O
ICR	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Electrothermal	B-I
arthroscopic	I-I
capsulorrhaphy	I-I
:	O
old	O
technology	O
,	O
new	O
evidence	O
.	O

A	O
multicenter	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Patients	B-P
(	I-P
>	I-P
14	I-P
years	I-P
)	I-P
diagnosed	I-P
with	I-P
multidirectional	I-P
instability	I-P
or	I-P
multidirectional	I-P
laxity	I-P
with	I-P
anteroinferior	I-P
instability	I-P
and	I-P
failed	I-P
nonoperative	I-P
treatment	I-P
were	O
enrolled	O
.	O

Patients	O
with	O
bone	O
lesions	O
or	O
labral	O
,	O
biceps	O
anchor	O
,	O
or	O
full	O
-	O
thickness	O
rotator	O
cuff	O
tears	O
were	O
excluded	O
intraoperatively	O
.	O

Outcomes	O
included	O
Western	B-O
Ontario	I-O
Shoulder	I-O
Instability	I-O
Index	I-O
,	O
function	B-O
and	O
recurrent	B-O
instability	I-O
at	O
2	O
years	O
postoperatively	O
,	O
and	O
surgical	B-O
times	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Compared	O
with	O
the	O
intake	O
of	O
commercial	B-C
vegetable	I-C
juice	I-C
,	O
the	O
intake	O
of	O
fresh	B-I
fruit	I-I
and	O
komatsuna	B-I
(	I-I
Brassica	I-I
rapa	I-I
L	I-I
.	I-I
var	I-I
.	I-I
perviridis	I-I
)	I-I
juice	I-I
mixture	I-I
reduces	O
serum	O
cholesterol	O
in	O
middle	B-P
-	I-P
aged	I-P
men	I-P
:	O
a	O
randomized	O
controlled	O
pilot	O
study	O
.	O

METHODS	O
:	O
This	O
study	O
was	O
performed	O
as	O
a	O
single	O
blind	O
and	O
randomized	O
controlled	O
trial	O
.	O

Subjects	B-P
were	I-P
16	I-P
men	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
46	I-P
.	I-P
4	I-P
	I-P
7	I-P
.	I-P
1	I-P
years	I-P
)	I-P
,	O
and	O
they	O
were	O
divided	O
into	O
two	O
groups	O
(	O
control	O
group	O
and	O
intervention	O
group	O
)	O
.	O

The	O
intervention	O
group	O
consumed	O
the	B-I
juice	I-I
mixture	I-I
of	I-I
fresh	I-I
fruit	I-I
and	O
B	B-I
.	I-I
rapa	I-I
.	O

The	O
control	O
group	O
consumed	O
commercial	B-C
vegetable	I-C
juice	I-C
.	O

Subjects	O
consumed	O
juice	O
twice	O
a	O
day	O
throughout	O
the	O
weekday	O
,	O
for	O
4	O
weeks	O
.	O

We	O
prepared	O
both	O
juices	O
with	O
an	O
equivalent	O
energy	O
balance	O
.	O

-DOCSTART-	O

Title	O
:	O
Vitamin	B-I
D	I-I
supplementation	I-I
ameliorates	O
hypoinsulinemia	O
and	O
hyperglycemia	O
in	O
static	B-P
magnetic	I-P
field	I-P
-	I-P
exposed	I-P
rat	I-P
.	O

-DOCSTART-	O

Title	O
:	O
A	O
further	O
investigation	O
of	O
goal	O
-	O
directed	O
intention	O
understanding	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Transcervical	B-I
Foley	I-I
'	I-I
s	I-I
catheter	I-I
versus	O
Cook	B-I
balloon	I-I
for	O
cervical	O
ripening	O
in	O
stillbirth	O
with	O
a	O
scarred	O
uterus	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
study	O
.	O

El	O
Minia	O
University	O
Hospital	O
,	O
El	O
Minia	O
,	O
Egypt	O
.	O

Two	B-P
-	I-P
hundred	I-P
pregnant	I-P
women	I-P
with	I-P
stillbirth	I-P
,	I-P
unfavorable	I-P
cervix	I-P
and	I-P
scarred	I-P
uterus	I-P
were	O
recruited	O
into	O
this	O
study	O
.	O

They	O
were	O
randomized	O
into	O
two	O
groups	O
.	O

In	O
group	O
I	O
(	O
n	O
=	O
100	O
)	O
,	O
cervical	B-I
ripening	I-I
was	O
done	O
using	O
Foley	B-I
'	I-I
s	I-I
catheter	I-I
.	O

In	O
group	O
II	O
(	O
n	O
=	O
100	O
)	O
,	O
cervical	B-I
ripening	I-I
was	O
done	O
using	O
Cook	B-I
cervical	I-I
ripening	I-I
balloon	I-I
.	O

Balloon	B-O
insertion	I-O
to	I-O
delivery	I-O
interval	I-O
,	O
successful	B-O
ripening	I-O
rate	I-O
,	O
cesarean	B-O
delivery	I-O
rate	I-O
,	O
maternal	B-O
adverse	I-O
events	I-O
and	O
maternal	B-O
satisfaction	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Coping	O
strategies	O
as	O
mediators	O
of	O
the	O
effect	O
of	O
the	B-I
START	I-I
(	I-I
strategies	I-I
for	I-I
RelaTives	I-I
)	I-I
intervention	I-I
on	O
psychological	O
morbidity	O
for	O
family	B-P
carers	I-P
of	I-P
people	I-P
with	I-P
dementia	I-P
in	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
260	B-P
family	I-P
carers	I-P
from	I-P
NHS	I-P
dementia	I-P
services	I-P
were	O
randomised	O
to	O
START	B-I
(	I-I
manualised	I-I
coping	I-I
skills	I-I
intervention	I-I
)	I-I
,	O
or	O
treatment	B-C
-	I-C
as	I-C
-	I-C
usual	I-C
(	I-C
TAU	I-C
)	I-C
.	O

Blinded	O
raters	O
administered	O
the	B-O
Hospital	I-O
Anxiety	I-O
and	I-O
Depression	I-O
Scale	I-O
(	I-O
HADS	I-O
-	I-O
T	I-O
)	I-O
and	O
Brief	B-O
COPE	I-O
inventory	O
at	O
baseline	O
,	O
4	O
and	O
8	O
months	O
.	O

HADS	B-O
-	I-O
T	I-O
improved	O
in	O
the	O
intervention	O
group	O
when	O
compared	O
to	O
TAU	B-C
at	O
all	O
levels	O
of	O
psychological	O
distress	O
.	O

We	O
tested	O
whether	O
coping	O
was	O
a	O
mediator	O
and	O
for	O
moderated	O
mediation	O
,	O
and	O
(	O
post	O
-	O
hoc	O
)	O
subgroup	O
treatment	O
effects	O
on	O
coping	O
.	O

-DOCSTART-	O

Title	O
:	O
Assessing	O
the	O
benefit	O
of	O
a	B-I
personalized	I-I
EHR	I-I
-	I-I
generated	I-I
informed	I-I
consent	I-I
in	O
a	O
dental	O
school	O
setting	O
.	O

METHODS	O
:	O
In	O
the	O
study	O
,	O
a	B-I
set	I-I
of	I-I
informed	I-I
consents	I-I
,	O
or	O
SmartConsents	B-I
,	O
were	O
developed	O
for	O
specific	O
diagnoses	O
and	O
procedures	O
,	O
enhanced	O
with	O
graphics	O
,	O
and	O
delivered	O
through	O
the	O
school	O
'	O
s	O
EHR	O
.	O

Fifty	B-P
patients	I-P
were	I-P
recruited	I-P
in	I-P
the	I-P
school	I-P
'	I-P
s	I-P
Urgent	I-P
Care	I-P
Clinic	I-P
and	O
divided	O
evenly	O
into	O
two	O
groups	O
:	O
one	O
(	O
control	O
)	O
receiving	O
the	B-C
standard	I-C
consent	I-C
,	O
with	O
the	O
second	O
receiving	O
a	B-I
SmartConsent	I-I
.	O

Following	O
treatment	O
,	O
patients	O
were	O
assessed	O
based	O
on	O
demographics	B-O
,	O
decisional	B-O
conflict	I-O
,	O
satisfaction	B-O
,	O
health	B-O
literacy	I-O
,	O
and	O
knowledge	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
effectiveness	O
of	O
bevacizumab	B-I
-	O
containing	O
treatment	O
for	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
:	O
final	O
results	O
of	O
the	O
ARIES	O
observational	O
cohort	O
study	O
.	O

METHODS	O
:	O
From	B-P
2006	I-P
to	I-P
2009	I-P
,	I-P
ARIES	I-P
enrolled	I-P
patients	I-P
with	I-P
locally	I-P
advanced	I-P
or	I-P
metastatic	I-P
NSCLC	I-P
who	O
were	O
eligible	O
for	O
bevacizumab	B-I
,	O
excluding	O
those	O
with	O
predominantly	O
squamous	O
histology	O
.	O

Patients	O
were	O
required	O
to	O
provide	O
informed	O
consent	O
and	O
to	O
have	O
initiated	O
bevacizumab	B-I
with	O
chemotherapy	B-I
within	O
4	O
months	O
before	O
enrollment	O
.	O

There	O
were	O
no	O
protocol	O
-	O
defined	O
treatments	O
or	O
assessments	O
.	O

The	O
dosing	O
of	O
bevacizumab	B-I
and	O
chemotherapy	B-I
,	O
and	O
the	O
choice	O
of	O
chemotherapy	O
regimen	O
,	O
was	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physician	O
.	O

-DOCSTART-	O

Title	O
:	O
GPs	B-I
'	I-I
experiences	I-I
with	I-I
brief	I-I
intervention	I-I
for	O
medication	O
-	O
overuse	O
headache	O
:	O
a	O
qualitative	O
study	O
in	O
general	O
practice	O
.	O

METHODS	O
:	O
Qualitative	O
study	O
in	O
Norwegian	O
general	O
practice	O
.	O

Data	O
were	O
collected	O
through	O
four	O
focus	O
group	O
interviews	O
with	O
22	B-P
GPs	I-P
who	O
participated	O
in	O
an	O
intervention	O
study	O
on	O
BI	O
for	O
MOH	O
.	O

Systematic	B-O
text	I-O
condensation	I-O
was	O
used	O
to	O
analyse	O
transcripts	O
from	O
the	O
focus	O
group	O
interviews	O
.	O

-DOCSTART-	O

Title	O
:	O
Gene	B-I
variants	I-I
in	I-I
CYP2C19	I-I
are	O
associated	O
with	O
altered	O
in	O
vivo	O
bupropion	O
pharmacokinetics	O
but	O
not	O
bupropion	O
-	O
assisted	O
smoking	O
cessation	O
outcomes	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
rhubarb	B-I
combined	O
with	O
early	B-I
enteral	I-I
nutrition	I-I
for	O
the	O
treatment	O
of	O
severe	O
acute	O
pancreatitis	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
126	I-P
patients	I-P
with	I-P
SAP	I-P
were	O
randomly	O
assigned	O
into	O
three	O
groups	O
:	O
parenteral	B-I
nutrition	I-I
group	O
,	O
treated	O
with	O
standard	O
solution	O
first	O
and	O
EN	B-I
14	O
days	O
later	O
;	O
EEN	B-I
group	O
,	O
treated	O
with	O
EN	B-I
suspension	I-I
;	O
or	O
EEN	B-I
combined	O
with	O
rhubarb	B-I
group	I-I
,	O
treated	O
with	O
rhubarb	B-I
and	O
then	O
EN	B-I
2	O
h	O
later	O
.	O

The	B-O
gastrointestinal	I-O
function	I-O
,	O
APACHE	B-O
II	I-O
scores	I-O
,	O
the	B-O
levels	I-O
of	I-O
plasma	I-O
IL	I-O
-	I-O
6	I-O
,	O
IL	B-O
-	I-O
11	I-O
,	O
C	B-O
-	I-O
reactive	I-O
proteins	I-O
(	I-O
CRP	I-O
)	I-O
and	O
the	B-O
liver	I-O
and	O
kidney	B-O
functional	I-O
measures	I-O
were	O
longitudinally	O
analyzed	O
.	O

-DOCSTART-	O

Title	O
:	O
Everolimus	B-I
for	O
subependymal	O
giant	O
cell	O
astrocytoma	O
in	O
patients	B-P
with	I-P
tuberous	I-P
sclerosis	I-P
complex	I-P
:	O
2	O
-	O
year	O
open	O
-	O
label	O
extension	O
of	O
the	O
randomised	O
EXIST	O
-	O
1	O
study	O
.	O

METHODS	O
:	O
We	O
assessed	O
data	O
from	O
a	O
prospective	O
,	O
open	O
-	O
label	O
extension	O
of	O
a	O
multicentre	O
,	O
phase	O
3	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
in	O
patients	B-P
with	I-P
tuberous	I-P
sclerosis	I-P
complex	I-P
who	I-P
had	I-P
SEGA	I-P
that	O
was	O
growing	O
and	O
needed	O
treatment	O
.	O

In	O
this	O
extension	O
study	O
,	O
we	O
included	O
all	O
patients	O
who	O
had	O
been	O
assigned	O
everolimus	B-I
during	O
the	O
double	O
-	O
blind	O
,	O
randomised	O
phase	O
of	O
the	O
trial	O
and	O
those	O
patients	O
who	O
crossed	O
over	O
from	O
the	B-C
placebo	I-C
group	O
to	O
receive	O
everolimus	B-I
during	O
the	O
randomised	O
phase	O
or	O
at	O
the	O
start	O
of	O
the	O
extension	O
phase	O
.	O

All	O
patients	O
received	O
oral	B-I
everolimus	I-I
at	O
a	O
starting	O
dose	O
of	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
.	O

Everolimus	B-I
dose	O
was	O
subsequently	O
adjusted	O
subject	O
to	O
tolerability	O
to	O
attain	O
blood	O
trough	O
concentrations	O
of	O
5	O
-	O
15	O
ng	O
/	O
mL	O
.	O

An	O
independent	O
central	O
radiology	O
review	O
team	O
assessed	O
SEGA	B-O
response	I-O
(	O
at	O
least	O
a	O
50	O
%	O
reduction	O
from	O
baseline	O
in	O
total	O
volume	O
of	O
all	O
target	O
SEGAs	O
;	O
the	O
primary	O
endpoint	O
)	O
by	O
MRI	B-O
at	O
12	O
,	O
24	O
,	O
and	O
48	O
weeks	O
,	O
then	O
every	O
year	O
thereafter	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	B-I
dose	I-I
of	I-I
everolimus	I-I
.	O

This	O
study	O
was	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
number	O
NCT00789828	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
low	B-I
versus	O
high	B-I
dialysate	I-I
sodium	I-I
concentration	I-I
on	O
blood	O
pressure	O
and	O
endothelial	O
-	O
derived	O
vasoregulators	O
during	O
hemodialysis	O
:	O
a	O
randomized	O
crossover	O
study	O
.	O

METHODS	O
:	O
3	O
-	O
week	O
,	O
2	O
-	O
arm	O
,	O
randomized	O
,	O
crossover	O
study	O
.	O

16	B-P
patients	I-P
with	I-P
intradialytic	I-P
hypertension	I-P
.	O

Low	B-I
(	I-I
5	I-I
mEq	I-I
/	I-I
L	I-I
below	I-I
serum	I-I
sodium	I-I
)	I-I
versus	O
high	B-I
(	I-I
5	I-I
mEq	I-I
/	I-I
L	I-I
above	I-I
serum	I-I
sodium	I-I
)	I-I
dialysate	I-I
sodium	I-I
concentration	I-I
.	O

METHODS	O
:	O
Mixed	O
linear	O
regression	O
was	O
used	O
to	O
compare	O
the	O
effect	O
of	O
dialysate	O
sodium	O
(	O
low	O
vs	O
high	O
)	O
and	O
randomization	O
arm	O
(	O
low	O
-	O
then	O
-	O
high	O
vs	O
high	O
-	O
then	O
-	O
low	O
)	O
on	O
intradialytic	O
changes	O
in	O
endothelin	B-O
1	I-O
,	O
NO2	B-O
(	I-O
-	I-O
)	I-O
,	O
and	O
BP	B-O
values	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Crohn	B-I
'	I-I
s	I-I
disease	I-I
management	I-I
after	O
intestinal	O
resection	O
:	O
a	O
randomised	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomised	O
trial	O
,	O
consecutive	B-P
patients	I-P
from	I-P
17	I-P
centres	I-P
in	I-P
Australia	I-P
and	I-P
New	I-P
Zealand	I-P
undergoing	I-P
intestinal	I-P
resection	I-P
of	I-P
all	I-P
macroscopic	I-P
Crohn	I-P
'	I-P
s	I-P
disease	I-P
,	I-P
with	I-P
an	I-P
endoscopically	I-P
accessible	I-P
anastomosis	I-P
,	I-P
received	I-P
3	I-P
months	I-P
of	I-P
metronidazole	I-P
therapy	I-P
.	O

Patients	O
at	O
high	O
risk	O
of	O
recurrence	O
also	O
received	O
a	B-I
thiopurine	I-I
,	O
or	O
adalimumab	B-I
if	O
they	O
were	O
intolerant	O
to	O
thiopurines	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
parallel	O
groups	O
:	O
colonoscopy	B-I
at	I-I
6	I-I
months	I-I
(	O
active	O
care	O
)	O
or	O
no	B-C
colonoscopy	I-C
(	O
standard	O
care	O
)	O
.	O

We	O
used	O
computer	O
-	O
generated	O
block	O
randomisation	O
to	O
allocate	O
patients	O
in	O
each	O
centre	O
to	O
active	O
or	O
standard	O
care	O
in	O
a	O
2	O
:	O
1	O
ratio	O
.	O

For	O
endoscopic	O
recurrence	O
(	O
Rutgeerts	O
score	O
?i2	O
)	O
at	O
6	O
months	O
,	O
patients	O
stepped	O
-	O
up	O
to	O
thiopurine	B-I
,	O
fortnightly	B-I
adalimumab	I-I
with	O
thiopurine	B-I
,	O
or	O
weekly	B-I
adalimumab	I-I
.	O

The	O
primary	O
endpoint	O
was	O
endoscopic	B-O
recurrence	I-O
at	O
18	O
months	O
.	O

Patients	O
and	O
treating	O
physicians	O
were	O
aware	O
of	O
the	O
patient	O
'	O
s	O
study	O
group	O
and	O
treatment	O
,	O
but	O
central	B-O
reading	I-O
of	I-O
the	I-O
endoscopic	I-O
findings	I-O
was	O
undertaken	O
blind	O
to	O
the	O
study	O
group	O
and	O
treatment	O
.	O

Analysis	O
included	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
number	O
NCT00989560	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
functional	O
outcomes	O
and	O
predictors	O
of	O
shunt	B-I
-	I-I
dependent	I-I
hydrocephalus	O
after	O
treatment	O
of	O
ruptured	O
intracranial	O
aneurysms	O
in	O
the	O
BRAT	O
trial	O
:	O
revisiting	B-I
the	I-I
clip	I-I
vs	O
coil	B-I
debate	I-I
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
471	I-P
patients	I-P
who	O
were	O
part	O
of	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
from	O
2003	O
to	O
2007	O
were	O
retrospectively	O
reviewed	O
.	O

All	O
variables	O
including	O
demographic	B-O
data	I-O
,	O
medical	B-O
history	I-O
,	O
treatment	B-O
,	O
imaging	B-O
,	O
and	O
functional	B-O
outcomes	O
were	O
included	O
as	O
part	O
of	O
the	O
trial	O
.	O

No	O
additional	O
variables	O
were	O
retrospectively	O
collected	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Effects	O
of	O
Naltrexone	B-I
on	O
Subjective	O
Response	O
to	O
Methamphetamine	O
in	O
a	O
Clinical	O
Sample	O
:	O
a	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
Controlled	O
Laboratory	O
Study	O
.	O

METHODS	O
:	O
Non	B-P
-	I-P
treatment	I-P
-	I-P
seeking	I-P
individuals	I-P
meeting	I-P
DSM	I-P
-	I-P
IV	I-P
criteria	I-P
for	I-P
MA	I-P
abuse	I-P
or	I-P
dependence	I-P
(	I-P
n=30	I-P
)	I-P
completed	O
two	O
separate	O
5	O
-	O
day	O
inpatient	O
stays	O
.	O

During	O
each	O
admission	O
,	O
participants	O
completed	O
testing	O
sessions	O
comprised	O
of	O
MA	B-O
cue	I-O
-	I-O
reactivity	I-O
and	O
intravenous	B-O
MA	I-O
administration	I-O
(	I-O
30	I-O
mg	I-O
)	I-O
after	O
receiving	O
oral	B-I
NTX	I-I
(	O
50	O
mg	O
)	O
or	O
placebo	B-C
for	O
4	O
days	O
.	O

This	O
study	O
tested	O
the	O
hypotheses	O
that	O
NTX	B-I
would	O
(	O
a	O
)	O
attenuate	O
cue	B-O
-	I-O
induced	I-O
MA	I-O
craving	I-O
,	O
and	O
(	O
b	O
)	O
reduce	O
subjective	B-O
responses	I-O
to	I-O
MA	I-O
administration	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Visual	O
Assessment	O
of	O
Relative	O
Apical	O
Sparing	O
Pattern	O
Is	O
More	O
Useful	O
Than	O
Quantitative	O
Assessment	O
for	O
Diagnosing	O
Cardiac	O
Amyloidosis	O
in	O
Borderline	O
or	O
Mildly	O
Increased	O
Left	O
Ventricular	O
Wall	O
Thickness	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
Quest	I-I
to	I-I
Lava	I-I
Mountain	I-I
Computer	I-I
Game	I-I
on	O
Dietary	O
and	O
Physical	O
Activity	O
Behaviors	O
of	O
Elementary	B-P
School	I-P
Children	I-P
:	O
A	O
Pilot	O
Group	O
-	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
Quasi	O
-	O
experimental	O
group	O
-	O
randomized	O
controlled	O
trial	O
conducted	O
during	O
the	O
2012	O
-	O
2013	O
school	O
year	O
.	O

A	O
total	O
of	O
107	O
children	O
in	O
fourth	O
and	O
fifth	O
grade	O
consented	O
.	O

There	O
was	O
an	O
attrition	O
rate	O
of	O
8	O
.	O
8	O
%	O
with	O
a	O
final	O
sample	O
size	O
of	O
44	O
children	O
in	O
three	O
intervention	O
schools	O
,	O
and	O
a	O
sample	O
of	O
50	O
children	O
in	O
three	O
comparison	O
schools	O
.	O

Dietary	O
intake	O
was	O
measured	O
using	O
two	O
random	O
24	O
-	O
hour	O
recalls	O
,	O
whereas	O
child	B-O
self	I-O
-	I-O
report	I-O
surveys	I-O
measured	O
diet	B-O
,	O
physical	B-O
activity	I-O
,	O
and	O
psychosocial	B-O
factors	I-O
before	O
and	O
after	O
the	O
intervention	O
.	O

Process	O
data	O
on	O
QTLM	B-O
usability	I-O
and	O
back	B-O
-	I-O
end	I-O
server	I-O
data	I-O
on	I-O
QTLM	I-O
exposure	O
and	O
progress	O
achieved	O
were	O
collected	O
.	O

QTLM	B-I
was	O
implemented	O
as	O
part	O
of	O
the	O
in	O
-	O
school	O
or	O
afterschool	O
program	O
.	O

Recommended	O
game	O
exposure	O
duration	O
was	O
90	O
min	O
/	O
wk	O
for	O
6	O
weeks	O
.	O

Analysis	O
of	O
covariance	O
or	O
logistic	O
regression	O
models	O
evaluated	O
effects	O
of	O
QTLM	B-I
on	O
diet	B-O
,	O
physical	B-O
activity	I-O
,	O
and	O
psychosocial	B-O
factors	I-O
.	O

Post	O
hoc	O
exploratory	O
analysis	O
examined	O
the	O
changes	O
before	O
and	O
after	O
the	O
intervention	O
in	O
outcome	O
variables	O
among	O
children	O
in	O
the	O
intervention	O
group	O
.	O

Significance	O
was	O
set	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Comparison	O
of	O
Teaching	O
Modalities	O
and	O
Fidelity	O
of	O
Simulation	O
Levels	O
in	O
Teaching	O
Resuscitation	O
Scenarios	O
.	O

METHODS	O
:	O
Totally	B-P
39	I-P
medical	I-P
students	I-P
and	I-P
physician	I-P
assistant	I-P
students	I-P
were	O
randomly	O
assigned	O
to	O
4	O
training	O
conditions	O
:	O
control	O
(	O
lecture	B-C
only	O
)	O
,	O
video	B-I
-	I-I
based	I-I
didactic	I-I
instruction	I-I
,	O
low	B-I
-	I-I
,	O
and	O
high	B-I
-	I-I
fidelity	I-I
simulation	I-I
activities	I-I
.	O

Participants	O
were	O
assessed	O
using	O
a	O
baseline	O
written	B-O
pretest	I-O
of	I-O
ACLS	I-O
knowledge	I-O
.	O

Following	O
this	O
,	O
all	O
participants	O
received	O
a	B-I
lecture	I-I
outlining	O
ACLS	O
science	O
and	O
algorithm	O
interpretation	O
.	O

Participants	O
were	O
then	O
trained	O
in	O
specific	O
aspects	O
of	O
ACLS	O
according	O
to	O
their	O
assigned	O
instructional	O
condition	O
.	O

After	O
training	O
,	O
each	O
participant	O
was	O
assessed	O
via	O
a	B-O
Megacode	I-O
performance	I-O
examination	I-O
and	O
a	B-O
written	I-O
posttest	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Supplementation	O
with	O
a	B-I
blend	I-I
of	I-I
krill	I-I
and	I-I
salmon	I-I
oil	I-I
is	O
associated	O
with	O
increased	O
metabolic	O
risk	O
in	O
overweight	B-P
men	I-P
.	O

METHODS	O
:	O
The	O
design	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
crossover	O
trial	O
.	O

A	B-P
total	I-P
of	I-P
47	I-P
men	I-P
with	I-P
a	I-P
mean	I-P
	I-P
SD	I-P
age	I-P
of	I-P
46	I-P
.	I-P
5	I-P
	I-P
5	I-P
.	I-P
1	I-P
y	I-P
,	I-P
who	I-P
were	I-P
overweight	I-P
[	I-P
body	I-P
mass	I-P
index	I-P
(	I-P
in	I-P
kg	I-P
/	I-P
m	I-P
(	I-P
2	I-P
)	I-P
)	I-P
from	I-P
25	I-P
to	I-P
30	I-P
]	I-P
but	I-P
otherwise	I-P
healthy	I-P
,	O
received	O
5	B-I
1	I-I
-	I-I
g	I-I
capsules	I-I
of	I-I
KS	I-I
oil	I-I
or	O
a	O
control	O
(	O
canola	B-C
oil	I-C
)	O
for	O
8	O
wk	O
and	O
crossed	O
over	O
to	O
another	O
treatment	O
after	O
an	O
8	O
-	O
wk	O
washout	O
period	O
.	O

The	O
primary	O
outcome	O
was	O
insulin	B-O
sensitivity	I-O
assessed	O
by	O
using	O
the	B-O
Matsuda	I-O
method	I-O
from	I-O
an	I-O
oral	I-O
-	I-O
glucose	I-O
-	I-O
tolerance	I-O
test	I-O
.	O

Secondary	O
outcomes	O
included	O
lipid	B-O
profiles	I-O
,	O
inflammatory	B-O
markers	I-O
,	O
24	B-O
-	I-O
h	I-O
ambulatory	I-O
blood	I-O
pressure	I-O
,	O
and	O
carotid	B-O
artery	I-O
intimamedia	I-O
thickness	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
2	B-I
doses	I-I
of	I-I
vortioxetine	I-I
in	O
adults	B-P
with	I-P
major	I-P
depressive	I-P
disorder	I-P
.	O

METHODS	O
:	O
Adults	B-P
aged	I-P
18	I-P
-	I-P
75	I-P
years	I-P
with	I-P
MDD	I-P
(	I-P
DSM	I-P
-	I-P
IV	I-P
-	I-P
TR	I-P
)	I-P
and	I-P
Montgomery	I-P
-	I-P
Asberg	I-P
Depression	I-P
Rating	I-P
Scale	I-P
(	I-P
MADRS	I-P
)	I-P
total	I-P
score	I-P
?	I-P
26	I-P
were	I-P
randomized	O
(	O
1:1:1	O
)	O
to	O
receive	O
vortioxetine	B-I
10	O
mg	O
or	O
15	O
mg	O
or	O
placebo	B-C
once	O
daily	O
,	O
with	O
the	O
primary	O
efficacy	O
end	O
point	O
being	O
change	O
from	O
baseline	O
at	O
week	O
8	O
in	O
MADRS	O
analyzed	O
by	O
mixed	O
model	O
for	O
repeated	O
measures	O
.	O

Adverse	B-O
events	I-O
were	O
recorded	O
during	O
the	O
study	O
,	O
suicidal	B-O
ideation	I-O
and	O
behavior	B-O
were	O
assessed	O
using	O
the	B-O
Columbia	I-O
-	I-O
Suicide	I-O
Severity	I-O
Rating	I-O
Scale	I-O
(	I-O
C	I-O
-	I-O
SSRS	I-O
)	I-O
,	O
and	O
sexual	B-O
dysfunction	I-O
was	O
assessed	O
using	O
the	B-O
Arizona	I-O
Sexual	I-O
Experience	I-O
(	I-O
ASEX	I-O
)	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Placebo	O
-	O
controlled	O
clinical	O
trial	O
evaluating	O
9	B-I
.	I-I
5	I-I
%	I-I
hydrogen	I-I
peroxide	I-I
high	I-I
-	I-I
adhesion	I-I
whitening	I-I
strips	I-I
.	O

METHODS	O
:	O
In	O
this	O
parallel	O
-	O
design	O
,	O
double	O
-	O
blind	O
clinical	O
trial	O
,	O
54	B-P
adult	I-P
volunteers	I-P
were	O
randomized	O
to	O
an	B-I
experimental	I-I
9	I-I
.	I-I
5	I-I
%	I-I
hydrogen	I-I
peroxide	I-I
whitening	I-I
strip	I-I
or	O
placebo	B-C
strip	I-C
balancing	O
for	O
age	O
and	O
baseline	O
tooth	O
color	O
,	O
and	O
received	O
treatment	O
.	O

Strips	B-I
were	O
worn	O
on	O
the	O
maxillary	O
arch	O
30	O
minutes	O
daily	O
for	O
20	O
days	O
.	O

Efficacy	B-O
was	O
measured	O
objectively	O
as	O
L	B-O
*	I-O
a	I-O
*	I-O
b	I-O
*	I-O
color	I-O
change	O
from	O
digital	B-O
images	I-O
at	O
Days	O
4	O
,	O
7	O
,	O
15	O
,	O
and	O
21	O
.	O

-DOCSTART-	O

Title	O
:	O
Gluten	B-I
and	O
casein	B-I
supplementation	I-I
does	O
not	O
increase	O
symptoms	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	O

METHODS	O
:	O
A	O
randomised	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
trial	O
was	O
performed	O
on	O
74	B-P
children	I-P
with	I-P
ASD	I-P
with	I-P
severe	I-P
maladaptive	I-P
behaviour	I-P
and	I-P
increased	I-P
urinary	I-P
I	I-P
-	I-P
FABP	I-P
.	O

Subjects	O
were	O
randomised	O
to	O
receive	O
gluten	B-I
-	I-I
casein	I-I
or	O
a	B-C
placebo	I-C
for	O
seven	O
days	O
.	O

We	O
evaluated	O
maladaptive	B-O
behaviour	I-O
before	O
and	O
after	O
supplementation	O
,	O
using	O
I	B-O
-	I-O
FABP	I-O
excretion	I-O
,	O
the	B-O
approach	I-O
withdrawal	I-O
problem	I-O
composite	O
subtest	O
of	O
the	B-O
Pervasive	I-O
Developmental	I-O
Disorder	I-O
Behavior	I-O
Inventory	I-O
and	O
the	B-O
Gastrointestinal	I-O
Symptom	I-O
Severity	I-O
Index	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
controlled	O
trial	O
of	O
the	B-I
SibworkS	I-I
group	I-I
program	I-I
for	O
siblings	B-P
of	I-P
children	I-P
with	I-P
special	I-P
needs	I-P
.	O

METHODS	O
:	O
SibworkS	B-I
is	O
a	O
six	O
-	O
week	O
manual	O
-	O
based	O
,	O
cognitive	B-I
-	I-I
behavioral	I-I
group	I-I
support	I-I
program	I-I
focussed	O
on	O
strengthening	B-O
siblings	I-O
'	I-O
perceived	I-O
social	I-O
support	I-O
,	O
self	B-O
-	I-O
esteem	I-O
,	O
problem	B-O
-	I-O
solving	I-O
skills	I-O
,	O
adaptive	B-O
coping	I-O
behaviors	I-O
and	O
positive	B-O
sibling	I-O
relationships	I-O
.	O

Fifty	B-P
-	I-P
six	I-P
children	I-P
aged	I-P
7	I-P
-	I-P
12	I-P
were	O
allocated	O
to	O
either	O
the	B-I
SibworkS	I-I
program	I-I
(	O
n=30	O
)	O
or	O
waitlist	B-C
control	O
(	O
n=26	O
)	O
in	O
alternating	O
sequence	O
.	O

The	O
primary	O
outcome	O
was	O
siblings	B-O
'	I-O
emotional	I-O
and	O
behavioral	B-O
functioning	I-O
.	O

Additional	O
outcomes	O
were	O
self	B-O
-	I-O
esteem	I-O
,	O
perceived	B-O
social	I-O
support	I-O
,	O
the	B-O
sibling	I-O
relationship	I-O
and	O
coping	B-O
behaviors	I-O
.	O

Siblings	B-P
were	O
followed	O
-	O
up	O
immediately	O
after	O
the	O
intervention	O
and	O
at	O
3	O
-	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Extended	B-I
-	I-I
Release	I-I
Guanfacine	I-I
for	O
Hyperactivity	O
in	O
Children	B-P
With	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
.	O

METHODS	O
:	O
In	O
a	O
multisite	O
,	O
randomized	O
clinical	O
trial	O
,	O
extended	B-I
-	I-I
release	I-I
guanfacine	I-I
was	O
compared	O
with	O
placebo	B-C
in	O
children	B-P
with	I-P
ASD	I-P
accompanied	O
by	O
hyperactivity	B-O
,	O
impulsiveness	B-O
,	O
and	O
distractibility	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Use	O
of	O
the	O
learning	O
conversation	O
improves	O
instructor	O
confidence	O
in	O
life	O
support	O
training	O
:	O
An	O
open	O
randomised	O
controlled	O
cross	O
-	O
over	O
trial	O
comparing	O
teaching	O
feedback	O
mechanisms	O
.	O

METHODS	O
:	O
Open	O
randomised	O
crossover	O
study	O
undertaken	O
between	O
October	O
2014	O
and	O
March	O
2015	O
at	O
the	O
University	O
of	O
Birmingham	O
,	O
United	O
Kingdom	O
.	O

Six	B-P
-	I-P
hundred	I-P
and	I-P
forty	I-P
healthcare	I-P
students	I-P
undertaking	I-P
a	I-P
European	I-P
Resuscitation	I-P
Council	I-P
(	I-P
ERC	I-P
)	I-P
BLS	I-P
course	I-P
were	O
enrolled	O
,	O
each	O
of	O
whom	O
was	O
randomised	O
to	O
receive	O
teaching	O
using	O
either	O
the	B-I
sandwich	I-I
technique	I-I
or	O
the	B-I
learning	I-I
conversation	I-I
.	O

Fifty	O
-	O
eight	O
instructors	O
were	O
randomised	O
to	O
initially	O
teach	O
using	O
either	O
the	B-I
learning	I-I
conversation	I-I
or	O
sandwich	B-I
technique	I-I
,	O
prior	O
to	O
crossing	O
-	O
over	O
and	O
teaching	O
with	O
the	O
alternative	O
technique	O
after	O
a	O
pre	O
-	O
defined	O
time	O
period	O
.	O

Outcome	O
measures	O
included	O
skill	O
acquisition	O
as	O
measured	O
by	O
an	B-O
end	I-O
-	I-O
of	I-O
-	I-O
course	I-O
competency	I-O
assessment	I-O
,	O
instructors	B-O
'	I-O
perception	I-O
of	I-O
teaching	I-O
with	I-O
each	I-O
feedback	I-O
technique	I-O
and	O
candidates	B-O
'	I-O
perception	I-O
of	I-O
the	I-O
feedback	I-O
they	O
were	O
provided	O
with	O
.	O

-DOCSTART-	O

Title	O
:	O
An	B-I
endovascular	I-I
simulation	I-I
exercise	I-I
among	O
radiology	B-P
residents	I-P
:	O
comparison	O
of	O
simulation	O
performance	O
with	O
and	O
without	O
practice	O
.	O

METHODS	O
:	O
Radiology	B-P
residents	I-P
were	O
guided	O
through	O
a	B-I
practice	I-I
simulation	I-I
and	O
lectured	B-I
on	I-I
endovascular	I-I
therapy	I-I
,	O
then	O
randomized	O
to	O
simulate	B-I
femoral	I-I
arterial	I-I
intervention	O
with	B-I
or	O
without	B-I
prior	I-I
iliac	I-I
simulation	I-I
.	O

Simulator	B-O
measurements	I-O
,	O
performance	B-O
grading	I-O
and	O
resident	B-O
surveys	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effectiveness	O
of	O
single	B-I
-	I-I
dose	I-I
metronidazole	I-I
therapy	I-I
for	O
patients	B-P
and	I-P
their	I-P
partners	I-P
with	I-P
bacterial	I-P
vaginosis	I-P
.	O

METHODS	O
:	O
In	O
addition	O
,	O
the	O
effectiveness	O
of	O
a	B-I
2	I-I
-	I-I
g	I-I
single	I-I
dose	I-I
of	I-I
metronidazole	I-I
was	O
compared	O
with	O
a	B-I
seven	I-I
-	I-I
day	I-I
course	I-I
of	I-I
500	I-I
mg	I-I
of	I-I
metronidazole	I-I
twice	O
a	O
day	O
in	O
patients	B-P
with	I-P
bacterial	I-P
vaginosis	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
trial	O
of	O
recombinant	B-I
alpha	I-I
2b	I-I
-	I-I
interferon	I-I
with	I-I
or	O
without	B-I
indomethacin	I-I
in	O
patients	B-P
with	I-P
metastatic	I-P
malignant	I-P
melanoma	I-P
.	O

METHODS	O
:	O
53	B-P
patients	I-P
were	O
stratified	O
according	O
to	O
performance	O
status	O
and	O
randomized	O
to	O
receive	O
alpha	B-I
2b	I-I
-	I-I
interferon	I-I
,	O
20	O
million	O
units	O
per	O
m2	O
i	O
.	O
v	O
.	O
,	O
5	O
days	O
per	O
week	O
for	O
4	O
weeks	O
followed	O
by	O
10	O
million	O
units	O
per	O
m2	O
s	O
.	O
c	O
.	O
three	O
times	O
per	O
week	O
,	O
either	O
with	B-I
or	O
without	B-I
indomethacin	I-I
,	O
25	O
mg	O
orally	O
three	O
times	O
a	O
day	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
propofol	B-I
and	O
isoflurane	B-I
on	O
haemodynamics	O
and	O
the	O
inflammatory	O
response	O
in	O
cardiopulmonary	O
bypass	O
surgery	O
.	O

METHODS	O
:	O
CRP	B-O
,	O
IL	B-O
-	I-O
6	I-O
,	O
IL	B-O
-	I-O
8	I-O
,	O
HIF	B-O
-	I-O
1?	I-O
(	O
ELISA	B-O
)	O
,	O
CD11	B-O
and	O
CD18	B-O
expression	I-O
(	O
flow	B-O
cytometry	I-O
)	O
,	O
and	O
haemoxygenase	B-O
(	O
HO	B-O
-	I-O
1	I-O
)	O
promoter	B-O
polymorphisms	I-O
(	O
PCR	B-O
/	O
electrophoresis	B-O
)	O
were	O
measured	O
before	O
anaesthetic	O
induction	O
,	O
4	O
hours	O
post	O
-	O
CPB	O
,	O
and	O
24	O
hours	O
later	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
therapeutic	B-I
horse	I-I
riding	I-I
on	O
gait	O
cycle	O
parameters	O
and	O
some	O
aspects	O
of	O
behavior	O
of	O
children	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
six	I-P
pupils	I-P
(	I-P
12	I-P
boys	I-P
and	I-P
14	I-P
girls	I-P
)	I-P
of	I-P
a	I-P
special	I-P
needs	I-P
school	I-P
participated	O
in	O
therapeutic	B-I
riding	I-I
.	O

We	O
analyzed	O
walking	B-O
twice	O
during	O
a	O
school	O
-	O
term	O
:	O
full	O
body	O
analyses	O
each	O
time	O
before	O
and	O
after	O
one	O
-	O
month	O
therapy	O
.	O

The	O
research	O
included	O
a	B-C
non	I-C
-	I-C
riding	I-C
control	O
group	O
.	O

All	O
together	O
104	O
analyses	O
were	O
performed	O
.	O

We	O
measured	O
mental	B-O
skills	I-O
using	O
Pedagogical	B-O
Analysis	I-O
and	I-O
Curriculum	I-O
(	I-O
PAC	I-O
)	I-O
test	I-O
consisting	O
of	O
four	O
parts	O
being	O
communication	B-O
,	O
self	B-O
care	I-O
,	O
motor	B-O
skills	I-O
and	O
socialization	B-O
.	O

The	B-O
Gait	I-O
Cycle	I-O
Analysis	O
consists	O
of	O
the	O
time	O
-	O
series	O
analysis	O
,	O
the	O
analysis	O
of	O
part	O
of	O
the	B-O
gait	I-O
cycle	I-O
and	O
the	B-O
measurement	I-O
of	I-O
joint	I-O
angles	I-O
in	O
each	O
plane	O
.	O

-DOCSTART-	O

Title	O
:	O
Amiprilose	B-I
hydrochloride	I-I
for	O
rheumatoid	O
arthritis	O
.	O

METHODS	O
:	O
Prospective	O
,	O
multicenter	O
,	O
randomized	O
,	O
parallel	O
group	O
,	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
12	O
-	O
week	O
trial	O
.	O

Two	B-P
hundred	I-P
and	I-P
one	I-P
functional	I-P
class	I-P
I	I-P
and	I-P
II	I-P
patients	I-P
with	I-P
definite	I-P
or	I-P
classic	I-P
rheumatoid	I-P
arthritis	I-P
,	I-P
previously	I-P
untreated	I-P
with	I-P
disease	I-P
modifying	I-P
antirheumatic	I-P
drugs	I-P
.	O

Patients	O
were	O
withdrawn	O
from	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
therapy	O
.	O

Those	O
who	O
flared	O
were	O
randomly	O
assigned	O
to	O
amiprilose	B-I
HCl	I-I
,	O
6	O
g	O
/	O
d	O
,	O
or	O
placebo	B-C
for	O
12	O
weeks	O
.	O

No	O
concomitant	O
anti	O
-	O
inflammatory	O
or	O
antirheumatic	O
drug	O
therapy	O
was	O
permitted	O
during	O
the	O
study	O
.	O

Combination	O
acetaminophen	O
and	O
propoxyphene	O
napsylate	O
was	O
the	O
only	O
supplemental	O
analgesic	O
medication	O
allowed	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Low	B-I
-	I-I
Dose	I-I
Buspirone	I-I
for	O
Restricted	O
and	O
Repetitive	O
Behavior	O
in	O
Young	B-P
Children	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
:	O
A	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
Children	B-P
2	I-P
-	I-P
6	I-P
years	I-P
of	I-P
age	I-P
with	I-P
ASD	I-P
(	I-P
N	I-P
=	I-P
166	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
placebo	B-C
or	O
2	B-I
.	I-I
5	I-I
or	O
5	O
.	B-I
0	I-I
mg	I-I
of	I-I
buspirone	I-I
twice	O
daily	O
.	O

The	O
primary	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
24	O
weeks	O
of	O
buspirone	B-I
on	O
the	B-O
Autism	I-O
Diagnostic	I-O
Observation	I-O
Schedule	I-O
(	I-O
ADOS	I-O
)	I-O
Composite	I-O
Total	I-O
Score	I-O
.	O

Secondary	O
objectives	O
included	O
evaluating	O
the	B-O
effects	I-O
of	I-O
buspirone	I-O
on	I-O
social	I-O
competence	I-O
,	O
repetitive	B-O
behaviors	I-O
,	O
language	B-O
,	O
sensory	B-O
dysfunction	I-O
,	O
and	O
anxiety	B-O
and	O
to	O
assess	O
side	B-O
effects	I-O
.	O

Positron	B-O
emission	I-O
tomography	I-O
measures	O
of	O
tryptophan	B-O
metabolism	I-O
and	O
blood	B-O
serotonin	I-O
concentrations	I-O
were	O
assessed	O
as	O
predictors	B-O
of	I-O
buspirone	I-O
efficacy	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Dacarbazine	B-I
versus	O
dacarbazine	B-I
-	O
vindesine	B-I
in	O
disseminated	O
malignant	O
melanoma	O
:	O
a	O
randomized	O
phase	O
II	O
study	O
.	O

METHODS	O
:	O
Dacarbazine	B-I
was	O
given	O
i	O
.	O
v	O
.	O
at	O
250	O
mg	O
m	O
-	O
2	O
per	O
day	O
X	O
V	O
every	O
4	O
weeks	O
.	O

In	O
the	O
combination	O
regimen	O
vindesine	B-I
given	O
at	O
3	O
mg	O
m	O
-	O
2	O
per	O
week	O
was	O
included	O
.	O

-DOCSTART-	O

Title	O
:	O
Methods	O
for	O
assessing	O
treatment	O
efficacy	O
in	O
trials	O
for	O
adjuvant	O
therapy	O
for	O
breast	O
cancer	O
.	O

-DOCSTART-	O

Title	O
:	O
Protective	O
effect	O
of	O
high	B-I
-	I-I
dose	I-I
medroxyprogesterone	I-I
acetate	I-I
(	I-I
HD	I-I
-	I-I
MPA	I-I
)	I-I
on	O
hematological	O
toxicity	O
induced	O
by	O
chemotherapy	O
for	O
advanced	O
solid	O
tumors	O
:	O
a	O
multicentric	O
controlled	O
clinical	O
trial	O
.	O

MPA	O
-	O
Hematology	O
Italian	O
Cooperative	O
Group	O
.	O

METHODS	O
:	O
A	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
was	O
conducted	O
comparing	O
active	O
treatment	O
with	O
placebo	B-C
in	O
227	B-P
patients	I-P
with	I-P
breast	I-P
,	I-P
colorectal	I-P
,	I-P
lung	I-P
and	I-P
other	I-P
solid	I-P
forms	I-P
of	I-P
cancer	I-P
.	O

Combination	B-I
therapy	I-I
,	I-I
(	I-I
CT	I-I
)	I-I
conventionally	O
employed	O
for	O
the	O
various	O
types	O
of	O
tumor	O
involved	O
,	O
was	O
associated	O
with	O
MPA	B-I
(	O
117	O
patients	O
)	O
or	O
placebo	B-C
(	O
110	O
patients	O
)	O
.	O

MPA	B-I
was	O
given	O
orally	O
as	O
tablets	O
,	O
as	O
a	O
dose	O
of	O
500	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Antibiotic	B-I
elimination	I-I
of	O
group	O
-	O
B	O
streptococci	O
in	O
urine	O
in	O
prevention	O
of	O
preterm	O
labour	O
.	O

METHODS	O
:	O
Urine	B-O
samples	I-O
from	O
4122	B-P
women	I-P
at	I-P
27	I-P
-	I-P
31	I-P
weeks	I-P
'	I-P
gestation	I-P
were	O
examined	O
for	O
bacteria	O
.	O

METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
,	O
controlled	O
study	O
these	O
patients	O
were	O
given	O
either	O
penicillin	B-I
(	O
10	O
(	O
6	O
)	O
IU	O
three	O
times	O
daily	O
for	O
6	O
days	O
;	O
37	O
patients	O
)	O
or	O
placebo	B-C
(	O
32	O
patients	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Bronchial	O
carcinoma	O
.	O

II	O
.	O

Quantitative	O
measurements	O
of	O
the	O
quality	O
of	O
survival	O
.	O

A	O
prospective	O
randomized	O
study	O
of	O
the	O
result	O
of	O
therapy	O
in	O
inoperable	B-P
patients	I-P
with	I-P
advanced	I-P
disease	I-P
.	O

METHODS	O
:	O
Forty	B-P
-	I-P
eight	I-P
bronchial	I-P
carcinoma	I-P
patients	I-P
in	I-P
clinicoanatomical	I-P
stage	I-P
4	I-P
of	I-P
the	I-P
disease	I-P
(	I-P
advanced	I-P
disease	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
groups	O
for	O
radiotherapy	B-I
,	O
chemotherapy	B-I
(	I-I
cyclophosphamide	I-I
)	I-I
and	O
placebo	B-C
treatment	I-C
,	O
respectively	O
.	O

The	O
results	O
were	O
assessed	O
by	O
the	B-O
survival	I-O
time	I-O
and	O
quality	B-O
of	I-O
survival	I-O
.	O

-DOCSTART-	O

Title	O
:	O
5	B-I
-	I-I
Fluorouracil	I-I
,	I-I
adriamycin	I-I
,	I-I
cyclophosphamide	I-I
(	I-I
FAC	I-I
)	I-I
vs	O
.	O
5	B-I
-	I-I
fluorouracil	I-I
,	I-I
epirubicin	I-I
,	I-I
cyclophosphamide	I-I
(	I-I
FEC	I-I
)	I-I
in	O
metastatic	O
breast	O
cancer	O
.	O

-DOCSTART-	O

Title	O
:	O
Flow	O
-	O
cytometric	O
studies	O
with	O
eleutherococcus	B-I
senticosus	I-I
extract	I-I
as	O
an	B-I
immunomodulatory	I-I
agent	I-I
.	O

METHODS	O
:	O
Volunteers	O
in	O
the	O
verum	O
group	O
received	O
10	B-I
ml	I-I
of	I-I
an	I-I
ethanolic	I-I
(	I-I
vincamine	I-I
free	I-I
)	I-I
eleutherococcus	I-I
senticosus	I-I
preparation	I-I
,	O
3	O
times	O
daily	O
for	O
4	O
weeks	O
.	O

In	O
the	B-C
placebo	I-C
,	O
the	B-I
eleutherococcus	I-I
extract	I-I
was	O
substituted	O
by	O
additional	B-C
wine	I-C
,	O
resulting	O
in	O
identical	O
final	O
concentrations	O
of	O
ethanol	O
in	O
both	O
preparations	O
.	O

The	O
purpose	O
of	O
the	O
double	O
-	O
blind	O
study	O
was	O
the	O
demonstration	O
of	O
possible	O
effects	O
on	O
the	B-O
cellular	I-O
immune	I-O
status	I-O
,	O
as	O
determined	O
by	O
quantitative	B-O
flow	I-O
cytometry	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Antihypertensive	O
effect	O
of	O
single	B-I
doses	I-I
of	I-I
enalapril	I-I
in	O
hypertensive	B-P
patients	I-P
treated	I-P
with	I-P
bendrofluazide	I-P
.	O

METHODS	O
:	O
Enalapril	B-I
in	O
single	O
doses	O
of	O
10	O
and	O
20	O
mg	O
was	O
given	O
to	O
13	B-P
hypertensive	I-P
patients	I-P
on	I-P
treatment	I-P
with	I-P
bendrofluazide	I-P
5	I-P
mg	I-P
daily	I-P
in	I-P
a	I-P
randomised	I-P
,	I-P
crossover	I-P
,	I-P
placebo	I-P
controlled	I-P
study	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Comparative	O
effects	O
of	O
pinacidil	B-I
and	O
nifedipine	B-I
in	O
the	O
treatment	O
of	O
arterial	O
hypertension	O
.	O

-DOCSTART-	O

Title	O
:	O
Dose	O
dependent	O
response	O
of	O
symptoms	O
,	O
pituitary	O
,	O
and	O
bone	O
to	O
transdermal	B-I
oestrogen	I-I
in	O
postmenopausal	B-P
women	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Antibiotic	B-I
prophylaxis	I-I
in	O
high	O
-	O
risk	O
head	O
and	O
neck	O
surgery	O
:	O
one	O
-	O
day	O
vs	O
.	O
five	O
-	O
day	O
therapy	O
.	O

METHODS	O
:	O
A	O
multi	O
-	O
institutional	O
prospective	O
randomized	O
double	O
-	O
blind	O
study	O
was	O
designed	O
.	O

Patients	O
who	O
were	O
identified	O
as	O
requiring	O
pedicled	O
flap	O
reconstruction	O
were	O
potential	O
candidates	O
for	O
the	O
study	O
.	O

Later	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
cefoperazone	B-I
sodium	I-I
for	O
either	O
24	O
hours	O
or	O
120	O
hours	O
.	O

In	O
each	O
case	O
,	O
the	O
drug	O
was	O
administered	O
intravenously	O
,	O
beginning	O
1	O
to	O
2	O
hours	O
preoperatively	O
and	O
continued	O
for	O
the	O
prescribed	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Total	O
parenteral	O
nutrition	O
in	O
colon	O
surgery	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Psoriasis	O
of	O
the	O
scalp	O
treated	O
with	O
Grenz	B-I
rays	I-I
or	O
topical	B-I
corticosteroid	I-I
combined	O
with	O
Grenz	B-I
rays	I-I
.	O

A	O
comparative	O
randomized	O
trial	O
.	O

METHODS	O
:	O
One	O
group	O
received	O
4	B-I
Gy	I-I
of	I-I
Grenz	I-I
rays	I-I
administered	O
on	O
six	O
occasions	O
at	O
intervals	O
of	O
1	O
week	O
and	O
the	O
other	O
group	O
was	O
given	O
the	B-I
same	I-I
Grenz	I-I
ray	I-I
treatment	I-I
plus	O
topical	B-I
corticosteroid	I-I
.	O

The	O
patients	O
were	O
assessed	O
before	O
and	O
after	O
Grenz	O
ray	O
therapy	O
and	O
were	O
followed	O
-	O
up	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Educational	B-I
intervention	I-I
for	O
altering	O
water	O
-	O
sanitation	O
behavior	O
to	O
reduce	O
childhood	O
diarrhea	O
in	O
urban	O
Bangladesh	O
:	O
impact	O
on	O
nutritional	O
status	O
.	O

METHODS	O
:	O
Fifty	B-P
-	I-P
one	I-P
communities	I-P
of	I-P
38	I-P
families	I-P
each	I-P
were	O
randomized	O
to	O
receive	O
the	O
intervention	O
or	O
no	O
intervention	O
.	O

-DOCSTART-	O

Title	O
:	O
Outpatient	O
management	O
of	O
asthma	O
with	O
regular	B-I
nebulized	I-I
beta	I-I
agonists	I-I
:	O
comparison	O
of	O
bitolterol	B-I
mesylate	I-I
and	O
isoproterenol	B-I
.	O

METHODS	O
:	O
In	O
this	O
multicenter	O
,	O
double	O
-	O
blind	O
trial	O
;	O
130	B-P
nonsteroid	I-P
-	I-P
dependent	I-P
patients	I-P
were	O
randomized	O
to	O
receive	O
one	O
of	O
the	B-I
two	I-I
treatments	I-I
concomitantly	O
with	O
their	O
regular	O
asthma	O
medications	O
.	O

On	O
study	O
days	O
,	O
at	O
the	O
beginning	O
of	O
the	O
study	O
and	O
after	O
2	O
and	O
4	O
weeks	O
,	O
treatments	O
were	O
given	O
in	O
the	O
office	O
or	O
laboratory	O
and	O
patients	O
were	O
monitored	O
with	O
pulmonary	B-O
function	I-O
tests	I-O
for	O
eight	O
hours	O
.	O

-DOCSTART-	O

Title	O
:	O
Therapeutic	O
strategies	O
in	O
acute	O
myelocytic	O
leukemia	O
:	O
a	O
status	O
report	O
of	O
the	O
experience	O
of	O
CALGB	O
.	O

Cancer	O
and	O
Leukemia	O
Group	O
B	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Prevention	O
of	O
migraine	O
with	O
flunarizine	B-I
and	O
acetylsalicylic	B-I
acid	I-I
.	O

A	O
double	O
-	O
blind	O
study	O
]	O
.	O

30	O
children	O
between	O
7	O
and	O
17	O
years	O
suffering	O
from	O
at	O
least	O
2	O
attacks	O
/	O
month	O
of	O
common	O
or	O
classical	O
migraine	O
since	O
more	O
than	O
1	O
year	O
were	O
studied	O
.	O

After	O
clinical	O
exclusion	O
of	O
symptomatic	O
headache	O
4	O
weeks	O
were	O
documented	O
by	O
means	O
of	O
a	O
migraine	O
diary	O
.	O

Prophylaxis	O
with	O
Calcium	O
entry	O
blocker	O
Flunarizine	O
(	O
Sibelium	O
)	O
or	O
Thromboxane	O
A	O
inhibitor	O
Acetylsalicylic	O
acid	O
(	O
ASS	O
)	O
was	O
carried	O
out	O
in	O
a	O
double	O
blind	O
design	O
for	O
3	O
months	O
.	O

Medication	O
was	O
given	O
as	O
one	O
dosage	O
in	O
the	O
evening	O
:	O
2	O
-	O
5	O
mg	O
/	O
kg	O
KG	O
ASS	O
or	O
5	O
-	O
10	O
mg	O
Flunarizine	O
.	O

Documented	O
attack	O
frequency	O
and	O
duration	O
were	O
controlled	O
at	O
monthly	O
physical	O
examinations	O
.	O

Final	O
results	O
showed	O
no	O
differences	O
in	O
significant	O
reduction	O
of	O
attack	O
frequency	O
or	O
symptoms	O
between	O
both	O
different	O
therapeutic	O
principals	O
.	O

72	O
.	O
4	O
%	O
(	O
ASS	O
73	O
.	O
3	O
%	O
;	O
Flunarizine	O
71	O
.	O
4	O
%	O
)	O
of	O
patients	O
were	O
attack	O
-	O
free	O
or	O
had	O
at	O
least	O
a	O
50	O
%	O
reduction	O
.	O

Migraine	O
frequency	O
of	O
initially	O
7	O
-	O
8	O
was	O
reduced	O
to	O
1	O
-	O
2	O
attacks	O
/	O
month	O
.	O

Duration	O
remained	O
constant	O
in	O
both	O
groups	O
(	O
1	O
-	O
3	O
h	O
)	O
.	O

Side	O
effects	O
were	O
slight	O
body	O
weight	O
gain	O
or	O
abdominal	O
pain	O
after	O
intake	O
,	O
prophylaxis	O
had	O
not	O
to	O
be	O
interrupted	O
therefore	O
.	O

Longtime	O
prognosis	O
is	O
not	O
yet	O
possible	O
because	O
the	O
time	O
of	O
observation	O
is	O
too	O
short	O
so	O
far	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	O
lignocaine	O
&	O
haemodynamic	O
responses	O
to	O
cystoscopy	O
.	O

-DOCSTART-	O

Title	O
:	O
Tinidazole	B-I
and	O
metronidazole	B-I
in	O
hepatic	O
amoebiasis	O
.	O

METHODS	O
:	O
Only	O
those	O
with	O
unequivocal	O
clinical	O
,	O
radiological	O
and	O
laboratory	O
evidence	O
of	O
hepatic	O
amoebiasis	O
were	O
included	O
;	O
diagnostic	B-O
and	O
therapeutic	B-O
aspiration	I-O
was	O
performed	O
where	O
necessary	O
.	O

15	O
patients	O
received	O
metronidazole	B-I
and	O
16	O
tinidazole	B-I
,	O
in	O
random	O
order	O
.	O

The	O
2	O
groups	O
were	O
comparable	O
.	O

Both	O
drugs	O
were	O
given	O
orally	O
in	O
a	O
single	O
daily	O
dose	O
of	O
2g	O
for	O
a	O
minimum	O
of	O
3	O
days	O
,	O
with	O
treatment	O
extended	O
if	O
considered	O
clinically	O
advisable	O
.	O

-DOCSTART-	O

Title	O
:	O
Postoperative	B-I
radiotherapy	I-I
in	O
breast	O
cancer	O
-	O
-	O
long	O
-	O
term	O
results	O
from	O
the	O
Oslo	O
study	O
.	O

METHODS	O
:	O
There	O
were	O
1115	B-P
patients	I-P
including	I-P
27	I-P
protocol	I-P
deviants	I-P
.	O

The	O
follow	O
-	O
up	O
time	O
is	O
11	O
-	O
20	O
years	O
.	O

In	O
the	O
first	O
part	O
a	B-C
conventional	I-C
roentgen	I-C
unit	I-C
was	O
used	O
,	O
and	O
in	O
the	O
second	O
part	O
a	B-I
60Co	I-I
unit	I-I
,	O
with	O
considerably	O
increased	O
dosage	O
and	O
altered	O
treatment	O
plan	O
.	O

-DOCSTART-	O

Title	O
:	O
Untoward	O
effects	O
of	O
fenfluramine	B-I
in	O
autistic	B-P
children	I-P
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
untoward	O
effects	O
of	O
fenfluramine	O
in	O
children	B-P
with	I-P
autism	I-P
,	O
12	B-P
subjects	I-P
were	O
systematically	O
studied	O
.	O

Medication	O
was	O
administered	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
cross	O
-	O
over	O
study	O
.	O

Parents	O
were	O
trained	O
in	O
monitoring	O
untoward	B-O
effects	I-O
.	O

These	O
observations	O
were	O
compiled	O
in	O
detailed	B-O
daily	I-O
notes	I-O
.	O

In	O
addition	O
,	O
four	O
cases	O
describing	O
unusual	B-O
effects	I-O
found	O
in	O
a	O
sample	O
of	O
170	O
patients	O
treated	O
with	O
fenfluramine	B-I
are	O
also	O
reported	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
study	O
of	O
fetal	O
abdominal	O
diameter	O
and	O
fetal	O
weight	O
estimation	O
for	O
detection	O
of	O
light	B-P
-	I-P
for	I-P
-	I-P
gestation	I-P
infants	I-P
in	I-P
low	I-P
-	I-P
risk	I-P
pregnancies	I-P
.	O

METHODS	O
:	O
An	O
additional	O
examination	O
was	O
performed	O
at	O
34	O
weeks	O
if	O
the	O
fetal	O
weight	O
in	O
the	O
32nd	O
week	O
was	O
estimated	O
to	O
be	O
less	O
than	O
95	O
%	O
of	O
the	O
expected	O
mean	O
weight	O
.	O

Light	O
-	O
for	O
-	O
gestational	O
age	O
(	O
LGA	O
)	O
was	O
suspected	O
if	O
the	O
estimated	O
birth	O
-	O
weight	O
was	O
less	O
than	O
85	O
%	O
of	O
the	O
expected	O
mean	O
birthweight	O
.	O

This	O
applied	O
to	O
186	B-P
uncomplicated	I-P
pregnancies	I-P
in	I-P
which	I-P
there	I-P
was	I-P
no	I-P
clinical	I-P
suspicion	I-P
of	I-P
poor	I-P
intrauterine	I-P
growth	I-P
.	O

These	O
pregnancies	O
were	O
randomly	O
allocated	O
to	O
a	O
treatment	O
group	O
(	O
AD	B-I
and	O
estimated	B-I
weight	I-I
reported	I-I
)	O
or	O
to	O
a	O
control	O
group	O
(	O
AD	B-C
and	O
estimated	B-C
weight	I-C
withheld	I-C
)	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Opposing	O
effects	O
of	O
propranolol	B-I
and	O
diltiazem	B-I
on	O
the	O
angina	O
threshold	O
during	O
an	O
exercise	O
test	O
in	O
patients	B-P
with	I-P
syndrome	I-P
X	I-P
]	O
.	O

METHODS	O
:	O
Patients	O
were	O
given	O
propranolol	B-I
(	O
160	O
mg	O
daily	O
)	O
,	O
diltiazem	B-I
(	O
360	O
mg	O
daily	O
)	O
and	O
placebo	B-C
for	O
2	O
weeks	O
,	O
using	O
a	O
randomized	O
single	O
blind	O
protocol	O
.	O

Upright	B-O
bicycle	I-O
ergometer	I-O
testing	I-O
was	O
performed	O
at	O
the	O
end	O
of	O
each	O
period	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Domperidone	B-I
,	O
metoclopramide	B-I
,	O
and	O
placebo	B-C
.	O

All	O
give	O
symptomatic	O
improvement	O
in	O
gastroesophageal	O
reflux	O
.	O

METHODS	O
:	O
Patients	O
were	O
divided	O
into	O
two	O
groups	O
on	O
the	O
basis	O
of	O
a	O
dual	O
-	O
isotope	O
mixed	O
-	O
meal	O
study	O
of	O
their	O
gastric	O
emptying	O
(	O
GE	O
)	O
.	O

Group	O
I	O
had	O
normal	O
GE	O
and	O
group	O
II	O
delayed	O
GE	O
.	O

Nine	B-O
gastrointestinal	I-O
symptoms	I-O
were	O
assessed	O
for	O
frequency	B-O
and	O
severity	B-O
before	O
treatment	O
.	O

The	O
trial	O
had	O
three	O
1	O
-	O
month	O
treatment	O
periods	O
using	O
metoclopramide	B-I
10	O
mg	O
q	O
.	O
i	O
.	O
d	O
.	O
,	O
domperidone	B-I
20	O
mg	O
q	O
.	O
i	O
.	O
d	O
.	O
,	O
or	O
placebo	B-C
on	O
a	O
random	O
basis	O
.	O

Symptoms	B-O
were	O
reassessed	O
at	O
the	O
end	O
of	O
each	O
month	O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
three	O
dosage	O
-	O
prediction	O
methods	O
for	O
initial	O
in	O
-	O
hospital	O
stabilization	O
of	O
warfarin	B-I
therapy	I-I
.	O

METHODS	O
:	O
Adult	B-P
inpatients	I-P
who	I-P
had	I-P
received	I-P
warfarin	I-P
sodium	I-P
10	I-P
mg	I-P
daily	I-P
for	I-P
less	I-P
than	I-P
three	I-P
days	I-P
were	O
eligible	O
for	O
the	O
study	O
.	O

After	O
receiving	O
their	O
third	O
warfarin	B-I
dose	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
have	O
their	O
warfarin	B-I
dosages	O
adjusted	O
using	O
one	O
of	O
three	O
dosage	O
-	O
prediction	O
methods	O
:	O
by	O
analog	O
computer	O
(	O
n	O
=	O
31	O
)	O
,	O
linear	O
regression	O
(	O
n	O
=	O
22	O
)	O
,	O
or	O
empiric	O
dosing	O
by	O
the	O
physician	O
(	O
n	O
=	O
34	O
)	O
.	O

A	B-O
prothrombin	I-O
time	I-O
(	I-O
PT	I-O
)	I-O
ratio	I-O
(	I-O
patient	I-O
PT	I-O
divided	I-O
by	I-O
control	I-O
PT	I-O
)	I-O
between	O
1	O
.	O
3	O
and	O
2	O
.	O
5	O
was	O
considered	O
to	O
be	O
in	O
the	O
therapeutic	O
range	O
.	O

For	O
patients	O
who	O
achieved	O
a	B-O
stable	I-O
PT	I-O
ratio	I-O
(	O
defined	O
as	O
a	O
PT	O
ratio	O
between	O
1	O
.	O
3	O
and	O
2	O
.	O
5	O
that	O
varied	O
by	O
less	O
than	O
0	O
.	O
05	O
on	O
two	O
consecutive	O
days	O
or	O
by	O
less	O
than	O
0	O
.	O
1	O
on	O
three	O
consecutive	O
days	O
without	O
a	O
dosage	O
change	O
)	O
before	O
discharge	O
,	O
the	B-O
number	I-O
of	I-O
days	I-O
(	I-O
time	I-O
to	I-O
stabilization	I-O
)	I-O
from	O
administration	O
of	O
the	O
first	O
warfarin	B-I
dose	O
to	O
achievement	O
of	O
the	B-I
warfarin	I-I
dosage	O
that	O
produced	O
a	B-O
stable	I-O
PT	I-O
ratio	I-O
(	I-O
stabilization	I-O
dosage	I-O
)	I-O
was	O
compared	O
.	O

-DOCSTART-	O

Title	O
:	O
Controlled	O
trial	O
of	O
induction	O
of	O
labor	O
by	O
vaginal	B-I
suppositories	I-I
containing	O
prostaglandin	B-I
E2	I-I
.	O

METHODS	O
:	O
A	B-P
group	I-P
of	I-P
84	I-P
women	I-P
at	I-P
39	I-P
-	I-P
43	I-P
weeks	I-P
of	I-P
pregnancy	I-P
were	O
randomly	O
allocated	O
to	O
a	O
blind	O
trial	O
of	O
induction	O
of	O
labor	O
with	O
vaginal	B-I
suppositories	I-I
containing	O
inert	B-C
material	I-C
or	O
either	O
0	B-I
.	I-I
2	I-I
mg	I-I
or	O
0	B-I
.	I-I
4	I-I
mg	I-I
of	I-I
prostaglandin	I-I
E2	I-I
.	O

The	B-I
suppositories	I-I
were	O
self	O
-	O
administered	O
every	O
two	O
hours	O
during	O
waking	O
hours	O
on	O
two	O
successive	O
days	O
until	O
labor	O
started	O
or	O
15	O
had	O
been	O
used	O
.	O

-DOCSTART-	O

Title	O
:	O
Chronic	O
lateral	O
humeral	O
epicondylitis	O
-	O
-	O
a	O
double	O
-	O
blind	O
controlled	O
assessment	O
of	O
pulsed	B-I
electromagnetic	I-I
field	I-I
therapy	I-I
.	O

METHODS	O
:	O
Treatment	O
was	O
continued	O
for	O
a	O
minimum	O
period	O
of	O
eight	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Beta	O
-	O
cytotrophic	O
effects	O
of	O
glucose	B-I
,	O
glucagon	B-I
,	O
and	O
tolbutamide	B-I
in	O
man	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
piracetam	B-I
on	O
regional	O
cerebral	O
blood	O
flow	O
and	O
mental	O
functions	O
in	O
patients	B-P
with	I-P
organic	I-P
dementia	I-P
.	O

METHODS	O
:	O
The	O
double	O
-	O
blind	O
crossover	O
design	O
included	O
nine	O
measurement	O
occasions	O
,	O
each	O
involving	O
rCBF	B-O
measurement	I-O
by	O
the	B-O
133	I-O
-	I-O
Xe	I-O
inhalation	I-O
method	I-O
,	O
ratings	B-O
of	I-O
symptoms	I-O
of	I-O
dementia	I-O
,	O
personality	B-O
changes	I-O
,	O
and	O
side	B-O
effects	I-O
,	O
and	O
a	B-O
psychometric	I-O
investigation	I-O
.	O

Three	O
investigations	O
were	O
included	O
in	O
each	O
of	O
three	O
treatment	O
periods	O
.	O

The	O
first	O
investigation	O
in	O
a	O
period	O
was	O
made	O
without	O
medication	O
.	O

Then	O
either	O
placebo	B-C
or	O
piracetam	B-I
4	O
.	O
8	O
g	O
/	O
day	O
or	O
9	O
.	O
6	O
g	O
/	O
day	O
was	O
given	O
during	O
four	O
weeks	O
with	O
measurements	O
after	O
2	O
weekks	O
and	O
4	O
weeks	O
.	O

There	O
were	O
intervals	O
of	O
4	O
weeks	O
without	O
medication	O
between	O
the	O
treatment	O
periods	O
.	O

-DOCSTART-	O

Title	O
:	O
Dipyrone	B-I
for	O
treatment	O
of	O
post	O
-	O
operative	O
pain	O
.	O

-DOCSTART-	O

Title	O
:	O
Letter	O
:	O
Cephaloridine	B-I
and	O
gentamicin	B-I
in	O
prophylaxis	O
of	O
surgical	O
wound	O
infection	O
.	O

-DOCSTART-	O

Title	O
:	O
Truncal	B-I
vagotomy	I-I
and	O
drainage	B-I
for	O
duodenal	O
ulcer	O
.	O

-DOCSTART-	O

Title	O
:	O
Persistent	O
phenothiazine	O
dyskinesia	O
treated	O
with	O
tetrabenazine	B-I
.	O

METHODS	O
:	O
Six	B-P
patients	I-P
with	I-P
persistent	I-P
phenothiazine	I-P
dyskinesia	I-P
were	O
treated	O
in	O
a	O
double	O
-	O
blind	O
controlled	O
trial	O
with	O
tetrabenazine	B-I
100	O
mg	O
in	O
divided	O
dosage	O
.	O

-DOCSTART-	O

Title	O
:	O
Propranolol	B-I
vs	O
acetazolamide	B-I
.	O

A	O
long	O
-	O
term	O
double	O
-	O
masked	O
study	O
of	O
the	O
effect	O
on	O
intraocular	O
pressure	O
and	O
blood	O
pressure	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
beta	B-I
-	I-I
adrenoceptor	I-I
blockade	I-I
on	O
left	O
ventricular	O
function	O
.	O

METHODS	O
:	O
Cardiac	B-O
function	I-O
was	O
investigated	O
by	O
M	B-O
-	I-O
Mode	I-O
and	O
2D	B-O
-	I-O
echo	I-O
-	I-O
cardiography	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
Naftidrofuryl	B-I
on	O
ethanol	O
-	O
induced	O
liver	O
damage	O
in	O
chronic	B-P
alcoholic	I-P
patients	I-P
.	O

METHODS	O
:	O
A	O
prospective	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
of	O
intramuscular	B-I
Naftidrofuryl	I-I
was	O
carried	O
out	O
on	O
32	B-P
randomly	I-P
selected	I-P
hospitalized	I-P
male	I-P
alcoholic	I-P
patients	I-P
with	I-P
clinical	I-P
,	I-P
biochemical	I-P
and	I-P
histological	I-P
evidence	I-P
of	I-P
hepatic	I-P
damage	I-P
.	O

Seventeen	O
patients	O
received	O
the	B-I
drug	I-I
(	O
40	O
mg	O
in	O
5	O
ml	O
i	O
.	O
m	O
.	O
three	O
times	O
daily	O
for	O
6	O
days	O
)	O
and	O
15	O
patients	O
received	O
a	B-C
placebo	I-C
(	O
5	O
ml	O
in	O
normal	O
saline	O
i	O
.	O
m	O
.	O
three	O
times	O
daily	O
for	O
6	O
days	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Bronchoscopic	O
findings	O
in	O
patients	B-P
with	I-P
a	I-P
complete	I-P
radiographic	I-P
regression	I-P
of	I-P
small	I-P
cell	I-P
bronchogenic	I-P
carcinoma	I-P
.	O

METHODS	O
:	O
Fibre	B-I
-	I-I
optic	I-I
bronchoscopy	I-I
was	O
performed	O
in	O
21	B-P
patients	I-P
with	I-P
small	I-P
cell	I-P
bronchogenic	I-P
carcinoma	I-P
who	I-P
demonstrated	I-P
a	I-P
complete	I-P
radiographic	I-P
regression	I-P
of	I-P
their	I-P
chest	I-P
lesions	I-P
after	I-P
3	I-P
-	I-P
4	I-P
months	I-P
of	I-P
combination	I-P
chemotherapy	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
comparison	O
of	O
liquid	B-I
antacid	I-I
and	O
placebo	B-C
in	O
the	O
treatment	O
of	O
symptomatic	O
reflux	O
esophagitis	O
.	O

METHODS	O
:	O
We	O
report	O
a	O
double	O
-	O
blind	O
comparison	O
of	O
liquid	B-I
antacid	I-I
vs	O
placebo	B-C
in	O
the	O
treatment	O
of	O
reflux	O
esophagitis	O
in	O
32	B-P
patients	I-P
with	I-P
chronic	I-P
heartburn	I-P
.	O

Entry	O
criteria	O
included	O
the	O
presence	O
of	O
symptomatic	O
gastroesophageal	O
reflux	O
confirmed	O
by	O
both	O
an	O
acid	O
perfusion	O
(	O
Bernstein	O
)	O
test	O
and	O
by	O
intraesophageal	O
pH	O
probe	O
.	O

Drug	O
treatment	O
consisted	O
of	O
15	B-I
ml	I-I
(	I-I
80	I-I
mEq	I-I
)	I-I
doses	I-I
of	I-I
antacid	I-I
(	I-I
Maalox	I-I
Therapeutic	I-I
Concentration	I-I
,	I-I
William	I-I
H	I-I
.	I-I

Rorer	I-I
)	I-I
or	O
placebo	B-C
taken	O
7	O
times	O
daily	O
,	O
ie	O
,	O
1	O
and	O
3	O
hr	O
after	O
meals	O
and	O
at	O
bedtime	O
.	O

-DOCSTART-	O

Title	O
:	O
Adjuvant	B-I
therapy	I-I
of	O
breast	O
cancer	O
:	O
the	O
Southwest	O
Oncology	O
Group	O
experience	O
.	O

METHODS	O
:	O
In	O
fully	B-P
and	I-P
partially	I-P
evaluable	I-P
patients	I-P
with	I-P
a	I-P
68	I-P
-	I-P
month	I-P
median	I-P
follow	I-P
-	I-P
up	I-P
,	O
treatment	B-O
failures	I-O
have	O
occurred	O
in	O
27	O
%	O
of	O
172	O
receiving	O
CMFVP	B-I
and	O
47	O
%	O
of	O
186	O
women	O
given	O
L	B-I
-	I-I
PAM	I-I
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
of	O
an	B-I
aqueous	I-I
and	O
a	B-I
pressurized	I-I
nasal	I-I
spray	I-I
of	I-I
beclomethasone	I-I
dipropionate	I-I
in	O
the	O
management	O
of	O
seasonal	O
rhinitis	O
.	O

METHODS	O
:	O
Beclomethasone	B-I
dipropionate	I-I
(	O
200	O
micrograms	O
)	O
was	O
administered	O
twice	O
daily	O
for	O
a	O
treatment	O
period	O
of	O
2	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Risk	O
of	O
infection	O
after	O
penetrating	O
abdominal	O
trauma	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
antihypertensive	B-I
drugs	I-I
on	O
cognitive	O
function	O
in	O
adolescents	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
adolescents	I-P
with	I-P
persistent	I-P
blood	I-P
pressure	I-P
elevation	I-P
(	I-P
greater	I-P
than	I-P
95th	I-P
%	I-P
)	I-P
on	I-P
placebo	I-P
were	O
randomized	O
double	O
blind	O
to	O
clonidine	B-I
or	O
hydrochlorothiazide	B-I
treatment	O
.	O

A	B-O
battery	I-O
of	I-O
cognitive	I-O
tests	I-O
were	O
performed	O
during	O
the	O
placebo	O
phase	O
and	O
after	O
16	O
weeks	O
of	O
active	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Tocolysis	O
with	O
hexoprenalin	B-I
and	O
salbutamol	B-I
in	O
a	O
clinical	O
comparison	O
]	O
.	O

METHODS	O
:	O
In	O
77	O
%	O
in	O
the	B-I
hexoprenalin	I-I
and	O
in	O
74	O
%	O
in	O
the	B-I
salbutamol	I-I
group	O
the	B-O
weight	I-O
of	I-O
the	I-O
newborn	I-O
was	O
greater	O
than	O
or	O
equal	O
to	O
2500	O
g	O
.	O

In	O
66	O
%	O
in	O
both	O
study	O
groups	O
the	B-O
birth	I-O
occurred	I-O
after	I-O
the	I-O
completed	I-O
37	I-O
weeks	I-O
of	I-O
gestation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
antacids	B-I
on	O
intragastric	O
pH	O
in	O
healthy	B-P
subjects	I-P
and	I-P
duodenal	I-P
ulcer	I-P
patients	I-P
.	O

Influence	O
of	O
the	B-I
size	I-I
of	I-I
the	I-I
antacid	I-I
dose	I-I
and	O
of	B-I
anticholinergics	I-I
.	O

METHODS	O
:	O
The	O
studies	O
were	O
performed	O
in	O
healthy	B-P
subjects	I-P
with	I-P
MAO	I-P
less	I-P
than	I-P
30	I-P
mmol	I-P
/	I-P
h	I-P
and	I-P
in	I-P
duodenal	I-P
ulcer	I-P
patients	I-P
with	I-P
MAO	I-P
greater	I-P
than	I-P
35	I-P
mmol	I-P
/	I-P
h	I-P
.	O

Gastric	B-O
pH	I-O
was	O
recorded	O
using	O
radiotelemetric	B-O
technique	I-O
(	I-O
Heidelberg	I-O
capsule	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Two	O
blind	O
randomized	O
cross	O
-	O
over	O
trials	O
in	O
the	O
treatment	O
of	O
primary	O
open	O
angle	O
glaucoma	O
.	O

-DOCSTART-	O

Title	O
:	O
Poylmerized	B-I
whole	I-I
ragweed	I-I
:	O
an	O
improved	O
method	O
of	O
immunotherapy	O
.	O

METHODS	O
:	O
Nineteen	B-P
ragweed	I-P
-	I-P
sensitive	I-P
patients	I-P
were	O
randomized	O
into	O
2	O
groups	O
;	O
10	O
received	O
the	B-I
polymerized	I-I
form	I-I
and	O
9	O
received	O
the	B-I
monomeric	I-I
form	I-I
.	O

Four	O
parameters	O
were	O
followed	O
:	O
serum	B-O
-	I-O
specific	I-O
IgE	I-O
against	I-O
antigen	I-O
E	I-O
,	O
total	B-O
blocking	I-O
antibody	I-O
against	I-O
antigen	I-O
E	I-O
,	O
local	B-O
and	O
systemic	B-O
reactions	I-O
to	O
injection	B-I
therapy	I-I
,	O
and	O
symptom	B-O
score	I-O
indices	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Value	O
of	O
an	B-I
anal	I-I
dilator	I-I
after	O
anal	O
stretch	O
for	O
haemorrhoids	O
.	O

-DOCSTART-	O

Title	O
:	O
Multimodal	B-I
therapy	I-I
for	O
the	O
management	O
of	O
primary	O
,	O
nonmetastatic	O
Ewing	O
'	O
s	O
sarcoma	O
of	O
bone	O
:	O
an	O
Intergroup	O
Study	O
.	O

-DOCSTART-	O

Title	O
:	O
Corticosteroid	O
-	O
induced	O
osteopenia	O
and	O
vitamin	O
D	O
metabolism	O
.	O

Effect	O
of	O
vitamin	B-I
D2	I-I
,	O
calcium	B-I
phosphate	I-I
and	O
sodium	B-I
fluoride	I-I
administration	I-I
.	O

METHODS	O
:	O
Group	O
A	O
received	O
prednisone	B-I
plus	O
'	B-I
triple	I-I
-	I-I
treatment	I-I
'	I-I
(	O
vitamin	B-I
D2	I-I
45000	O
iu	O
twice	O
weekly	O
,	O
sodium	B-I
fluoride	I-I
50	O
mg	O
and	O
calcium	B-I
phosphate	I-I
4	O
.	O
5	O
g	O
daily	O
)	O
,	O
group	O
B	O
received	O
only	B-C
prednisone	I-C
.	O

The	O
study	O
was	O
undertaken	O
in	O
order	O
to	O
evaluate	O
the	O
effect	O
of	O
prednisone	B-I
-	I-I
and	O
triple	B-I
-	I-I
treatment	I-I
upon	O
bone	B-O
mineral	I-O
content	I-O
(	I-O
BMC	I-O
)	I-O
and	O
vitamin	B-O
D	I-O
metabolism	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Non	O
-	O
Hodgkin	O
'	O
s	O
malignant	O
lymphomas	O
:	O
treatment	O
of	O
localized	B-I
relapses	I-I
with	O
chemo	B-I
+	O
radio	B-I
+	O
BCG	B-I
-	I-I
therapy	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Perception	O
of	O
social	B-I
interactions	I-I
in	O
depressed	B-P
psychiatric	I-P
patients	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Antibiotic	B-I
therapy	I-I
of	O
acute	O
exacerbations	O
of	O
chronic	O
bronchitis	O
.	O

A	O
controlled	O
study	O
using	O
tetracycline	O
.	O

METHODS	O
:	O
All	O
patients	O
were	O
sufficiently	O
ill	O
to	O
require	O
hospitalization	O
although	O
none	O
needed	O
ventilatory	O
support	O
;	O
the	O
presence	O
of	O
pneumonia	O
was	O
excluded	O
.	O

Treatment	O
consisted	O
of	O
bronchodilators	B-I
,	O
corticosteroids	B-I
,	O
and	O
either	O
tetracycline	B-I
,	O
500	O
mg	O
,	O
or	O
placebo	B-C
by	O
mouth	O
every	O
6	O
hours	O
for	O
1	O
week	O
.	O

Arterial	B-O
blood	I-O
gases	I-O
,	O
spirometric	B-O
tests	I-O
,	O
bacteriologic	B-O
evaluation	I-O
of	I-O
sputum	I-O
,	O
and	O
patient	O
and	O
physician	O
evaluation	O
of	O
the	B-O
severity	I-O
of	I-O
illness	I-O
were	O
assessed	O
at	O
the	O
beginning	O
and	O
end	O
of	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
the	O
therapeutic	O
effects	O
of	O
adriamycin	B-I
alone	I-I
versus	O
adriamycin	B-I
plus	O
vincristine	B-I
versus	O
adriamycin	B-I
plus	O
cyclophosphamide	B-I
in	O
the	O
treatment	O
of	O
advanced	O
carcinoma	O
of	O
the	O
cervix	O
.	O

-DOCSTART-	O

Title	O
:	O
Intraoperative	B-I
microscopy	I-I
of	O
bile	O
-	O
-	O
is	O
it	O
useful	O
?	O
.	O

-DOCSTART-	O

Title	O
:	O
Inhibition	O
of	O
spontaneous	O
platelet	O
aggregation	O
and	O
adhesion	O
by	O
indobufen	B-I
(	I-I
K	I-I
3920	I-I
)	I-I
.	O

A	O
randomized	O
,	O
double	O
-	O
blind	O
crossover	O
study	O
on	O
platelet	O
,	O
coagulation	O
and	O
fibrinolysis	O
function	O
tests	O
.	O

-DOCSTART-	O

Title	O
:	O
Antipyrine	O
clearance	O
and	O
response	O
to	O
interferon	B-I
treatment	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
active	I-P
hepatitis	I-P
C	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Reducing	O
the	O
risk	O
of	O
coronary	O
events	O
:	O
evidence	O
from	O
the	O
Scandinavian	O
Simvastatin	B-I
Survival	O
Study	O
(	O
4S	O
)	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
4	I-P
,	I-P
444	I-P
patients	I-P
with	I-P
angina	I-P
pectoris	I-P
or	I-P
previous	I-P
myocardial	I-P
infarction	I-P
and	I-P
serum	I-P
cholesterol	I-P
levels	I-P
of	I-P
213	I-P
-	I-P
310	I-P
mg	I-P
/	I-P
dl	I-P
(	I-P
5	I-P
.	I-P
5	I-P
-	I-P
8	I-P
.	I-P

0	I-P
mmol	I-P
/	I-P
liter	I-P
)	I-P
while	I-P
treated	I-P
with	I-P
a	I-P
lipid	I-P
-	I-P
lowering	I-P
diet	I-P
were	O
randomly	O
assigned	O
to	O
double	O
-	O
blind	O
treatment	O
with	O
simvastatin	B-I
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Why	O
are	O
there	O
sometimes	O
concreteness	O
effects	O
in	O
memory	O
for	O
prose	O
?	O
.	O

METHODS	O
:	O
Four	O
experiments	O
explored	O
on	O
-	O
line	O
encoding	O
strategies	O
and	O
memory	B-O
for	I-O
high	I-O
imagery	I-O
and	O
low	B-O
imagery	I-O
texts	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Quantifying	O
the	O
extent	O
of	O
osteonecrosis	O
of	O
the	O
femoral	O
head	O
.	O

A	O
new	O
method	O
using	O
MRI	O
.	O

METHODS	O
:	O
After	O
the	O
initial	O
clinical	O
evaluation	O
,	O
including	O
plain	O
radiography	O
and	O
MRI	O
,	O
37	B-P
hips	I-P
with	I-P
early	I-P
-	I-P
stage	I-P
osteonecrosis	I-P
(	I-P
ON	I-P
)	I-P
in	I-P
33	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
a	B-I
core	I-I
-	I-I
decompression	I-I
group	O
or	O
a	B-C
conservatively	I-C
-	I-C
treated	I-C
group	O
.	O

All	O
were	O
followed	O
regularly	O
by	O
clinical	B-O
evaluation	I-O
,	O
plain	B-O
radiography	I-O
and	O
MRI	B-O
at	O
intervals	O
of	O
three	O
months	O
.	O

The	B-O
extent	I-O
of	I-O
ON	I-O
was	O
estimated	O
on	O
the	B-O
basis	I-O
of	I-O
abnormal	I-O
signal	I-O
intensity	I-O
in	I-O
the	I-O
weight	I-O
-	I-O
bearing	I-O
portion	I-O
of	I-O
the	I-O
femoral	I-O
head	I-O
as	O
determined	O
from	O
a	B-O
combination	I-O
of	I-O
coronal	I-O
and	I-O
sagittal	I-O
MRIs	I-O
.	O

The	B-O
arc	I-O
of	I-O
the	I-O
necrotic	I-O
portion	I-O
in	I-O
the	I-O
mid	I-O
-	I-O
coronal	I-O
image	I-O
(	O
A	O
)	O
and	O
that	O
in	O
the	B-O
mid	I-O
-	I-O
sagittal	I-O
image	I-O
(	O
B	O
)	O
were	O
used	O
to	O
quantify	O
the	B-O
extent	I-O
of	I-O
necrosis	I-O
by	O
the	O
formula	O
:	O
(	O
A	O
/	O
180	O
)	O
x	O
(	O
B	O
/	O
180	O
)	O
x	O
100	O
.	O

-DOCSTART-	O

Title	O
:	O
Cisplatin	B-I
plus	O
etoposide	B-I
with	I-I
and	O
without	B-I
ifosfamide	I-I
in	O
extensive	O
small	O
-	O
cell	O
lung	O
cancer	O
:	O
a	O
Hoosier	O
Oncology	O
Group	O
study	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
extensive	I-P
SCLC	I-P
with	I-P
a	I-P
Karnofsky	I-P
performance	I-P
score	I-P
(	I-P
KPS	I-P
)	I-P
>	I-P
or	I-P
=	I-P
50	I-P
and	I-P
adequate	I-P
renal	I-P
function	I-P
and	I-P
bone	I-P
marrow	I-P
reserve	I-P
were	O
eligible	O
.	O

Patients	O
with	O
CNS	O
metastases	O
were	O
eligible	O
and	O
received	O
concurrent	O
whole	O
-	O
brain	O
radiotherapy	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
cisplatin	B-I
(	O
20	O
mg	O
/	O
m2	O
)	O
plus	O
etoposide	B-I
(	O
100	O
mg	O
/	O
m2	O
)	O
(	O
VP	O
)	O
both	O
given	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
on	O
days	O
1	O
to	O
4	O
or	O
cisplatin	B-I
(	O
20	O
mg	O
/	O
m2	O
)	O
,	O
ifosfamide	B-I
(	O
1	O
.	O
2	O
g	O
/	O
m2	O
)	O
,	O
and	O
etoposide	B-I
(	O
75	O
mg	O
/	O
m2	O
)	O
(	O
VIP	O
)	O
all	O
given	O
i	O
.	O
v	O
.	O
on	O
days	O
1	O
to	O
4	O
.	O

Cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
for	O
four	O
cycles	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Contractubex	B-I
gel	I-I
in	O
the	O
treatment	O
of	O
fresh	O
scars	O
after	O
thoracic	O
surgery	O
in	O
children	B-P
and	I-P
adolescents	I-P
.	O

METHODS	O
:	O
Patients	O
were	O
randomly	O
assigned	O
either	O
to	O
a	O
group	O
which	O
was	O
treated	O
topically	O
with	O
Contractubex	B-I
gel	I-I
(	O
Merz	O
+	O
Co	O
.	O
,	O
D	O
-	O
Frankfurt	O
/	O
Main	O
)	O
,	O
containing	O
10	B-I
%	I-I
onion	I-I
extract	I-I
,	O
50	B-I
/	I-I
U	I-I
of	I-I
sodium	I-I
heparin	I-I
per	O
one	O
g	O
of	O
gel	O
and	O
1	B-I
%	I-I
allantoin	I-I
,	O
or	O
to	O
a	O
group	O
receiving	O
no	B-C
treatment	I-C
.	O

The	O
treatment	O
began	O
on	O
average	O
26	O
days	O
after	O
the	O
operation	O
and	O
was	O
continued	O
for	O
one	O
year	O
.	O

The	B-O
scars	I-O
of	I-O
all	I-O
treated	I-O
and	O
untreated	B-O
patients	I-O
were	O
evaluated	O
at	O
monthly	O
intervals	O
.	O

The	B-O
appearance	I-O
of	I-O
the	I-O
scar	I-O
,	O
including	O
scar	B-O
type	I-O
and	O
scar	B-O
size	I-O
as	O
well	O
as	O
scar	B-O
colour	I-O
,	O
was	O
assessed	O
by	O
the	O
physician	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
controlled	O
study	O
of	O
chemoprophylaxis	B-I
in	O
transurethral	O
prostatectomy	O
.	O

METHODS	O
:	O
Before	O
transurethral	O
prostatectomy	O
the	O
patients	O
were	O
randomized	O
into	O
3	O
groups	O
:	O
group	O
1	O
-	O
-	O
197	O
patients	O
given	O
single	B-I
-	I-I
dose	I-I
ceftriaxone	I-I
(	O
2	O
gm	O
.	O
)	O
,	O
group	O
2	O
-	O
-	O
203	O
patients	O
given	O
160	B-I
/	I-I
800	I-I
mg	I-I
.	I-I

trimethoprimsulfamethoxazole	I-I
and	O
group	O
3	O
-	O
-	O
199	O
controls	O
given	O
no	B-C
antimicrobial	I-C
prophylaxis	I-C
.	O

Patients	O
with	O
a	O
preoperative	O
indwelling	O
catheter	O
,	O
positive	O
urine	O
culture	O
,	O
signs	O
of	O
active	O
infection	O
or	O
preoperative	O
antibiotic	O
treatment	O
were	O
excluded	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
patient	B-I
position	I-I
on	O
the	O
reproducibility	O
of	O
cardiac	O
output	O
measurements	O
.	O

METHODS	O
:	O
Prospective	O
,	O
two	O
-	O
group	O
quasi	O
-	O
experimental	O
design	O
.	O

Convenience	O
sample	O
.	O

The	O
study	O
involved	O
two	O
intensive	O
care	O
units	O
in	O
two	O
adult	O
acute	O
care	O
hospitals	O
.	O

Thirty	B-P
patients	I-P
admitted	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
who	I-P
had	I-P
a	I-P
thermodilution	I-P
pulmonary	I-P
artery	I-P
catheter	I-P
in	I-P
place	I-P
.	O

Ages	O
ranged	O
from	O
39	O
to	O
80	O
years	O
(	O
mean	O
of	O
66	O
.	O
4	O
+	O
/	O
-	O
11	O
.	O
3	O
years	O
)	O
.	O

Thermodilution	B-O
cardiac	I-O
output	I-O
measurements	I-O
.	O

The	O
subjects	O
were	O
placed	O
in	O
one	O
of	O
two	O
groups	O
,	O
initially	O
by	O
flipping	O
a	O
coin	O
then	O
into	O
alternate	O
groups	O
.	O

Group	O
A	O
subjects	O
were	O
placed	O
supine	B-I
,	O
and	O
after	O
5	O
minutes	O
had	O
cardiac	B-O
output	I-O
measurements	I-O
performed	O
.	O

They	O
were	O
then	O
placed	O
in	O
the	B-I
45	I-I
-	I-I
degree	I-I
upright	I-I
position	I-I
,	O
and	O
after	O
an	O
additional	O
5	O
minutes	O
had	O
cardiac	B-O
output	I-O
measurements	I-O
performed	O
.	O

Group	O
B	O
subjects	O
were	O
first	O
placed	O
in	O
the	B-I
45	I-I
-	I-I
degree	I-I
upright	I-I
position	I-I
,	O
and	O
after	O
5	O
minutes	O
had	O
cardiac	B-O
output	I-O
measurements	I-O
performed	O
.	O

They	O
were	O
then	O
placed	O
in	O
the	B-I
supine	I-I
flat	I-I
position	I-I
,	O
and	O
after	O
an	O
additional	O
5	O
minutes	O
had	O
cardiac	B-O
output	I-O
measurements	I-O
performed	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Postoperative	B-I
analgesia	I-I
:	O
peridural	B-I
morphine	I-I
versus	O
sublingual	B-I
buprenorphine	I-I
.	O

Comparative	O
clinical	O
study	O
]	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
conducted	O
on	O
44	B-P
patients	I-P
,	I-P
both	I-P
male	I-P
and	I-P
female	I-P
,	I-P
classified	I-P
as	I-P
ASA	I-P
II	I-P
and	I-P
III	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Physiological	B-I
pacing	I-I
improves	O
symptoms	O
and	O
increases	O
exercise	O
capacity	O
in	O
the	B-P
elderly	I-P
patient	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Interferon	B-I
treatment	I-I
for	O
hairy	O
cell	O
leukemia	O
.	O

An	O
update	O
on	O
a	B-P
cohort	I-P
of	I-P
69	I-P
patients	I-P
treated	I-P
from	I-P
1983	I-P
to	I-P
1986	I-P
.	O

METHODS	O
:	O
Follow	O
-	O
up	O
through	O
April	O
,	O
1993	O
shows	O
that	O
only	O
14	O
patients	O
have	O
expired	O
.	O

-DOCSTART-	O

Title	O
:	O
Naltrexone	B-I
in	O
young	B-P
autistic	I-P
children	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
.	O

METHODS	O
:	O
Thirteen	B-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
,	I-P
aged	I-P
3	I-P
.	I-P
4	I-P
to	I-P
8	I-P
.	I-P
3	I-P
years	I-P
(	I-P
mean	I-P
5	I-P
.	I-P
4	I-P
)	I-P
,	I-P
were	I-P
studied	I-P
in	I-P
home	I-P
,	I-P
school	I-P
,	I-P
and	I-P
outpatient	I-P
laboratory	I-P
.	O

Naltrexone	B-I
,	O
1	O
.	O
0	O
mg	O
/	O
kg	O
,	O
was	O
given	O
daily	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
design	O
.	O

Dependent	O
measures	O
included	O
parent	B-O
and	I-O
teacher	I-O
Clinical	I-O
Global	I-O
Impressions	I-O
(	I-O
CGI	I-O
)	I-O
,	O
Conners	B-O
Rating	I-O
Scales	I-O
,	O
and	O
Naltrexone	B-O
Side	I-O
-	I-O
Effects	I-O
(	I-O
SE	I-O
)	I-O
Rating	I-O
Scale	I-O
;	O
laboratory	B-O
CGI	I-O
,	O
movement	B-O
actometer	I-O
readings	I-O
,	O
and	O
a	B-O
10	I-O
-	I-O
second	I-O
interval	I-O
recording	I-O
system	I-O
analysis	O
of	O
on	O
-	O
task	O
,	O
communication	B-O
initiations	I-O
,	O
disruptive	B-O
behavior	I-O
,	O
and	O
self	B-O
-	I-O
stimulation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
an	O
intervention	O
to	O
change	O
benzodiazepine	O
-	O
prescribing	O
behavior	O
in	O
a	O
prepaid	O
group	O
practice	O
setting	O
.	O

METHODS	O
:	O
Our	O
setting	O
was	O
a	O
270	O
,	O
000	O
member	O
group	O
-	O
model	O
PPGP	O
in	O
Colorado	O
,	O
from	O
1990	O
to	O
1991	O
.	O

Participants	B-P
included	I-P
91	I-P
physicians	I-P
,	I-P
62	I-P
men	I-P
and	I-P
29	I-P
women	I-P
;	I-P
median	I-P
age	I-P
was	I-P
38	I-P
.	I-P
7	I-P
years	I-P
.	O

Group	O
1	O
received	O
a	B-I
one	I-I
-	I-I
on	I-I
-	I-I
one	I-I
educational	I-I
presentation	I-I
by	I-I
a	I-I
clinical	I-I
pharmacist	I-I
,	O
written	B-I
educational	I-I
materials	I-I
,	O
a	B-I
brief	I-I
follow	I-I
-	I-I
up	I-I
visit	I-I
,	O
and	O
feedback	B-I
with	I-I
recommendations	I-I
.	O

Group	O
2	O
received	O
only	B-I
a	I-I
face	I-I
-	I-I
to	I-I
-	I-I
face	I-I
presentation	I-I
,	O
given	B-I
to	I-I
departmental	I-I
groups	I-I
,	O
as	O
well	O
as	O
the	B-I
same	I-I
written	I-I
educational	I-I
materials	I-I
used	I-I
in	I-I
group	I-I
1	I-I
.	O

Controls	O
received	O
no	B-C
intervention	I-C
.	O

Our	O
primary	O
outcome	O
measure	O
was	O
the	B-O
benzodiazepine	I-O
"	I-O
on	I-O
/	I-O
off	I-O
"	I-O
status	I-O
of	I-O
the	I-O
elderly	I-O
PPGP	I-O
members	I-O
.	O

The	O
secondary	O
outcome	O
measure	O
was	O
the	O
median	O
change	O
(	O
preintervention	O
minus	O
postintervention	O
)	O
in	O
a	B-O
standardized	I-O
amount	I-O
of	I-O
benzodiazepines	I-O
prescribed	I-O
per	I-O
physician	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Report	O
of	O
a	O
controlled	O
clinical	O
trial	O
of	O
a	O
new	O
synthetic	O
drug	O
,	O
parsalmide	B-I
,	O
in	O
rheumatic	O
arthropathies	O
(	O
inflammatory	O
and	O
degenerative	O
)	O
]	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
carried	O
out	O
in	O
30	B-P
subjects	I-P
using	O
the	O
controlled	O
experiment	O
technique	O
according	O
to	O
the	O
"	O
between	O
patient	O
"	O
pattern	O
,	O
attributing	O
parsalmide	B-I
and	O
indomethacin	B-I
at	O
random	O
to	O
two	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
fish	I-I
-	I-I
oil	I-I
and	O
vegetable	B-I
-	I-I
oil	I-I
formula	I-I
on	O
aggregation	O
and	O
ethanolamine	O
-	O
containing	O
lysophospholipid	O
generation	O
in	O
activated	O
human	O
platelets	O
and	O
on	O
leukotriene	O
production	O
in	O
stimulated	O
neutrophils	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
consuming	O
a	B-I
liquid	I-I
formula	I-I
containing	I-I
either	I-I
fish	I-I
oil	I-I
enriched	I-I
in	I-I
omega	I-I
-	I-I
3	I-I
fatty	I-I
acids	I-I
or	O
vegetable	B-I
oil	I-I
enriched	I-I
in	I-I
oleic	I-I
acid	I-I
was	O
evaluated	O
in	O
20	B-P
male	I-P
subjects	I-P
randomly	O
allocated	O
into	O
two	O
groups	O
over	O
a	O
42	O
-	O
d	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Brief	O
report	O
:	O
a	O
controlled	O
evaluation	O
of	O
facilitated	O
communication	O
using	O
open	B-I
-	I-I
ended	I-I
and	O
fill	B-I
-	I-I
in	I-I
questions	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Peripheral	B-I
intravenous	I-I
line	I-I
survival	O
and	O
phlebitis	O
prevention	O
in	O
patients	B-P
receiving	I-P
intravenous	I-P
antibiotics	I-P
:	O
heparin	B-I
/	O
hydrocortisone	B-I
versus	O
in	B-I
-	I-I
line	I-I
filters	I-I
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
cystic	I-P
fibrosis	I-P
receiving	I-P
intermittent	I-P
i	I-P
.	I-P
v	I-P
.	I-P
antibiotics	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
their	O
drugs	O
either	O
through	O
an	B-I
in	I-I
-	I-I
line	I-I
filter	I-I
using	O
a	B-I
drug	I-I
-	I-I
free	I-I
infusate	I-I
or	O
with	B-I
no	I-I
filter	I-I
and	O
an	B-I
infusate	I-I
containing	I-I
heparin	I-I
500	O
units	O
and	O
hydrocortisone	B-I
10	O
mg	O
/	O
L	O
.	O

Infusion	B-O
sites	I-O
were	O
assessed	O
daily	O
.	O

-DOCSTART-	O

Title	O
:	O
Videofluoroscopic	O
evidence	O
of	O
aspiration	O
predicts	O
pneumonia	O
and	O
death	O
but	O
not	O
dehydration	O
following	O
stroke	O
.	O

METHODS	O
:	O
The	B-I
videofluoroscopic	I-I
modified	I-I
barium	I-I
swallow	I-I
technique	I-I
included	O
5	B-I
ml	I-I
-	I-I
thin	I-I
and	O
thick	B-I
liquid	I-I
barium	I-I
,	O
5	B-I
ml	I-I
barium	I-I
pudding	I-I
,	O
and	O
1	B-I
/	I-I
4	I-I
cookie	I-I
coated	I-I
with	I-I
barium	I-I
,	O
plus	O
additional	B-I
20	I-I
and	O
30	B-I
ml	I-I
of	I-I
thin	I-I
liquid	I-I
barium	I-I
.	O

Patients	O
were	O
assessed	O
a	O
mean	O
of	O
2	O
+	O
/	O
-	O
1	O
SD	O
months	O
poststroke	O
and	O
were	O
followed	O
for	O
a	O
mean	O
of	O
16	O
+	O
/	O
-	O
8	O
SD	O
months	O
poststroke	O
.	O

-DOCSTART-	O

Title	O
:	O
Cyclosporin	B-I
versus	O
cyclophosphamide	B-I
for	O
patients	B-P
with	I-P
steroid	I-P
-	I-P
dependent	I-P
and	I-P
frequently	I-P
relapsing	I-P
idiopathic	I-P
nephrotic	I-P
syndrome	I-P
:	O
a	O
multicentre	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Open	O
,	O
prospective	O
,	O
randomized	O
,	O
multicentre	O
,	O
controlled	O
study	O
for	O
parallel	O
groups	O
,	O
stratified	O
for	O
adults	O
and	O
children	O
.	O

The	O
setting	O
was	O
in	O
nephrological	O
departments	O
in	O
Italy	O
.	O

Seventy	B-P
-	I-P
three	I-P
patients	I-P
with	I-P
steroid	I-P
-	I-P
sensitive	I-P
idiopathic	I-P
NS	I-P
admitted	I-P
to	I-P
the	I-P
study	I-P
were	O
randomly	O
assigned	O
to	O
cyclophosphamide	B-I
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
8	O
weeks	O
or	O
CsA	B-I
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
in	O
adults	O
,	O
6	O
mg	O
/	O
kg	O
/	O
day	O
in	O
children	O
)	O
for	O
9	O
months	O
,	O
tapered	O
off	O
by	O
25	O
%	O
every	O
month	O
until	O
complete	O
discontinuation	O
at	O
month	O
12	O
.	O

Seven	O
patients	O
lost	O
to	O
follow	O
up	O
were	O
not	O
considered	O
in	O
the	O
analysis	O
.	O

The	O
remaining	O
66	O
patients	O
were	O
followed	O
up	O
for	O
3	O
-	O
24	O
months	O
after	O
randomization	O
.	O

Relapse	B-O
-	I-O
free	I-O
survival	I-O
;	O
number	B-O
of	I-O
N	I-O
.	I-O
S	I-O
.	I-O
relapses	I-O
/	I-O
patient	I-O
/	I-O
year	I-O
;	O
cumulative	B-O
dose	I-O
of	I-O
prednisone	I-O
/	I-O
patient	I-O
;	O
laboratory	B-O
investigations	I-O
(	O
kidney	B-O
and	O
liver	B-O
functions	I-O
,	O
haematological	B-O
parameters	I-O
)	O
;	O
incidence	B-O
of	I-O
adverse	I-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
High	O
purity	O
factor	O
VIII	O
and	O
immune	O
state	O
in	O
HIV	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
double	O
-	O
blind	O
comparison	O
of	O
oral	B-I
ketoprofen	I-I
'	O
controlled	O
release	O
'	O
and	O
indomethacin	B-I
suppository	I-I
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
with	O
special	O
regard	O
to	O
morning	O
stiffness	O
and	O
pain	O
on	O
awakening	O
.	O

METHODS	O
:	O
Patients	O
were	O
allocated	O
at	O
random	O
to	O
receive	O
a	O
daily	O
bedtime	O
dose	O
of	O
either	O
1	B-I
ketoprofen	I-I
tablet	I-I
or	O
1	B-I
indomethacin	I-I
suppository	I-I
plus	O
the	B-I
dummy	I-I
of	I-I
the	I-I
other	I-I
formulation	I-I
for	O
a	O
period	O
of	O
3	O
weeks	O
.	O

They	O
were	O
then	O
crossed	O
over	O
to	O
the	O
alternative	O
treatment	O
for	O
a	O
further	O
3	O
weeks	O
.	O

Daily	B-O
diary	I-O
records	I-O
were	O
kept	O
by	O
patients	O
of	O
the	B-O
number	I-O
of	I-O
night	I-O
-	I-O
time	I-O
awakenings	I-O
due	I-O
to	I-O
pain	I-O
,	O
pain	B-O
severity	I-O
at	I-O
awakening	I-O
in	I-O
the	I-O
morning	I-O
and	O
the	B-O
duration	I-O
of	I-O
early	I-O
morning	I-O
stiffness	I-O
.	O

Treatment	B-O
efficacy	I-O
was	O
also	O
assessed	O
at	O
the	O
end	O
of	O
each	O
trial	O
period	O
by	O
means	O
of	O
an	B-O
articular	I-O
index	I-O
and	O
by	O
physician	B-O
'	I-O
s	I-O
and	O
patient	B-O
'	I-O
s	I-O
overall	I-O
evaluation	I-O
of	I-O
response	I-O
.	O

Adverse	B-O
effects	I-O
spontaneously	O
mentioned	O
by	O
the	O
patients	O
or	O
elicited	O
by	O
direct	O
questioning	O
using	O
a	B-O
symptom	I-O
check	I-O
-	I-O
list	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
tidal	O
volumes	O
obtained	O
by	O
one	B-I
-	I-I
handed	I-I
and	O
two	B-I
-	I-I
handed	I-I
ventilation	I-I
techniques	I-I
.	O

METHODS	O
:	O
Subjects	B-P
(	I-P
108	I-P
healthcare	I-P
providers	I-P
from	I-P
a	I-P
500	I-P
-	I-P
bed	I-P
teaching	I-P
hospital	I-P
)	I-P
were	O
assigned	O
randomly	O
to	O
one	O
of	O
two	O
procedures	O
:	O
one	O
-	O
followed	O
by	O
two	B-I
-	I-I
handed	I-I
compression	I-I
or	O
two	O
-	O
followed	O
by	O
one	B-I
-	I-I
handed	I-I
compression	I-I
.	O

A	B-O
1	I-O
-	I-O
liter	I-O
resuscitation	I-O
bag	I-O
,	O
lung	B-O
performance	I-O
analyzer	I-O
and	O
Wright	B-O
spirometer	I-O
were	O
used	O
to	O
measure	O
tidal	B-O
volume	I-O
.	O

Data	O
collection	O
occurred	O
in	O
a	O
simulated	O
situation	O
.	O

-DOCSTART-	O

Title	O
:	O
Omeprazole	B-I
ameliorates	O
aspirin	O
-	O
induced	O
gastroduodenal	O
injury	O
.	O

METHODS	O
:	O
Twenty	B-P
healthy	I-P
volunteers	I-P
were	O
randomized	O
to	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
to	O
determine	O
if	O
omeprazole	B-I
,	O
40	O
mg	O
/	O
day	O
prevents	O
gastroduodenal	B-O
injury	I-O
due	O
to	O
two	O
weeks	O
of	O
aspirin	O
administration	O
(	O
650	O
mg	O
four	O
times	O
a	O
day	O
)	O
.	O

The	B-O
severity	I-O
of	I-O
mucosal	I-O
injury	I-O
was	O
quantitated	O
by	O
endoscopy	B-O
and	O
stratified	O
by	O
a	B-O
scale	I-O
from	I-O
0	I-O
(	I-O
normal	I-O
)	I-O
to	I-O
4	I-O
(	I-O
ulcer	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
multicenter	O
study	O
on	O
the	O
use	O
of	O
pulsed	B-I
low	I-I
-	I-I
intensity	I-I
direct	I-I
current	I-I
for	O
healing	O
chronic	O
stage	O
II	O
and	O
stage	O
III	O
decubitus	O
ulcers	O
.	O

METHODS	O
:	O
Pulsed	B-I
low	I-I
-	I-I
intensity	I-I
direct	I-I
current	I-I
(	O
300	O
to	O
600	O
microA	O
)	O
has	O
been	O
used	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
multicenter	O
study	O
in	O
the	O
treatment	O
of	O
stage	O
II	O
and	O
stage	O
III	O
chronic	O
decubitus	O
ulcers	O
.	O

-DOCSTART-	O

Title	O
:	O
Cimetidine	B-I
is	O
not	O
more	O
effective	O
than	O
placebo	B-C
in	O
acute	O
infectious	O
mononucleosis	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
reduced	B-I
alcohol	I-I
consumption	I-I
on	O
blood	O
pressure	O
in	O
untreated	B-P
hypertensive	I-P
men	I-P
.	O

METHODS	O
:	O
The	O
purpose	O
of	O
the	O
trial	O
was	O
to	O
test	O
the	O
effects	O
of	O
alcohol	B-I
reduction	I-I
on	O
blood	B-O
pressure	I-O
.	O

After	O
a	O
2	O
-	O
week	O
familiarization	O
period	O
,	O
the	O
participants	O
were	O
assigned	O
to	O
either	O
a	B-I
reduced	I-I
alcohol	I-I
drinking	I-I
group	O
or	O
a	B-C
usual	I-C
drinking	I-C
group	O
for	O
3	O
weeks	O
(	O
experimental	O
period	O
1	O
)	O
.	O

The	O
situation	O
was	O
then	O
reversed	O
for	O
the	O
next	O
3	O
weeks	O
(	O
experimental	O
period	O
2	O
)	O
.	O

The	O
participants	O
were	O
requested	O
to	O
limit	O
their	O
daily	O
alcohol	O
consumption	O
to	O
zero	O
or	O
reduce	O
it	O
as	O
much	O
as	O
possible	O
for	O
the	O
reduced	O
alcohol	O
consumption	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Prevention	O
of	O
pneumonia	O
by	O
endotracheal	B-I
micronebulization	I-I
of	I-I
tobramycin	I-I
]	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
clinical	O
evaluation	O
of	O
a	B-I
blood	I-I
conservation	I-I
device	I-I
in	O
medical	B-P
intensive	I-P
care	I-P
unit	I-P
patients	I-P
.	O

METHODS	O
:	O
Prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

A	O
clinical	O
trial	O
using	O
prospective	O
,	O
random	O
allocation	O
of	O
consecutive	O
eligible	O
patients	O
.	O

The	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
a	O
university	O
hospital	O
located	O
in	O
a	O
large	O
metropolitan	O
area	O
.	O

A	B-P
total	I-P
of	I-P
100	I-P
patients	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
the	I-P
medical	I-P
ICU	I-P
,	I-P
required	I-P
arterial	I-P
line	I-P
monitoring	I-P
for	I-P
clinical	I-P
purposes	I-P
,	I-P
and	I-P
were	I-P
managed	I-P
by	I-P
the	I-P
ICU	I-P
medical	I-P
service	I-P
.	O

Exclusion	O
criteria	O
included	O
active	O
bleeding	O
or	O
chronic	O
renal	O
failure	O
at	O
the	O
time	O
of	O
ICU	O
admission	O
.	O

Patients	O
in	O
the	O
experimental	O
group	O
had	O
a	B-I
blood	I-I
conservation	I-I
device	I-I
incorporated	O
into	O
the	O
arterial	O
pressure	O
monitoring	O
system	O
,	O
while	O
patients	O
in	O
the	O
control	O
group	O
received	O
a	B-C
conventional	I-C
arterial	I-C
pressure	I-C
monitoring	I-C
system	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Recurrence	O
of	O
condylomata	O
acuminata	O
following	O
cryotherapy	O
is	O
not	O
prevented	O
by	O
systemically	B-I
administered	I-I
interferon	I-I
.	O

METHODS	O
:	O
Randomised	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

Statistical	O
analysis	O
was	O
by	O
2	O
-	O
tailed	O
Fisher	O
'	O
s	O
Exact	O
Test	O
.	O

97	B-P
patients	I-P
with	I-P
recurrent	I-P
condylomata	I-P
acuminata	I-P
.	O

49	O
patients	O
were	O
treated	O
with	O
cryotherapy	O
plus	O
subcutaneously	O
administered	O
interferon	B-I
alpha	I-I
-	I-I
2a	I-I
,	O
and	O
48	O
received	O
cryotherapy	B-I
plus	O
placebo	B-C
.	O

Of	O
these	O
,	O
36	O
and	O
37	O
patients	O
,	O
respectively	O
,	O
completed	O
the	O
study	O
and	O
were	O
evaluable	O
.	O

Clinical	B-O
eradication	I-O
of	I-O
condylomata	I-O
for	O
six	O
months	O
following	O
adjuvant	O
chemotherapy	O
.	O

-DOCSTART-	O

Title	O
:	O
0	B-I
.	I-I
1	I-I
%	I-I
bupivacaine	I-I
does	O
not	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
infusion	O
after	O
major	O
abdominal	O
surgery	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
fentanyl	B-I
(	O
10	O
micrograms	O
/	O
mL	O
)	O
or	O
a	B-I
fentanyl	I-I
/	O
bupivacaine	B-I
(	O
0	O
.	O
1	O
%	O
)	O
mixture	O
epidurally	O
corresponding	O
to	O
the	O
dermatome	O
of	O
the	O
surgical	O
incision	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
for	O
the	O
first	O
18	O
hours	O
after	O
major	O
abdominal	O
surgery	O
.	O

The	O
infusion	O
was	O
titrated	O
for	O
each	O
patient	O
to	O
the	O
rate	O
required	O
for	O
pain	O
relief	O
during	O
forced	O
inspiration	O
(	O
pain	O
score	O
<	O
or	O
=	O
2	O
,	O
maximum	O
10	O
)	O
.	O

Pain	B-O
scores	I-O
,	O
the	B-O
fentanyl	I-O
doses	I-O
required	I-O
,	O
plasma	B-O
concentrations	I-O
of	I-O
fentanyl	I-O
at	O
18	O
hours	O
,	O
and	O
the	B-O
incidence	I-O
and	O
severity	B-O
of	I-O
adverse	I-O
effects	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Measurement	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
in	O
multiple	O
myeloma	O
.	O

Nordic	O
Myeloma	O
Study	O
Group	O
.	O

METHODS	O
:	O
We	O
used	O
the	B-I
questionnaire	I-I
(	I-I
QLQ	I-I
-	I-I
C30	I-I
)	I-I
developed	O
by	O
the	O
European	O
Organization	O
of	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
Study	O
Group	O
on	O
Quality	O
of	O
Life	O
.	O

The	B-I
QLQ	I-I
-	I-I
C30	I-I
incorporates	O
five	B-O
functional	I-O
scales	I-O
,	O
three	B-O
symptom	I-O
scales	I-O
,	O
a	B-O
global	I-O
health	I-O
and	O
quality	B-O
-	I-O
of	I-O
life	I-O
scale	I-O
and	O
some	B-O
single	I-O
symptom	I-O
measures	I-O
.	O

The	B-I
questionnaire	I-I
was	O
completed	O
prior	O
to	O
treatment	O
and	O
after	O
1	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
36	O
and	O
48	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Processing	O
familiar	B-I
and	O
unfamiliar	B-I
auditory	I-I
stimuli	I-I
during	O
general	O
anesthesia	O
.	O

METHODS	O
:	O
Stimuli	B-I
were	O
presented	O
via	O
headphones	O
and	O
consisted	O
of	O
common	B-C
facts	I-C
(	O
Group	O
A	O
,	O
29	O
patients	O
)	O
,	O
or	O
familiar	B-I
or	O
unfamiliar	B-I
full	I-I
names	I-I
of	I-I
fictitious	I-I
people	I-I
(	O
GRoup	O
B	O
,	O
29	O
patients	O
)	O
.	O

Group	O
A	O
was	O
expected	O
to	O
give	O
more	O
correct	B-O
answers	I-O
to	I-O
questions	I-O
about	I-O
the	I-O
common	I-O
facts	I-O
than	O
Group	O
B	O
,	O
when	O
tested	O
postoperatively	O
,	O
and	O
Group	O
B	O
to	O
attribute	O
more	O
fame	O
to	O
presented	O
names	O
than	O
Group	O
A	O
(	O
famous	B-O
names	I-O
test	I-O
)	O
.	O

Because	O
the	O
process	O
for	O
learning	O
new	O
or	O
unfamiliar	B-I
stimuli	I-I
(	O
elaboration	O
)	O
in	O
particular	O
may	O
be	O
impaired	O
under	O
general	O
anesthesia	O
,	O
more	O
memory	O
priming	O
was	O
expected	O
for	O
familiar	O
than	O
for	O
unfamiliar	O
material	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
early	O
phase	O
II	O
study	O
of	O
bicalutamide	B-I
(	I-I
Casodex	I-I
)	I-I
in	O
patients	B-P
with	I-P
prostatic	I-P
cancer	I-P
]	O
.	O

METHODS	O
:	O
The	O
patients	O
were	O
given	O
50	B-I
,	O
80	B-I
or	O
100	B-I
mg	I-I
of	I-I
bicalutamide	I-I
orally	O
once	O
a	O
day	O
in	O
fixed	O
doses	O
for	O
12	O
weeks	O
;	O
122	B-P
patients	I-P
were	O
eligible	O
for	O
evaluation	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
diclofenac	B-I
sodium	I-I
and	O
morphine	B-I
sulphate	I-I
for	O
postoperative	O
analgesia	O
after	O
day	O
case	O
inguinal	O
hernia	O
surgery	O
.	O

METHODS	O
:	O
This	O
study	O
compared	O
two	O
postoperative	O
oral	O
analgesic	O
protocols	O
after	O
day	O
case	O
inguinal	O
hernia	O
repair	O
;	O
30	B-I
mg	I-I
morphine	I-I
sulphate	I-I
(	I-I
MST	I-I
)	I-I
and	O
10	B-I
mg	I-I
metoclopramide	I-I
every	O
8	O
h	O
for	O
48	O
h	O
or	O
75	B-I
mg	I-I
diclofenac	I-I
twice	O
daily	O
for	O
48	O
h	O
.	O

The	B-O
pain	I-O
reported	O
in	O
the	B-I
MST	I-I
group	O
was	O
significantly	O
greater	O
on	O
both	O
the	O
day	O
of	O
operation	O
and	O
the	O
first	O
postoperative	O
day	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Mann	O
-	O
Whitney	O
U	O
test	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
analgesic	O
effect	O
of	O
locally	B-I
and	O
systemically	B-I
administered	I-I
ketorolac	I-I
in	O
mastectomy	B-P
patients	I-P
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
60	B-P
group	I-P
I	I-P
-	I-P
II	I-P
(	I-P
American	I-P
Society	I-P
of	I-P
Anesthesiology	I-P
criteria	I-P
)	I-P
mastectomy	I-P
patients	I-P
,	O
20	O
in	O
each	O
group	O
.	O

Near	O
the	O
end	O
of	O
surgery	O
and	O
every	O
6	O
h	O
postoperatively	O
,	O
20	B-I
ml	I-I
of	I-I
the	I-I
study	I-I
solution	I-I
containing	O
normal	B-I
saline	I-I
with	I-I
or	O
without	B-C
30	I-C
mg	I-C
of	I-C
ketorolac	I-C
were	O
administered	O
simultaneously	O
either	O
via	O
a	O
Jackson	O
-	O
Pratt	O
drain	O
or	O
intravenously	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
.	O

The	B-O
quality	I-O
of	I-O
pain	I-O
control	I-O
,	O
the	B-O
amount	I-O
and	O
character	B-O
of	I-O
the	I-O
drain	I-O
fluid	I-O
,	O
incidence	B-O
of	I-O
nausea	I-O
and	O
vomiting	B-O
,	O
length	B-O
of	I-O
stay	I-O
in	I-O
the	I-O
postoperative	I-O
care	I-O
unit	I-O
,	O
and	O
amount	B-O
of	I-O
morphine	I-O
used	I-O
for	I-O
treatment	I-O
of	I-O
break	I-O
-	I-O
through	I-O
pain	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
of	O
chronic	B-I
naltrexone	I-I
treatment	I-I
in	O
young	B-P
autistic	I-P
children	I-P
:	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
crossover	O
study	O
.	O

METHODS	O
:	O
Drug	B-O
effects	I-O
were	O
monitored	O
with	O
behavior	B-O
checklists	I-O
rated	O
by	O
parents	O
and	O
teachers	O
,	O
and	O
ethological	B-O
playroom	I-O
observations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
practice	B-I
on	O
laterality	O
in	O
a	O
mental	O
rotation	O
task	O
.	O

METHODS	O
:	O
Forty	B-P
-	I-P
six	I-P
females	I-P
and	I-P
46	I-P
males	I-P
completed	O
four	B-I
blocks	I-I
of	I-I
64	I-I
trials	I-I
in	O
a	O
lateralized	O
mental	O
rotation	O
task	O
.	O

-DOCSTART-	O

Title	O
:	O
Levels	O
of	O
recombinant	B-I
human	I-I
granulocyte	I-I
colony	I-I
-	I-I
stimulating	I-I
factor	I-I
in	O
serum	O
are	O
inversely	O
correlated	O
with	O
circulating	O
neutrophil	O
counts	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
relationship	O
between	O
serum	B-O
G	I-O
-	I-O
CSF	I-O
levels	I-O
and	O
circulating	B-O
neutrophil	I-O
counts	I-O
and	O
the	B-O
pharmacokinetics	I-O
of	O
rhG	B-I
-	I-I
CSF	I-I
for	O
patients	B-P
with	I-P
lung	I-P
cancer	I-P
who	I-P
had	I-P
been	I-P
treated	I-P
with	I-P
myelosuppressive	I-P
chemotherapy	I-P
and	I-P
then	I-P
with	I-P
subcutaneous	I-P
rhG	I-P
-	I-P
CSF	I-P
(	I-P
lenograstim	I-P
,	I-P
2	I-P
micrograms	I-P
per	I-P
kg	I-P
of	I-P
body	I-P
weight	I-P
per	I-P
day	I-P
)	I-P
.	O

Twelve	B-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
four	O
groups	O
with	O
different	B-I
rhG	I-I
-	I-I
CSF	I-I
therapy	I-I
schedules	O
.	O

Serum	B-O
G	I-O
-	I-O
CSF	I-O
levels	I-O
were	O
measured	O
by	O
an	B-O
enzyme	I-O
immunoassay	I-O
method	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
evolving	O
clinical	O
status	O
of	O
patients	B-P
after	I-P
a	I-P
myocardial	I-P
infarction	I-P
:	O
the	O
importance	O
of	O
post	O
-	O
hospital	O
data	O
for	O
mortality	O
prediction	O
.	O

METHODS	O
:	O
An	B-P
inception	I-P
cohort	I-P
of	I-P
patients	I-P
enrolled	I-P
in	I-P
the	I-P
Beta	I-P
-	I-P
Blocker	I-P
in	I-P
Heart	I-P
Attack	I-P
Trial	I-P
(	I-P
n	I-P
=	I-P
2830	I-P
)	I-P
was	O
included	O
.	O

Forty	O
-	O
three	O
variables	O
(	O
including	O
in	O
-	O
hospital	O
and	O
post	O
-	O
hospital	O
data	O
)	O
were	O
evaluated	O
using	O
stepwise	O
logistic	O
regression	O
.	O

-DOCSTART-	O

Title	O
:	O
Age	B-I
and	O
autonomic	B-I
effects	I-I
on	O
interrelationships	O
between	O
lung	O
volume	O
and	O
heart	O
rate	O
.	O

METHODS	O
:	O
Estimates	O
of	O
respiratory	B-O
and	O
heart	B-O
rate	I-O
power	I-O
spectra	I-O
and	O
linear	B-O
transfer	I-O
functions	I-O
between	O
the	O
two	O
groups	O
were	O
generated	O
by	O
Fourier	O
analysis	O
.	O

Age	B-O
,	O
double	B-O
blockade	I-O
effects	I-O
,	O
the	B-O
age	I-O
-	I-O
drug	I-O
interactions	I-O
were	O
determined	O
by	O
analysis	O
of	O
variance	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
age	O
at	O
introduction	O
of	O
complementary	B-I
foods	I-I
to	O
breast	B-P
-	I-P
fed	I-P
infants	I-P
on	I-P
duration	I-P
of	I-P
lactational	I-P
amenorrhea	I-P
in	I-P
Honduran	I-P
women	I-P
.	O

METHODS	O
:	O
Data	O
on	O
LA	O
were	O
collected	O
during	O
and	O
after	O
a	O
2	O
-	O
mo	O
intervention	O
trial	O
in	O
which	O
low	B-P
-	I-P
income	I-P
Honduran	I-P
women	I-P
who	I-P
had	I-P
breast	I-P
-	I-P
fed	I-P
fully	I-P
for	I-P
4	I-P
mo	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
continued	B-I
full	I-I
breast	I-I
-	I-I
feeding	I-I
until	O
6	O
mo	O
(	O
FBF	B-I
,	O
n	O
=	O
50	O
)	O
,	O
introduction	B-I
of	I-I
complementary	I-I
foods	I-I
at	O
4	O
mo	O
with	O
ad	O
libitum	O
breast	O
-	O
feeding	O
from	O
4	O
to	O
6	O
mo	O
(	O
SF	B-I
,	O
n	O
=	O
47	O
)	O
,	O
or	O
introduction	B-I
of	I-I
complementary	I-I
foods	I-I
at	O
4	O
mo	O
with	O
maintenance	O
of	O
baseline	O
breast	O
-	O
feeding	O
frequency	O
from	O
4	O
to	O
6	O
mo	O
(	O
SF	B-I
-	I-I
M	I-I
,	O
n	O
=	O
44	O
)	O
.	O

Women	O
were	O
followed	O
up	O
until	O
the	O
infant	O
was	O
12	O
mo	O
of	O
age	O
,	O
or	O
later	O
if	O
menses	O
had	O
not	O
occurred	O
by	O
then	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
pretreatment	I-I
of	I-I
hypertonic	I-I
saline	I-I
can	O
prevent	O
systemic	O
hypotension	O
induced	O
by	O
spinal	O
anesthesia	O
.	O

METHODS	O
:	O
Sixty	B-P
ASA	I-P
class	I-P
I	I-P
patients	I-P
scheduled	I-P
for	I-P
herniorrhapy	I-P
under	I-P
spinal	I-P
anesthesia	I-P
were	O
assigned	O
randomly	O
into	O
two	O
groups	O
.	O

Group	O
1	O
=	O
patients	O
were	O
prehydrated	O
with	O
isotonic	B-I
lactated	I-I
Ringer	I-I
'	I-I
s	I-I
solution	I-I
at	O
7	O
mg	O
/	O
kg	O
(	O
n	O
=	O
30	O
)	O
;	O
Group	O
2	O
=	O
patients	O
were	O
given	O
prehydration	O
with	O
3	B-I
%	I-I
hypertonic	I-I
saline	I-I
at	O
7	O
ml	O
/	O
kg	O
(	O
n	O
=	O
30	O
)	O
.	O

Following	O
prehydration	O
,	O
arterial	B-O
blood	I-O
pressure	I-O
and	O
heart	B-O
rate	I-O
were	O
recorded	O
and	O
serum	B-O
electrolyte	I-O
concentrations	I-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Acute	O
rejection	O
and	O
heart	O
infection	O
rates	O
in	O
FK	B-I
506	I-I
-	I-I
versus	O
cyclosporine	B-I
A	I-I
-	O
treated	O
heart	B-P
transplant	I-P
recipients	I-P
:	O
an	O
endomyocardial	O
biopsy	O
pathologic	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
open	O
,	O
parallel	O
group	O
comparison	O
of	O
quinapril	B-I
and	O
captopril	B-I
,	O
when	O
added	O
to	O
diuretic	B-I
therapy	I-I
,	O
in	O
the	O
treatment	O
of	O
elderly	B-P
patients	I-P
with	I-P
heart	I-P
failure	I-P
.	O

METHODS	O
:	O
The	O
study	O
was	O
performed	O
at	O
a	O
single	O
centre	O
as	O
an	O
open	O
randomised	O
parallel	O
-	O
group	O
study	O
,	O
patients	O
being	O
selected	O
for	O
inclusion	O
from	O
the	O
outpatient	O
population	O
.	O

Following	O
a	O
starting	O
dose	O
of	O
either	O
2	B-I
.	I-I
5	I-I
mg	I-I
once	I-I
-	I-I
daily	I-I
quinapril	I-I
,	O
or	O
6	B-I
.	I-I
25	I-I
mg	I-I
twice	I-I
-	I-I
daily	I-I
captopril	I-I
,	O
patients	O
were	O
reviewed	O
at	O
two	O
-	O
weekly	O
intervals	O
,	O
and	O
following	O
clinical	O
assessment	O
a	O
decision	O
was	O
made	O
either	O
to	O
titrate	O
up	O
to	O
the	O
next	O
medication	O
stage	O
or	O
to	O
enter	O
the	O
patient	O
into	O
the	O
16	O
-	O
week	O
maintenance	O
phase	O
.	O

Efficacy	B-O
was	O
assessed	O
using	O
a	B-O
six	I-O
-	I-O
minute	I-O
walking	I-O
test	I-O
,	O
the	B-O
New	I-O
York	I-O
Heart	I-O
Association	I-O
(	I-O
NYHA	I-O
)	I-O
class	I-O
,	O
a	B-O
functional	I-O
lifescale	I-O
(	I-O
FLS	I-O
)	I-O
questionnaire	I-O
and	O
the	B-O
cardiothoracic	I-O
ratio	I-O
(	I-O
CTR	I-O
)	I-O
-	O
at	O
study	O
entry	O
and	O
at	O
the	O
end	O
of	O
the	O
maintenance	O
phase	O
.	O

Blood	B-O
pressure	I-O
was	O
measured	O
for	O
5	O
h	O
post	O
-	O
first	O
-	O
dose	O
of	O
medication	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
drug	O
interaction	O
study	O
between	O
ticlopidine	B-I
and	O
cyclosporin	B-I
in	O
heart	B-P
transplant	I-P
recipients	I-P
.	O

METHODS	O
:	O
Twenty	B-P
heart	I-P
-	I-P
transplant	I-P
recipients	I-P
were	O
randomised	O
into	O
either	O
a	B-I
treated	I-I
or	O
a	B-C
placebo	I-C
group	O
.	O

Blood	B-O
samples	I-O
were	O
drawn	O
for	O
time	O
-	O
course	O
evaluation	O
of	O
cyclosporin	B-O
blood	I-O
levels	I-O
over	O
a	O
period	O
of	O
12	O
h	O
,	O
following	O
the	B-I
morning	I-I
intake	I-I
of	I-I
cyclosporin	I-I
and	O
,	O
for	O
platelet	O
aggregation	O
studies	O
,	O
before	O
and	O
after	O
14	B-I
days	I-I
of	I-I
ticlopidine	I-I
administration	O
.	O

Twenty	B-O
four	I-O
-	I-O
hour	I-O
urine	I-O
samples	I-O
were	O
collected	O
for	O
6	B-O
-	I-O
beta	I-O
-	I-O
hydroxycortisol	I-O
measurements	I-O
,	O
before	O
and	O
after	O
14	O
days	O
of	O
ticlopidine	B-I
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
preoperative	B-I
antibiotics	I-I
on	O
success	O
of	O
endosseous	O
implants	O
up	O
to	O
and	O
including	O
stage	O
II	O
surgery	O
:	O
a	O
study	O
of	O
2	B-P
,	I-P
641	I-P
implants	I-P
.	O

METHODS	O
:	O
As	O
part	O
of	O
the	O
comprehensive	O
Dental	O
Implant	O
Clinical	O
Research	O
Group	O
clinical	O
implant	O
study	O
,	O
the	B-O
preoperative	I-O
or	O
postoperative	B-O
use	I-O
of	I-O
antibiotics	I-O
,	O
the	B-O
type	I-O
used	I-O
,	O
and	O
the	B-O
duration	I-O
of	I-O
coverage	I-O
was	I-O
left	I-O
to	I-O
the	I-O
discretion	I-O
of	I-O
the	I-O
surgeon	I-O
.	O

These	O
data	O
were	O
recorded	O
and	O
correlated	O
with	O
failure	B-O
of	I-O
osseointegration	I-O
during	O
healing	O
(	O
stage	O
I	O
)	O
and	O
at	O
stage	O
II	O
surgery	O
(	O
uncovering	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
reliability	O
of	O
catheter	B-I
-	I-I
tip	I-I
transducers	I-I
for	O
the	O
measurement	O
of	O
intrauterine	O
pressure	O
in	O
the	O
third	O
stage	O
of	O
labour	O
.	O

METHODS	O
:	O
In	O
each	O
case	O
in	O
the	O
first	O
group	O
two	O
catheters	O
were	O
tied	O
together	O
and	O
introduced	O
transcervically	O
into	O
the	O
uterine	O
cavity	O
after	O
delivery	O
of	O
the	O
placenta	O
.	O

In	O
each	O
case	O
in	O
the	O
second	O
group	O
two	O
catheters	O
were	O
inserted	O
independently	O
into	O
the	O
same	O
uterine	O
cavity	O
.	O

The	B-O
active	I-O
and	O
cumulative	B-O
active	I-O
pressures	I-O
recorded	O
from	O
the	O
pairs	O
of	O
catheters	O
within	O
each	O
uterine	O
cavity	O
were	O
compared	O
.	O

-DOCSTART-	O

Title	O
:	O
Zolmitriptan	B-I
(	I-I
311C90	I-I
)	I-I
does	O
not	O
interact	O
with	O
fluoxetine	B-I
in	O
healthy	B-P
volunteers	I-P
.	O

METHODS	O
:	O
Twenty	B-P
volunteers	I-P
were	O
given	O
single	B-I
doses	I-I
of	I-I
fluoxetine	I-I
20	O
mg	O
or	O
an	B-C
identical	I-C
placebo	I-C
daily	O
for	O
28	O
days	O
prior	O
to	O
receiving	O
a	B-I
single	I-I
10	I-I
mg	I-I
oral	I-I
dose	I-I
of	I-I
zolmitriptan	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Improved	O
survival	O
with	O
early	B-I
intensification	I-I
:	O
combined	O
results	O
from	O
the	O
Medical	O
Research	O
Council	O
childhood	O
ALL	O
randomised	O
trials	O
,	O
UKALL	O
X	O
and	O
UKALL	O
XI	O
.	O

Medical	O
Research	O
Council	O
Working	O
Party	O
on	O
Childhood	O
Leukaemia	O
.	O

METHODS	O
:	O
This	O
paper	O
examines	O
the	O
effect	O
of	O
the	B-I
addition	I-I
of	I-I
the	I-I
early	I-I
intensification	I-I
block	I-I
to	O
treatment	O
which	O
included	O
late	O
intensification	O
,	O
combining	O
the	O
data	O
from	O
UKALL	O
X	O
and	O
the	O
first	O
part	O
of	O
UKALL	O
XI	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Treatment	O
of	O
Lead	B-P
-	I-P
exposed	I-P
Children	I-P
(	O
TLC	O
)	O
trial	O
:	O
design	O
and	O
recruitment	O
for	O
a	O
study	O
of	O
the	O
effect	O
of	O
oral	O
chelation	O
on	O
growth	O
and	O
development	O
in	O
toddlers	O
.	O

METHODS	O
:	O
TLC	O
clinical	O
sites	O
were	O
in	O
Baltimore	O
,	O
Cincinnati	O
and	O
Columbus	O
,	O
Newark	O
and	O
Philadelphia	O
.	O

Children	O
were	O
eligible	O
for	O
TLC	O
if	O
they	O
were	O
between	O
12	O
and	O
33	O
months	O
of	O
age	O
,	O
had	O
a	O
confirmed	O
blood	O
lead	O
concentration	O
between	O
20	O
and	O
44	O
micrograms	O
/	O
dL	O
and	O
lived	O
in	O
a	O
residence	O
suitable	O
for	O
lead	O
dust	O
reduction	O
.	O

Randomised	O
children	O
received	O
up	O
to	O
three	B-I
26	I-I
-	I-I
day	I-I
courses	I-I
of	I-I
succimer	I-I
or	O
placebo	B-C
,	O
and	O
were	O
then	O
followed	O
for	O
3	O
years	O
.	O

The	O
study	O
can	O
detect	O
a	B-O
three	I-O
-	I-O
point	I-O
difference	I-O
in	I-O
full	I-O
-	I-O
scale	I-O
IQ	I-O
at	O
3	O
-	O
year	O
follow	O
-	O
up	O
.	O

Statistical	O
power	O
for	O
the	O
other	O
end	O
points	O
is	O
more	O
difficult	O
to	O
estimate	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
sequential	O
annual	B-I
vaccination	I-I
and	O
of	O
DHEA	B-I
administration	I-I
on	O
the	O
efficacy	O
of	O
the	O
immune	O
response	O
to	O
influenza	O
vaccine	O
in	O
the	B-P
elderly	I-P
.	O

METHODS	O
:	O
Seventy	B-P
-	I-P
one	I-P
elderly	I-P
volunteers	I-P
,	I-P
aged	I-P
61	I-P
-	I-P
89	I-P
years	I-P
,	O
enrolled	O
in	O
a	O
prospective	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
to	O
receive	O
either	O
DHEA	B-I
(	O
50	O
mg	O
qd	O
p	O
.	O
o	O
.	O
for	O
4	O
consecutive	O
days	O
starting	O
2	O
days	O
before	O
immunization	O
)	O
or	O
placebo	B-C
.	O

Antibody	B-O
response	I-O
against	O
the	O
three	O
strains	O
of	O
vaccine	O
was	O
measured	O
before	O
and	O
28	O
days	O
after	O
vaccination	O
,	O
and	O
compared	O
between	O
previously	O
vaccinated	O
and	O
non	O
-	O
vaccinated	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Treatment	O
of	O
children	B-P
with	I-P
autism	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
a	B-I
caregiver	I-I
-	I-I
based	I-I
intervention	I-I
program	I-I
in	O
community	O
day	O
-	O
care	O
centers	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
five	I-P
preschool	I-P
children	I-P
with	I-P
a	I-P
DSM	I-P
III	I-P
-	I-P
R	I-P
diagnosis	I-P
of	I-P
autism	I-P
or	I-P
pervasive	I-P
developmental	I-P
disorder	I-P
were	O
randomized	O
to	O
an	O
experimental	O
or	O
control	O
group	O
.	O

Children	O
in	O
the	O
experimental	O
group	O
were	O
enrolled	O
in	O
day	O
care	O
and	O
their	O
parents	O
and	O
child	O
care	O
workers	O
received	O
a	B-I
12	I-I
-	I-I
week	I-I
intervention	I-I
consisting	O
of	O
lectures	B-I
and	O
on	B-I
-	I-I
site	I-I
consultations	I-I
to	I-I
day	I-I
-	I-I
care	I-I
centers	I-I
.	O

In	O
addition	O
,	O
supportive	O
work	O
was	O
undertaken	O
with	O
families	O
.	O

Control	O
subjects	O
received	O
day	B-C
care	I-C
alone	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Accuracy	O
and	O
feasibility	O
of	O
contrast	B-I
echocardiography	I-I
for	O
detection	O
of	O
perfusion	O
defects	O
in	O
routine	O
practice	O
:	O
comparison	O
with	O
wall	B-I
motion	I-I
and	O
technetium	B-I
-	I-I
99m	I-I
sestamibi	I-I
single	I-I
-	I-I
photon	I-I
emission	I-I
computed	I-I
tomography	I-I
.	O

The	O
Nycomed	O
NC100100	O
Investigators	O
.	O

METHODS	O
:	O
Fundamental	B-C
or	O
harmonic	B-I
MCE	I-I
was	O
performed	O
with	O
continuous	O
or	O
triggered	O
imaging	O
in	O
203	B-P
patients	I-P
with	I-P
a	I-P
previous	I-P
MI	I-P
using	I-P
bolus	I-P
doses	I-P
of	I-P
a	I-P
perfluorocarbon	I-P
-	I-P
filled	I-P
contrast	I-P
agent	I-P
(	I-P
NC100100	I-P
)	I-P
.	O

All	O
patients	O
underwent	O
single	B-I
-	I-I
photon	I-I
emission	I-I
computed	I-I
tomography	I-I
(	I-I
SPECT	I-I
)	I-I
after	O
the	B-I
injection	I-I
of	I-I
technetium	I-I
-	I-I
99m	I-I
(	I-I
Tc	I-I
-	I-I
99m	I-I
)	I-I
sestamibi	I-I
at	O
rest	O
.	O

Quantitative	B-O
and	O
semiquantitative	B-O
SPECT	I-O
,	O
wall	B-O
motion	I-O
and	O
digitized	B-O
echocardiographic	I-O
data	I-O
were	O
interpreted	O
independently	O
.	O

The	B-O
accuracy	I-O
of	I-O
MCE	I-O
was	O
assessed	O
for	O
detection	B-O
of	I-O
segments	I-O
and	O
patients	B-O
with	I-O
moderate	I-O
and	I-O
severe	I-O
sestamibi	I-O
-	I-O
SPECT	I-O
defects	I-O
,	O
as	O
well	O
as	O
for	O
detection	B-O
of	I-O
patients	I-O
with	I-O
extensive	I-O
perfusion	I-O
defects	I-O
(	I-O
>	I-O
12	I-O
%	I-O
of	I-O
left	I-O
ventricle	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Ten	O
-	O
year	O
results	O
of	O
a	O
randomised	O
trial	O
comparing	O
cisplatin	B-I
with	O
cisplatin	B-I
and	O
cyclophosphamide	B-I
in	O
advanced	O
,	O
suboptimally	O
debulked	O
ovarian	O
cancer	O
.	O

METHODS	O
:	O
176	B-P
eligible	I-P
patients	I-P
with	I-P
advanced	I-P
suboptimally	I-P
operated	I-P
ovarian	I-P
carcinoma	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
cisplatin	B-I
75	O
mg	O
/	O
m2	O
or	O
cisplatin	B-I
50	O
mg	O
/	O
m2	O
and	O
cyclophosphamide	B-I
500	O
mg	O
/	O
m2	O
(	O
CP	O
)	O
every	O
28	O
days	O
for	O
six	O
courses	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
seven	I-P
platinum	I-P
-	I-P
resistant	I-P
and	I-P
27	I-P
platinum	I-P
-	I-P
sensitive	I-P
tumours	I-P
were	O
treated	O
with	O
carboplatin	B-I
or	O
cisplatin	B-I
as	O
second	O
-	O
line	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparative	O
efficacy	O
and	O
safety	O
of	O
calcium	B-I
carbasalate	I-I
plus	O
metoclopramide	B-I
versus	O
ergotamine	B-I
tartrate	I-I
plus	O
caffeine	B-I
in	O
the	O
treatment	O
of	O
acute	O
migraine	O
attacks	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
296	I-P
patients	I-P
fulfilling	I-P
the	I-P
International	I-P
Headache	I-P
Society	I-P
diagnostic	I-P
criteria	I-P
for	I-P
migraine	I-P
were	O
enrolled	O
.	O

In	O
total	O
,	O
one	O
or	O
two	O
migraine	O
attacks	O
were	O
treated	O
in	O
268	O
and	O
235	O
patients	O
,	O
respectively	O
.	O

The	O
primary	O
endpoint	O
for	O
the	O
first	O
treated	O
attack	O
was	O
headache	B-O
relief	I-O
,	O
with	O
intensity	O
decreasing	O
from	O
moderate	O
or	O
severe	O
to	O
mild	O
or	O
absent	O
2	O
h	O
after	O
drug	O
intake	O
.	O

Usual	O
secondary	O
efficacy	O
endpoints	O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
preparation	O
of	O
patients	B-P
for	I-P
cardiac	I-P
surgery	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Network	O
support	O
for	O
drinking	O
,	O
Alcoholics	O
Anonymous	O
and	O
long	O
-	O
term	O
matching	O
effects	O
.	O

METHODS	O
:	O
Outpatients	O
were	O
re	O
-	O
interviewed	O
3	O
years	O
following	O
treatment	O
.	O

ANCOVAs	O
tested	O
the	O
matching	O
hypothesis	O
.	O

Outpatients	B-P
from	I-P
five	I-P
clinical	I-P
research	I-P
units	I-P
distributed	I-P
across	I-P
the	I-P
United	I-P
States	I-P
.	O

Eight	B-P
hundred	I-P
and	I-P
six	I-P
alcohol	I-P
-	I-P
dependent	I-P
clients	I-P
.	O

Clients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	B-I
12	I-I
-	I-I
week	I-I
,	I-I
manually	I-I
-	I-I
guided	I-I
,	I-I
individual	I-I
treatments	I-I
:	O
TSF	B-I
,	O
MET	B-I
or	O
Cognitive	B-I
Behavioral	I-I
Coping	I-I
Skills	I-I
Therapy	I-I
(	I-I
CBT	I-I
)	I-I
.	O

Network	B-O
support	I-O
for	I-O
drinking	I-O
prior	I-O
to	I-O
treatment	I-O
,	O
Alcoholics	B-O
Anonymous	I-O
(	I-O
AA	I-O
)	I-O
involvement	I-O
during	I-O
and	O
following	B-O
treatment	I-O
,	O
percentage	B-O
of	I-O
days	I-O
abstinent	I-O
and	O
drinks	B-O
per	I-O
drinking	I-O
day	I-O
during	O
months	O
37	O
-	O
39	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
alanyl	B-I
-	I-I
glutamine	I-I
in	O
postoperative	O
total	O
parenteral	O
nutrition	O
on	O
postoperative	O
immunosuppression	O
and	O
morbidity	O
.	O

Preliminary	O
results	O
of	O
a	O
prospective	O
randomized	O
study	O
]	O
.	O

METHODS	O
:	O
To	O
analyze	O
immune	B-O
competence	I-O
,	O
the	B-O
expression	I-O
of	I-O
CD3	I-O
,	O
CD4	B-O
,	O
and	O
CD8	B-O
on	I-O
lymphocytes	I-O
and	O
of	O
HLA	B-O
-	I-O
DR	I-O
and	O
CD14	B-O
on	I-O
monocytes	I-O
as	O
well	O
as	O
the	B-O
plasma	I-O
levels	I-O
of	I-O
IL	I-O
-	I-O
6	I-O
and	O
IL	B-O
-	I-O
10	I-O
was	O
evaluated	O
before	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
7	O
days	O
after	O
surgery	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
ventricular	O
fibrillation	O
duration	O
on	O
defibrillation	O
efficacy	O
using	O
biphasic	B-I
waveforms	I-I
in	O
humans	O
.	O

METHODS	O
:	O
Thirty	B-P
patients	I-P
undergoing	I-P
primary	I-P
ICD	I-P
implantation	I-P
or	I-P
pulse	I-P
generator	I-P
replacement	I-P
were	O
randomly	O
assigned	O
to	O
have	O
the	B-O
DFT	I-O
determined	O
using	O
biphasic	B-I
shocks	I-I
at	O
two	O
durations	O
of	O
VF	O
each	O
(	O
5	O
and	O
10	O
s	O
,	O
10	O
and	O
20	O
s	O
or	O
5	O
and	O
20	O
s	O
)	O
.	O

